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The HIV-1 accessory protein Vpu counteracts the restriction factor tetherin, and 
induces its cell surface downregulation and ubiquitin-dependent endosomal 
degradation. 
We have identified an acidic/dileucine based-sorting determinant, ExxxLV, in the 
second alpha helix of the Vpu cytoplasmic tail as being required for efficient tetherin 
antagonism. Mutation of this motif prevents tetherin degradation and downregulation, 
but not Vpu/tetherin interaction. This effect is similar to Vpu phospho-mutants, which 
are unable to recruit the SCF-β-TrCP E3 ubiquitin ligase complex. However, ExxxLV 
mutants are able to bind to β-TrCP and ESCRT-0 component HRS. Tetherin and 
ExxxLV mutants accumulate at the cell surface and in early endosomes implying that 
post-binding trafficking of Vpu/tetherin complexes is required to prevent tetherin transit 
to viral assembly sites on the plasma membrane. Our preliminary data shows that the 
ExxxLV motif interacts with the trafficking machinery via the clathrin adaptor AP-1 in a 
manner that is dependent on the tyrosine-based sorting signal in tetherin, although 
functional redundancy in clathrin trafficking pathways cannot yet rule out other adaptor 
proteins being involved.      
A study performed in our laboratory examined the variation of vpu alleles in HIV-1 
infection, and identified several variants in which isoleucine residues in the first alpha 
helix of the cytoplasmic tail were mutated. We show that these isoleucine mutants were 
defective for inducing tetherin degradation, despite being capable of interacting with 
tetherin, thus pheno-copying ExxxLV and phospho-mutants. However, unlike both 
these mutants, isoleucine mutants fail to interact with HRS, which is required for Vpu-
mediated tetherin degradation and antagonism. 
Vpu ExxxLV, isoleucine and phospho-mutants share localisation defects, in which they 
accumulate at the plasma membrane and in early endosomes. Interestingly, tetherin 
antagonism, in all of these mutants, can be rescued by C-terminal addition of a clathrin-
binding motif. This implies that these mutants might be defective for the same reason: 
they fail to interact with the clathrin trafficking machinery. Further experiments that will 
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Chapter 1 INTRODUCTION 
1.1 HIV-1: the pandemic 
1.1.1 HIV/AIDS in context 
Acquired immunodeficiency syndrome (AIDS) was first described in 1981 among young 
homosexual men that presented with unusual opportunistic infections (Gottlieb et al., 
1981). Subsequently the human immunodeficiency virus type 1 (HIV-1) was identified 
as the causative agent of AIDS, which has turned into the most destructive infectious 
disease worldwide since its discovery more than 30 years ago. In 2008, Luc 
Montagnier and Françoise Barré-Sinoussi received the Nobel Prize in Physiology and 
Medicine for the discovery of HIV.  
HIV is transmitted through the exchange of bodily fluids including blood, breast milk, 
semen and vaginal secretions. The most common form of acquiring HIV among adults 
(approximately 80%) is through sexual transmission. Since the start of the HIV 
pandemic 75 million people have been infected, with a total number of individuals living 
with HIV worldwide approximately 35.3 million at the end of 2012 (Figure 1-1). Despite 
the decrease in new HIV infections and AIDS-related deaths that has been observed in 
recent years, there are still 2-3 million new infections annually, 30% of them in children. 
Highly active antiretroviral therapy (HAART) is widely accessible in developed 
countries (approximately 9.7 million individuals are currently on HAART), which has 
reduced the number of AIDS-related deaths tremendously. However, even more than 
30 years after the discovery of HIV there is no curative treatment, consequently, the 
HIV/AIDS pandemic will continue to be a threat for decades to come (Source: “2013 
Global Report Epidemiology Slides”, obtained from the UNAIDS). 
 
Figure 1-1 HIV global epidemic in numbers 
World map displays number of people (adults and children) estimated to be living with HIV in different 
geographical areas at the end of 2012. The worldwide number of HIV infected individuals is about 35.3 




1.2 HIV-1 genome and structure 
The Retroviridae are a large viral family of enveloped viruses that store their nucleic 
acid in the form of positive stranded RNA, and share common features such as: 
structure, genomic organisation and replication properties. Retroviruses encode 
reverse transcriptase (RT), which converts the genomic RNA (gRNA) into double-
stranded DNA (dsDNA) that is integrated into the host genome by another virally 
encoded enzyme, integrase (IN). The genus Lentivirus belongs to the family of 
Retroviridae. Lentiviruses are associated with long incubation times and the cause of 
slow progressive diseases that result in severe immunological or neurological 
dysfunction (reviewed by (Swanson and Malim, 2008)).  
The HIV proviral DNA is approximately 9.7 kb. It is constituted of non-coding 
sequences that control gene expression as well as protein synthesis, and encodes nine 
viral genes, including gag, pol and env genes common to all replicating retroviruses 
(see Figure 1-2). Flanking the retroviral provirus are the long terminal repeats (LTRs). 
The 5’ LTR is a promoter that initiates transcription of the viral genome, while the 3’ 
LTR is important for the polyadenylation signal (poly(A) tail). The pol gene encodes 
three enzymes: reverse transcriptase, which transcribes viral RNA into DNA; IN, which 
mediates insertion of the DNA template into the host genome to establish the provirus; 
and protease (PR), which is responsible for maturation into fully infectious virus 
particles. The HIV genome also encodes two structural genes, gag and env. The Gag 
polyprotein is cleaved by PR, resulting in the production of the three main structural 
proteins: matrix (MA), capsid (CA) and nucleocapsid (NC) (reviewed by (Swanson and 
Malim, 2008)). The env gene encodes two glycoproteins, called surface (SU) gp120 
and transmembrane (TM) gp41 subunits. The gp120 protein possesses a high affinity 
for the CD4 receptor present on the plasma membrane of HIV-1 target cells. Upon 
binding of gp120 to CD4, a conformational change in the Env spike takes place that 
allows binding to the co-receptor CCR5 or CXCR4, and in turn activates the fusion 
mechanism (reviewed by (Wilen et al., 2012)).  
In addition to Gag, Pol and Env proteins, HIV also encodes six additional regulatory/ 
accessory genes: tat, rev, vif, vpr, vpu and nef. The regulatory Tat protein interacts with 
cellular proteins and binds to the TAR (trans-activation response) sequence in the viral 
RNA to stimulate and promote viral transcriptional elongation. Rev interacts with the 
Rev responsive element (RRE), a cis-acting sequence located in the env gene, 
allowing efficient nuclear export of unspliced and partially spliced viral messenger RNA. 
The accessory proteins Vif, Vpr, Vpu and Nef regulate innate and adaptive immune 





Figure 1-2 Organisation of the HIV-1 proviral genome and virus particle  
(A) Schematic representation of the proviral HIV-1 genome. Depicted are the nine open reading frames of 
HIV-1: gag, pol, vif, vpr, tat, rev, vpu, env and nef. Abbreviations: LTR (long terminal repeat), U5 (5’ 
untranslated region), R (repeat element), U3 (3’ untranslated region), MA (matrix), CA (capsid), NC 
(nucleocapsid), PR (protease), RT (reverse transcriptase), IN (integrase), SU (surface), TM 
(transmembrane), TAT (trans-activator of transcription), ψ (packaging signal), PBS (primer-binding site for 
tRNA3 (Lys)), RRE (rev response element), PPT (polypurine tract). (B) Schematic representation of the 
HIV-1 virus particle.  
 
The HIV-1 virion is about 100 nm in size and contains two copies of the positive-
stranded RNA genome. RNA and RT are enclosed and protected by the core NC 
protein that in turn is surrounded by the conical shaped CA, which also encloses PR 
and IN enzymes. The viral CA on the other hand is surrounded by the MA protein, 
which is connected to the envelope formed from the host cell’s lipid bilayer membrane 
(see Figure 1-2B) (reviewed by (Sundquist and Kräusslich, 2012)). 
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1.3 HIV-1 replication cycle 
The HIV replication cycle can be divided into two parts, the “early” and “late” stages. 
The early stage encompasses virus entry until integration into the host cell genome, 
while the late stage occurs from integration of the provirus until viral release and 
formation of a fully infectious virus particle (see Figure 1-3). 
Briefly, HIV predominantly infects CD4-positive T cells through interactions between 
the viral envelope protein gp120 with cellular CD4 and co-receptors CXC chemokine 
receptor type 4 (CXCR4) or CC chemokine receptor type 5 (CCR5), leading to 
membrane fusion-mediated by gp41, which induces release of the viral core into the 
cytoplasm. The core protects the two copies of single-stranded positive sense RNA 
genomes, tRNA primers and the viral enzymes IN, PR and RT. Once in the cytoplasm 
the reverse transcription complex (RTC) mediates reverse transcription of the viral 
RNA genome into double-stranded cDNA. This results in the formation of the pre-
integration complex (PIC), which contains matrix protein p17 and/or capsid protein p24, 
linear double-stranded DNA, viral IN, RT, accessory protein Vpr and a number of host 
cell-derived proteins. The virus uses microtubules for retrograde transport, which is 
dependent on dynein to position itself at the nuclear pore. The pre-integration complex 
initiates transport into the nucleus followed by integration into the host cell genome 
through the activity of the host chromatin-binding protein lens epithelium-derived 
growth factor (LEDGF), or formation of LTR-containing double stranded DNA circles 
(reviewed by (Coiras et al., 2009) and (Engelman and Cherepanov, 2012)). 
Transcription is regulated by the recruitment of host cell transcription factors nuclear 
factor-κB (NF-κB) and specificity protein 1 (SP1) that initiate the recruitment and 
binding of the host RNA polymerase II (RNA Pol II) to the TATA box, located at the 5’ 
LTR, to initiate mRNA transcription. Through the formation of secondary RNA structure, 
transcription forms the trans-activation response element (TAR) that is used by the viral 
Tat protein to ensure efficient elongation by recruiting the positive transcription 
elongation factor b (P-TEFb). Viral mRNA is processed by the viral Rev protein, which 
also regulates nuclear export of spliced mRNA. HIV proteins are then synthesised and 
processed in the cellular cytoplasm. Subsequently, HIV-1 virions assemble at the host 
cell plasma membrane, which is followed by budding and maturation of virus particles 







Figure 1-3 The HIV-1 replication cycle 
Schematic representation of the HIV-1 replication cycle. (Step 1) The viral replication cycle begins with 
binding of the viral Env coat protein to the cellular CD4 receptor and the co-receptor CCR5 (or CXCR4 not 
indicated). (Step 2) Binding leads to fusion of the virion membrane with the host membrane and entry of 
the viral core into the cytoplasm. (Step 3 and 4) The viral core is uncoated which leads to reverse 
transcription of the viral RNA into DNA. (Step 5) Formation of the pre-integration complex (PIC) leads to 
nuclear import. (Step 6) The viral enzyme integrase mediates formation of the integrated provirus into the 
host genome with the help of the host chromatin-binding protein lens epithelium-derived growth factor 
(LEDGF). (Step 7) Proviral transcription is mediated by host RNA polymerase II (RNA Pol II) and positive 
transcription elongation factor b (P-TEFb), resulting in viral mRNAs of different sizes. (Step 8) Large viral 
mRNAs require energy mediated nuclear export by host protein Crm1. (Step 9) Viral mRNA serves as 
template for protein translation. (Step 10) Viral proteins and full length genomic RNA is packaged into 
virus particle at the host cell membrane. (Step 11) Budding of the virus is mediated by interaction of Gag 
with the ESCRT abscission machinery. (Step 12) Viral release. (Step 13) Maturation of virion into a fully 
infectious virus particle by viral protease. HIV restriction factor TRIM5, APOBEC3G, SAMHD1 and tetherin 
(boxed in blue) that act at various stages in the viral lifecycle are indicated. Antiretroviral small molecule 
inhibitors are indicated (boxed in white) at their site of action. Abbreviations: nucleoside reverse 
transcriptase inhibitor (NRTI), non-nucleoside reverse transcriptase inhibitor (NNRTI), integrase strand 






1.3.1 Host cell binding and virus entry 
The first step in the HIV-1 replication cycle is cell attachment and entry into the host 
cell. This mechanism plays an important role in determining viral tropism and the ability 
of HIV to destroy the host immune system. Even before the actual discovery of the HIV 
virus, Gottlieb and colleagues reported the decline in CD4-positive T cells in four male 
homosexual patients who presented with unusual opportunistic infections. A few years 
after the initial observation it was demonstrated that HIV preferentially infects CD4-
positive T cells (Dalgleish et al., 1984) (Klatzmann et al., 1984), that CD4 was able to 
bind to the viral Env protein in co-immunoprecipitation studies (McDougal et al., 1986), 
and that non-permissive cells could be infected by exogenous expression of CD4 
(Maddon et al., 1986).   
First, the HIV particle attaches to the host cell membrane, a process that is relatively 
nonspecific. The viral envelope protein itself or a host transmembrane protein within 
the virus particle membrane can mediate binding to target cell attachment factors. 
Attachment factors for the viral envelope protein include the negatively charged heparin 
sulphate proteoglycans (Saphire et al., 2001) or the α4β7 integrin, resulting in a more 
specific interaction (Arthos et al., 2008) (Cicala et al., 2009). Nonetheless, attachment 
factors are not essential for viral replication and their role in vivo remains unclear.  
The first essential step of virus entry is the binding of the viral Env protein to CD4, its 
initial host receptor (Kwong et al., 1998). CD4 is a member of the immunoglobulin 
superfamily and its physiological role is to enhance T cell receptor (TCR)-mediated 
signalling. The HIV envelope spike is made up of trimers of surface glycoprotein gp120 
and transmembrane glycoprotein gp41 that form non-covalently linked heterodimers. 
The surface gp120 protein subunit is made up of five relatively conserved domains 
(C1-C5) and five variable regions (V1-V5); where the first four variable regions form 
loops that contain disulphide bonds at their bases. Variable regions, especially V3, play 
a major role in immune evasion and co-receptor binding. Upon binding of Env to CD4 a 
conformational rearrangement of the variable loops V1/V2 and consequently V3 
occurs, leading to the formation of the bridging sheet (Kwong et al., 1998) that allows 
co-receptor binding.       
HIV and related viruses have been shown to engage different chemokine receptors, 
predominately CCR5 (viruses using this receptor are termed R5 tropic) or CXCR4 
(viruses using this receptor are termed X4 tropic), but, some viruses can use both co-
receptors (termed R5X4 tropic). Co-receptor binding to gp120 leads to the insertion of 
the hydrophobic fusion peptide, located at the amino terminus of transmembrane gp41 




Insertion of the fusion peptide into the host cell membrane effectively crosslinks viral 
and host membranes. This initiates folding of each gp41 subunit, bringing the amino 
terminal helical region (N-HR) and the carboxyl terminal helical region (C-HR) of gp41 
together, which results in the formation of a six-helix bundle (6HB) (Chan et al., 1997). 
Formation of the 6HB brings the two membranes into close proximity, resulting in the 
formation of a fusion pore and release of the viral core into the host cell cytoplasm 
(reviewed by (Wilen et al., 2012) and (Melikyan, 2008)).  
After the entry mechanism had been solved successfully, research concentrated on the 
movement of viral particles to sites where efficient entry can occur. HIV virions are 
thought to travel along the surface of target cells, hijacking cellular transport 
machineries to reach specific destinations that make entry more effective. For example, 
some viruses, including HIV, have been shown to travel from distant attachment sites 
to regions of the cell body in close proximity to the nucleus, where virus entry is thought 
to be most efficient (Lehmann et al., 2005) (Sherer et al., 2010).  
 
 
Figure 1-4 Mechanism of HIV-1 entry 
Schematic representation of HIV entry. (1) HIV-1 Env is made up of gp120 (SU) that contains variable 
loops and gp41 (TM). (2) The gp120 protein binds to host membrane protein CD4, initiating a 
conformational change in Env. (3) This allows co-receptor binding which is facilitated by the variable loop 3 
region and insertion of the gp41 fusion peptide into the host membrane. (4) Formation of the six-helix 




1.3.2 Reverse transcription  
Once the particle has fused with the target cell membrane and released its viral core 
into the cytoplasm, the single stranded RNA (ssRNA) genome serves as a template for 
the formation of double stranded DNA (dsDNA). Once integrated into the host 
chromosome, the viral dsDNA is translated into mRNAs coding for viral proteins and 
full-length single stranded RNA HIV genome, which together form new HIV particles. In 
1975, Howard Temin and David Baltimore received the Nobel Prize in Physiology and 
Medicine for their discovery of a specific enzyme in RNA tumour viruses that could 
make DNA out of an RNA copy; this enzyme was later termed reverse transcriptase 
(RT). The transcription of viral ssRNA into dsDNA is a common feature for all 
retroviruses and is mediated by the virally encoded enzyme RT in combination with 
cellular factors. RT has been the subject of extensive study and is a major target for 
anti-retroviral therapy; the first anti-HIV drug approved was AZT which targets RT 
(reviewed by (Hu and Hughes, 2012)).  
RT is produced from the Gag-Pol polyprotein through cleavage by the viral enzyme PR. 
The active HIV-1 RT enzyme forms a heterodimer composed of two related subunits: 
p66 and p51, derived by cleavage of p66 between Phe440 and Tyr441 by PR. The p66 
subunit contains both DNA polymerase and RNase H activities (reviewed by (Hu and 
Hughes, 2012) and (Le Grice, 2012)). The DNA polymerase domain is composed of 
subdomains that are analogous to a human right hand, containing fingers, palm and a 
thumb that are connected by subdomains (Kohlstaedt et al., 1992). The same four 
subdomains in the p55 subunit are folded differently, providing a structural support for 
the p66 catalytic subunit during tRNA-primed initiation of RT (reviewed by (Le Grice, 
2012)).  
The mechanism of conversion of the viral ssRNA genome into integration-competent 
linear dsDNA is well understood, as only purified RT and the HIV RNA genome are 
required for successful DNA synthesis in vitro. However, the mechanism that mediates 
viral replication is more complicated and involves both cellular and viral elements. The 
separable steps of HIV DNA synthesis by RT are summarised in a simplified, 
schematic diagram in Figure 1-5.  
To initiate the reverse transcription process, the host cellular-derived tRNA3 (Lys), 
which is packaged in the virus, whose 3’ end (18 nucleotides) is complementary to the 
primer-binding site (PBS) near the 5’ end of the RNA genome, hybridises to the PBS. 
DNA is then synthesised by RT, creating an RNA-DNA duplex that is targeted for 
degradation by the RNase H activity of RT, exposing the newly formed minus strand 




direct repeats, called R. The 3’ R repeat serves as binding site for the minus strand 
DNA. After transfer of this strand, synthesis of minus-stranded DNA continues along 
the entire length of the genomic RNA template, while RNase H degrades the positive-
stranded RNA. There are two purine-rich sequences in the HIV genome, polypurine 
tracts (PPT), where the RNA cannot be degraded by RNase H and serve as primers for 
the initiation of positive strand DNA synthesis. However, only the 3’ PPT and not the 
central PPT is essential for viral replication. Positive DNA synthesis along the minus 
strand DNA also leads to the synthesis of the first 18 nucleotides of the transfer (tRNA) 
Lys3 primer, which is followed by the cleavage of the tRNA one nucleotide away from 
the 3’ terminus, resulting in a single A ribonucleotide appendix. Once the DNA 
synthesis of the minus-stranded DNA is completed, a second plus strand DNA transfer 
occurs, in which the PBS from the 3’ end anneals to the PBS at the 5’ end and DNA 
synthesis continues on both DNA strands until it is completed, resulting in the synthesis 
of the complete double-stranded linear viral DNA (reviewed by (Hu and Hughes, 2012) 
and (Le Grice, 2012)).            
Where and when reverse transcription is initiated in vivo has been a matter of debate 
for some time. Some evidence suggests that reverse transcription starts in producer 
cells through initiation by a small number of nucleotides before the virus particle infects 
its target cell (Whitcomb et al., 1990). However, the entire double strand DNA synthesis 
cannot take place in virions due to a limited supply of dNTPs (deoxynucleotide 
triphosphates) (Lori et al., 1992) (Trono, 1992). Therefore, it is commonly accepted that 
most of the DNA synthesis takes place in newly infected cells during early stages of the 
viral replication cycle. DNA synthesis in vivo occurs in the reverse transcription 
complex (RTC) that contains MA, CA, NC, IN and the viral accessory protein Vpr 
(reviewed by (Hu and Hughes, 2012)). The RTC is the target for cellular restriction 
factors that are discussed in section 1.5, and the role of Vpr in section 1.5.4.  CA and 
IN proteins provide the structural stability of the RTC. CA might also play a role in 
transport of the RTC along microtubules to the nuclear pore and in nuclear import 
(Dismuke and Aiken, 2006) (Lee et al., 2010). The NC protein has been shown to 
possess nucleic acid chaperone activity, is thought to help RT to overcome secondary 
structures and assists during the strand transfer process (reviewed by (Hu and 
Hughes, 2012)).  
The structure of the RTC has not yet been solved and the mechanism behind 
uncoating has been a matter debate. One hypothesis is that uncoating occurs 
continuously, while the RTC complex changes and DNA synthesis takes place until the 
PIC has been formed (Forshey et al., 2002) (reviewed by (Craigie and Bushman, 




been completed, providing a confined environment for the RT reaction to take place in. 
This would direct the RTC towards the nuclear compartment by moving along the 
microtubule network until the pre-integration complex (PIC) has been formed and 
penetrated the nuclear membrane (reviewed by (Arhel, 2010)). 
 
 
Figure 1-5 Mechanism of conversion of viral single-stranded RNA to double stranded DNA  
Simplified schematic representation of the HIV reverse transcription mechanism. (1) Reverse transcription 
is initiated by annealing of the tRNA3 (LYS) primer to the 18 nucleotide overlapping PBS site near the 5’ 
end of the viral positive-strand RNA. Reverse transcriptase starts to catalyse synthesis of negative-strand 
DNA. (2) RNase H activity of RT degrades the positive ssRNA that has been reverse transcribed. (3) 
Minus-strand transfer. (4) Elongation of the minus-strand DNA and positive-strand RNA degradation by 
RNase H resume. The PPT region cannot be degraded by RNase H, and serves as a primer to initiate 
plus-strand DNA synthesis. (5) RT copies the u3, u5 and r regions of the minus-strand DNA, including the 
tRNA3 (Lys) primer and therefor reconstituting the PBS. (6) PPT primers and tRNA3 (Lys) removal by 
RNase H. (7) Plus-strand transfer and circularisation of the two DNA strands. (8) Minus- and plus-strand 
DNA elongation, resulting in a linear dsDNA with a long terminal repeat (LTR) at each end. Viral genomic 
RNA is shown in red, minus-stranded DNA in blue, plus-strand DNA is shown in green. The tRNA3 (Lys) 
primer is represented in orange and attached to a ‘clover-leaf’. Short red rectangles represent fragments 




1.3.3 Nuclear entry and integration 
Once reverse transcription is completed, the linear double-stranded viral DNA 
associates with IN, and other viral and cellular proteins to form the pre-integration 
complex (PIC). Lentiviruses are able to replicate in non-dividing cells, which is 
dependent on the CA protein (Yamashita and Emerman, 2004). Therefore the PIC 
must be transported through nuclear pores into the nucleus using an active form of 
transport. However, the exact mechanism is still unclear. Viral components involved in 
nuclear import have been subject to much debate (reviewed by (Fassati, 2012)). Viral 
proteins RT, MA, NC and Vpr can be found in PICs in addition to viral DNA and IN. 
However, none of these proteins was shown to play a specific role in nuclear entry. 
Cellular proteins can also be packed into PICs or bind to CA directly. Cellular 
components associated with PICs include LEDGF, which stimulates targeted 
integration into the host chromosome; high-mobility group protein A1 (HMGA1), which 
stimulates IN activity; and barrier to auto-integration factor (BAF) a suppressor of auto-
integration (reviewed by (Fassati, 2012) and (Craigie and Bushman, 2012)). Since both 
viral and cellular proteins have been described to play a role in active nuclear import, 
nuclear import mechanisms might be redundant, or viruses might be are able to hijack 
different nuclear import pathways. 
Several genome-wide siRNA screens have been performed to identify cellular genes 
that are important for viral replication (Brass et al., 2008) (König et al., 2008). These 
have identified transportin 3 (TNPO3) and nucleoporins (Nup) 358 and 153 as 
important for nuclear entry and integration. TNPO3 is a member of the importin β family 
that serve as nuclear import and export receptors, of which the direction is determined 
by interaction with RanGTP. TNPO3 mainly affects post-nuclear import steps, and as 
such is thought to bind to CA and to mediate its nuclear export (Zhou et al., 2011) (De 
Iaco and Luban, 2011). Nup358 is part of the NPC and contains a Cyp-domain and 
forms long filaments that protrude into the cytoplasm. The HIV-1 CA protein has been 
shown to bind the Cyp-domain of Nup358, and Nup358 knockdown results in HIV 
nuclear import defects (Schaller et al., 2011). Furthermore, the capsid mutant N74, 
selected by passaging HIV-1 in the presence of dominant negative form of the splicing 
factor CPSF6, determined the ability of CA to use TNPO3, Nup153 and to some extent 
Nup358 for nuclear import (Lee et al., 2012). However, knockdown of Nup153 had an 
evident effect on integration and only a small effect on nuclear import (Matreyek and 
Engelman, 2011). Nonetheless, the N74 CA mutant is thought to induce premature 
uncoating, making it unable to interact with Nup153, TNPO3 and Nup358 (reviewed by 
(Fassati, 2012)). Furthermore, recent data demonstrated that the N74 CA mutant 




innate signalling cascade, suggesting that CPSF6/CA binding is required to cloak HIV 
replication and to allow evasion of innate immune sensors (Rasaiyaah et al., 2013). 
Once inside the nucleus, the viral enzyme IN mediates integration (Figure 1-6) into the 
host DNA genome. The HIV-1 IN protein is encoded by the Gag-Pol polyprotein and is 
generated during virion maturation by cleavage of Gag-Pol, which is catalysed by HIV 
PR. IN is made up of three structural domains: the amino-terminal domain (NTD), the 
catalytic core domain (CCD) and the carboxyl-terminal domain (CTD) (reviewed by 
(Craigie and Bushman, 2012)).  
During the mechanism of integration, IN removes nucleotides from the 3’ end of the 
viral linear dsDNA in order to generate reactive 3′-hydroxyl groups at both ends. The 3′-
hydroxyl ends of the viral DNA will then ligate to the host DNA by binding to a pair of 
phosphodiester bonds, which are located on different host cell DNA strands, 5 
nucleotides apart from each other. This step results in integration intermediates. 
Completion of integration requires trimming of the last two nucleotides of the 5’ viral 
DNA end and extension from the 3’ end of the genomic DNA. The identity of the 
cellular enzymes required for these processes is still unknown (reviewed by (Craigie 
and Bushman, 2012)).      
With genome-wide high-throughput sequencing becoming broadly available, HIV 
integration sites have been studied in many different acutely infected cell types, 
demonstrating that the HIV-1 provirus preferably integrates in active transcription units 
that are favourable for efficient transcription (Schröder et al., 2002) (Mitchell et al., 
2004) (Wang et al., 2007). It is possible that cellular host proteins, such as the cellular 
transcription factor LEDGF, play an important role in the selection of integration sites 
within transcribing genes. LEDGF was first identified as a cellular protein that was able 
to bind tightly to HIV IN using an affinity-based screen (Cherepanov et al., 2003). 
LEDGF localises to the nucleus and contains a chromatin binding domain, an A/T hook 
important for DNA binding, and a carboxyl-terminal domain that is responsible for IN 
interaction (reviewed by (Craigie and Bushman, 2012)). Only a complete depletion of 
LEDGF results in a decrease of infectivity caused by inhibition of selective integration, 
as even minute levels of LEDGF can promote integration (Llano et al., 2006). The 
model for LEDGF-mediated HIV-1 integration is that LEDGF binding to IN tethers the 
PICs to chromatin at active transcription units, directing integration to a nearby 






Figure 1-6 HIV-1 provirus integration into target cell chromosome  
Schematic representation of the HIV-1 provirus integration process. (A) HIV-1 proviral dsDNA. (B) IN 
catalyses 3’ terminus processing, generating reactive 3′-hydroxyl groups at both ends of the viral DNA. (C) 
Strand transfer is mediated by the two 3′-hydroxyl viral DNA ends ligating with the host DNA. (D) Strand 
transfer results in a five-base, single-stranded gap and a two-base overhang at the 5′-ends of the viral 





























1.3.4 Transcription and nuclear export 
After integration into the host cell genome, the HIV-1 provirus acts like a host gene. 
Viral mRNA transcription is initiated at the 5’ LTR, which contains DNA regulatory 
elements that serve as binding sites for cellular transcription factors. 
The core LTR promoter acts as an extremely efficient transcription initiator and 
contains several distal (upstream) DNA regulatory elements which mediate binding to 
cellular transcription initiation factors (Rittner et al., 1995). The core of the LTR 
promoter is optimally designed for cooperative binding of cellular transcription elements 
and is comprised of three tandem SP1 binding sites (Jones et al., 1986), a TATA box 
(Garcia et al., 1989) and a highly active initiator (INR) sequence (Zenzie-Gregory et al., 
1993). The additional non-core promoter elements include the transactivation-response 
region (TAR) and an enhancer region that includes two NF-κB binding motifs (Nabel 
and Baltimore, 1987), that can interact with both the NF-κB family (Liu et al., 1992) and 
nuclear factor of activated T cells (NFAT) (Kinoshita et al., 1998), coupling transcription 
to T cell activation. Furthermore, core promoter elements are important for the binding 
of multiple subunit transcription factor complexes that contain DNA-helicase and CTD-
kinase activities.  
During transcription initiation, RNA polymerase II (RNAP II) is recruited to the 5’ LTR by 
transcription factors IID and IIH (TFIID and TFIIH respectively), as well as the co-factor 
TBP-associated factor (TAF) (Figure 1-7). RNAP II then clears the promoter and starts 
transcribing along the viral genome. Cyclin-dependent kinase 7 (CDK7) is part of the 
TFIIH complex and mediates partial phosphorylation of the carboxyl-terminal domain of 
RNAP II. The partially phosphorylated RNAP II pauses at the transactivation response 
element (TAR) that forms a highly stable RNA stem-loop. Binding of the negative 
elongation factor (NELF), which contains an RNA-recognition motif to the stem in TAR, 
and recruitment of DRB sensitivity-inducing factor (DSIF), ensures that RNAP II does 
not elongate further (reviewed by (Karn and Stoltzfus, 2012) and (Yankulov and 
Bentley, 1998)). Next, a larger complex is formed that includes elongation factors such 
as ELL2, which enhances transcription elongation by preventing RNAP II backtracking.  
Although the viral LTR promoter can initiate transcription efficiently, it fails to promote 
elongation of transcripts due to the low processing capacity of RNAP II. Therefore, in 
the absence of the viral transcription activator Tat, most viral transcripts terminate 
prematurely at different positions throughout the proviral genome. The role of Tat is to 
stimulate RNAP II processivity by causing an increase of transcripts that extend until 
the 3′ end of the provirus. To this end, Sodroski and co-workers were the first to 




Tat. Deletion studies of the LTR revealed that Tat function requires TAR (Sodroski et 
al., 1985a) (Sodroski et al., 1985b). Furthermore, Tat recognises TAR as an RNA 
element and recruits components of the positive acting elongation factor (P-TEFb) 
complex. This P-TEFb complex contains the cyclin T1 (CycT1) component that 
enhances Tat binding to TAR and also recruits the cyclin-dependent kinase 9 (CDK9) 
to form a stable complex (Marshall et al., 1996) (Wei et al., 1998). After the recruitment 
of the P-TEFb complex, CDK9 mediates phosphorylation of the elongation suppressor 
Spt5 in DSIF, converting it into a positive elongation factor, and of NELF, which 
subsequently dissociates from TAR. CDK9 also completes the phosphorylation of the 
CTD of RNAP II, thereby modifying RNAP II so that it can bind elongation factors, such 
as capping enzymes, splicing apparatus and polyadenylation factors, to mediate 
efficient elongation and viral replication (reviewed by (Karn and Stoltzfus, 2012)and 
(Yankulov and Bentley, 1998)).      
 
 
Figure 1-7 HIV-1 transactivation by Tat 
Initiation: RNAP II is recruited to the 5’ LTR by TFIID, TFIIH and cofactor TAF. The CDK7 subunit of 
TFIIH mediates phosphorylation of the CTD of RNAP II and elongation is initiated. Pausing: After 
transcription through the TAR element, NELF and DSIF are recruited to the elongation complex and 
interaction with TAR pauses elongation. Elongation: Tat/P-TEFb bind the TAR element and CDK9 
induces phosphorylation of NELF that leads to its release, and phosphorylation of Spt5 and RNAP II, 






Once transcribed, viral pre-mRNA has to be processed by a large complex of cellular 
factors referred to as the spliceosome, to ensure production of the full range of mRNAs 
needed to encode all viral proteins. The spliceosome is a large macromolecular 
complex that contains more than 150 proteins and 5 small nuclear ribonucleoproteins 
(snRNPs) (U1, U2, U4/U6 ad U5). It removes introns and joins the exons of pre-mRNA, 
creating an obstacle for HIV-1 because most HIV proteins are translated from 
incompletely spliced or unspliced transcripts (reviewed by (Karn and Stoltzfus, 2012)). 
Upon infection, HIV first produces fully spliced ~1.8 kb messenger RNAs (mRNAs) 
encoding Tat, Rev and Nef proteins, followed by longer ~4 kb unspliced mRNAs 
encoding Env and viral accessory proteins Vif, Vpr and Vpu, and full-length transcripts 
that serve as genomic HIV RNA and templates for the Gag-Pol polyprotein (Kim et al., 
1989) (Pomerantz et al., 1990). The role of Rev is to protect incompletely spliced and 
unspliced transcripts from degradation by mediating their nuclear export, achieved 
through interaction with the Rev-responsive element (RRE), a highly structural RNA 
element in the HIV env gene (Sodroski et al., 1986) (Malim et al., 1989) (Figure 1-8).  
 
 
Figure 1-8 HIV-1 mRNA splicing 
(A) Early phase of mRNA expression: Only the completely spliced ~1.8 kb mRNA encoding Tat, Rev and 
Nef is exported into the cytoplasm by the normal nuclear export cellular pathway and translated. The 
unspliced ~9 kb and incompletely spliced ~4 kb mRNAs are retained in the nucleus where they undergo 
splicing or degradation. (B) Late phase of mRNA expression: When Rev concentrations in the nucleus 
exceed a threshold, Rev binds to the Rev-responsive element (RRE) in the env gene to mediate export to 





Rev is a 19 kDa phosphoprotein that contains three distinct domains. An arginine-rich 
motif at the N-terminus serves as a nuclear localisation signal (NLS) that is responsible 
for Rev’s nuclear localisation as well as interaction with the RNA stem loop of the RRE. 
An N-terminal nuclear inhibitory signal (NIS) maintains Rev distribution and activity, 
and a C-terminal leucine rich sequence serves as nuclear export signal (NES) that 
interacts with cellular proteins needed for export of viral mRNA, termed the active 
domain (reviewed by (Suhasini and Reddy, 2009)). Rev-mediated viral mRNA nuclear 
export (Figure 1-9) requires binding to the RRE, followed by cooperative binding of up 
to 12 additional molecules of Rev. Transport of HIV mRNA into the cytoplasm requires 
nuclear pore complexes (NPC), and cellular proteins Crm1 and importin-β. Crm1 
interacts with the NES of mRNA-bound Rev in the presence of the GTP-bound form of 
Ran GTPase (Ran-GTP), bridging Rev to the NPC, which is followed by crossing of the 
nuclear membrane into the cytosol. The dissociation of Crm1 and Rev/RRE complexes 
in the cytoplasm requires hydrolysis of Ran-GTP to Ran-GDP, which is mediated by 
RanGAP1 and RanBP1, causing Crm1 to be released and to return to the nucleus. The 
NLS in Rev binds directly to the nuclear import factor, importin-β, and Ran-GDP, which 
mediates the release of the RRE RNA and mediates Rev transport back into the 
nucleus through the nuclear pore. Once inside the nucleus Ran-GDP is converted into 
Ran-GTP, which causes Rev to dissociate from importin-β, which returns to the 
cytoplasm to be imported again, while Rev is able to interact with the next RRE to 
repeat the transport cycle. This constant shuttling of host and viral factors in and out of 
the nucleus is efficient, requiring only small amounts of Rev (reviewed by (Suhasini and 








Figure 1-9 Rev-mediated nuclear export of viral mRNA 
Rev binds unspliced or incompletely spliced mRNA transcripts through RRE and interacts with Crm1. This 
complex crosses the nuclear membrane by interaction with nuclear pore proteins. In the cytoplasm, Ran-
GTP is converted into Ran-GDP leading to the release of Rev, Crm1 and viral mRNA. Crm1 is transported 
back into the nucleus and Rev binds to importin-β together with Ran-GDP to facilitate transport back into 
the nucleus. Once in the nucleus Ran-GDP is converted into Ran-GTP and Rev is released to initiate 




1.3.5 Protein translation and viral assembly 
HIV-1 protein synthesis relies on the host cell translation machinery to provide 
ribosomes, tRNAs, amino acids, and initiation, elongation and termination factors. As a 
product of the cellular RNAP II, the 9.5 kb HIV-1 genomic RNA and all subgenomic 
mRNAs harbour a 7-methyl-guanosine cap at its 5’ end and a poly(A) tail at its 3’ 
terminus. Following nuclear export the genomic RNA is translated on free ribosomes in 
the cytoplasm of infected host cells to produce viral proteins.  
HIV protein synthesis as for eukaryotic protein synthesis, may be divided into four 
separate phases: (1) the first phase incudes the recruitment of the small charged 43S 
ribosomal complex to viral mRNA, followed by scanning until it localises to an initiator 
AUG codon with an appropriate Kozak sequence; (2) the 60S ribosomal subunit joins 
the complex to form the 80S ribosomal complex, proceeding to elongation wherein the 
mRNA is decoded by the ribosomes that assemble the appropriate amino acids to 
synthesise the viral proteins; (3) once the ribosome reaches a termination codon it  
releases the nascent polypeptides; (4) finally, the ribosome is recycled for the next 
round of translation (reviewed by (de Breyne et al., 2013)).  
Translation initiation is the rate-limiting step in protein synthesis. It involves multiple 
eukaryotic initiation factors (eIFs) and other proteins that control recruitment of the 
ribosome, and requires scanning until it localises the authentic AUG start codon. The 
HIV-1 exon 1 contains multiple highly structured regions and some upstream AUG 
sequences that interfere with translation initiation. Furthermore, HIV-1 env mRNAs are 
bicistronic and contain an overlapping upstream vpu open reading frame. To overcome 
these impediments two molecular mechanisms have been described, 5’ cap-dependent 
translation initiation and internal ribosome entry sites (IRES). These circumvent 
inhibition of scanning ribosomes by the complex 5' UTR structure (reviewed by (de 
Breyne et al., 2013)). Posttranscriptional control elements (PCEs) that bind to cellular 
RNA binding proteins can also act as enhancers, facilitating translation initiation. For 
example, translation can be enhanced by the DEIH helicase RHA (Bolinger et al., 
2010) as well as by the RNA binding proteins SRp40 and SRp55 (Swanson et al., 
2010). Another mechanism that facilitates env/vpu translation is 5’ cap-dependent 
ribosome shunting in which the ribosome jumps over large regions of mRNA to locate 
an AUG initiation codon (Krummheuer et al., 2007). To ensure translation of all viral 
proteins, HIV-1, like all other retroviruses, has evolved programmed frameshifting in 
which mRNA reading frames can be changed during translation. For instance, in HIV-1 
the -1 shift in translation is required to shift from the gag to the pro and pol reading 




of the gag termination codon, which occurs approximately 5% of the time (reviewed by 
(Karn and Stoltzfus, 2012)).  
HIV-1 virion assembly occurs at the host cell membrane in specialised micro-domains, 
also called lipid rafts, and is entirely orchestrated by the Gag polyprotein. The roles of 
Gag include packaging of two copies of full length HIV-1 genomic RNA, binding to the 
plasma membrane, incorporating the envelope glycoprotein, and interaction with 
cellular host proteins to mediate formation and release of viral particles (Figure 1-10).  
En route to the plasma membrane, Gag NC is responsible for the binding of two full-
length viral genomic RNA (gRNA) strands that are non-covalently dimerised at their 5’ 
UTR. gRNA binding occurs via two retroviral zinc finger motifs and several clusters of 
basic amino acids in NC and the RNA packaging sequence Ψ located in the 5’ region, 
spanning the major splice donor and the Gag start codon (reviewed by (D’Souza and 
Summers, 2005)). These Gag/gRNA protein complexes then traffic to the plasma 
membrane where they oligomerise and undergo nucleate assembly (Kutluay and 
Bieniasz, 2010). 
HIV-1 Gag and Gag-Pro-Pol polyproteins are synthesised in the host cytoplasm and 
trafficked to the plasma membrane using intracellular vesicle trafficking pathways, but 
the mechanism is still poorly understood. Gag membrane targeting is mediated by its 
MA domain that undergoes N-terminal myristoylation. MA interaction with the plasma 
membrane, by binding to phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2), 
triggers the exposure of the myristoyl group in MA which then, leads to stabilised 
anchoring of Gag to the inner leaflet of the membrane (reviewed by (Martin-Serrano 
and Neil, 2011) and (Sundquist and Kräusslich, 2012)). In the cytoplasm, Gag 
molecules oligomerise poorly but when they reach the plasma membrane in 
association with HIV gRNA, Gag molecules are able to form high-order multimers 
(Kutluay and Bieniasz, 2010). The role of Gag CA domain is to stabilise the formation 
of the immature lattice by Gag protein-protein interactions involving the carboxyl-
terminal domain of CA and the SP1 regions during virus assembly (Forshey et al., 
2002).   
Env proteins are synthesised in the endoplasmic reticulum (ER) and use the cellular 
secretory pathway to reach virus assembly domains at the plasma membrane. Env 
molecules are highly glycosylated, assembled into trimeric complexes and are 
processed by the cellular protease, of the furin family, into the transmembrane (gp41) 
and surface (gp120) domains. At the plasma membrane, Gag MA is also responsible 




approximately 7 to 14 Env trimers per virion (reviewed by (Sundquist and Kräusslich, 
2012)). 
The Gag p6 protein plays a role in recruitment and incorporation of the accessory 
protein Vpr (Kondo et al., 1995) and also contains two late-budding domains that are 
crucial for the recruitment of the endosomal Sorting Complexes Required for Transport 
(ESCRT) scission machinery and subsequent virus particle release (reviewed by 
(Martin-Serrano and Neil, 2011)). 
 
 
Figure 1-10 Overview of HIV-1 assembly and virus release 
Schematic representation illustrating the different stages of HIV-1 assembly, release and maturation. HIV-
1 Gag is synthesised in the host cell cytoplasm. Upon binding of two copies of full length HIV-1 genomic 
RNA, Gag molecules bind to phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2 and oligomerise at the 
plasma membrane. The p6 domain of Gag recruits the ESCRT membrane scission machinery that 
resolves the membrane neck between the cell and the immature virus particle. Gag and Gag-Pol 
polyprotein multimerisation activates the viral protease enzyme that processes Gag into its subunits; 
followed by a conformational change that renders the virion fully infectious (adapted from (Martin-Serrano 





1.3.6 HIV-1 budding and virus release 
The Gag polyprotein orchestrates virion assembly and incorporation of host factors at 
the plasma membrane, and recruits the cellular ESCRT machinery using late-domain 
(L-domain) motifs in HIV-1 p6 in order to terminate Gag multimerisation and to catalyse 
abscission. The ESCRT machinery mediates topologically equivalent membrane 
scission events that include vesicle release into multivesicular bodies (MVBs) and 
membrane scission during cytokinesis (the ESCRT machinery is discussed in detail in 
1.9). L-domains encoded by structural proteins of enveloped viruses are short amino 
acid motifs that are functionally interchangeable and work in a position-independent 
manner. L-domains are able to promote Gag ubiquitination, but proteasome inhibitors 
block L-domain function suggesting that ubiquitin and ubiquitin ligases play an 
important role in retroviral budding. Subsequent discoveries demonstrated that L-
domains recruit the ESCRT machinery to mediate membrane scission events. The 
HIV-1 p6 protein contains two different late-domains, the primary PTAP motif which 
binds to tumour susceptibility gene 101 (TSG101), and the second YPXL motif which 
binds to the ESCRT associated factor ALIX (Figure 1-11) (reviewed by (Martin-Serrano 
and Neil, 2011)).  
The primary P(S/T)AP motif (Pro-Thr/Ser-Ala-Pro) interacts with TSG101 using an 
extended groove on the ubiquitin E2 variant (UEV) domain of TSG101. PTAP domains 
can also be found within the ESCRT-0 component HRS and other related proteins that 
recruit the ESCRT machinery to endosomal membranes (reviewed by (Ren and Hurley, 
2011)). Therefore, HIV-1 p6 mimics the PTAP late domain of a cellular ESCRT-I-
recruiting protein. PTAP-dependent membrane scission requires the recruitment of 
ESCRT-I components VPS28, VPS37 and multivesicular body sorting factor 12 
(MVB12). The mechanisms by which TSG101 and ESCRT-I components recruit the 
core ESCRT-III subunits (namely CHMP2 and CHMP4) and the ATPase VPS4 
complexes is not fully understood, and needs to be answered for a complete 
understanding of HIV-1 budding (Figure 1-11).  
The second late domain in HIV-1 p6 (L)YPXnL (Tyr-Pro-X-Leu, where “X” can vary in 
sequence and length) binds to the ESCRT-associated factor ALIX via a conserved 
hydrophobic groove on arm 2 of the V-domain of ALIX dimers, and is thought to 
support viral budding in different cell types. In a similar manner to the PTAP domains, it 
mimics a host cell derived late domain to recruit ALIX. The recruitment of the core 
ESCRT membrane fission machinery by ALIX is well characterised and occurs through 
interaction of the Bro1 domain of ALIX with the amphipathic C-terminal helices of 
CHMP4. This interaction recruits CHMP2 proteins that in turn bind to the MIT domains 




Furthermore, the Bro1 domain of ALIX is also able to interact with zinc-fingers in the 
NC protein of HIV-1 Gag. However, depletion studies of ALIX using short interfering 
RNA had a minor effect on HIV-1 budding, and other cellular Bro1-containing proteins 
are thought to compensate by providing alternative NC interactions. Possible Bro1-
containing protein candidates that promote virus release by overexpression of their 
respective Bro1 domains include BROX, HDPTP and rhophilin 1 (Popov et al., 2009); 
suggesting that Bro1 domains facilitate virus release through interaction with an 
unknown co-factor/s or by physical interaction with NC. Furthermore, the E3 ubiquitin 
ligase NEDD4-2 interacts with the carboxy-terminal domain of HIV-1 CA but contributes 
only modestly to HIV-1 release, suggesting in turn that NEDD4-mediated ubiquitination 
of Gag might facilitate the p6 L-domain-mediated recruitment of the ESCRT machinery  
(reviewed by (Martin-Serrano and Neil, 2011) and (Sundquist and Kräusslich, 2012)).     
The ESCRT-mediated membrane deformation and abscission events have been an 
area of extensive research, and three different membrane fission models have been 
suggested: the spiral, tube and dome models, of which the dome model is the most 
accepted mechanism of membrane scission. In this model, L-domains in p6 recruit the 
ESCRT-III components CHMP4 and CHMP2 that form spiralling filaments within the 
neck of the budding virion. These filaments spiral inwards and form dome-like 
structures that constrict the opposing membrane stalks and promote abscission.  VPS4 
is recruited to budding virions immediately before pinching off and is thought to 
promote dome structure formation and/or ESCRT-III protein removal to promote virus 
budding (reviewed by (Sundquist and Kräusslich, 2012)). 
 
 





Figure 1-11 Gag-mediated recruitment of cellular host factors required for budding 
The HIV-1 Gag protein encodes two late-budding domains (yellow boxes) that recruit the cellular ESCRT 
machinery through direct interaction with TSG101 (green) and ALIX (red). These ESCRT adaptor proteins 
recruit the core ESCRT‑III machinery and the vacuolar protein sorting‑associated protein 4 (VPS4), to 
mediate virus release. Interactions with Bro1-containing proteins and NEDD4 are also illustrated in this 
figure. Abbreviations: capsid (CA); carboxyl-terminal domain (CTD); matrix (MA); multivesicular body 
sorting factor 12 (MVB12); nucleocapsid (NC); amino-terminal domain (NTD); rhophilin 1 (RHPN1); His 
domain phosphotyrosine phosphatase (HDPTP); BRO1 domain and CAAX motif-containing protein 
(BROX).  
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1.3.7 Virion maturation by the viral protease enzyme 
The last step of the HIV-1 replication cycle is proteolytic maturation which is essential 
to form fully infectious virus particles. HIV-1 virions are released from the host cell as 
non-infectious particles called immature virions. The virus particle then undergoes a 
dramatic conformational rearrangement that begins concomitant with virus budding, 
resulting in a mature and infectious virus particle (Figure 1-12). The structural 
rearrangement is triggered by cleavage of Gag and Gag-Pol polyproteins by the virally 
encoded enzyme PR. Pol is cleaved into viral enzymes PR, RT and IN, while Gag is 
cleaved into the structural proteins: MA, CA, NC, p6 and two spacer peptides (p1 and 
p2) (reviewed by (Sundquist and Kräusslich, 2012)). CA proteins assemble into 
hexamers to form the core structure. Sporadically, CA can associate into pentamers 
causing irregularities in the hexameric organisation, resulting in a cone structure 
(Ganser, 1999) (Briggs et al., 2006) (Ganser-Pornillos et al., 2008).  
The catalytically active form of the aspartic acid protease PR consists of a homodimer 
of two identical subunits that form the substrate-binding pocket at the centre and 
interact with different Gag and Gag-Pol sequences. The initiation mechanism that 
activates PR is currently not well understood, but Gag and Gag-Pol multimerisation 
during budding is required and is thought to allow dimerisation of two PR domains in a 
process called auto-processing (reviewed by (Fun et al., 2012)). Once activated, PR 
recognises the overall shape of cleavage sites in Gag-Pol rather than a specific peptide 
sequence (Prabu-Jeyabalan et al., 2002). Slight differences in the otherwise 
superimposable secondary structure of the cleavage sites results in distinctive affinities 
for PR; as a result the cleavage process is highly regulated and occurs in an ordered 
stepwise process (Wiegers et al., 1998). The in-depth knowledge of HIV-1 protease 
and substrate structures led to the development of protease inhibitors that inhibit 
enzymatic activity and prevent cleavage of Gag and Gag-Pol, resulting in the 
production of immature and non-infectious particles.        
 
Figure 1-12 Virion maturation 
Schematic representation of the organisation of an immature HIV-1 virion (A) and a mature HIV-1 virion 
(B) Indicated in yellow (matrix); orange (capsid); and red (nucleocapsid) (adapted from (Sundquist and 





1.4 Pathogenesis and innate immune responses to HIV-1 infection 
The immune response to HIV consists of an “early” nonspecific innate response, which 
can be seen as a first line of defence to protect the host against the virus without any 
prior exposure. The “late” and highly specific adaptive response consists of humoral 
and T cell-mediated responses (reviewed by (Flint et al., 2009)). This chapter will 
describe the early phase of infection that results in the activation of a complex network 
of innate immune factors, and the corresponding innate immune evasion strategies 
employed by HIV-1.  
HIV-1 is most frequently transmitted by sexual contact across mucosal surfaces of 
genital or rectal tissues. This results in the establishment of a new infection, typically 
starting from one single virus particle that preferentially infects memory T cells 
expressing high levels of CD4 and CCR5, inference of transmitted/founder viruses. The 
infected cells disseminate to lymphoid tissues throughout the body, including the gut-
associated lymphoid tissue (GALT) that contains high numbers of CD4+ T cells. A 
switch in cell tropism occurs with the onset of immunodeficiency, where CXCR4 and 
macrophage-tropic viruses evolve from CCR5 progenitors. However, both of these 
variants are not efficiently transmitted (reviewed by (Coffin and Swanstrom, 2013)).  
During the early phase of HIV infection the innate immune system is activated. This 
comprises inflammatory cytokines, an array of different cell types, the complement 
system and inducible intracellular antiviral proteins. The major cell types critically 
involved in the innate immune response and production of inflammatory factors are 
macrophages, dendritic cells (DCs), neutrophils, natural killer cells (NK cells). Most of 
these cells express various pattern recognition receptors (PRRs) that recognise 
structurally conserved motifs of proteins, carbohydrates or nucleic acids that are unique 
to pathogens and not normally produced in human cells. These exogenous motifs are 
also known as pathogen-associated molecular patterns (PAMPs). The most thoroughly 
characterised PRRs are: toll-like receptors (TLRs), which are present on the cell 
surface or endoplasmic compartments and respond to viral glycoproteins, nucleic acids 
or unmethylated CpG DNA sequences; cytoplasmic (RIG-I)-like receptors (RLRs), 
which recognise long and short 5’ phosphorylated viral dsRNA; and the nucleotide 
oligomerisation domain (NOD)-like receptor (NLRs) family, which detects the presence 
of PAMPs and endogenous molecules in the cytosol. Activation of host receptors by 
viral ligands leads to downstream signalling events that result in the induction of 
specific transcription factors that in turn induce the production of inflammatory 




Plasmacytoid dendritic cells (pDCs) are specialized in the production of high levels of 
IFN-α and are the major source of type I IFNs during the early stages of HIV-1 
infection. pDCs express a range of surface and endocytic PRRs that detect viral 
PAMPs. Several lines of evidence suggest that pDCs sense HIV in a TLR-dependent 
mechanism, particularly by TLR7 and TLR9 (reviewed by (Guha and Ayyavoo, 2013)).  
Infection of T cells and macrophages with HIV-1 does not induce interferon expression. 
This may be due to the presence of the host exonuclease TREX1 (Yan et al., 2010). 
TREX1 induces the degradation of HIV dsDNA and prevents activation of intrinsic 
PRRs. HIV DNA can be sensed in the absence of TREX1 or in the presence of high 
HIV dsDNA concentrations. Excess HIV-1 DNA is sensed by the IFN-inducible protein 
16 (IFI16) (Jakobsen et al., 2013); or is sensed by and activates cyclic guanosine 
monophosphate-adenosine monophosphate (cGAMP) synthase (cGAS) to produce 
cGAMP (Gao et al., 2013). Both DNA sensors activate the adaptor protein stimulator of 
interferon genes (STING) to induce transcription of type I IFNs and other cytokines. 
Other recently identified factors that potentially contribute to the ability of HIV-1 to 
replicate in macrophages without being sensed are: cleavage and polyadenylation 
specificity factor subunit 6 (CPSF6) and cyclophilins (Nup358 and CypA) (Rasaiyaah et 
al., 2013). CPSF6 and CypA bind to the HIV-1 capsid ensuring reverse transcription, 
uncoating and nuclear entry by cloaking replication. Their binding to HIV-1 capsid 
allows immune evasion and blocks innate sensors. However, in the absence of 
CPSF6/CypA and capsid interactions, macrophages are able to activate innate immune 
signals in a TREX1-independent manner. 
NK cells are among the most important innate immune cells involved in the control and 
clearance of virally infected cells and the regulation of adaptive immune responses. 
The inflammatory milieu generated during HIV-1 infection, especially following 
secretion of IFN-α and IL-15, leads to the activation and rapid expansion of NK cells 
(reviewed by (Biron, 1999)). NK cells largely use a family of germ-line encoded 
negative or inhibitory killer immunoglobulin-like receptors (KIR) to monitor MHC class I 
expression on other cells. Many viruses, including HIV-1, downregulate MHC class I 
molecules from the cell surface of infected cells in order to avoid detection by CD8+ T 
cells, which in turn puts the infected cell at risk of triggering NK cell activation. 
However, loss of MHC class I expression on the cell surface of infected cells is not 
sufficient to trigger NK cell-mediated killing. A second activating signal, achieved 
through the recognition of stress-ligands is required to induce destruction of infected 
cells. The HIV-1 accessory protein Nef, for example, can overcome NK cell-mediated 




ligands MIC-A and ULBP-1/2 for the c-type lectin NK-cell (NKG2D) receptor (Cerboni et 
al., 2007) (reviewed by (Carrington and Alter, 2012)).     
Acutely infected HIV-1 patients have high levels of circulating type I IFN (von Sydow et 
al., 1991), which helps to suppress HIV infection and increases the ability of the 
adaptive immune response to recognise and eliminate infected cells. Interferon 
signalling through the Jak-STAT pathway induces the expression of interferon 
stimulatory genes (ISGs) (reviewed by (Stark and Darnell, 2012)), but, only a small 
number of these ISGs have been studied. ISGs with anti-HIV activities are: Trim22 
which interferes with HIV-1 Gag assembly; ISG15, a small ubiquitin like protein, which 
conjugates with HIV Gag also interfering with assembly; and the IFITM proteins which 
block HIV entry (reviewed by (Doehle and Gale, 2012). The most recently 
characterised member of the group is the myxovirus resistance 2 (MX2) protein, which 
inhibits nuclear import or destabilises nuclear HIV-1 DNA (Goujon et al., 2013) (Kane et 
al., 2013) (Liu et al., 2013). Amongst the interferon up-regulated genes are also the 
well-characterised HIV restriction factors: APOBEC3G, tetherin, SAMHD1 and TRIM5α 





1.5 Restriction factors and the role of HIV accessory proteins in 
their evasion  
HIV-1, like all other viruses, hijacks host cellular factors and pathways to complete its 
own life cycle. In addition to proteins that support viral replication, infected cells can 
also express a number of inhibitory or dominantly acting proteins that suppress virus 
replication at various steps.  
The concept of retroviral restriction factors was first proposed when murine leukemia 
virus (MLV) infection was shown to be inhibited by the Friend virus susceptibility factor-
1 (Fv1) gene. Inbred mice encode two different allelic forms of Fv1 (Fv1n and Fv1b). 
Fv1n/n mice are 1000-fold more susceptible to N-tropic MLV than B-tropic MLV strains, 
and vice versa in Fv1b/b animals, which are susceptible to B-tropic MLV. Interestingly, 
heterozygous Fv1n/b cells are resistant to both MLV strains, indicating the presence of a 
dominantly acting restriction factor (Tennant et al., 1974). The Fv1 gene is located on 
the mouse chromosome 4 and resembles an endogenous retrovirus gag-like gene 
(Best et al., 1996). Furthermore, Fv1-restricted MLV tropism is determined by 
sequences within the viral CA. To this end, Fv1 binds to CA and blocks integration of 
the reverse transcribed retroviral pre-integration complex (Hilditch et al., 2011), 
however, the exact mechanism is still not well understood. 
The identification of additional restriction factors in mammalian cells followed soon after 
the discovery of Fv1. HIV restriction factors, identified to date share common 
characteristics: they are able to dominantly inhibit HIV replication; show hallmarks of 
positive selection; their expression is connected to the host cell’s innate immune 
response and is IFN-inducible; and in some cases HIV and its evolutionary 
predecessors have evolved a potent countermeasure (reviewed by (Harris et al., 
2012)). To date, four major HIV restriction factors have been identified that act at 
different stages of the virus replication cycle, namely APOBEC3G, tetherin, TRIM5α 
and SAMHD1 (see Figure 1-3 (blue boxes)).  
Discussed in this section are APOBEC3G, TRIM5α and SAMHD1, together with viral 
countermeasures in the form of HIV accessory proteins. Discussed additionally are the 
roles of HIV-1 Vpr and Nef in virus replication and immune evasion. Tetherin-
dependent virus restriction and Vpu-mediated tetherin antagonism are discussed in 




1.5.1 APOBEC3G and Vif 
Studies to understand the role of the 192 amino acid Vif protein (viral infectivity factor), 
during HIV-1 replication in primary cell types showed that it is dispensable in some T 
cell lines but not in others. Cell fusion experiments of permissive and non-permissive 
cells suggested the presence of a dominant acting restriction factor (Simon et al., 
1998). This phenotype led to the subsequent discovery of apolipoprotein B messenger 
RNA (mRNA)-editing enzyme catalytic polypeptide-like 3 (APOBEC3G also known as 
A3G or CEM15) using a cDNA subtraction-based screen (Sheehy et al., 2002). 
Importantly, the same group also demonstrated that expression of APOBEC3G in 
permissive T cells was sufficient to render these cells restrictive for viral replication of 
Vif-deficient HIV-1 (Sheehy et al., 2002).  
APOBEC3G is a member of a protein family that possess cytidine deaminase activity, 
which are expressed in a wide variety of human tissues (in particular in hematopoietic 
cells) and can be transcriptionally induced by type 1 IFN (Koning et al., 2009). All 
members of the APOBEC3 family contain at least one copy of a zinc-coordinating 
deaminase domain (Z domain). APOBEC3G contains two such domains, where the C-
terminal Z domain possesses deamination activity, while the non-catalytically active N-
terminal Z domain mediates interaction with the NC region of Gag, which is required for 
APOBEC3G incorporation into viral particles in the absence of Vif. APOBEC3G is 
packaged into nascent virions by association with NC and viral RNA (Zennou et al., 
2004). In the target cell, APOBEC3G associates with the RTC in infected target cells, 
where it deaminates cytidine residues in single-stranded negative strand viral cDNA, 
resulting in the production of deoxyuridine that is misread by RT as thymidine. This 
results in the insertion of adenine instead of guanine in the positive strand. APOBEC3G 
has a strong intrinsic preference for deaminating 5’-CCCA cytidine residues (the 
underlined cytidine is target for deamination) (reviewed by (Malim and Bieniasz, 2012) 
and (Harris et al., 2012)). Hypermutations are not the only function of APOBEC3G 
associated with anti-viral activity, as levels of viral cDNA that accumulate during 
infection are also reduced. This was initially thought to be a result of uridine-containing 
DNA degradation induced by cellular host DNA repair mechanisms. However, inhibition 
of uracil DNA glycosidases had no effect on cDNA levels. Instead, it is now thought that 
APOBEC3G impedes translocation of viral RT along its RNA template (Bishop et al., 
2006) (Gillick et al., 2013), but further experimental evidence is needed to fully explain 
this observation (reviewed by (Malim and Bieniasz, 2012)).  
Expression of Vif enables HIV-1 to overcome the antiviral activities of APOBEC3G by 
inducing its degradation, thus preventing its incorporation into nascent virions. Vif binds 




ubiquitin ligase complex CRL5. This complex consists of cullin5, elongin B and C, Rbx2 
and a to date unidentified E2 conjugating enzyme. This in turn results in poly-
ubiquitination and proteasomal degradation of APOBEC3G (see Figure 1-13) (reviewed 
by(Malim and Bieniasz, 2012)). Furthermore, Vif-induced degradation of APOBEC3G 
was found to involve the cellular transcription factor CBFβ (Jäger et al., 2012). 
Recently, one study demonstrated that direct binding of CBFβ to Vif-CRL5 enhances 
catalytic activity, blocks Vif oligomerisation, and promotes formation of a well-ordered 
Vif E3 ligase complex (Kim et al., 2013).  
In addition to APOBEC3G, other members of the APOBEC3 family have been shown 
to possess antiviral activity, namely APOBEC3F (A3F), APOBEC3H (A3H) and 
APOBEC3D (A3D). All four APOBEC3 proteins share common characteristics: they are 
expressed in CD4+ T cells, packaged into virus particles, possess antiviral activity, are 
able to induce G to A mutations, and are sensitive to HIV-1 Vif. However, 
APOBEC3F/H and D cause 5’-TC deamination rather than 5’-CC and are expressed at 
lower levels than APOBEC3G, indicating that A3G is the most significant family 
member as HIV restriction factor (reviewed by (Malim and Bieniasz, 2012) and (Harris 







Figure 1-13 Mechanism of HIV-1 restriction by APOBEC3 proteins 
Schematic representation of APOBEC3 inhibition of HIV-1 infection and Vif antagonism. APOBEC3 
molecules can encapsidate into Vif-deficient HIV virions (left) and infect a target cell (right). In the target 
cell, APOBEC3 molecules associate with the reverse transcription complex (RTC) and induce deamination 
of cytidine residues to uridine residues in viral cDNA causing hypermutations. The proviral cDNAs are 
subsequently degraded or integrated. HIV-1 Vif overcomes APOBEC3-mediated restriction in the producer 
cell by recruiting an E3 ubiquitin ligase complex to poly-ubiquitinate APOBEC3 molecules and target them 




1.5.2 TRIM5α  and capsid  
Studies from the Sodroski laboratory (Hofmann et al., 1999) demonstrated that 
infection of non-human primate cells by HIV-1 was inefficient in a manner independent 
of envelope-mediated entry. The existence of a dominant acting antiviral protein that 
targets HIV-1, SIV, and other retroviral capsid proteins was predicted by fusion 
experiments of permissive with non-permissive target cells (Cowan et al., 2002). 
Interestingly, the resistance phenotypes were very similar to those displayed by Fv1, 
but resistance was also evident in non-murine cells, including humans and monkeys, 
which lack the Fv1 gene (Towers et al., 2000) (Besnier et al., 2002). Subsequently, a 
screen for rhesus macaque genes that were able to restrict HIV-1 infection when 
expressed in human cells resulted in the identification of TRIM5α (Stremlau et al., 
2004). 
TRIM5α is a ∼500 amino acid cytoplasmic protein that belongs to the tripartite motif 
(TRIM)-containing protein family. TRIM proteins are involved in various cellular 
processes, such as proliferation, differentiation, development, apoptosis, oncogenesis 
and innate immunity. In humans the TRIM family includes close to 100 members that 
can be classified on the basis of domain organisation. The TRIM family are 
characterised by an N-terminal RING zinc-finger domain with E3 ubiquitin ligase 
activity, one or two B-boxes (possibly involved in protein-protein interactions), and a 
coiled-coil region for homo-multimerisation or hetero-multimerisation. Two-thirds of the 
human TRIM family proteins also encode a C-terminal SPRY (SplA and ryanodine 
receptor) domain alone or fused to a PRY forming the PRY-SPRY domain (also 
referred as B30.2 domain). PRY-SPRY domains have a conserved structure that forms 
a protein-binding interface (James et al., 2007) (reviewed by (Rahm and Telenti, 
2012)).   
Unlike rhesus TRIM5α, human TRIM5α only weakly inhibits HIV-1 laboratory adapted 
strains. However, some primary isolates are more sensitive, and human TRIM5α 
potently blocks EIAV and N-tropic MLV infection. The difference in specificity between 
human and rhesus TRIM5α has been mapped to the PRY-SPRY domain of the protein 
that forms the binding interface for capsid recognition. Once the TRIM5α protein was 
cloned, it became clear that TRIM5 orthologues in some macaque and owl monkeys 
were created by LINE1-mediated retrotransposition of cyclophilin A into the TRIM5 
locus, resulting in the so-called TRIMCyp protein. Like the rhesus macaque TRIM5α 
protein, TRIMCyp is able to restrict HIV-1 infection (reviewed by (Grütter and Luban, 




The mechanism of retroviral inhibition by TRIM5α is not completely understood. 
However, it is clear that TRIM5α and TRIMCyp bind directly to the HIV-1 capsid via 
their PRY-SPRY and cyclophilin A domains, respectively, and this leads to a block in 
reverse transcription and premature disassembly of the viral core (Stremlau et al., 
2006). Higher-order TRIM5α multimerisation into hexagonal lattices, which is 
dependent on its coiled-coil and B-Box-2 domains, may increase efficiency of TRIM5α 
interaction with the capsid lattice, which in turn promotes antiviral activity (Ganser-
Pornillos et al., 2011). The RING domain of TRIM5α confers E3 ubiquitin ligase activity 
(Xu, 2003), which leads to auto-ubiquitination, explaining its short half-life (Diaz-Griffero 
et al., 2006). TRIM5α does not induce ubiquitination of viral proteins; instead it is 
thought to recruit viral components for proteasomal degradation. Inhibition of the 
proteasome or disruption of the RING domain, however, prevent capsid disassembly 
and restores reverse transcription but do not allow infection. A possible explanation is 
that TRIM5α might act at different stages in the replication cycle that lead up to 
integration into the host DNA (reviewed by (Luban, 2012)). 
TRIM5α promotes AP-1 and NF-κB signalling and was recently identified as a pattern 
recognition receptor (PRR) that is specific for the retroviral capsid lattice (Pertel et al., 
2011). In combination with E2 ubiquitin ligases UBC13 and UEV1A, TRIM5α catalyses 
the formation of K63-linked ubiquitin chains that activate TAK1 which leads to 
inflammatory cytokine transcription. Other TRIM proteins play an important role in 
regulating the innate immune response and are up-regulated by type I and II IFNs in 
CD4+ T cells. For example, TRIM25 promotes ubiquitination of the viral sensor 
retinoid-inducible gene I (RIG-I) leading to downstream activation of NF-κB (Gack et 
al., 2007). Another example is the cytosolic antibody receptor TRIM21, which promotes 
ubiquitination of the interferon regulatory factor (IRF)-8, which in turn leads to the 
expression of cytokines (McEwan et al., 2013).  
Of note, HIV does not encode a TRIM5α countermeasure as it does in case of 
APOBEC3G, tetherin and SAMHD1, which are antagonised by Vif, Vpu or Vpx 
respectively. Instead, sequence variations within CA and the recruitment of cellular 






Figure 1-14 Role of TRIM5α  in antiviral activity  
Schematic representation of TRIM5α-mediated retroviral restriction. (A) TRIM5 molecules bind to the viral 
capsid, causing structural alterations that lead to capsid fragmentation and block in reverse transcription. 
(B) TRIM5 molecules bind to the viral capsid, and together with E2 ubiquitin ligases UBC13 and UEV1A 
catalyse the formation of K63-linked ubiquitin chains that stimulate TAK1 phosphorylation leading to 














1.5.3 SAMHD1 and Vpx 
The vpx (viral protein X) gene is thought to have derived from duplication of the primate 
lentivirus vpr gene. Rhesus macaque SIV (SIVmac) and HIV-2 encode both proteins, 
while chimpanzee SIV (SIVcpz) and HIV-1 only encode Vpr but not Vpx. However, 
these closely related proteins have evolved different functions in the viral replication 
cycle. Vpx and Vpr are unique among lentiviral accessory proteins in that they are 
present in significant quantities in the virus particle. The packaging of Vpx and Vpr 
proteins is virus specific and requires a specific interaction with the p6 C-terminal 
domain of Gag (Yu et al., 1990) (Lu et al., 1993) (Paxton et al., 1993) (Kondo et al., 
1995). Studies performed using SIV and HIV-2 Vpx proteins in the context of HIV-1 
replication demonstrated that Vpx expression significantly promoted HIV-1 infection in 
myeloid cells, such as human dendritic cells and macrophages, compared to CD4+ T 
cells (Goujon et al., 2006). Furthermore, Vpx facilitated the accumulation of full-length 
HIV cDNA. SIVmac and HIV-2 Vpx proteins were also found to interact with the host 
cell E3 ubiquitin ligase complex containing DCAF1, CUL4A and DDB1 (Srivastava et 
al., 2008) (Bergamaschi et al., 2009), suggesting that the unknown factor was being 
degraded (reviewed by (Wu, 2013)). These findings led to the discovery of the SAM 
domain HD domain-containing protein 1 (SAMHD1) as a HIV restriction factor in human 
myeloid cells, by isolation of Vpx-interacting proteins from differentiated human 
monocytic THP-1 cells (Laguette et al., 2011). At the same time, SAMHD1 was 
identified as a Vpx interacting protein in HEK 293T cells using a similar proteomic 
approach (Hrecka et al., 2011). 
SAMHD1 is composed of a sterile alpha motif (SAM) that is involved in protein-protein 
interaction as well as nucleic acid binding; and a dNTP phosphohydrolase domain 
containing conserved histidine and aspartate residues (also referred to as an HD 
domain), which is crucial for its enzymatic activity and RNA binding. Multiple 
phosphorylation sites within SAMHD1 have been identified. In particular residue T592 
(Cribier et al., 2013) (White et al., 2013) (Welbourn et al., 2013), which is 
phosphorylated by cyclin A2 and CDK1, and plays a role in the regulation of SAMHD1 
function during the cell cycle. Targeted mutation of residue T592 releases SAMHD1-
mediated HIV-1 restriction. Furthermore, mutations in SAMHD1 are associated with the 
Aicardi-Goutières syndrome (AGS), a rare autoimmune disorder that leads to chronic 
inflammation through DNA sensing (reviewed by (Sze et al., 2013)).   
Identification of SAMHD1 as a restriction factor highlights the importance of metabolic 
regulation as a restriction mechanism to constrain virus replication. SAMHD1 degrades 
dNTPs (dATP, dCTP, dTTP and dGTP), the building blocks for DNA synthesis. By 




transcription thereby blocking full-length cDNA synthesis and efficient HIV-1 replication 
(Goldstone et al., 2011) (Lahouassa et al., 2012). Furthermore, Vpx induces poly-
ubiquitination and proteasomal degradation of SAMHD1 by serving as a scaffolding 
protein for the DCAF1, DDB1, and CUL4 E3 ubiquitin ligase complex (Laguette et al., 
2011) (Hrecka et al., 2011). This function has been predominately recognised in in non-
cycling cell types including monocytes (Berger et al., 2011), macrophages (Hrecka et 
al., 2011), dendritic cells (Laguette et al., 2011), and resting CD4-positive T cells 
(Baldauf et al., 2012) (reviewed by (Wu, 2013)).  
Recently, retroviral DNA intermediates have been associated with innate DNA sensors 
cGAS (Gao et al., 2013) and IFI16 (Jakobsen et al., 2013), which activate downstream 
STING resulting in an innate immune response. SAMHD1 activity leads to the 
accumulation of reverse transcription intermediates in the cytoplasm that can be 
detected by the innate immune sensing machinery. These can be degraded by the 
TREX1. TREX1 is also associated with the Aicardi-Goutières syndrome (reviewed by 
(Sze et al., 2013)). However, more work needs to be done to fully understand the link 
between retroviral restriction and SAMHD1-mediated innate signalling events.          
 
 
Figure 1-15 Mechanism of HIV-2 restriction by SAMHD1 
In myeloid cells, SAMHD1 induces depletion of cellular dNTPs resulting in a block of reverse transcriptase 
(RT). HIV-2 and SIV Vpx proteins can overcome SAMHD1-mediated restriction by recruiting an E3 
ubiquitin ligase complex that poly-ubiquitinates SAMHD1 and targets it for degradation by the 26S 





1.5.4 The role of Vpr in HIV and SIV infection 
Unlike Vpx, Vpr (viral protein R) is conserved amongst all primate lentiviruses. The Vpr 
protein contains a flexible N-terminus, three alpha-helical domains and a flexible C-
terminal region. Vpr is packaged into mature virions through its interaction with p6, 
localises to the nucleus and nuclear membrane, and is cytopathic to cells when 
overexpressed. Some SIV Vpr proteins are able to mediate degradation of SAMHD1, 
while HIV-1 Vpr proteins are unable to counteract the restriction factor. Many functions 
have been attributed to Vpr over the years, including nuclear transport of the HIV-1 pre-
integration complex, suppression of immune activation, modulation of transcription, 
stimulation of defects in mitosis and apoptosis, and disruption of cell-cycle control 
(reviewed by (Romani and Engelbrecht, 2009)). Interestingly, sequence analysis from 
an accidentally infected laboratory worker, with an HIV strain that encoded a disrupted 
vpr gene, revealed that the gene reverted back to an intact vpr open reading-frame two 
years later (Goh et al., 1998). Furthermore, in studies using rhesus macaques infected 
with SIVmac239 Vpr minus virus, 3 out of 5 animals reverted to wild-type (reviewed by 
(Mashiba and Collins, 2012)). Therefore, both studies highlight the importance of Vpr 
function in vivo. 
The cell-cycle arrest at the G2/M transition is the only well established phenotype of 
Vpr. Induction of the G2 arrest in infected cells is thought to provide replication 
advantages, because transcription levels of the virus are higher during G2 (Goh et al., 
1998); and a higher number of HIV-1 infected individuals displayed more CD4+ T cells 
in the G2 step compared to the healthy control group. Several studies have identified 
the DDB1-CUL4 E3 ligase complex as a cellular Vpr binding partner to interfere with 
the DNA replication machinery of infected cells, resulting in cell-cycle arrest (Wen et 
al., 2007) (Hrecka et al., 2007). As the DDB1-CUL4 E3 ligase complex is involved in 
proteasomal degradation, it was suggested that Vpr induces the G2 arrest through 
degradation of an unidentified protein that is needed for progression of cells from G2 
arrest to mitosis (Wen et al., 2007).    
Recently, the structure-specific endonuclease (SSE) regulator SLX4 complex 
(SLX4com) has been identified as a Vpr interacting protein using a biochemical 
approach. This direct interaction leads to the untimely activation of SLX4com by Vpr-
mediated recruitment of PLK1 and VPRBP; which activates SLX4-associated 
endonucleases resulting in DNA cleavage. This in turn results in cell-cycle arrest at the 
G2/M transition (Laguette et al., 2014). However, there remains the possibility that G2 
arrest is a by-product of the degradation of another host factor that plays an important 





1.5.5 HIV-1 Nef and its role in immune evasion  
Nef (standing for the misleading name: negative factor) is a ∼27 kd myristoylated 
protein, encoded by all primate lentiviruses. Nef mainly localises to peri-nuclear regions 
and is associated with cellular membranes. Nef displays diverse functions in vivo 
including downregulation of a number of cell surface molecules, enhancement of viral 
infection and virus replication capacity, playing a critical role in consistent high plasma 
viremia and progression to AIDS. The protein structure of Nef can be divided into three 
domains: a C-terminal flexible loop; a central structured core domain that is involved in 
protein-protein interactions and encodes multiple intracellular trafficking motifs; and an 
N-terminal anchor domain that is crucial for membrane binding and localisation into 
lipid rafts (reviewed by (Foster and Garcia, 2008) and (Mwimanzi et al., 2012)).  
CD4 is downregulated from the cell surface by Nef proteins (Guy et al., 1987) (Garcia 
and Miller, 1991), a common feature of a HIV and SIV Nef proteins, presumably to 
increase virion release and infectivity, to enhance viral replication and to prevent super-
infection. Nef binds to CD4 and recruits the clathrin adaptor AP-2 to induce endocytosis 
of CD4 via a canonical dileucine motif, ExxxLL. Furthermore, acidic residues 
downstream of the trafficking motif are also required for stabilising AP-2 binding 
(Lindwasser et al., 2008). Endocytosis is followed by the delivery of CD4 to lysosomes 
for degradation (reviewed by (Foster and Garcia, 2008)). Of note, HIV-1 Vpu is also 
able to induce CD4 degradation by targeting newly synthesised CD4 in the ER for 
lysosomal degradation (see 1.7.2).  
CD4 binding to gp120 induces conformational changes in gp120 that promote its 
interaction with the chemokine receptors; result in the exposure of a helical heptad 
repeat (HR1) segment of the gp41 ectodomain; and expose antibody-dependent cell-
mediated cytotoxicity (ADCC) epitopes. Therefore, HIV-1 Nef and Vpu-mediated CD4 
cell surface downregulation might help to avoid the killing of HIV-1-infected cells by 
ADCC (Veillette et al., 2014) (Pham et al., 2014). 
Nef also induces downregulation of major histocompatibility complex (MHC) class I 
molecules HLA-A and B on infected cells, and thereby reduces viral peptide 
presentation to cytotoxic T cells (CTLs). Two pathways have been described to explain 
Nef-mediated HLA-I downregulation. In the first model Nef alters the trafficking of HLA-I 
by interacting with newly synthesised HLA-I molecules within the secretory pathway 
and redirecting them to the lysosome for degradation. Nef directly binds to AP-1 
(Bresnahan et al., 1998) and ß-COP (Piguet et al., 1999), which are important factors 
in protein transport between the trans-Golgi network (TGN) and endosomes. 




structural study recently demonstrated that interaction between Nef and AP-1 µ creates 
a binding pocket in the µ subunit that is capable of binding the YxxA motif in HLA-I in 
order to stabilise the complex (Jia et al., 2012). In the more controversial second model 
Nef enhances HLA-I turnover. Mechanistically, a series of protein interactions and 
signalling events lead to the enhanced clathrin-independent endocytosis of HLA-I that 
requires a small GTPase known as ADP-ribosylation factor 6 (ARF) 
(Blagoveshchenskaya et al., 2002) (reviewed by (Mwimanzi et al., 2012)).  
SIV infections are usually non-pathogenic in their natural host, which correlates with 
low levels of T cell activation and activation-induced cell death (AICD). HIV-1 
infections, however, are characterised by high levels of immune activation and 
apoptotic cell death. Nef proteins from HIV-2, SIVsm and SIVmac efficiently 
downmodulate cell surface TCR-CD3 and reduce TCR-induced NFAT activation 
(Schindler et al., 2006), thereby suppressing the responsiveness of infected T cells to 
activation and AICD. By contrast, HIV-1 Nef is devoid of this function and this 
difference has been proposed to govern the pathogenic outcome of lentiviral infections. 
Thus, demonstrating that Nef exerts an important protective function that was lost 
during lentiviral evolution. By downmodulating TCR-CD3, SIV Nef proteins might adjust 
T cell activation to an optimal level to maintain viral persistence in the context of an 
intact host immune system. 
Nef is not only expressed “early” during infection but also at “later” stages of the virus 
life cycle. This is thought to be important for Nef to enhance the infectivity of virus 
particles. The mechanism is dependent on the interaction of Nef with the GTPase 
dynamin 2 that regulates the last step of clathrin-mediated endocytosis. Depletion of 
dynamin 2 or clathrin by siRNA diminishes the enhancement of Nef-mediated 
infectivity, indicating the dependence on dynamin 2 and clathrin-mediated membrane 
invagination for this process (Pizzato et al., 2007). Furthermore, HIV-1 Nef and murine 
leukemia virus glycoGag similarly enhance the infectivity of HIV-1 virus particles, which 
is determined by variable regions of HIV-1 gp120 that control Env trimer association 
and neutralisation sensitivity. This indicates that the effects of Nef and glycoGag on 
HIV-1 virion infectivity are determined by the quaternary conformation of the apex of 
the Env trimer (Usami and Göttlinger, 2013). However, how this regulates infectivity is 
not yet understood.  
Although the role of Nef in HIV pathogenesis is not completely understood, it has 
become increasingly clear that Nef mediates functions that act at different times during 




Furthermore, SIV Nef but not HIV-1 Nef proteins are able to antagonise the restriction 






Before tetherin (CD317; HM1.24 or bone marrow stromal cell antigen 2 (BST-2)) was 
discovered as a HIV-1 restriction factor, it was identified in a proteomic screen looking 
for novel proteins targeted for degradation by K5 (Bartee et al., 2006), a RING-CH 
(MARCH) ubiquitin ligase from the human Kaposi sarcoma-associated herpesvirus 
(KSHV). Tetherin protein levels were reduced in K5 expressing cells, which was 
dependent on the catalytically active form of K5. However, the relevance of tetherin 
antiviral activity at the time was unclear. 
It had been known for a long time, that the HIV-1 accessory protein Vpu is required for 
efficient release of newly formed viral particles from HIV-1 infected CD4+ T cells and 
macrophages (reviewed by (Bour and Strebel, 2003)). The Vpu-deficient HIV-1 
phenotype was visualised as mature viral particles remaining attached to the cell 
surface and accumulating in endosomal compartments (Klimkait et al., 1990) 
(Göttlinger et al., 1993). However, this effect was cell type- and species-specific 
(Varthakavi et al., 2003) (Neil et al., 2006). Heterokaryon analysis of fusions between 
cells in which Vpu was required for virus release (restrictive or non-permissive) and 
these in which Vpu was distensible (permissive) revealed that the requirement for Vpu 
was dominant. This indicated that Vpu-defective HIV-1 release was hindered by the 
expression of an unknown dominant acting cellular “restriction” factor, which made 
virus release dependent on the presence of Vpu (Varthakavi et al., 2003). Transient 
expression of Vpu in restricted cell types was sufficient to rescue virus release of HIV-
1, MLV as well as Ebola virus-like particles (Neil et al., 2006) (Neil et al., 2007) 
(Göttlinger et al., 1993). The requirement for Vpu in permissive cell types was inducible 
by treatment with IFNα (Neil et al., 2007). Trapped virions could be released by 
protease treatment, indicating the presence of a protein-based tether that prevented 
cell-free virus particle release (Neil et al., 2007). Taken together these findings 
suggested the presence of an IFN-inducible protein-based tethering mechanism that 
trapped nascent virions on the cell surface of infected cells. 
By comparative gene expression arrays of permissive and non-permissive cell types, 
Neil and colleagues identified BST-2 as a putative IFN regulated factor. Ectopic 
expression of BST-2 in permissive cells led to tethered virus particles on the surface of 
HIV-1 infected cells and was sufficient to induce a requirement for Vpu in HIV-1 release 
(Neil et al., 2008) (Van Damme et al., 2008). Therefore the novel restriction factor was 




1.6.1 Tetherin: structure and cellular localisation 
Tetherin is a type II integral membrane protein whose molecular weight varies between 
28 kDa and 36 kDa depending on its glycosylation state (Ohtomo et al., 1999) (Kupzig 
et al., 2003). Tetherin has an unusual topology in which both ends of the protein are 
embedded in the cellular membrane (Kupzig et al., 2003); a structure that is only 
shared by one minor isoform of the prion protein (PrP) (Moore et al., 1999). Tetherin is 
comprised of a short N-terminal cytoplasmic tail, an alpha helical transmembrane 
domain, followed by an extracellular coiled-coil domain and a C-terminal glycosyl-
phosphatidylinositol (GPI) anchor that covalently anchors tetherin to the outer leaflet of 
the cellular membrane (Kupzig et al., 2003) (Figure 1-16). Immature tetherin proteins 
are predicted to contain a C-terminal membrane-spanning helix that is processed into a 
GPI anchor by the ER-resident enzyme, PIGL. Cells that lack the pigl gene fail to 
modify tetherin’s GPI anchor, resulting in retention of unprocessed tetherin proteins in 
the ER membrane, and therefore preventing tetherin from entering the secretory 
pathway (Perez-Caballero et al., 2009).  
 
 





























































(A) Schematic representation of the predicted secondary structure of tetherin monomer at the plasma 
membrane, indicated are the major domains of tetherin including the N-terminal cytoplasmic tail, the 
transmembrane domain, the long α-helical extracellular coiled-coil domain, and the C-terminal GPI anchor. 
The tyrosine-based endocytosis/signalling (YDYCRV) motif and potential ubiquitin-acceptor lysine residues 
(K-18 and K-21) are indicated on the cytoplasmic tail. Three cysteine residues (C-53, C-63 and C-91) 
involved in dimerization and two glycosylation sides (N-65 and N-92) are indicated on the extracellular 
domain. (B) Amino acid sequence of human tetherin. Molecular features from (A) are indicated together 
with residues within the transmembrane domain that are required for Vpu binding.   
 
The mature form of tetherin exists as a homo-dimer that is linked by disulphide bonds 
formed by three cysteine residues (C-53, C-63 and C-91) in the N-terminal part of the 
extracellular domain. The ectodomain also contains two conserved asparagine 
residues (N-65 and N-92) that serve as N-linked glycosylation sites, which are 
important for folding of tetherin as well as sub-cellular trafficking in overexpression 
experiments (Andrew et al., 2009), but the asparagine residues have been shown to be 
dispensable for tetherin’s antiviral function (Perez-Caballero et al., 2009). The crystal 
structures of human and murine tetherin ectodomains have been solved by several 
research groups (Figure 1-17) (Hinz et al., 2010) (Schubert et al., 2010) (Yang et al., 
2010) (Swiecki et al., 2011), which revealed that two tetherin ectodomains form a 
parallel dimeric disulphide-linked coiled-coil domain that is hinged at residues A88 and 
G109 to allow N-terminal flexibility, and to accommodate membrane dynamics during 
the budding process (Schubert et al., 2010) (Yang et al., 2010). Furthermore, 
ectodomain integrity is crucial for tetherin molecules to form membrane micro-domain 
clusters and also allows controlled lateral mobility (Hammonds et al., 2012).     
 
 
Figure 1-17 Structure of tetherin ectodomain dimer 
Tertiary structure of a human tetherin ectodomain dimer based on X-ray crystallography (Yang et al., 
2010).  
 
Tetherin localises to the plasma membrane and the TGN, but can also be found in 
early and recycling endosomes (Kupzig et al., 2003) (Masuyama et al., 2009) 
(Habermann et al., 2010). In HIV-1 infected cells, tetherin localises to sites of virion 
assembly at the plasma membrane (Neil et al., 2008) (Lehmann et al., 2011). 
Furthermore, tetherin is inserted into cholesterol-rich micro-domains (also termed lipid 




in tetherin’s antiviral function is still unclear at present. One study suggested that 
tetherin molecules form a “tethered picket fence” between raft and non-raft domains 
that play a role in the organisation of lipid rafts and distribution of membrane proteins 
(Billcliff et al., 2013).  
The tetherin cytoplasmic tail contains a non-canonical dual tyrosine motif (YxYxxφ) that 
serves as an endocytic signal. The internalisation of tetherin is clathrin dependent and 
requires direct binding of the clathrin adaptor AP-2 µ subunit to the highly conserved 
endocytic motif (Rollason et al., 2007). The dual tyrosine motif has also been shown to 
interact with the AP-2 α subunit. However, this interaction has been shown in yeast 
two-hybrid assays (Masuyama et al., 2009), which are prone to giving false positive 
results. In fact, tyrosine base endocytic motifs are not known to bind to clathrin adaptor 
α subunits, and therefore the observed interaction between tetherin and the AP-2 α 
subunit might be misleading. Following endocytosis, tetherin is transported to 
endosomes and back to the plasma membrane via the TGN in a process often referred 
to as the “slow-recycling pathway”. Delivery of tetherin from endosomal compartments 
to the TGN is dependent on binding of the AP-1 µ subunit to the dual tyrosine motif in 
the cytoplasmic domain of tetherin (Rollason et al., 2007).  
In polarized epithelial cells, tetherin localises particularly to the apical surface, where it 
has been shown to interact indirectly with the sub-apical actin cytoskeleton. The 
linkage between tetherin and the cytoskeleton is mediated by an interaction through the 
Rho GTPase-activating protein RICH2; EBP50; and ezrin (Figure 1-18). Knockdown 
studies of tetherin or RICH2 led to the disappearance of the apical actin network. 
Furthermore, disruption of tetherin/RICH2 interactions led to the activation of Rac1 and 






Figure 1-18 Tetherin indirectly interacts with the cortical actin cytoskeleton 
Schematic representation of human tetherin at the plasma membrane of polarised cells in indirect 
association with the cortical actin cytoskeleton by an interaction between its cytoplasmic tail and RICH2, 
EBP50 and ezrin. Disruption of tetherin/RICH2 interactions activates the Rho GTPase Rac1 leading to the 
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1.6.2 Mechanism of tetherin-mediated virion restriction 
Most biochemical, structural and cellular data suggest that tetherin restricts the release 
of enveloped viruses by directly tethering them to the cell surface, in a model in which 
tetherin dimers are embedded into the host and viral membranes simultaneously 
(Figure 1-19). The unusual topology of tetherin enables virus retention, where both 
membrane anchors, the integrity of the coiled-coil ectodomain and the formation of 
stable disulphide-linked dimers are essential in for this process (Perez-Caballero et al., 
2009) (Hammonds et al., 2012).  
This model is supported by several observations. Firstly, tetherin-restricted virus 
particles can be released by protease treatment, suggesting that tethers consist of 
proteins (Neil et al., 2008). Interestingly, studies using an artificial tetherin molecule, 
which contains the same overall topological arrangement as wild-type tetherin, showed 
that the artificial molecule was also able to trap virions on the plasma membrane. This 
suggests that it is the unique topology of tetherin, rather than the amino acid sequence 
per se, that confers its retention activity (Perez-Caballero et al., 2009). These data also 
suggests that no cellular co-factor is required for tetherin-mediated physical particle 
restriction. Further evidence came from electron microscope (EM) studies that allowed 
visualisation of electron-dense tethers between virus and host cell membranes or 
between virions themselves (Figure 1-19 A and B) (Neil et al., 2007) (Neil et al., 2008) 
(Hammonds et al., 2010). Immunogold labelling EM studies showed that tetherin 
molecules can be detected at the interface between the host cell membrane and 
restricted virions (Fitzpatrick et al., 2010) (Hammonds et al., 2010) (Habermann et al., 
2010), and super-resolution microscopy revealed that 4 to 7 tetherin dimers cluster at 
HIV-1 assembly sites (Lehmann et al., 2011).  
Taking all data together, a model in which tetherin forms parallel dimers with either N- 
or C-terminus inserted into the virion membrane (Figure 1-19), is favoured. A recent 
study suggests that there is a three- to five-fold preference for the insertion of the GPI 
anchor into viral particles, rather than the transmembrane domain (Venkatesh and 
Bieniasz, 2013). Indeed, this preference would allow tetherin to activate NF-κB 
signalling events through a highly conserved YDYCRV motif in its cytoplasmic tail (see 
1.6.7). It is currently unknown if the recruitment of tetherin to viral assembly sites 
requires any signalling events or if the linkage to the actin cytoskeleton recruits tetherin 
to viral budding zones. However, a recent study suggests that Gag-induced membrane 
curvature may promote tetherin recruitment to viral budding zones (Grover et al., 
2013). Indeed, the relative flexibility of tetherin’s extracellular domain would allow 
recruitment by membrane curvature as tetherin dimers partition into host and virion 




Following cell surface retention, virions are internalised into endosomal compartments, 
which most likely results in their degradation. Tetherin mutants that lack the YDYCRV 
endocytic motif show a reduction in virion accumulation in endosomal compartments, 
suggesting that tetherin might play a role in virion delivery to endosomes (Galão et al., 
2012). Furthermore, internalisation can be blocked by a dominant-negative Rab5 
mutant that controls early endosome formation (Neil et al., 2006). The association of 
tetherin with the actin cytoskeleton through RICH2 (Rollason et al., 2009) might also 
play a role in virion internalisation. Interestingly, a rare single-nucleotide polymorphism 
in the RICH2 gene is associated with HIV-1 disease progression (Le Clerc et al., 2011). 
Therefore the role of RICH2/tetherin interactions in relation to tetherin’s antiviral activity 
requires further investigation.   
 
Figure 1-19 Tetherin-mediated restriction of virus particle release 
(A) Electron micrographs showing virion surface accumulations of Vpu-defective HIV-1 infected HT1080 
cells expressing tetherin (adapted from (Neil et al., 2008)). (B) Virus particle tethered to the plasma 
membrane of Vpu-defective HIV-1 infected Jurkat cells, images visualised using transmission electron 
microscopy (adapted from (Jolly et al., 2010)). (C) Schematic representation of the predicted configuration 
of tetherin dimers directly inhibiting virus particle release. Tetherin monomers are arranged in a parallel 
orientation with either the GPI anchors or the N-terminal transmembrane domains inserted into the virion 





1.6.3 Tissue expression and transcriptional regulation of tetherin 
BST-2 (tetherin) was initially discovered as a marker of terminally differentiated B cells 
and bone marrow stromal cells. It has also been identified as a tumour antigen that is 
expressed on multiple myeloma cells, and it was therefore initially proposed as a 
selective target for immunotherapy (Goto et al., 1994) (Ishikawa et al., 1995) (Ohtomo 
et al., 1999). However, a large immunohistochemistry study of human tissues revealed 
that tetherin is expressed in a broad variety of tissues including hepatocytes, 
pneumocytes, ducts of major salivary glands, pancreas and kidney, epithelia, plasma 
cells, bone marrow stromal cells, monocytes, and vascular endothelium (Erikson et al., 
2011). This wide constitutive expression suggests that tetherin is not suited as a target 
for immunotherapy of B cell malignancies. Furthermore, expression of tetherin can also 
be induced by interferon and other pro-inflammatory stimuli in usually tetherin negative 
cell types (Neil et al., 2008) (Van Damme et al., 2008)  (Bego et al., 2012) (Homann et 
al., 2011).  
Investigations into the nature of the transcriptional regulation of tetherin by type I IFN 
revealed multiple putative cis-regulatory elements for transcription factors in its 
promoter region including: nuclear factor of activated T cells (NF-AT), signal transducer 
and activator of transcription (STAT) and NF-κB (Bego et al., 2012). The promoter also 
possesses an overlapping sequence containing an interferon-stimulated response 
element (ISRE), an γ-interferon activation site (GAS), IFN regulatory factor elements 
(IRF-E) and NF-AT (see Figure 1-20). Interestingly, tetherin expression is directly 
inducible by IRF-3 and IRF-7, independent of its type I IFN-mediated up-regulation. 
Consistent with this notion, tetherin expression can also be induced downstream of 
TLR3 and TLR8 (Bego et al., 2012) (Homann et al., 2011). Taken together, these 
results indicate that pattern recognition can directly induce tetherin expression, 
suggesting that tetherin plays a crucial role in early anti-viral responses. 
Recent evidence suggests that tetherin exists in two isoforms (Cocka and Bates, 
2012). Mammalian tetherins have a methionine at position 13, downstream of the 
tyrosine-base sorting signal. The AUG codons at position 13 as well as the +1 
translational initiating codon have weak Kozak consensus sequences, resulting in leaky 







Figure 1-20 Tetherin promoter region 
Schematic representation of predicted regulatory elements in the human tetherin promoter region. 
Abbreviations: GAS (γ-activated site); STAT (signal transducer and activator of transcription); NF-AT 
(nuclear factor of activated T cells); IRF-E (IFN regulatory factor element); ISRE (IFN-stimulated response 







1.6.4 Viral countermeasures 
Tetherin inhibits the release of enveloped virus particles from a variety of viral groups 
that share little or no homology, thus highlighting tetherin’s broad anti-viral function. 
Mechanistically, tetherin targets the host-derived lipid envelope of viruses, the one 
component that the virus cannot mutate. There are several examples of mammalian 
viruses that have evolved tetherin antagonists and most use different mechanisms to 
induce tetherin cell surface removal. The HIV-1 accessory protein Vpu is used as the 
prototype countermeasure, but to date seven other virally encoded mammalian 
counter-tetherin proteins have also been characterised: SIV Vpu; SIV Nef; HIV-2 Env; 
SIVtan Env; KSHV K5; HSV-1 gM/Vhs; and Ebola GP. 
 
 
Figure 1-21 Tetherin and its virally encoded antagonists  
Schematic representation of the five well characterised tetherin antagonists (as displayed from top left to 
right bottom): HIV-1 Vpu, SIV Nef, HIV-2/ SIV Envs, KSHV K5 and Filovirus GP. A short summary of 






1.6.4.1 HIV-1 and SIV Vpu 
The HIV-1 accessory protein Vpu is a small N-terminally anchored transmembrane 
protein that for many years had two known functions: degradation of CD4 and 
enhancement of virus progeny virions release from certain cell types. The discovery of 
tetherin as a restriction factor answered the more than 20 year old question regarding 
the role of Vpu during virus release (Neil et al., 2008) (Van Damme et al., 2008). SIV 
chimpanzee (SIVcpz) and certain members of the SIV lineage that infect african 
guenon monkeys including the SIV greater spot-nosed monkeys (SIVgsn), SIV 
mustached monkey (SIVmus), SIV mona monkey (SIVmon), as well as SIV dents 
monkey (SIVden), also encode Vpu proteins (reviewed by (Sharp and Hahn, 2011)) 
which display anti-tetherin activity, at least against their host species orthologous 
proteins (Sauter et al., 2009).  
HIV-1 Vpu reduces tetherin cell surface levels (Van Damme et al., 2008) and re-directs 
tetherin for ESCRT-dependent degradation in lysosomal compartments (Douglas et al., 
2009) (Iwabu et al., 2009) (Mitchell et al., 2009) (Kueck and Neil, 2012) (Agromayor et 
al., 2012). Vpu antagonises tetherin through direct interactions of their respective 
transmembrane domains (Kobayashi et al., 2011) (Vigan and Neil, 2010) and displays 
a species-specificity governed by residues that form the interaction face (McNatt et al., 
2009) (Gupta et al., 2009a). The mechanism by which Vpu overcomes tetherin 
restriction has been studied extensively and will be discussed below (1.7.3)  
     
1.6.4.2 SIV Nef 
SIV lineages that do not encode a Vpu protein use their Nef proteins as tetherin 
antagonists. The Nef accessory proteins of phylogenetically diverse SIVs, including 
SIVmac (macaque), SIVagm (African green monkey), SIVsmm (sooty mangabey 
monkey), SIVblu (blu monkey), SIVrcm (red capped monkey) and SIVcpz 
(chimpanzee), counteract tetherin orthologues derived from their simian hosts (Jia et 
al., 2009) (Zhang et al., 2009) (Lim et al., 2010). Nef-mediated anti-tetherin activity is 
primate species-specific, and all SIV Nef proteins fail to antagonise human tetherin. 
This specificity results from the five amino acid deletion, G/DIWKK, in the cytoplasmic 






Figure 1-22 Primate tetherin cytoplasmic tail alignment  
Amino acid alignment of primate tetherin cytoplasmic tails. Regions differing from human tetherin are 
depicted in red and blue, the tyrosine-based endocytosis/signalling motif is illustrated in green.    
 
Interestingly, the tryptophan residue in the G/DIWKK motif has been under high 
selective pressure, possibly imposed by Nef-like viral antagonists, which determines 
species-specificity, and may have forced tetherin molecules to mutate into a resistant 
form during primate evolution. Insertion of the G/DIWKK motif into human tetherin 
renders it sensitive to SIV Nef proteins (Lim et al., 2010) (Zhang et al., 2009). Like HIV-
1 Vpu, SIV Nef proteins are able to reduce tetherin surface levels, but do not induce 
tetherin degradation. Mechanistically, Nef targeting to cellular membranes by 
myristoylation of a glycine residue at position 2 is required for tetherin cell surface 
downregulation (Zhang et al., 2011a). The core domain of Nef has been shown to 
directly interact with the N-terminus of rhesus tetherin. However, the interaction is also 
stabilized by residues in the N-terminal and flexible loop region of Nef that are thought 
to affect membrane association or the recruitment of unknown cellular co-factors 
(Serra-Moreno et al., 2013). A highly conserved acidic dileucine motif (D/E)xxxL(L/M) 
and supporting acidic residues in Nef proteins bind to the clathrin adaptor AP-2, which 
is crucial for tetherin removal from virus assembly zones (Zhang et al., 2011a) (Serra-
Moreno et al., 2013). AP-2-mediated endocytosis is also required for Nef to induce cell 
surface downmodulation of the HIV-1 entry receptor CD4 (Lindwasser et al., 2008). 
However, the mechanism of tetherin antagonism by SIV Nef is otherwise genetically 
separable from additional functional activities of Nef, like CD4 and MHC 
downregulation (Serra-Moreno et al., 2013).  
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1.6.4.3 HIV-2 and SIV envelopes  
HIV-2 is a zoonotic infection of SIV from sooty mangabey monkeys (SIVsmm) 
transmitted to humans. The low virus loads and transmission rates in humans make 
HIV-2 less pathogenic than HIV-1. Interestingly, HIV-2 does not encode a vpu gene 
(reviewed by (Sharp and Hahn, 2011)).  
The ability of the HIV-2 envelope protein to promote virus release in certain cell lines, in 
a Vpu-like manner, was recognised before this effect was attributed to the counter-
action of tetherin (Bour and Strebel, 1996) (Bour et al., 2003). Subsequently, it has 
been shown that the HIV-2 ROD10 envelope glycoprotein interacts with tetherin via 
ectodomain interactions, and is able to mediate its cell surface removal, whereas HIV-2 
ROD14 and the SIVmac Env proteins do not (Bour et al., 2003) (Le Tortorec and Neil, 
2009) (Hauser et al., 2010). HIV-2 Env also displays a broader species-specificity for 
tetherin than Vpu but the Env antagonism is less potent than Vpu or Nef, at least in in 
vitro assays (Hauser et al., 2010). HIV-2 Env removes tetherin from virus assembly 
sites by inducing intracellular sequestration in TGN-associated compartments, but like 
SIV Nef, does not induce tetherin degradation (Le Tortorec and Neil, 2009) (Hauser et 
al., 2010).  
The exact determinants required for tetherin antagonism in HIV-2 Env are still under 
investigation. However, the highly conserved membrane-proximal binding site for the 
AP-2 µ subunit, GYxxφ , is essential for tetherin endocytosis (Abada et al., 2005) (Noble 
et al., 2006) (Le Tortorec and Neil, 2009). Tantalus SIV (SIVtan) Env, like HIV-2 Env, 
counteracts human and several primate tetherin orthologues. The SIVtan Env protein 
also relies on the AP-2 binding site in its cytoplasmic tail to induce tetherin cell surface 
downregulation (Gupta et al., 2009b). However, SIVtan is a laboratory adapted strain 
and was co-cultured in tantalus monkey and human CD4+ T cells before isolation, and 
may not reflect tetherin antagonism in the natural host. However, another SIV Env 
protein has been reported to be able to antagonise tetherin, isolated from 
experimentally infected rhesus macaques, with Nef-deleted SIVmac viruses, that 
reverted to pathogenicity (Serra-Moreno et al., 2011). Upon investigation of the 
determinants it was shown that the Env protein had acquired activity against rhesus 
tetherin by a five amino acid substitution in the gp41 cytoplasmic tail. Like the HIV-2 
Env mechanism of counteraction, this Env was able to interact with rhesus tetherin and 
removed tetherin from sites of viral assembly in the presence of an intact GYxxφ  
sorting motif in its cytoplasmic tail. The ectodomain of this Env protein was dispensable 
for tetherin antagonism, as gp41/CD4 chimeric proteins sufficiently antagonised 
tetherin, with physical association mediated by gp41. In terms of tetherin itself, Nef-




determined by differences in residues that flank the dual tyrosines (PILYDY(R/C)KM 
versus STSYDYCRV) between rhesus and human tetherin molecules respectively (see 
Figure 1-22).       
Proteolytic processing of the envelope protein into the subunits gp120 and gp41 is also 
required for tetherin antagonism (Bour et al., 2003) (Le Tortorec and Neil, 2009). The 
HIV-2 Env extracellular domain is likely to be involved in tetherin interaction, as 
exchange of the gp41 transmembrane domain and cytoplasmic tail with SIVmac did not 
abolish anti-tetherin function (Le Tortorec and Neil, 2009). In further support of 
ectodomain interactions, a substitution of a single positively selected amino acid in 
human tetherin, A100D, rendered tetherin resistant to SIVtan Env without 





1.6.4.4 HSV-1 encodes two tetherin antagonists: gM and Vhs 
The herpes simplex virus 1 (HSV-1) is a large DNA virus that belongs to the alpha-
herpesvirus family. Like all Herpesviridae, HSV-1 has a complex assembly pathway, in 
which the final envelopment occurs at membranes derived from TGN compartments 
(Flint et al., 2009).  
Two recent publications demonstrated that HSV-1 particle release is restricted by 
tetherin overexpression (Zenner et al., 2013) (Blondeau et al., 2013). One group 
identified the viral envelope glycoprotein M (gM) as a moderate anti-tetherin factor 
(Blondeau et al., 2013) (Nathan and Lehner, 2009). They demonstrated that gM 
expression reduced cell surface tetherin levels and induced tetherin intracellular 
localisation to TGN46-positive compartments. Furthermore, the HSV-1 gM glycoprotein 
specifically rescued Vpu deficient HIV-1 virus particle release. However, gM only had 
minor effects on HSV-1 replication, and tetherin degradation was found to be 
independent of gM. Thus, this raised the possibility that HSV-1 may encode another 
partially redundant tetherin antagonist. A second research group identified the virion 
host shut-off protein (Vhs) as a tetherin countermeasure (Zenner et al., 2013). Vhs is 
an endoribonuclease that causes destabilization of a broad spectrum of mRNA 
molecules and has been shown to antagonise both innate and adaptive immune 
responses. This group demonstrated that Vhs is able to overcome tetherin restriction 
by reducing tetherin mRNA levels, and potentially avoiding tetherin-mediated NF-κB 
signalling events. This is a novel mechanism that has never been described before. 
However, more work is needed to clarify the role of HSV-1 gM and Vhs proteins in 
tetherin antagonism and to explore tetherin-induced signalling events in HSV-1 
infection.  
 
1.6.4.5 KSHV K5 
K5 is a membrane attached RING-CH (MARCH) domain E3 ubiquitin ligase encoded 
by the gamma herpesvirus Kaposi’s sarcoma-associated herpesvirus (KSHV), and has 
been shown to downregulate a number of different cell surface proteins including NK 
receptor ligands, MHC class I and II as well as adhesion proteins (reviewed by (Nathan 
and Lehner, 2009). Before tetherin was recognised as an HIV-1 restriction factor, it had 
been identified in a proteomic screen for novel K5 targets (Bartee et al., 2006). K5 
counteracts tetherin activity in a species-specific manner and promotes ESCRT-
dependent lysosomal degradation of tetherin similar to the degradation seen with HIV-1 
Vpu (Mansouri et al., 2009) (Pardieu et al., 2010) (Agromayor et al., 2012). Knockdown 
of the ESCRT-I component ubiquitin-associated protein 1 (UBAP1) results in the 




(Agromayor et al., 2012). Furthermore, it has also been shown that dominant negative 
VPS4 is able to block cell surface down-modulation of tetherin by K5 (Pardieu et al., 
2010), suggesting that K5 is, like Vpu, able to redirect tetherin from the cell surface to 
late endosomes and routes tetherin for lysosomal degradation. Interestingly, K5 
selectively ubiquitinates the lysine residue at position 18 in tetherin’s cytoplasmic tail, 
and this ubiquitination is absolutely required for K5 to counteract tetherin (Mansouri et 
al., 2009) (Pardieu et al., 2010).  
Unlike HIV, herpes viruses undergo two envelopments to complete assembly, the first 
at the nuclear membrane and the second in TGN-associated compartments that leads 
to virion egress via the secretory pathway (Mettenleiter et al., 2006). Tetherin is thought 
to inhibit KSHV virion release in TGN-associated compartments, which gives rise to the 
question whether other herpes virus families are restricted by tetherin and encode 
countermeasures.  
 
1.6.4.6 Ebola envelope glycoprotein 
The highly pathogenic Ebola virus (EBOV) was first described in 1976 and is the 
causative agent of severe viral haemorrhagic fever outbreaks in humans and non-
human primates. EBOV is a negative single-stranded RNA virus, forms filamentous 
virions and belongs, like Marburg virus (MARV), to the Filoviridae family. To date five 
different EBOV species have been identified, which vary in sequence and mortality 
rates (Flint et al., 2009). 
Vpu is able to enhance the release of EBOV virus-like particles (VLPs) from tetherin 
expressing cells, demonstrating that filovirus virions are sensitive to tetherin-mediated 
restriction (Neil et al., 2007). Indeed, the EBOV envelope glycoprotein (GP) is able to 
antagonise tetherin function (Kaletsky et al., 2009), an ability which is conserved in the 
Filoviridae family, given that the MARV GP is also able to rescue Vpu deficient HIV-1 
release (Kühl et al., 2011). The EBOV GP, unlike HIV-1 Vpu and most other tetherin 
antagonists, is able to counteract human, primate and murine tetherin molecules 
(Lopez et al., 2010). This broad activity might be due to the breadth of mammalian host 
species infected by EBOV. The exact mechanism of GP-mediated tetherin antagonism 
is unclear but requires direct interaction of GP and tetherin via its GP2 subunit 
(Kaletsky et al., 2009) (Kühl et al., 2011). Tetherin is not removed from the cell surface 
in the presence of EBOV GP and remains associated with lipid rafts (Lopez et al., 
2010) (Lopez et al., 2012), which is surprising to some extent as EBOV GP has been 
shown to induce downregulation of other cell surface molecules like MHC class I and 




might physically interfere with tetherin restriction of virions at the plasma membrane, 
however, it does not rely on a specific domain in tetherin, because it is able to 
antagonise a completely synthetic tetherin molecule (Lopez et al., 2010). Tetherin 
levels remain constant in EBOV infected cells, indicating that GP does not induce 
tetherin degradation, unlike HIV-1 Vpu and KSHV K5. However, tetherin has no effect 
on EBOV spread using infectious EBOV replication assays (Radoshitzky et al., 2010), 
which could be a result of a cell type specific function of GP (Kühl et al., 2011). Clearly, 
more studies are required to fully understand the mechanism of EBOV GP-mediated 
tetherin antagonism.    
 
1.6.5 Tetherin and other viruses  
To date, tetherin has been shown to restrict the virus particle release of all retroviruses 
tested as well as filoviruses (Ebola virus and Marburg virus), arenaviruses (Lassa virus 
and Machupo virus), paramyxoviruses (Nipah virus, Hendra virus and Sendai virus), 
gamma-herpesviruses (KSHV), alpha-herpesviruses (HSV-1), rhabdoviruses (vesicular 
stomatitis virus) and flaviviruses (Dengue virus) (reviewed by (Le Tortorec et al., 2011) 
and (Neil, 2013)). The capability of tetherin to restrict such a broad range of viruses 
resides in its ability to trap enveloped viruses that bud from cellular membranes by 
incorporation into the host-derived envelope. However, some viruses that are highly 
sensitive to tetherin expression in vitro do not encode a tetherin countermeasure. 
Tetherin might not be expressed in their natural target cells or the assembly 
mechanism of these enveloped viruses itself might be insensitive to tetherin restriction.  
Studies performed with influenza A virus (IAV) showed opposing results regarding the 
sensitivity to tetherin. Initial observations revealed that tetherin was unable to restrict 
IAV budding, excluding tetherin incorporation into virions (Watanabe et al., 2011). 
However, the same group also reported that tetherin expression inhibited influenza 
VLP release, which could be overcome by HIV-1 Vpu expression. At the same time the 
neuraminidase (NA) protein of some IAV strains was reported to possess a Vpu-like 
function on VLP release (Yondola et al., 2011). An independent study showed that 
ectopic expression of tetherin strongly inhibited the release of newly formed IAV 
particles and could be overcome by the influenza virus NS1 protein, which reduced 
IFN-mediated up-regulation of ISGs including tetherin (Mangeat et al., 2012). However, 
two different reports have challenged these results since (Winkler et al., 2012) (Bruce 
et al., 2012). One research group used microscopic imaging techniques to demonstrate 
that filamentous and spherical assembly of various IAV strains was unaffected by 




budding of filamentous virions (Bruce et al., 2012). Thus, more work needs to be done 
to clarify the effects of tetherin on IAV.              
Interestingly, tetherin was suggested to act as an entry co-factor for the beta-
herpesvirus human cytomegalovirus (HCMV) (Viswanathan et al., 2011). Tetherin 
expression enhanced viral entry, as more virions were released into tetherin positive 
cells compared to tetherin negative cells. Therefore, the authors suggested that 
tetherin is incorporated into virions and is able to interact with monomeric tetherin 
molecules expressed at the surface of their target cells, which leads to enhancing 
HCMV entry. However, the underlying mechanism of these observations remains to be 
determined.  
 
1.6.6 Tetherin and cell to cell transmission 
HIV-1 and other human enveloped viruses can disseminate within an infected host by 
two mechanisms: cell-free virus release and virus transfer by physical interaction 
between infected donor and uninfected target cells (reviewed by (Sattentau, 2008) and 
(Mothes et al., 2010)). The latter mechanism is called cell-to-cell transfer and is thought 
to be up to 10-100 times more efficient than cell-free virus spread. There are several 
advantages in direct cell-to-cell transfer that can be exploited by viruses. First, direct 
cell-to-cell spread is more rapid because it reduces rate-limiting early steps in the virus 
life cycle. Second, the limited exposure time to extracellular space may help viruses to 
evade elements of the innate immune system, such as neutralising antibodies and 
complement. A supramolecular structure, termed the virological synapse (VS), was 
shown to mediate the cell-to-cell dissemination of HTLV-I and HIV-1 (Igakura et al., 
2003) (Jolly et al., 2004). For HIV-1 the VS is formed by binding of the Env protein, 
which is displayed at the surface of infected cells, to its entry receptors expressed on 
the target cell membrane (Jolly et al., 2004) (Chen et al., 2007). Cytoskeletal 
rearrangements and a variety of adhesion molecules, including LFA-1, ICAM-1 and 
ICAM-3, are required to maintain the stability of the virological synapse (Jolly et al., 
2004) (Jolly et al., 2007). The relative contribution of cell-free and cell-to-cell HIV-1 
dissemination in vivo is still unclear. However, a recent study that examined the 
migratory behaviour of HIV-1 infected T cells in lymph nodes of humanised mice 
discovered that infected T cells are motile and are the major route of virus 
dissemination to distal tissues (Murooka et al., 2012).    
Some studies that have addressed the role of HIV-1 Vpu in cell-to-cell transmission 
were performed before the discovery of tetherin as a viral restriction factor, and 




accumulation in the supernatant was reduced while spread within the culture was 
unimpaired (Strebel et al., 1989) (Terwilliger et al., 1989) (Klimkait et al., 1990) (Yao et 
al., 1992) (Schubert et al., 1995). Consistent with this notion, selection for HIV-1 
variants that spread more efficiently by cell-to-cell dissemination resulted in viruses 
with mutation in their vpu gene (Gummuluru et al., 2000). However, since viruses 
restricted by tetherin are fully infectious, the question whether these viruses can be 
transferred by cell-to-cell contact through virological synapses remained.  
Studies that have directly addressed the role of tetherin in cell-to-cell spread have 
reported opposing results. There is agreement that tetherin co-localises with Env at 
virological synapses. Furthermore, VS formation in T cells infected with Vpu-defective 
HIV-1 was increased compared to wild-type. But the consequences of tetherin-
mediated virus retention on cell-to-cell spread have been controversial (Jolly et al., 
2010) (Casartelli et al., 2010). One study demonstrated that tetherin-mediated retention 
of virions could promote cell-to-cell spread between Jurkat T cells infected with Vpu-
defective HIV-1 and primary CD4+ T cells, presumably by providing immobilised and 
infectious virions at the contact side (Jolly et al., 2010). This effect could be reversed 
by siRNA-mediated depletion of tetherin. However, two other studies reported that 
tetherin expression reduced cell-to-cell transfer (Casartelli et al., 2010) (Kuhl et al., 
2010). These contradictory results might be explained by differences in tetherin 
expression levels between cell types used in the different studies. HeLa and tetherin-
inducible 293T cells express higher amounts of tetherin than Jurkat and primary CD4+ 
T cells. It is possible, that at high tetherin expression levels cell-to-cell transfer is 
impaired whereas at low expression levels cell-to-cell transfer is increased. Jolly et al 
showed that increased tetherin expression by IFN treatment had only minor effects on 
cell-to-cell spread. Furthermore, the Vpu 2/6 phospho-mutant, which is strongly 
impaired in its ability to antagonize tetherin, replicates less efficiently in macrophages, 
which express high levels of tetherin, compared to primary CD4+ T cells (Schindler et 
al., 2010). Another possible explanation for the contradictory results is that the 
dynamics of cell-to-cell spread may be dependent on specific features in donor and 
target cell types (Zhong et al., 2013).  
Another interesting possibility is that tetherin itself might be involved in the formation 
and stabilisation of virological synapses. To this end, depletion of tetherin impaired 
wild-type HIV-1 cell-to-cell dissemination (Jolly et al., 2010), suggesting that reduced 
tetherin levels at the cell surface might negatively affect HIV-1 transmission. Tetherin 
was shown to indirectly interact with the actin cytoskeleton, in polarised epithelial cells, 
via the BAR-RacGAP protein RICH2 (Rollason et al., 2009). This interaction physically 




to the organisation of lipid rafts (Billcliff et al., 2013). HIV-1 assembles in lipid rafts and 
the integrity of these rafts as well as the underlying actin cytoskeleton is required for 
efficient cell-to-cell spread (reviewed by (Ono, 2010)). Thus, it remains to be solved 






1.6.7 Tetherin as a viral immune sensor 
Tetherin concentrates virus particles at the surface of infected cells. Therefore one 
might speculate that: (1) tetherin enhances antibody opsonisation and clearance of 
infected cells by the recruitment of complement or natural killer cells through Fc 
receptor recognition; (2) tetherin increases MHC class II antigen presentation and 
therefore provides a link between innate and adaptive immunity; or (3) tetherin acts as 
pattern-recognition receptor to activate immune signalling pathways (Figure 1-23). 
Indeed, before its discovery as a restriction factor, tetherin was identified in a genome 
wide cDNA screen, looking for factors that induce NF-κB activation (Matsuda et al., 
2003).   
Recently, the potential importance of tetherin in regulating immune responses to viral 
infection has started to emerge as tetherin was found to be able to stimulate NF-κB 
activation and trigger antiviral responses (Cocka and Bates, 2012) (Galão et al., 2012) 
(Tokarev et al., 2013). Cross-linking of surface tetherin by antibody, budding of 
tetherin-sensitive HIV-1 and EBOV particles (Galão et al., 2012), and overexpression of 
tetherin, enhanced NF-κB activation (Cocka and Bates, 2012) (Galão et al., 2012) 
(Tokarev et al., 2013). Furthermore, human primary CD4+ T cells infected with Vpu-
defective HIV-1 produced high levels of pro-inflammatory cytokines, including CXCL10, 
IL-6 and type I IFN, in a tetherin-dependent manner, suggesting that tetherin acts as a 
PRR for enveloped viruses (Galão et al., 2012). However, tetherin-mediated 
endocytosis of virions is not required to trigger NF-κB activation. Unpublished data from 
our laboratory (personal communication with Galao, Pickering and Neil) indicates that 
the tyrosine residues within the YDYCRV signalling motif in the cytoplasmic tail of 
tetherin are phosphorylated by a member of the Src family kinase, which leads to the 
subsequent recruitment of a signalling complex that includes TRAF6, TRAF2 and 
Ubc13. This in turn leads to an Ubc13-dependent activation of TAK1 through 
polymerisation of K63-linked ubiquitin chains. Polymerisation leads to IKK 
phosphorylation and IκB degradation, allowing translocation of NF-κB and expression 
of pro-inflammatory genes (Galão et al., 2012). Interestingly, the signalling activity of 
tetherin might be an evolutionary recent acquired function, as it has only been 
observed in human and chimpanzee tetherin orthologues (Galão et al., 2012). HIV-1 
Vpu and KSHV K5, thus far, are the only known antagonists of human tetherin that 
induce its degradation, therefore it is tempting to speculate that only the final 
degradation of tetherin ensures inhibition of tetherin-mediated immune activation.                       
Viral retention and re-routing of tethered virions to endosomal compartments may also 
promote the availability of virus components to other host pathogen recognition factors 




mediated IFN responses in infected CD4+ T cells can be blocked by inhibition of the 
TLR3 adaptor protein TRIF. This suggests that tetherin may also be able to indirectly 
enhance the expression of type I IFNs and pro-inflammatory cytokines via the IRF 
pathway.        
Finally, tetherin was proposed to bind to the immunoglobulin-like transcript 7 (ILT7) 
(Cao et al., 2009). ILT7 is a negative regulatory receptor that is found on resting pDCs, 
and which downregulates TLR responses after viral stimulation (Cho et al., 2007). 
Therefore, it was proposed that tetherin/ILT7 interaction may downregulate TLR-
mediated IFN and cytokine responses in a negative-feedback manner (reviewed by 
(Cao and Bover, 2010)). However, blockade of tetherin/ILT7 interactions, in peripheral 
blood mononuclear cell cultures, did not affect the ability of ILT7 to dampen TLR9 
responses (Tavano et al., 2013), suggesting that tetherin/ILT7 interactions might act as 
a homeostatic regulatory mechanism on immature pDCs, rather than a negative-









Figure 1-23 Reported roles of tetherin in immune signalling events 
HIV-1 virus particles bind to CD4 on the surface of plasmacytoid dendritic cells (pDC), followed by their 
endocytosis and recognition of viral RNA by TLR7/9 in endosomal compartments. This leads to the 
expression of type I IFN and IL-6 that bind to their subsequent receptors on T cells to mediate transcription 
of interferon-induced genes (including tetherin), pro-inflammatory cytokines, and type I IFN, through the 
JAK-STAT signalling pathway. At the plasma membrane, tetherin molecules restrict the release of mature 
virus particles, which induces TRAF- and Ubc13-dependent ubiquitin-mediated activation of TAK1 that in 
turn induces IKK-mediated phosphorylation, followed by proteasomal degradation of IκB to allow NF-κB-
dependent gene expression. HIV-1 Vpu interferes with this process by mediating tetherin degradation 
and/or sequestering β-TrCP. Internalisation of tetherin-retained virions for degradation may increase the 
recognition of virus particle-associated PAMPs by endosomal pattern recognition receptors, promoting the 
expression of antiviral genes such as type I IFN and pro-inflammatory cytokines, via the IRF pathway. 
Tetherin interaction with ILT7, expressed on the surface of pDCs, induces an inhibitory feedback loop that 
reduces TLR-mediated expression of type I IFN and pro-inflammatory cytokines. Tetherin may also 
facilitate antibody opsonisation by increasing the number of viral antigens at the cell surface, which might 
lead to the recognition of antibodies by Fc receptors expressed on the surface of NK cells, leading to 





1.6.8 Tetherin and viral pathogenesis in vivo  
The role of tetherin in pathogenesis and antiviral immune responses in vivo has so far 
addressed only in murine systems. One study used tetherin knockout mice infected 
with Moloney murine leukemia virus (Mo-MLV) or a pathogenic MLV strain LP-BM5, 
and showed that tetherin plays a direct antiviral role in vivo (Liberatore and Bieniasz, 
2011). Extensive immuno-phenotyping of tetherin -/- mice showed that tetherin is not 
required for the development of the functional adaptive immune system. Initially, Mo-
MLV infection did not induce tetherin expression on target cells and type I IFN 
treatment of tetherin -/- mice was required to reveal the anti-Mo-MLV activity of 
tetherin. However, tetherin-deficient mice infected with LP-BM5 had higher levels of 
plasma viremia and induced exaggerated pathology reminiscent of HIV/AIDS, 
indicating that tetherin plays a direct antiviral role in vivo. Another study identified a 
single nucleotide polymorphism in the tetherin gene of NZW/LacJ (NZW) mice. This 
homozygous polymorphism leads to the exclusive expression of short-tetherin isoforms 
that lack the tyrosine-based endocytic motif (YxYxxφ) (Barrett et al., 2012). Cell surface 
tetherin expression on lymphoid and myeloid cells in these mice was increased 
compared to control C57BL/6 mice expressing full-length tetherin. Increased surface 
tetherin expression in NZW mice correlated with a decrease in Friend murine leukemia 
virus (F-MuLV) replication and pathogenesis. A humanised NOD-SCID IL2Rγnull (NSG) 
mouse model of acute HIV infection has also been used to assess the role of Vpu-
mediated tetherin antagonism in establishing plasma viremia and viral dissemination in 
lymphoid tissues (Dave et al., 2013). This study demonstrated that optimal tetherin 
antagonism by HIV-1 Vpu is critical for the establishment of efficient plasma viremia 
and dissemination during acute infection. 
Further compelling evidence for the importance of tetherin in human HIV/AIDS disease 
comes from the adaptation of a fully functional Vpu protein that correlates with efficient 
spread of group M (Sauter et al., 2009), and the characterisation of a group N Vpu 
protein that has evolved to become a tetherin antagonist (Sauter et al., 2012). 
Recently, single genome analysis of vpu alleles from HIV-1 clade B infected individuals 
showed that despite extensive amino acid diversity of the Vpu protein, anti-tetherin 
function of Vpu was rarely impaired (Pickering et al., 2014). Therefore, highlighting the 
importance of maintaining anti-tetherin function throughout HIV-1 infection. Another 
study tested the association of tetherin gene variants with disease progression and 
reported a faster HIV-1 disease progression in individuals with a 19 base-pair insertion 





1.7 HIV-1 Vpu 
The accessory protein Vpu was first identified in 1988 as a previously undetected open 
reading frame located between the first exon of the tat gene and the env gene of HIV-1 
(Cohen et al., 1988) (Strebel et al., 1988). This was also when the gene was given its 
name vpu, standing for: viral protein unique. Antibodies to the newly identified protein 
could be detected in patient serum from infected HIV-1 individuals. Interestingly, Vpu 
distinguished HIV-1 isolates from HIV-2 and some SIV (SIVsmm and SIVmac) isolates, 
as these viruses do not encode an equivalent protein (Cohen et al., 1988) (Strebel et 
al., 1988). With time, homologues have been identified in SIVcpz, SIVmon, SIVgsn, 
SIVmus, SIVden and SIVgor (reviewed by (Sharp and Hahn, 2011)). Initial studies 
ascribed Vpu with a functional property of facilitating virus release from infected cells. 
However, since the identification of Vpu its list of functions has increased. To date the 
major roles attributed to Vpu are: rapid degradation of the cell surface receptor CD4, 
enhancement of virus particle release by counteraction of tetherin, and 
downmodulation of CD1d and NTB-A.  
 
1.7.1 Structure and cellular localisation of Vpu 
HIV-1 Vpu is a small 77-86 amino acid type I integral membrane protein capable of 
homo-oligomerisation (Maldarelli et al., 1993). Vpu is translated from a Rev-dependent 
bicistronic mRNA, which also encodes the viral envelope glycoprotein (Schwartz et al., 
1990). The prototype NL4.3 Vpu protein is predicted to have a short luminal N-terminal 
domain, an N-terminal hydrophobic transmembrane domain (residues 4-27) followed 
by 54 amino acids that form the C-terminal cytoplasmic tail (residues 27-81) (Figure 
1-24) (Maldarelli et al., 1993) (reviewed by (Bour and Strebel, 2003)). The crystal 
structure of the full-length Vpu protein is yet to be solved. However, several NMR 
structures of both TM and cytoplasmic tails have been determined (Henklein et al., 
1993) (Federau et al., 1996) (Wray et al., 1995). The N-terminal membrane-spanning 
domain is predicted to form an alpha helix with an average tilt angle of 13 degrees in a 
lipid environment (Park et al., 2003) (Park and Opella, 2005). Interestingly, the 
transmembrane domain of Vpu is also critical for oligomerisation and the pentameric 
structure has been predicted to form a cation-selective ion channel (Schubert et al., 
1996a) (Lopez et al., 2002) (Hussain et al., 2007). Notably, the ion channel activity of 
Vpu does not appear to be required for anti-tetherin or anti-CD4 function.  
The cytoplasmic tail of Vpu comprises two predicted alpha helices, the first of which is 
thought to be partially submerged in the lipid bilayer by virtue of a juxta-membrane 




forms a loop-like structure. The location of the second helix still remains unclear. Upon 
interaction with cellular host factors CD4 or tetherin the tertiary structure of Vpu is 
thought to undergo conformational change (reviewed by (Bour and Strebel, 2003)).  
The flexible cytoplasmic domain contains a region bearing a highly conserved 
DSGNES motif. The pair of serine residues (S52 and S56) is constitutively 
phosphorylated by casein kinase II (Schubert et al., 1992) (Schubert and Strebel, 1994) 
(Friborg et al., 1995). This phosphorylation mediates binding to β-TrCP and the 
cytosolic Skp1-Cullin1-F-Box (SCF) E3 ubiquitin ligase complex (SCFTrCP) (Margottin et 
al., 1998).  
The laboratory-adapted NL4.3 Vpu protein and those encoded by other subtype B 
strains localise to internal membrane structures, predominantly the trans-Golgi 
network, as well as endosomes and endoplasmic reticulum, little or no accumulation of 
Vpu is detected at the cell surface (Varthakavi et al., 2006) (Dubé et al., 2009). An 
important domain for the TGN localisation was mapped to residues R30 and K31 in the 
first alpha helix of subtype-B Vpu (Dubé et al., 2009). These residues are part of a 
putative overlapping tyrosine Yxxφ  and acidic/dileucine motif in the hinge region 
between the transmembrane domain and cytoplasmic tail (Figure 1-24B). The second 
alpha helix bears a putative acidic/dileucine-based sorting motif, ExxxLV, that is 
required for efficient virus release from interferon treated CD4+ T cells, tetherin cell 
surface downregulation and ESCRT-dependent degradation of Vpu/tetherin complexes 
(Kueck and Neil, 2012). The evidence for this is presented in Chapter 4 of this thesis. 
In addition, it has been shown that certain strains of HIV-1 subtype C possess a di-
leucine based (D/E)xxxL(L/I/V) transmembrane proximal sorting signal and localise 
predominantly to the plasma membrane (Ruiz et al., 2008). The fact that rare defective 
primary isolates of HIV-1 harbour vpu genes with mutations within these trafficking 
motifs (Pickering et al., 2014) raises the possibility that subcellular localisation of Vpu 





Figure 1-24 Vpu topology and molecular features 
(A) Predicted secondary structure of the prototype NL4.3 Vpu protein. Indicated are: the N-terminal 
transmembrane domain with the predicted 13° angle; the cytoplasmic tail containing two α-helices and 
phosphorylated serine residues (S52 and S56, highlighted in blue). (B) NL4.3 Vpu topology. The red boxes 
indicate the transmembrane domain and α-helices. Highlighted in green is the alanine face 
(AxxxAxxxAxxxW) located in the TM domain. Highlighted in blue are phosphorylated serine residues within 
the DSGNES β-TrCP-binding motif. Also depicted is the hinge region containing the putative overlapping 
trafficking motif and the ExxxLV motif in the second α-helix.  













































1.7.2 Vpu and CD4 degradation 
Despite its compact genome, HIV-1 dedicates two accessory proteins, Nef and Vpu, to 
reducing CD4 levels at the plasma membrane, implying that surface downregulation of 
CD4 plays an important role in HIV-1 replication. Indeed, newly synthesised CD4 
molecules are able to retain the envelope precursor gp160 in the ER, therefore 
preventing Env incorporation into virions, resulting in non-infectious virus particles. CD4 
expression on the surface of infected cells promotes super-infection, which is known to 
inhibit efficient virus particle release (Wildum et al., 2006). Furthermore, very recent 
studies suggest that in the absence of Vpu and Nef, CD4-induced epitopes of gp120 
are exposed on infected cell surfaces, sensitising the cell to enhanced antibody-
dependent cytotoxicity (Veillette et al., 2014) (Pham et al., 2014). Early during infection, 
Nef enhances endocytosis of mature CD4 proteins at the cell surface in a mechanism 
that is dependent on clathrin and AP-2, followed by the delivery of CD4 molecules to 
lysosomes. Vpu on the other hand is expressed later during the viral replication cycle 
and induces rapid degradation of newly synthesised CD4 proteins in the ER (reviewed 
by (Dubé et al., 2010a) and (Andrew and Strebel, 2010)). 
Vpu-mediated degradation of CD4 molecules in the ER is well characterised and 
thought to be initiated by Vpu/CD4 physical interactions via their respective cytoplasmic 
tails. While Vpu and CD4 transmembrane domains are thought not to be required for 
binding (Bour et al., 1995) (Schubert et al., 1996b), their hydrophobic nature might 
stabilise Vpu/CD4 interactions (Magadán et al., 2010). The cytoplasmic determinant 
required for direct Vpu binding in CD4 has been mapped to a short motif (414 LSEKKT 
419) and a α-helix located in the membrane proximal region (Bour et al., 1995) 
(Lenburg and Landau, 1993) (Vincent et al., 1993) (Willey et al., 1994) (Yao et al., 
1995). The first alpha helix of the Vpu cytoplasmic tail was thought to be required for 
CD4 binding (Hill et al., 2010) (Tiganos et al., 1997), however recent NMR data 
suggests that both cytoplasmic helices are involved in CD4 binding (Singh et al., 2012). 
Physical interaction between either alone is not sufficient for CD4 degradation.  
The highly conserved di-phosphoserine (DSGNES) motif in Vpu is required to interact 
with β-TrCP1/2 (Margottin et al., 1998) (Butticaz et al., 2007). β-TrCP is a F-box 
adaptor protein that is part of the cytosolic SCF E3 ubiquitin ligase complex (Margottin 
et al., 1998). The phosphorylated serine residues bind directly to the WD-repeat in the 
β-propeller of β-TrCP, creating a CD4/Vpu/β-TrCP ternary complex that allows poly-
ubiquitination of CD4 on lysine as well as serine/threonine residues (Binette et al., 





Although it is now well established that Vpu induces CD4 degradation via a 
proteasomal-dependent pathway, it is still unclear how CD4 is trans-located from the 
ER membrane into the cytoplasm for ubiquitin ligase-mediated degradation. This 
degradation appears to be through some form of the endoplasmic reticulum-associated 
protein degradation (ERAD) pathway, that targets misfolded membrane and luminal 
proteins for degradation in the cytosol. Vpu-induced CD4 degradation is distinct from 
the classical ERAD pathway in that Vpu relies on the SCFTrCP complex rather than on 
the typical ER membrane-bound E3 ubiquitin ligases, including the HRD1-SEL1L 
complex, TEB4/MARCH-VI, and the GP78-RMA1 complex (reviewed by (Dubé et al., 
2010a) and (Andrew and Strebel, 2010)). However, like classical ERAD, it has been 
shown that the VCP-UFD1L-NPL4 complex, that includes the AAA-ATPase p97/VCP, 
is recruited to provide the energy for the extraction or dislocation of Vpu-induced CD4 
degradation from the ER membrane (Binette et al., 2007) (Magadán et al., 2010). 
Therefore, Vpu bypasses the early substrate recognition stage of ERAD but joins the 
pathway at later steps. Taken together a model emerges in which Vpu binds newly 
synthesised CD4 molecules in the ER membrane, recruits the SCFTrCP complex, 
induces CD4 poly-ubiquitination followed by dislocation into the cytosol and 






Figure 1-25 Vpu-mediated ERAD-dependent degradation of CD4 
Schematic representation of Vpu-mediated CD4 degradation. Vpu retains CD4 in the endoplasmic 
reticulum by interaction through their transmembrane domains. The formation of Env/CD4 complexes 
might contribute to Vpu capture of CD4 molecules. The cytoplasmic tail of Vpu (mediated by the first alpha 
helix) interacts with CD4 (residues 414-LSEKKT-419) and recruits the SCF-β-TrCP E3 ubiquitin ligase 
complex, which induces poly-ubiquitination of CD4 and targets CD4 for proteasomal degradation. This 
targeting involves a dislocation step mediated by the ERAD associated p97-UFD1L-NPL4 complex, 
through the recognition of K-48-linked ubiquitin chains on the CD4 cytosolic tail by UFD1L. The ATPase 
activity of p97(VCP) mediates dislocation of CD4 from the ER membrane into the cytosol where CD4 
becomes readily accessible for proteasomal degradation (adapted from(Dubé et al., 2010a)).  




1.7.3 Vpu-mediated tetherin antagonism 
Vpu-mediated tetherin antagonism is distinct from CD4 degradation as tetherin 
inactivation takes place outside the ER, but the exact mechanism still remains 
somewhat unclear. Artificial retention of Vpu in the ER results in its inability to 
counteract tetherin-mediated virus restriction (Schubert and Strebel, 1994) (Skasko et 
al., 2011) (Vigan and Neil, 2011). However, it is known that Vpu downmodulates cell 
surface tetherin (Van Damme et al., 2008) and decreases total cellular tetherin levels 
(Goffinet et al., 2009). This is achieved by redirecting tetherin to endosomal 
compartments for lysosomal degradation through an ESCRT-dependent mechanism 
(Douglas et al., 2009) (Janvier et al., 2011) (Agromayor et al., 2012). 
 
1.7.3.1 Vpu and tetherin interaction 
Vpu and tetherin directly interact via their respective TM domains, and this physical 
interaction is essential for Vpu-mediated tetherin antagonism (Iwabu et al., 2009) 
(Mangeat et al., 2009) (Perez-Caballero et al., 2009) (Dubé et al., 2010b) (Vigan and 
Neil, 2010) (McNatt et al., 2013). This interaction is also species-specific and explains 
the inability of HIV-1 Vpu to counteract other primate tetherins with the exception of 
chimpanzee and gorilla (McNatt et al., 2009) (Gupta et al., 2009a). In particular the 
species-specific amino acids I34, L37 and L41 in the TM domain of tetherin are crucial 
for direct interaction with HIV-1 Vpu, and mutations at any of these residues make 
tetherin molecules resistant to Vpu activity (Kobayashi et al., 2011) (McNatt et al., 
2009) (Gupta et al., 2009a). The residues I34, L37 and L41 also lie along one face of 
the tetherin TM helix (Figure 1-26), suggesting that they present a binding interface 
between the two proteins (Dubé et al., 2010b) (Kobayashi et al., 2011). In addition to 
the TM residues, a threonine at position 45 in the transmembrane/ectodomain 
boundary of tetherin is essential for tetherin/Vpu interaction (Gupta et al., 2009a) 
(McNatt et al., 2009) (Kobayashi et al., 2011).     
Extensive mutagenesis studies of the transmembrane domain of HIV-1 NL4.3 Vpu 
identified three amino acid positions A14, A18 and W22 that are required for direct 
tetherin binding. Interestingly, these residues are part of a highly conserved “alanine 
face” in the TM domain of Vpu, A10xxx(A/V)14xxxA18xxxW22 (Figure 1-26). Amino acids 
important for direct interaction in both proteins lie on the same helical interface, 
suggesting that Vpu molecules target tetherin as a monomer (Vigan and Neil, 2010) 
(Kobayashi et al., 2011) (Skasko et al., 2011). The alanine face is conserved in HIV-1 




in the predicted multimeric form of Vpu (Park et al., 2003), the alanine face would be 
obstructed by neighbouring monomers (Vigan and Neil, 2010).  
The tryptophan residue at position 22 in the Vpu TM domain has been suggested to 
regulate the transition of Vpu between monomeric and multimeric forms inside the ER 
(Magadán and Bonifacino, 2012). According to this study, Vpu induces CD4 
degradation in its monomeric form, mutations of W22 stabilise multimeric complexes 
and therefore inhibit CD4 degradation. Whether this scenario is also true for tetherin 




Figure 1-26 Vpu and tetherin transmembrane domains directly interact 
(A) Schematic representation of direct binding between Vpu and tetherin transmembrane domains. (B) 
NMR-based model of Vpu and tetherin transmembrane domain interactions. Highlighted in red are 
residues in the Vpu alanine face; highlighted in blue are residues in tetherin that are important for physical 














1.7.3.2 Subversion of tetherin’s trafficking by Vpu 
Vpu induces tetherin cell surface downmodulation, and this is required for tetherin 
antagonism at high surface expression levels. However, the endocytosis rate of 
tetherin is not increased by Vpu expression (Mitchell et al., 2009) (Miyagi et al., 2009) 
(Dubé et al., 2010b) (Schmidt et al., 2011), neither does Vpu remove tetherin from lipid 
rafts (Fritz et al., 2012) (Lopez et al., 2012), highlighting the importance of differential 
trafficking and sequestration of tetherin in cellular compartments like the TGN and/or 
endosomes as a mechanism of Vpu activity (Varthakavi et al., 2006). Tetherin 
degradation is dispensable in some systems for the ability of Vpu to antagonise its 
function, indicating that alteration of cellular tetherin trafficking and/or recycling by Vpu 
is the key to keeping tetherin away from the site of virus particle release. Multiple 
studies have demonstrated that Vpu and tetherin co-localise predominantly in the TGN 
and endosomal compartments where tetherin appears to be sequestered (Dubé et al., 
2010b) (Dubé et al., 2011) (Schmidt et al., 2011).  Furthermore, Vpu mutants that are 
not able to localise in the TGN have an intermediate effect on tetherin antagonism, 
again suggesting that re-direction of tetherin into the TGN is important for Vpu-
mediated antagonism (Dubé et al., 2009).  
As discussed in section 1.6.1, clathrin adaptors AP-2 and AP-1 are involved in tetherin 
endocytosis and its subsequent delivery to the TGN for recycling. Inhibition of tetherin 
endocytosis by AP-2 knockdown or overexpression of dominant negative dynamin 2 
rescues tetherin cell surface levels in Vpu-expressing cells to some extent (Iwabu et 
al., 2009) (Mitchell et al., 2009) (Lau et al., 2011). However, this treatment also 
interferes with the natural turnover and recycling of tetherin, making these results 
difficult to interpret. Treatment of cells with monensin, an inhibitor of the fast recycling 
route, indicated that tetherin recycles through a slow-recycling pathway (Figure 1-27A) 
(Dubé et al., 2011) (Schmidt et al., 2011). Therefore, Vpu potentially has to antagonise 
two different tetherin pools in infected cells: newly synthesised and slow-recycling 
tetherin. By using the anti-malaria drug primaquine, a lysosomotropic amine, tetherin 
cellular trafficking can be subverted and HIV-1 virus release can be rescued similar to 
Vpu’s effect on tetherin, implicating that Vpu alters tetherin trafficking/recycling as well 
as anterograde trafficking pathways (Figure 1-27B) (Schmidt et al., 2011). Another 
study highlighted the trafficking subversion effect of tetherin by Vpu using brefeldin A 
(BFA) (Lau et al., 2011), a reagent that increases the retrograde protein transport from 
the Golgi network to the endoplasmic reticulum by causing the collapse of the Golgi 
network, and therefore induces protein accumulation in the ER (Miller et al., 1992). Vpu 
inhibits tetherin recycling to the plasma membrane in BFA treated cells, suggesting an 





Figure 1-27 Model of Vpu-mediated cell surface downmodulation of tetherin 
(A) Schematic representation of tetherin trafficking/recycling in the absence of Vpu. Tetherin reaches the 
plasma membrane through the anterograde trafficking pathway. Tetherin is endocytosed in AP-2-mediated 
clathrin-coated pits, transported to the TGN through the interaction with AP-1, and recycles back to the cell 
surface. (B) Schematic representation of tetherin trafficking/recycling in the presence of Vpu. Vpu interacts 
with tetherin in the endoplasmic reticulum (ER) or Golgi compartments, thereby targeting either newly 
synthesized or recycling tetherin molecules. Vpu/tetherin complexes are then targeted to endosomal 
compartments, simultaneously Vpu-mediated recruitment of SCF-β-TrCP leads to the ubiquitination of 
tetherin on multiple cytoplasmic tail residues. In early/sorting endosomal compartments, ubiquitin-
dependent recruitment of HRS promotes sorting of Vpu/tetherin complexes for ESCRT-dependent 


































Overexpression experiments with the C-terminal domain of the clathrin sequestering 
protein AP180, demonstrated a requirement for clathrin in the cellular redistribution of 
tetherin molecules and counteraction by Vpu (Lau et al., 2011) (Kueck and Neil, 2012). 
Further evidence for the importance of differential trafficking of tetherin in the TGN 
and/or recycling compartments comes from the identification of an acidic di-leucine 
trafficking motif, ExxxLV, in the second alpha helix of Vpu. This motif is required for 
efficient virus release from interferon-treated CD4+ T cells, tetherin cell surface 
downregulation and ESCRT-dependent degradation of tetherin/Vpu complexes (Kueck 
and Neil, 2012). However, the ExxxLV motif is missing in the second alpha helix in 
HIV-1 subgroup C and F Vpu proteins, and instead both Vpu proteins contain ExxxLL 
motifs in their first alpha helices (Ruiz et al., 2008). Whether these putative trafficking 
motifs also play a role in tetherin antagonism is not yet known. The exact role of 
clathrin in this mechanism remains unclear and requires further investigation. There are 
still open questions about the mechanism of Vpu-mediated tetherin antagonism, 
including where within the cellular compartments Vpu redirects tetherin molecules for 
degradation and directions of trafficking per se. Results presented in Chapter 4 and 
Chapter 6 concentrate on answering some of the above-mentioned questions and will 





1.7.3.3 Degradation of tetherin mediated by Vpu 
Vpu diminishes cell surface tetherin levels and induces subsequent tetherin 
degradation in both HIV-1 infected cells as well as in cells expressing Vpu in trans (Van 
Damme et al., 2008). It has been under debate whether this degradation is 
proteasomal or endo-lysosomal as inhibitors for both pathways restore cellular tetherin 
levels. However, reports that tetherin was degraded by the proteasome were 
subsequently shown to be artificial (reviewed by (Le Tortorec et al., 2011)).  
Furthermore, tetherin degradation by Vpu has been shown to be ubiquitin-dependent, 
but there have been conflicting reports about which residues in the tetherin cytoplasmic 
tail are ubiquitinated and important for antagonism. Tetherin undergoes mono-
ubiquitination on lysine residues 18 and/or 21 (Pardieu et al., 2010), and mutation of 
these residues completely blocks Vpu-mediated tetherin degradation (Goffinet et al., 
2010). Further studies also demonstrated the importance of serine and threonine 
residues, in the tetherin cytoplasmic tail, as poly-ubiquitin acceptors required for cell 
surface downregulation and efficient virus particle release (Tokarev et al., 2011). 
However, another study showed that mutation of all the above-mentioned possible 
ubiquitin acceptor residues still led to ubiquitination and subsequent tetherin 
degradation, indicating that Vpu might also target tyrosine residues within the 
cytoplasmic tail or the NH2 terminus of tetherin for ubiquitination (Gustin et al., 2012). 
Taken together, these results demonstrate the involvement of ubiquitin in Vpu-
mediated tetherin cell surface downregulation, degradation and subsequent virus 
particle release. However, this appears to be a complex process that requires further 
clarification.  
The ubiquitination of tetherin is thought to be dependent on the phosphorylation of two 
serine residues within the conserved DSGNES motif in cytoplasmic tail of Vpu and 
subsequent recruitment of the E3 ubiquitin ligase complex SCFTrCP (Margottin et al., 
1998) (Butticaz et al., 2007) (Mangeat et al., 2009) (Douglas et al., 2009) (Mitchell et 
al., 2009) (Iwabu et al., 2009) (Goffinet et al., 2009). Targeted mutagenesis of the two 
serine residues leads to the disruption of Vpu and β-TrCP interactions, resulting in a 
partial block of tetherin surface down-modulation. However, this Vpu phospho-mutant 
still retains some capacity to promote virus particle egress (Van Damme et al., 2008) 
(Mitchell et al., 2009), indicating that other cellular pathways such as protein trafficking 
might also play an important role in Vpu-mediated tetherin antagonism. Therefore, one 
could conclude that Vpu-mediated tetherin antagonism is not solely dependent on the 
degradation of the restriction factor and further studies are required to clear 




Evidence for an endo-lysosomal degradation of tetherin by Vpu comes from studying 
Rab GTPases, which are required for diverse membrane trafficking events. The 
GTPase Rab7A plays a role in the organisation and maturation of endocytic 
compartments as well as fusion of endosomes and phagosomes with lysosomal 
compartments (reviewed by (Huotari and Helenius, 2011)). Rab7A is involved in Env 
processing and therefore required for HIV-1 virus release and virus particle infectivity. 
Importantly, depletion of Rab7A leads to the accumulation of virions at the cell surface. 
This implies a role for Rab7A in the late stages of the HIV-1 replication cycle and 
highlights the importance of multi-vesicular trafficking events during the HIV-1 
propagation cycle (Caillet et al., 2011).  
The ESCRT machinery is required for natural tetherin turnover. In particular, the 
ESCRT-0 component HRS, which binds ubiquitinated transmembrane cargo molecules 
and induces sorting of these ubiquitin-tagged molecules for lysosomal degradation 
(Raiborg and Stenmark, 2009). Janvier and colleagues demonstrated that HRS is 
required for efficient virus particle release and Vpu-mediated tetherin cell surface 
downregulation as well as degradation (Janvier et al., 2011). The recently discovered 
UBAP1, a subunit of the human ESCRT-I complex, which is required for the endosomal 
degradation of ubiquitinated proteins but not for any other ESCRT-I-related functions 
(Stefani et al., 2011) (Agromayor et al., 2012), makes it possible to differentiate 
between Vpu-mediated tetherin antagonism and subsequent tetherin degradation 
(results are presented in Chapter 5) (Agromayor et al., 2012). Depletion of cellular 
UBAP1 levels resulted in a block of tetherin degradation and an increase of highly 
ubiquitinated tetherin forms in HIV-1 infected cells, suggesting that, in the presence of 
Vpu, tetherin is sorted for degradation by an ubiquitin-dependent multivesicular body 
(MVB) pathway (Agromayor et al., 2012). Therefore, despite increased cellular tetherin 
levels in UBAP1 depleted cells, the release of infectious virus from cells infected with 
wild-type HIV-1 is not affected, suggesting that Vpu inactivates tetherin by shuttling it 
into endosmal compartments from which it cannot escape (Agromayor et al., 2012). In 
other words, the commitment of Vpu/tetherin complexes for degradation is enough to 
enhance virus particle release but the final degradation is dispensable for Vpu-





1.7.3.4 Tetherin, a significant barrier to SIV zoonoses 
The chimpanzee simian immunodeficiency virus (SIVcpz) was generated by 
recombination events between two SIV lineages that infect old world monkeys (Figure 
1-28). The 3’ end of the SIVcpz genome including the nef gene is closely related to SIV 
red-capped mangabeys (SIVrcm), while the vpu, tat, rev and env genes are related to 
SIVs that infect several species, including SIV greater spot-nosed (SIVgsn), SIV 
mustached (SIVmus) and SIV mona (SIVmon) monkeys (reviewed by (Sharp and 
Hahn, 2011)). This complex mosaic genome suggests that chimpanzees obtained SIV 
by hunting and killing of other monkeys. In turn, there have been at least four 
independent cross-species transmission events that transferred SIVcpz into humans, 
resulting in distinct lineages of HIV-1 called groups M, N, O and P. While groups M and 
N are derived from SIVcpz strains found in Pan troglodytes troglodytes (SIVcpzPtt), 
group P is derived from SIV gorilla (SIVgor) and the origins of group O remain unclear 
(Figure 1-28) (reviewed by (Sharp and Hahn, 2011)). The HIV-1 group M gave rise to 
the AIDS pandemic whereas group O represents less than 1% of global HIV-1 
infections, while for group N and group P only a limited number of sequences is 
available due to a low number of incidences and/or documented cases.       
 
 
Figure 1-28 Human immunodeficiency virus origins 
Schematic representation of the origins of HIV viruses. Old work monkeys are naturally infected with more 
than 40 different simian immunodeficiency viruses (SIVs), the suffix denotes their primate species of origin, 
for example SIVsmm stands for sooty mangabey. Highlighted in red are known cross-species 





HIV-1 and viruses from the SIVgsn/mus/mon lineage use their Vpu protein to bind to 
the tetherin transmembrane domain and to induce cell surface removal and 
degradation (Sauter et al., 2009). Yet, despite encoding a vpu gene, SIVcpz uses its 
Nef protein to counteract tetherin restriction. Upon cross-species transmission into 
humans, however, the SIVcpz Nef protein was inactive against the human tetherin 
protein due to the deletion of the Nef target motif in human tetherin (G/DIWKK) that 
occurred at least 800,000 years ago, as the deletion was present in Neanderthals and 
Denisovans (Sauter et al., 2011a). During cross-species transmission, only HIV-1 
group M switched from Nef to Vpu to enhance virus release in its new human host. On 
the other hand, HIV-2, which originated from SIV sooty mangabey monkeys (SIVsmm) 
(Figure 1-29) and does not encode a vpu gene, switched from Nef to its Env 
glycoprotein to suppress tetherin restriction. This switch might have come at a price, as 
Env is a major structural protein that is required for virus entry and has evolved to 
downregulate tetherin from the cell surface and to sequester tetherin in intracellular 
compartments, which might reduce the number of Env molecules incorporated into 
virus particles. One could speculate that this is one of the reasons why HIV-2 is less 
virulent than HIV-1.  
 
Figure 1-29 Tetherin antagonists in primate hosts 
Schematic representation of tetherin antagonists in HIV-1 and HIV-2 as well as in their predecessors. 
SIVcpz acquired its vpu gene from the SIVgsn/mus/mon lineage and its nef gene from the SIVrcm lineage. 
During adaptation in chimpanzees, Nef has evolved to become a tetherin countermeasure. Both SIVgor 
and SIVsmm also use their Nef proteins to antagonise tetherin function. During adaptation in humans, 
SIVcpz, SIVgor, and SIVsmm Nef proteins were unable to counteract human tetherin due to a five amino 
acid deletion in tetherins cytoplasmic tail. In HIV-1 group M, Vpu has evolved to regain efficient anti-
tetherin function. Both Nef and Vpu proteins of HIV-1 groups O and P are poor tetherin countermeasures, 
while the HIV-1 group N Vpu protein regained modest anti-tetherin function. HIV-2 group A has evolved to 
use Env to counteract tetherin function. Highlighted in red are proteins that are able to antagonise tetherin 




Of note, HIV-1 group M is the only group that successfully regained Vpu-mediated anti-
tetherin function (Figure 1-29). HIV-1 group O Vpu proteins have no anti-tetherin 
activity due to their lacking of the tetherin-interacting alanine face in their TM domain 
(Yang et al., 2011) (Vigan and Neil, 2011). So far, only two group P Vpu proteins have 
been isolated and tested for their ability to antagonise tetherin and both fail to inactivate 
tetherin function. Nor can group P Nef or Env proteins remove tetherin from virus 
budding zones (Sauter et al., 2011b) (Yang et al., 2011). However, both groups O and 
P Vpu proteins maintain the ability to induce CD4 degradation (Sauter et al., 2009) 
(Sauter et al., 2011b). Most group N Vpu proteins are also poor tetherin antagonists 
(Sauter et al., 2009), yet, in contrast to group O, Vpu proteins from group N have the 
above-mentioned alanine face and interact with tetherin (Vigan and Neil, 2010). 
However, most N Vpu proteins lack the DSGNES phosphorylation and ExxxLV 
trafficking motifs rendering them unable to degrade CD4 and tetherin (Sauter et al., 
2012). Interestingly, one group N Vpu has undergone adaptation to tetherin, which has 
been associated with pathogenesis. This new N Vpu has been isolated from an 
individual returning to France from a trip to Togo, a country with no prior record of non-
group M HIV-1 infections. The adaptation determinants map to residues in the 
transmembrane domain, and repair of the DSGNES and ExxxLV motifs, resulting in a 
highly efficient N Vpu protein that is able to reduce tetherin surface expression and to 
induce degradation (Sauter et al., 2012). This case demonstrates that the HIV-1 group 
N is under strong host-specific pressure, and that adaptation to acquire an effective 
tetherin countermeasure may increase viral fitness. Thus, the general inability of HIV-1 
groups N, O and P to efficiently antagonise human tetherin might explain the limited 





1.7.4 Vpu suppresses cellular innate immune responses by downmodulation of 
NTB-A and CD1d  
NK cells play an important role in the innate immune system. They possess the ability 
to produce immunoregulatory cytokines and to mediate target cell lysis through the 
release of cytoplasmic lytic granules in a process called degranulation. The ability of 
NK cells to destroy virus-infected cells is dependent on interactions between NK cell 
surface receptors and their corresponding ligands presented on the surface of target 
cells. NKG2D is one such NK cell activation receptor that recognises stress-induced 
molecules, such as MIC-A, as well as ULBP-1 and -2. Activation of NK cells via 
NKG2D (referred to as signal 1 in Figure 1-30) is necessary but not sufficient to induce 
production of lytic granules. Degranulation also requires the concomitant activation of a 
co-receptor (referred to as signal 2) (reviewed by (Bryceson et al., 2006)). The NK-T 
and B cell antigen (NTB-A (also termed SLAMF6)) serves as such an activation co-
receptor to mediate the release of lytic granules. NTB-A is a type 1 transmembrane 
protein that functions as a homotypic ligand-co-activator of NK receptors and belongs 
to the signalling lymphocytic activation molecule (SLAM) family. 
HIV has developed strategies to regulate various NK cell ligands, making the infected 
cell surprisingly refractory to NK cell lysis (Bonaparte and Barker, 2003). This is baffling 
because the HIV-1 accessory protein Vpr is able to enhance expression levels of 
ligands for NKG2D (Ward et al., 2009), and Nef is able to remove the inhibitory ligands 
HLA-A and -B from the surface of infected cells (Cohen et al., 1999).  
A recent study demonstrated that the HIV-1 Vpu protein interferes with NK cell 
degranulation by reducing NTB-A cell surface levels of infected cells (Shah et al., 
2010). NTB-A downregulation by Vpu is mechanistically distinct from CD4 and tetherin 
cell surface downmodulation. The reduction of surface NTB-A levels was shown to be 
independent of β-TrCP recruitment and Vpu did not affect steady-state levels of NTB-A. 
However, Vpu/NTB-A interaction was dependent on Vpu’s transmembrane domain, 
and Vpu did not increase the endocytosis rate of NTB-A to reduce cell surface 
expression. Therefore the authors suggested a mechanism in which Vpu alters the 
trafficking and/or recycling of NTB-A and sequesters NTB-A in an intracellular 
compartment. Indeed, Vpu has been shown to affect the glycosylation pattern of newly 
synthesised NTB-A molecules by a post-ER mechanism, suggesting that Vpu interferes 
with the anterograde transport of NTB-A in the TGN (Bolduan et al., 2013). Therefore, 
Vpu-induced downmodulation of NTB-A might provide an explanation for the inability of 
NK cells to mediate killing of virus-infected cells despite their strong activation status. 
However, in vivo studies using humanized mouse models of acute HIV infection 




Vpu-dependent manner, unlike CD4 and tetherin (Sato et al., 2012) (Dave et al., 2013). 
More studies are required to understand how HIV-1 balances activation and inhibition 
of degranulation in vivo. 
Polymorphisms in the HIV-1 Vpu/Env overlapping coding region have been associated 
with the inhibitory receptor killer immunoglobulin-like receptor, two domains, long 
cytoplasmic tail, 2 (KIR2DL2) and its ligand HLA-C. This link suggested that the 
polymorphisms enhance the ability of the inhibitory receptor KIR2DL2 to bind to HIV-1-
infected cells, providing a strong inhibitory signal to KIR2DL2 positive NK cells and 
thereby protecting HIV-1 infected cells (with Vpu/Env polymorphisms) from lysis by NK 
cells (Alter et al., 2011). 
Vpu has also been reported to downmodulate CD1d from the surface of HIV-1 infected 
DCs (Figure 1-30) (Moll et al., 2010). CD1d is a MHC class I-like membrane-associated 
protein expressed by antigen-presenting cells (APCs). The role of CD1d during a viral 
infection is to present pathogen-derived lipid antigens to CD1d-restricted natural killer T 
(NKT) cells, resulting in the mutual activation of both cells and subsequent initiation of 
cellular immune responses. Activated NKT cells rapidly secrete T helper type 1 and 2 
cytokines to activate and regulate various other cell types, including DCs, NK cells, B 
cells and conventional T cells. As observed with NTB-A, Vpu did not enhance CD1d 
endocytosis or induced rapid CD1d degradation. Instead, Vpu was found to interact 
with CD1d and to inhibit CD1d recycling from endosomal compartments back to the cell 
surface by retaining CD1d in early endosomes. Therefore, preventing antigen loading 
of CD1d in late endosomes strongly inhibits the ability of infected DC to activate CD1d-
restricted NKT cells. 
The increasing number of membrane-associated cell surface receptors involved in 
innate immune responses, and targeted by HIV-1 Vpu, promotes the potential role of 






Figure 1-30 Vpu induces CD1d and NTB-A cell surface downregulation 
Vpu expression leads to the cell surface downmodulation of tetherin (left), CD1d (middle) and NTB-A 
(right). Reduced CD1d cell surface levels prevent the presentation of lipid antigens to CD1d-restricted NKT 
cells, therefore avoiding their activation. Reduced cell surface levels of NTB-A protect infected cells from 
NK-cell-mediated killing, since both NTB-A- and NKG2D-triggered signals are required for NK-cell-





1.8 The clathrin adaptor machinery and its role in cellular vesicle 
trafficking 
1.8.1 Clathrin coats involved in vesicular transport 
Clathrin-coated vesicles (CCVs) are important for lipid and soluble macromolecule 
transport between membrane-bound compartments. Vesicles bud from a cellular donor 
compartment and fuse with an acceptor compartment. Selection of cargo molecules 
and vesicle budding are mediated by coat-proteins that are recruited from the 
cytoplasm to assemble at membranes; the most common scaffolding coat protein is 
clathrin. Sites of clathrin assembly are differentially marked by either phosphoinositides 
and/or Arf proteins, which recruit adaptor proteins (APs). Adaptor proteins bind to 
signals present within cytosolic domains of transmembrane cargo molecules and 
simultaneously serve as clathrin anchors for coat formation, leading to the capture of 
cargo proteins at sites of vesicle formation (Figure 1-34). The donor membrane curves 
and a spherical clathrin-coated vesicle is formed, the role of which is to transport cargo 
molecules to their corresponding destination (Canagarajah et al., 2013). The GTPase 
dynamin 2 mediates the pinching of CCVs at the donor membrane, by formation of a 
spiral around the neck of the vesicle that is restrained through GTP hydrolysis 
(Bonifacino and Traub, 2003). The clathrin adaptor machinery plays an important role 
in the biogenesis and function of endosomes and lysosomes. The correct transport 
orientations are crucial: at the plasma membrane proteins can be endocytosed and 
delivered to endosomes; at the TGN there is the choice between transport to the 
plasma membrane or endosomes; and at endosomes proteins can be recycled, 
delivered back to the TGN, or delivered to lysosomes for degradation (Figure 1-31). 
This complicated system is highly regulated by sorting signals and the different highly 







Figure 1-31 Adaptor protein sorting pathways 
Simplified representation of adaptor protein sorting pathways leading to endosomal and lysosomal 
compartments. The assumed cellular localisation and sites of action of different adaptor proteins are 
indicated next to the corresponding cellular organelle or arrows. 
 
Abnormalities in clathrin adaptor transport pathways can lead to a variety of diseases 
including Huntington’s disease, leukaemia, Alzheimer’s disease, Hermansky Pudlack 
syndrome and familial hypercholesterolemia (Lafer, 2002). Viruses hijack clathrin-
mediated trafficking pathways both to gain entry into host cells and for immune 
evasion.  
 
1.8.2 Clathrin-binding and coat formation 
At least 20 clathrin-binding proteins have been identified in the last few years, including 
well-characterised adaptor proteins AP-1, AP-2, HRS, AP180 and gamma adaptin ear-
containing, ARF-binding (GGA) proteins. All adaptor proteins contain long unstructured 
regions that contain one or more mostly short and linear clathrin-binding motifs. 
These motifs interact with the β-propeller head of clathrin, which is located at the N-
terminus of the clathrin heavy chain (CHC), called the terminal domain (TD). The 
nature of these interactions is of a relatively weak binding strength and short half-life 
(Kd= 1-100 µM and t1/2= 1-10 seconds respectively) (Edeling et al., 2006). Clathrin-
binding peptides are often called “clathrin boxes”. As more and more clathrin boxes are 
discovered it becomes increasingly difficult to find a common consensus sequence. 
However, when all known clathrin-binding sequences are aligned the best consensus 
match is ρLφρφρ (ρ= polar residue and φ= aliphatic hydrophobic residue) in which 

















The unassembled cytosolic form of clathrin is comprised of 3 heavy and 3 light chain 
molecules, which is termed a triskelion. As the triskelia assemble, they form basket like 
structures with pentagonal and hexagonal faces. The light chains regulate clathrin-
coated vesicle dynamics (Figure 1-32 A and B) (Lafer, 2002).  
 
 
Figure 1-32 The clathrin triskelion 
(A) Schematic representation of a clathrin basket with a single triskelion highlighted in blue. (B) Clathrin 
triskelion representation. Three clathrin heavy chains are depicted and highlight the various heavy chain 
domains using different colours (see key) (adapted from (Edeling et al., 2006)).  
 
1.8.3 Structure and function of adaptor protein complexes 
Adaptor proteins (APs) play a major role in selecting cargo molecules designated for 
intracellular transport via clathrin-coated vesicles. The first identified and best-
characterised clathrin adaptor proteins are AP-1 and AP-2. They are part of a larger 
heterotetrameric adaptor complex family that also includes AP-3, AP-4 and newly 
identified AP-5. All five adaptor protein complexes are made up of two large, one 
medium and one small subunit. All complexes form a large core domain with two 
unstructured joint segments, each ending with an ear or appendage region (Figure 
1-33) (Canagarajah et al., 2013). The medium µ subunit is part of the core and has 
been shown to swing out of the core upon activation of the complex on membranes. 
The µ subunit and the small σ subunit form the core complex and are responsible for 
binding of tyrosine-based and acidic dileucine-based sorting signals respectively 
(binding to the interface of AP-1 γ-σ and AP-2 α-σ subunits). The hinge or joint 
domains contain direct clathrin-binding sequences that are known to bind to the clathrin 














Figure 1-33 Adaptor protein (AP) complexes 
Schematic representation of all members of the heterotetrameric adaptor protein machinery. Listed 
properties include the scaffolding protein with which they are known to associate, the sorting signals that 
they interact with, and their intracellular localisation (adapted from (Canagarajah et al., 2013)). 
 
The AP-1 complex (consisting of subunits: β, γ, µ and σ) machinery has mainly been 
described to mediate bi-directional transport between the TGN and endosomes. The 
GTPase Arf1 targets AP-1 to membranes and induces an allosteric change in AP-1, 
therefore activating the complex. The phosphoinositide, PI(4)P, might complement 
Arf1-mediated activation of the AP-1 complex (Figure 1-34) (reviewed by (Canagarajah 
et al., 2013)). The AP-2 complex (consisting of subunits: β, α, µ and σ) has been 
shown to be exclusively responsible for endocytosis of transmembrane cargo proteins 
and subsequent delivery to endosomal compartments. AP-2 is activated on 
membranes by interaction with the phosphoinositide, PI(4,5)P2, however the 
mechanism is still unclear (Figure 1-34) (reviewed by (Canagarajah et al., 2013)).   
 
 
Figure 1-34 Clathrin coat formation 
Schematic representation of clathrin coat formation in case of AP-1 and AP-2. Left diagram: AP-1 is 
recruited to membranes by interaction with GTP-bound Arf1 and PI(4)P which are located at TGN or 
endosomal compartments. Right diagram: AP-2 is recruited to membranes by interaction with PI(4,5)P2  
which is located at the plasma membrane. Recruitment to membranes positions the adaptor proteins to 
interact with transmembrane cargo proteins, and the adaptor proteins also serve as attachment sites for 
formation of clathrin into a polyhedral coat (adapted from (Canagarajah et al., 2013)). 
‘‘locked’’ conformation where the binding sites for
both types of signal are occluded and an ‘‘unlocked’’
conformation where both sites are accessible for bind-
ing.15–18 The hinge sequences have clathrin-binding
motifs that bind to the ‘‘terminal domain’’ of the cla-
thrin heavy chain, while the ears bind a slew of
‘‘accessory proteins’’ that serve as additional adaptors,
regulators of AP activation or CCV formation, or
links to cytoskeletal elements.4 The hinge-ear
domains are also thought to undergo conformational
changes relative to the core that regulate interactions
of AP complexes with their binding partners.19 Differ-
ential interactions with Arf and phosphoinositides,
with probable contributions of accessory proteins,
determine distinct intracellular localizations and
functions for AP-1 and AP-2.4 AP-1 has been ascribed
multiple functions, including transport between the
trans-Golgi network (TGN) and endosomes (in both
directions) and sorting from the TGN or endosomes
to different plasma membrane domains of polarized
cells. AP-2, on the other hand, is exclusively involved
in rapid endocytosis of a subset of transmembrane
proteins from the plasma membrane.
The YxxU Binding Site
The structure of the YxxU binding site was eluci-
dated first for the l2 subunit of AP-2.9 YxxU signals
bind to the C-terminal domain of l2, a nearly all
b-sheet sandwich structure that consists of two
subdomains, A and B. The YxxU motif binds by
b-augmentation to one edge of a sheet on subdomain
A [Fig. 3(A)].9 ‘‘b-augmentation’’ refers to a peptide
or protein binding mode involving the incorporation
of the bound ligand as one or more additional
strands of the b-sheet. The other key interactions
are made by the Tyr residue and the hydrophobic
residue U. The aromatic side-chain of the Tyr stacks
with those of surrounding Trp, Tyr, and Arg resi-
dues, and its hydroxyl is hydrogen-bonded with a
conserved Asp residue. The U residue is bound in a
hydrophobic pocket formed at the juncture of the b-
sheet sandwich. It was anticipated that the l subu-
nits of other AP complexes would bind YxxU signals
in the same way, given that the interaction site is
well conserved. Although there is no available crys-
tal structure of l1 bound to a canonical YxxU com-
plex structure, a YSQA sequence from the cytosolic
tail of MHC-I in complex with HIV-1 Nef binds to
the equivalent site on l1 [Fig. 3(B)].20 Recent evi-
dence shows that the l3 subunit of AP-3 binds the
canonical YQRL sequence from TGN at the pre-
dicted site.21 In an exception to this pattern, an
unconventional version of the signal, YKFFE, binds
to the l4 subunit of AP-4 on the opposite edge of the
Figure 2. The adaptor protein (AP) complex family. Schematic representation of members of the heterotetrameric adaptor
protein (AP) complex family and summary of their properties. The color scheme reflects the homology among the
corresponding subunits. The listed properties include the scaffolding prot in with which they associate, the GTPase and/or
phosphoinositide lipid that regulate their recruitment to membranes, the sorting signals that they recognize, and their
intracellular localization. SPG11 is a ‘‘clathrin-like’’ protein that is mutated in autosomal recessive spastic paraplegia type 11.
The a-b’-e-COP subcomplex plays a role similar to that of clathrin in the COPI coat. Sorting signal motifs are denoted
according to the PROSITE pattern syntax. U is a bulky hydrophobic amino acid.
Canagarajah et al. PROTEIN SCIENCE VOL 22:517—529 519
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The mammalian AP-3 complex (consisting of subunits: β, δ, µ and σ) has been shown 
to bind to clathrin in vitro and to co-localise with clathrin in vivo, however the exact 
function of AP-3 is still unclear. It is thought to play a role in clathrin-independent 
sorting from tubular endosomes to late endosomes and lysosomes (Hirst et al., 2011). 
The AP-4 complex (consisting of subunits: β, ε, µ and σ) localises to the TGN and 
contains putative clathrin-binding sequences, however, no binding to clathrin has been 
detected to date. AP-4 is thought to be part of a non-clathrin coat associated with the 
TGN (Lafer, 2002) and has been shown to traffic the amyloid precursor protein from the 
TGN to endosomes (Hirst et al., 2011). Whether AP-3 and AP-4 are involved in 
clathrin-dependent sorting requires further research. The recently identified and 
probably final member of the clathrin adaptor family is AP-5 (consisting of subunits: β, 
ζ, µ and σ), which has been shown to localise to late endosomal compartments and is 
a component of non-clathrin coats. AP-5 is thought to participate in endosomal sorting 
and is linked to hereditary spastic paraplegia, which is a human genetic disorder that 
causes progressive spasticity (Hirst et al., 2011). 
 
1.8.4 Tyrosine-based sorting signals 
The best-characterised tyrosine-based sorting signals are Yxxφ  motifs. This clathrin 
adaptor binding site is known to mediate rapid endocytosis from the plasma 
membrane; targeting of cargo proteins for lysosomal degradation; and cargo trafficking 
from the TGN to endosomes, and vice versa. The Y position is indispensable and 
cannot be replaced by other aromatic amino acids. The residue φ at position 4 can 
accommodate different bulky hydrophobic residues, which are thought to specify the 
nature of the signal. Positions 2 and 3 can be flexible but tend to be hydrophilic 
residues. Residues flanking the Yxxφ  motif can also contribute specificity and strength 
of the signal. Yxxφ  motifs have been shown to interact with clathrin adaptors AP-1, AP-
2, AP-3 and AP-4. They bind to the core subunit µ with relatively weak affinity (Kd= 
0.05-100 µM). The binding of APs to the tyrosine-based sorting signal is dependent on 
the Y and φ residues. The different µ subunits tend to bind to distinctive sets of Yxxφ  
motifs (Bonifacino and Traub, 2003).  
There is also flexibility in the distal end of tyrosine-based sorting motifs. For example, 
the tetherin cytoplasmic tail contains a YxYxxφ  tyrosine sorting motif (discussed in 
1.6.1) that has been shown to bind to the large AP-2 α subunit (Masuyama et al., 2009) 




1.8.5 Dileucine-based sorting signals 
The most studied acidic dileucine-based sorting signal is the (D/E)xxxL(L/I) motif. This 
clathrin adaptor motif is known to mediate rapid endocytosis as well as vesicle 
transport to endosomal and lysosomal compartments. The first leucine residue is 
critical for function. The second leucine residues can be replaced by isoleucine without 
loss of function. An acidic residue at the first position is thought to be responsible for 
the targeting of cargo proteins to late endosomal and lysosomal compartments. A 
second acidic residue or a serine residue further downstream of the (D/E)xxxL(L/I) 
motif can add potency to the signals. The position of the motif within the protein, for 
example, close to the plasma membrane domains (6-11 residues) or close positioning 
to the C-terminus can influence the nature of the signal and is thought to enable 
optimal binding conditions for AP complexes (Bonifacino and Traub, 2003). Some 
(D/E)xxxL(L/I) motifs are recognised by the core of AP complexes at the interface of 
the small σ and the large γ subunit of AP-1; the large α subunit of AP-2; or the large δ 
subunit of AP-3 (Canagarajah et al., 2013). Binding of dileucine-based sorting motifs to 
µ subunits of AP-1, -2, and -3 has also been demonstrated, but, dileucine motifs bind to 
different sites at the µ subunit than tyrosine-based sorting signals (Bonifacino and 
Traub, 2003).  
The HIV-1 accessory protein Nef contains two acidic (D/E)xxxL(L/I) motifs that have 
been shown to bind to µ subunits of AP-1, -2, and -3 and to the  σ- α hemi-complex of 
AP-2, and are important for the downregulation of CD4 (Janvier et al., 2003) 
(Chaudhuri et al., 2007) (Lindwasser et al., 2008) (Ren et al., 2014). 
Another distinct class of dileucine-based sorting signals are the DxxLL motifs, 
important in mediating cargo transport between the TGN and endosomes. The position 
1, 4 and 5 (D, L and L respectively) are strictly required, while the residues 2 and 3 are 
less important for function. DxxLL motifs are unable to bind to traditional clathrin AP 
complexes. Instead they have been shown to interact with the VHS domain of human 
monomeric clathrin-binding GGA proteins (Bonifacino and Traub, 2003). 





1.9 ESCRT pathway and MVB biogenesis 
The conserved ESCRT machinery was first identified in yeast and later on in 
mammalian cells. Early studies performed in yeast knock-out systems identified a 
crucial role for the “class E” vacuolar protein sorting (vps) genes in delivery of cargo 
molecules to the yeast vacuole and endsosome morphology (Raymond et al., 1992). 
These studies helped to characterise the ESCRT-I complex and its role in sequestering 
ubiquitinated cargo at the endosomal membrane and its subsequent delivery into 
multivesicular bodies, (Katzmann et al., 2001) as well as ESCRT-II and -III complexes 
as mediators for the delivery of ubiquitinated cargo to the yeast vacuole (Babst et al., 
2002a) (Babst et al., 2002b). Interestingly, the ESCRT machinery induces 
invaginations that bulge away from the cytoplasm, in a process that is topologically 
inverted from the clathrin-mediated vesicle budding pathways. To date the ESCRT 
machinery consists of five complexes (ESCRT-0, -I, -II, -III and the AAA ATPase 
VPS4), and was found to be involved in topologically-related membrane scission 
events. These can occur during sorting of ubiquitin-labelled membrane proteins into 
invaginations of endosomal membranes, cytokinesis, viral budding of a number of 
enveloped viruses, exosome secretion and autophagy (Figure 1-35) (reviewed by 
(Henne et al., 2011)). 
 
 
Figure 1-35 Divers roles of ESCRT-mediated processes 
The ESCRT machinery plays a role in at least three distinct pathways in mammalian cells (I) MVB 
formation, which delivers ubiquitinated transmembrane cargo proteins to the lysosome for degradation. (II) 











During sorting of ubiquitinated membrane proteins into MVBs all five ESCRT 
complexes are required to be recruited in a sequential manner (see Figure 1-37). The 
ESCRT-0 complex consists of two subunits, HRS (hepatocyte growth factor- regulated 
tyrosine kinase substrate) (for HRS schematic see Figure 5-9A top lane) and STAM1/2 
(signal transducing adaptor molecule 1/2), which interact via their respective coiled-coil 
domains in a 1:1 ratio. The unique feature of ESCRT-0 component HRS is a FYVE 
(Fab-1, YGL023, VPS27 and EEA1) zinc finger domain that binds to the endosomal 
lipid phosphatidylinositol 3-phosphate (PtdIns(3)P), providing specificity and membrane 
recruitment. Both HRS and STAM1/2 have been shown to contain several ubiquitin-
binding motifs. HRS binds mono- and lysine 63-linked poly-ubiquitinated cargo via a 
double-sided ubiquitin-interacting motif (DUIM) (Hirano et al., 2006) and a N-terminal 
VHS (VPS27, HRS and STAM) domain (demonstrated in vitro only) (Ren and Hurley, 
2010). STAM1/2 also contains an ubiquitin-binding domain and an amino-terminal VHS 
domain for ubiquitin binding. It is unclear why the ESCRT-0 complex contains distinct 
ubiquitin interaction domains, but several explanations have been suggested, namely 
to sequester of several different cargo molecules simultaneously, binding of one cargo 
molecule very tightly via multiple interactions, or to engage poly-ubiquitinated cargo 
membrane proteins with high affinity (Ren and Hurley, 2010). In addition to using 
ubiquitin-interacting motifs, ESCRT-0 complexes may also interact with cargo 
molecules through the clathrin machinery. Both HRS and STAM1/2 contain clathrin-
binding motifs. HRS has been shown to bind to the clathrin heavy chain at the 
endosomal membrane, resulting in recruitment into flat clathrin lattice micro-domains 
(Raiborg et al., 2006). There has also been debate as to whether HRS and STAM1/2 
are the only ESCRT-0 components which are able to sort ubiquitinated cargo for 
lysosomal degradation, as there are structurally similar proteins that might provide an 
alternative into the ESCRT machinery (Figure 1-36). Potential candidates are members 
of the GGA protein family and TOM1 or TOM1L1-like proteins which all share common 
molecular features such as VHS domains, ubiquitin-binding motifs, clathrin-binding 







Figure 1-36 Schematic representation of selected VHS domain containing proteins 
Schematic representation of ESCRT-0 VHS domain containing proteins HRS and STAM1 as well as other 
potential ESCRT-0 proteins: GGA3 (GGA1 and GGA2 are similar to GGA3), TOM1 and TOM1L1. In blue 
VHS domain (VPS27, HRS and STAM), in orange FYVE domain (Fab-1, YGL023, VPS27 and EEA1), in 
purple UIM or DUIM motif (double-sided or ubiquitin-interacting motif), in red CB (clathrin box), in pink SH3 
(Src homology-3 domain), in green GAT or GA domain (GGA and TOM1), in yellow GAE (gamma adaptin 
ear) domain, and PSAP and PTAP are ESCRT-I binding motifs. ESCRT-0 core and GAT regions are 
responsible for heterodimerisation. 
 
The ESCRT-I complex consists of TSG101, VPS28, VPS37 and either MVB12 or 
UBAP1 (in a 1:1:1:1 ratio), and is recruited by HRS to the endosome. This recruitment 
is crucial for cargo molecule sorting for lysosomal degradation because ESCRT-I is 
unable to bind to membrane lipids directly. The PSAP motif in HRS binds to the 
ubiquitin E2 variant domain (UEV) at the N-terminus of TSG101. However, as is the 
case with HRS and STAM1/2, ESCRT-I proteins TSG101, MVB12 and UBAP1 have 
been shown to bind ubiquitin. Unlike ESCRT-0, ESCRT-I is not thought to be involved 
in the capture of ubiquitinated cargo proteins. All described ESCRT ubiquitin-binding 
domains bind to the same hydrophobic isoleucine residue 44 of ubiquitin with roughly 
the same low affinity. Therefore ubiquitinated cargo proteins are thought to be passed 
over in a sequentially specific manner from complex to complex (reviewed by (Raiborg 
and Stenmark, 2009)).   
The ESCRT-II complex consists of EAP45, EAP30 and EAP20 (in a 1:1:2 ratio). The 
direct link between ESCRT-I and ESCRT-II in mammalian cells remains unknown. 
However, ESCRT-II recruitment is dependent on the ESCRT-I VPS28 C-terminal 
domain through a helix that is C-terminal to the GLUE domain (reviewed by (Raiborg 
and Stenmark, 2009)). The GRAM-like ubiquitin-binding in Eap45 (GLUE) domain in 
VPS36 binds to ubiquitin and engages PtdIns(3)P lipids and therefore provides specific 
localisation to cellular membranes in a similar manner to the FYVE domain in HRS only 




The mammalian ESCRT-III complex consists of four major “core” subunits called 
charged multivesicular body proteins (CHMP6; 4; 3; 2 and their isoforms). The auto-
inhibited, “closed” conformation and therefore inactive monomeric forms do not localise 
to the endosome. During membrane sculpting events the ESCRT-III components 
recruit one another transiently in a sequential manner to endosomes, where the 
physical contact between subunits induces a conformational change and activates the 
subunits. However, the initial trigger for ESCRT-III subunit release from auto-inhibition 
is still unknown (reviewed by (Henne et al., 2013)). In addition to the “core” subunits, 
there are apoptosis-linked gene-2 interacting protein X (ALIX) and CHMP1 subunits 
that are necessary for MVB sorting and cytokinesis, and increased salt tolerance-1 
(IST1) which is important in cytokinesis only. ESCRT-III lacks the ability to bind 
ubiquitin. However, recently ALIX has been shown to bind to ubiquitin directly, and its 
yeast homolog BCK1-like resistance to osmotic shock protein-1 (Bro1) has been shown 
to function as a cargo recognition subunit for ubiquitinated proteins (Dowlatshahi et al., 
2012) (Pashkova et al., 2013).  
Before cargo proteins are delivered to the lysosome, they must be de-ubiquitinated, a 
process which is important to maintain cellular ubiquitin pools constant. The DUBs 
associated molecular with SH3 domain of STAM (AMSH) and ubiquitin isopeptidase Y 
(UBPY) are recruited by ESCRT-III and ALIX, as well as by the ESCRT-0 component 
STAM. AMSH interacts with both ESCRT-0 and ESCRT-III and has been shown to only 
recognise Lys-63-linked poly-ubiquitin chains, while UBPY interacts only with ESCRT-0 
and has been shown to recognise Lys-63-linked and Lys-48-linked poly-ubiquitin 
chains. The DUBs are thought to de-ubiquitinate cargo proteins that are wrongly sorted 
into the MVB pathway, or to relieve auto-inhibitory mono-ubiquitination of ESCRT-0 
components and remodelling of ubiquitin chains (reviewed by (Raiborg and Stenmark, 
2009)).  
Once the ESCRT-III complex is assembled at the endosomal membrane it requires 
energy to dissociate from the membrane. The only known energy input in MVB 
membrane scission events is provided by the AAA ATPase VPS4. VPS4 binds to 
ESCRT-III components via an microtubule-interacting and trafficking (MIT) domain that 
recognises MIT-interacting motif (MIMs) in ESCRT-III subunits. The role of VPS4 in 
membrane fission is not clear. A possible model for the role of VPS4 involves the 
recycling of ESCRT-III components after abscission, or the stepwise removal of 
ESCRT-III to generate constrictive forces that are crucial for abscission (reviewed by 





Figure 1-37 ESCRT machinery and sorting of ubiquitinated cargo proteins  
(A) Recognition of ubiquitinated transmembrane cargo proteins by ESCRT-0, which are sorted and 
concentrated in clathrin-coated micro-domains. ESCRT-0 recruits ESCRT-I that in turn recruits ESCRT-II, 
this process might initiate membrane involution. (B) ESCRT-III complexes are activated and recruited by 
binding to the ESCRT-II subunit EAP20. Leading to the formation of spiral formed filaments that gate cargo 
proteins into invaginations. Cargo proteins are also de-ubiquitinated by DUBs recruited by ESCRT-III. (C) 
VPS4 disassembles ESCRT-III filaments into its subunits that are being recycled. Followed by membrane 
abscission. 
 
In short, during the final stages of cytokinesis the centrosomal protein 55 (CEP55) is 
recruited to the midbody, in turn recruiting ESCRT-I and ALIX. In the absence of 
ESCRT-II, this functions as a platform to activate and recruit ESCRT-III to the midbody. 
The details of the release of auto-inhibition of ESCRT-III subunits are not known, but 
three models of ESCRT-III-mediated abscission have been proposed. The “spiral-
ingression” model, where ESCRT-III subunit-containing spirals form around and narrow 
the intracellular bridge to initiate final abscission. The “sliding model”, which is similar to 
the above but spirals slide along the midbody to induce abscission. And the “vesicle-
mediated ingression” model, where vesicles derived from the recycling endosome 
cause narrowing of the midbody by fusion with the plasma membrane. VPS4 activity is 
essential during final stages of cell division. The AAA ATPase VPS4 has been shown 
to be recruited by IST1, which can be negatively regulated MIT-domain-containing-
protein 1 (MITD1). Interestingly, IST1 activity is dispensable for MVB formation and 




























thought to generate constrictive forces for membrane severing, or as discussed above 
it might disassembles ESCRT-III subunits that serve as a recycling pool (reviewed by 
(Henne et al., 2013)).           
In short (see 1.3.6 for more detail), during HIV-1 budding, Gag, the major HIV-1 
structural protein recruits ESCRT-I and ESCRT-III complexes through its C-terminal p6 
late-budding domain (L-domains). The p6 P(S/T)AP motif binds the ESCRT-I complex 
TSG101 that in turn recruits ESCRT-III, therefore bypassing the need to bind ESCRT-0 
component HRS. Similarly, the (L)YPXnL motif in p6 provides another platform to 
recruit the ESCRT machinery by binding ALIX. Failure to recruit the ESCRT machinery 
leads to the accumulation of budding deficient virions at the plasma membrane of 





Chapter 2 AIM OF THESIS RESEARCH 
One of the best-characterised examples that illustrate the role of HIV-1 Vpu in 
antagonising cellular innate immune defences is the restriction factor tetherin. The 
studies of the mechanism by which Vpu antagonises the anti-viral function of tetherin 
provide a powerful tool to understand the complex interactions between virus and host. 
In that regard, the aim of this thesis is to contribute to the understanding of the 
mechanism by which Vpu targets tetherin. This thesis includes three chapters of 
experimental data that aim to demonstrate: 
1. The role of the second alpha helix of HIV-1 Vpu in tetherin antagonism. We identified 
a putative sorting signal, ExxxLV, which is required for post-binding trafficking of 
Vpu/tetherin complexes and inhibition of antiviral activity in primary CD4+ T cells.  
2. The importance of the hydrophobic residues in Vpu cytoplasmic helix 1, essential for 
Vpu/HRS interaction, which is dependent on residues that bind ubiquitin in the DUIM of 
HRS.  
3. The cytoplasmic tail mutants Vpu ELV, Vpu LILI and Vpu 2/6A all have the same 







Chapter 3 MATERIALS AND METHODS 
3.1 WORKING WITH DNA 
3.1.1 Polymerase Chain Reaction (PCR)  
PCR is an in vitro method designed to amplify short DNA fragments. It is used to 
replicate the original DNA sample using an enzyme called DNA polymerase, which 
produces new complementary DNA strands.  Two primer pairs are required which 
determine the beginnings of the region to be amplified. This method consists of a 
repetition of a series of cycles and each cycle consists of three different steps. First, 
the double stranded DNA is separated in the denaturation step. The next step is the 
annealing where the primers bind to the single stranded DNA templates. In the last 
step DNA polymerase catalyses the synthesis of DNA and extends between primer 
pairs using the complementary DNA strand as a template. These three steps make up 
one cycle, which can be repeated up to 30 times. 
 
The standard PCR method was used mainly for subcloning of DNA fragments into 
expression vectors with different multiple cloning sites. All proteins in pCR3.1 were 
generated with a Kozak consensus (GCCACC) sequence located immediately 
upstream of the ATG start codon, and all primers were synthesised by MWG Eurofins. 
For Vpu subcloning, the forward primer encoded an EcoRI cloning site. The reverse 
primer encoded a XhoI or NotI cloning site, and if required contained a TAG or TGA 
stop codon. Standard PCR reactions were carried out as described in Table 1 and PCR 
machine (Eppendorf Mastercycler) was set to below described cycle conditions (Table 
2).  
 
Overlapping PCR was used to generate pCR3.1 Vpu ELV and pCR3.1 CD8-CI-M6PR 
expression vectors. In case of the Vpu ELV mutant wild-type Vpu was used as a 
template for the first of two separate PCR reactions. Standard setting were used to 
carry out overlapping PCR (Table 1 and Table 2) in which forward and reverse 
oligonucleotides containing the desired ELV mutation were used in combination with 
Vpu full-length forward and reverse primers to generate two small DNA fragments. 
Subsequently specific fragments were gel purified as described in 3.1.7. and 10 µl of 
each was used as template DNA in a second PCR reaction with full-length forward and 





Site directed mutagenesis, also termed QuickChange was employed to generate 
Vpu triple alanine mutants in the second alpha helix of Vpu using forward and reverse 
complementary oligonucleotide, containing the desired mutation. The required mutation 
is located in the middle of the oligonucleotides with 10-15 bases on either side. Primers 
were between 25 and 50 bases in length with a desired melting temperature (Tm) of 
≥78°C, a minimum GC content of 40%, and terminate in one or more G or C bases. 
PCR reactions were carried out as described in Table 1 and PCR machine (Eppendorf 
Mastercycler) was set to the below described cycle conditions for QuickChange (Table 
2). 
      
Table 1 PCR reaction setup 
Reagent Final concentration 
Primer forward 1 pmol (standard PCR) 
 
100 ng (QuickChange) 
Primer reverse 1 pmol (standard PCR) 
 
100 ng (QuickChange) 
dNTPs (Sigma) 0.2 mM 
DNA template 200 ng (standard PCR) 
 
10 ng (QuickChange) 
Phusion ® High-Fidelity DNA Polymerase  
(New England Biolabs) 
1 µl (2 units) 
Phusion HF buffer 
(New England Biolabs) 
1x 
ddH2O x µl 
Total 50 µl 
 
 
Table 2 PCR cycle conditions 
Step Temperature Time Cycle repeats 
Denaturation 95°C 30 seconds 1x 
Denaturation 95°C 30 seconds  
30x (standard PCR) 
 
18x (QuickChange) 
Primer annealing 55°C 30 seconds (standard PCR) 
 
1 minute (QuickChange) 
Extension 72°C 30 seconds (standard PCR) 
 
7 minutes (QuickChange) 
 
(Phusion DNA Polymerase extension time:  
15 seconds per 1 kb of DNA)    
Extension 72°C 5 minutes 1x 





3.1.2 Extraction and purification of DNA fragments 
Agarose gel electrophoresis was used to separate DNA fragments by molecular 
weight after PCR or restriction digest. For a 1% agarose gel, 0.5 g of electrophoresis 
grade agarose (Invitrogen) was added to 50 ml of 1x TAE buffer (1x TAE buffer: 40 mM 
Tris-acetate, 1 mM EDTA, 0.114% glacial acetic acid pH 8.2-8.3) and heated until 
completely dissolved. Once cooled down 2 µl of ethidium bromide (Sigma) was added 
and the solution poured into a gel cast to set. Subsequently, samples were loaded 
alongside a 2-log DNA ladder (New England BioLabs) and samples and run in 1x TAE 
buffer at 100 volt (V). DNA bands were visualised using Chemi Doc UV system (Bio-
Rad).  
   
Gel purification. The DNA band was cut out from the agarose gel and DNA was 
extracted using a Quickgel Extraction Kit (QIAGEN). The Quickgel Extraction Kit 
follows a bind-wash-elute procedure. Briefly, the DNA was absorbed to the silica 
membrane of the spin-column, the impurities were then washed away and the pure 
DNA was eluted, see manufacturer’s instructions for detailed protocol.  
 
3.1.3 DNA digest by restriction endonucleases 
Restriction endonucleases are used to cleave DNA at specific nucleotide sequences in 
order to isolate fragments of interest or confirm the presence of a ligated insert. The 
choice of enzyme depends upon the following: specific sequence sites available, easily 
distinguishable sizes of fragments (when separated), conditions under which the 
enzymes cut most efficiently, and if blunt or sticky ends are required (sticky ends are 
easier to ligate into a vector).  
XhoI, NotI, NheI, EcoRI, EcoRV and DpnI (New England BioLabs) were commonly 
used enzymes and ratios of reagents used in the restriction digest mix are shown in 
Table 3. Once combined the mix was left incubating at 37°C for 2 hours, and if 
necessary the 5’ phosphatase group of the linearized expression vector was removed 
by Antarctic Phosphatase (New England BioLabs), to prevent recirculation or self-
ligation of DNA. In these cases, 1x of Antarctic buffer (New England BioLabs) and 5 
units of Antarctic Phosphatase enzyme (New England BioLabs) were added to the 






Table 3 Restriction digest setup 
Reagent Final volume 
Buffer (appropriate for enzymes used) 5 µl 
BSA 1x 
Restriction enzyme 1 10 units 
Restriction enzyme 2 10 units 
DNA (2.5 µg) x µl 
ddH2O x µl 
Total 50 µl 
 
 
3.1.4 DNA ligation 
Ligation of DNA fragments into expression vectors (Table 6) was carried out using T4 
DNA Ligase (New England BioLabs). In short, DNA inserts were previously generated 
by PCR, isolated by agarose gel electrophoresis and purified. DNA and expression 
vectors were cut with restriction enzymes (New England BioLabs) in order to produce 
sticky ends and linear vectors.  
Ratios of the reagents used for the ligation reaction are shown in Table 4. Once all 
reagents were mixed the solution was left incubating at room temperature for 1 hour. 
For the negative control the insert was replaced with sterile water to detect the number 
of background colonies, due to self-ligation of the expression vector.  
 
Table 4 Ligation setup 
Reagent Final volume 
Vector x µl 
DNA insert x µl (3-fold molar excess of insert) 
T4 Ligase Buffer 10x 2 µl 
T4 DNA Ligase 1 µl 
ddH2O x µl 
Total 20 µl 
 
 
3.1.5 Preparation of chemically competent cells  
The DH10 (Invitrogen) Escherichia coli (E.coli) cells were grown in 10 ml of Luria-
Bertani (LB) medium and incubated in a shaking incubator at 220 rpm and 37°C for 16 
hours. 50 ml of LB broth was inoculated with 0.5 ml of overnight culture and incubated 
in a shaking incubator at 220 rpm and 37°C until OD550=0.45. Cells were then chilled 




at 3000 x g. Cells were resuspended in 20 ml of filter-sterilized buffer 1 (Table 5) and 
incubated on ice for 5 minutes before pelleting as described above. Next, cells were 
resuspended in filter-sterilized buffer 2 (Table 5) and incubated for 10 minutes on ice. 
The now chemically competent E.coli cells were snap-frozen on dry ice in 100 µl 
aliquots and stored at -80 °C.  
 
Table 5 List of buffers for chemically competent cells 
Buffer 1  Buffer 2 
30 mM KAc 10 mM PIPES 
100 mM RbCl 75 mM CaCl2 
10 mM CaCl2 10 mM RbCl 
50 mM MnCl2 15% glycerol  
15% glycerol  
 
 
3.1.6 Transformation of plasmid DNA into competent E.coli cells 
50 µl of chemically competent DH10 E.coli cells were thawed and stored on ice before 
being incubated with 5-50 ng of plasmid DNA or with 3 µl of the ligation reaction mix. 
After 20 minutes incubation on ice, the cells were heat shocked for 45 seconds at 42°C 
and immediately put back on ice. The bacteria were then incubated with 200 µl of fresh 
LB broth for 45 minutes at 30°C or 37°C in a shaking incubator at 220 rpm. The 
bacterial solution was spread onto a LB/amp (100 µl/ml) agar plate and placed into an 
incubator at 30°C or 37°C overnight. Retroviral vectors were grown at 30°C to avoid 
genetic recombination. Single colonies were picked and transferred into a 2 ml LB/amp 
culture in order to amplify the bacterial clone. This culture was either used directly to 
screen colonies by PCR, for plasmid extraction (mini-prep) to screen of colonies by 
restriction digest or sequencing, or used as a starter culture to inoculate 50 ml of 
LB/amp for large-scale plasmid amplification.   
 
3.1.7 Plasmid amplification and purification 
100 µl of a 2 ml starter culture was used to inoculate 50 ml LB/amp and incubated 
overnight in a 500 ml flask at 30°C or 37°C in a shaking incubator at 220 rpm. Cells 
were harvested by centrifugation in a bench top centrifuge at 6000 x g for 15 minutes at 
4°C. Plasmid extraction from pelleted bacterial cells was performed using a Plasmid 
Midi kit (QIAGEN), which follows a simple bind-wash-elute method. Briefly, bacterial 




QIAprep column where the plasmid DNA is absorbed by the silicagel membrane. 
Subsequently, impurities were washed out and plasmid DNA was eluted. The elution 
buffer/DNA solution was supplemented with isopropanol to precipitate plasmid DNA by 
centrifugation. Finally, the eluted DNA was washed in 70% ethanol and resuspended in 
ddH2O.  
Alternatively, plasmid extraction was carried out from 2 ml overnight cultures obtained 
from 3.1.6. The method is based on the above-described principle using the QIAprep 
Spin Miniprep kit (QIAGEN). See manufacturer handbooks for detailed protocols on 
midi-prep and mini-prep plasmid DNA extraction.  
 
3.1.8 DNA sequencing and vector features  
DNA concentrations of plasmid preparations (list of all DNA vectors displayed in Table 
6) were measured using a Nanodrop ND-100 Spectrophotometer (Labtech 
International) and 15 µl of a 50-100 ng/µl plasmid DNA solution in ddH2O was sent for 
sequencing to Eurofins MWG Operon.  
The T7 primer site was used for forward sequencing and BGH was used for reverse 
sequencing in pCR3.1. Sequencing primers for NL4.3, pCMS28, pLHCX and pAIP 
were directed against down- and up-stream sequences of the respective multiple 
cloning sites.    
  
Table 6 List of DNA vectors and proviruses used in this study 
Vector  Source Features 
pCR3.1 Invitrogen Encodes Ampicillin resistance gene and pUC origin for selection in E. coli. 
Large multiple cloning site is downstream of the human cytomegalovirus 
(CMV) promoter region. Encodes Bovine Growth Hormone (BGH) 
polyadenylation signal and transcription termination sequence for enhanced 
mRNA stability. 
NL4.3 NIH AIDS 
Reagent 
Program 
Full-length, replication and infection competent chimeric HIV-1 DNA 
molecular clone.  
NL4.3 
delVpu 
Stuart Neil Derived from NL4.3 by replacing the ATG start codon of the vpu ORF with 
BamHI restriction site to intoduce a frame shift (Neil et al., 2006). 
pLHCX Clonetech Retroviral based vector, contains elements derived from Moloney murine 
leukemia and Moloney murine sarcoma viruses. 5' viral LTR contains 
promoter sequences that control expression of the hygromycin resistance 
gene. The multiple cloning site is immediately downstream of the human 
cytomegalovirus (CMV) promoter region. 
pCMS28 M. Malim Derived from pMigR1 retroviral based vector, encodes puromycin resistance 
gene linked via an IRES to the multi-cloning site. 
pAIP Andrea 
Cimarelli 
Retroviral based vector, encodes puromycin resistance gene, contains 





Table 7 List of DNA plasmids 





YFP pCR3.1  No tag Amp Paul Bieniasz 





Amp/ Purom Anna Le Tortorec 
Cherry pCR3.1  No tag Amp Paul Bieniasz 








HA (position 463) 



















Anna Le Tortorec 
Anna Le Tortorec 
Tetherin delGPI pLHCX XhoI/NotI No tag Amp/ Hygrom Rui Pedro Galao 



















NIH AIDS Reagent Program  
delVpu NL4.3  No tag Amp Stuart Neil 
Vpu  pCMS2
8 
 IRES/ GFP 
(C-terminus) 











Vpu 59-61A pCR3.1 EcoRI/XhoI HA (C-terminus) Amp Site directed mutagenesis 
Vpu 60-62A pCR3.1 EcoRI/XhoI HA (C-terminus) Amp Site directed mutagenesis 
Vpu 61-63A pCR3.1 EcoRI/XhoI HA (C-terminus) Amp Site directed mutagenesis 
Vpu 62-64A pCR3.1 EcoRI/XhoI HA (C-terminus) Amp Site directed mutagenesis 
Vpu 63-65A pCR3.1 EcoRI/XhoI HA (C-terminus) Amp Site directed mutagenesis 
Vpu 64-66A pCR3.1 EcoRI/XhoI HA (C-terminus) Amp Site directed mutagenesis 
Vpu 65-67A pCR3.1 EcoRI/XhoI HA (C-terminus) Amp Site directed mutagenesis 
Vpu 66-68A pCR3.1 EcoRI/XhoI HA (C-terminus) Amp Site directed mutagenesis 
Vpu 67-69A pCR3.1 EcoRI/XhoI HA (C-terminus) Amp Site directed mutagenesis 
Vpu 68-70A pCR3.1 EcoRI/XhoI HA (C-terminus) Amp Site directed mutagenesis 














Vpu 64I pCR3.1 EcoRI/XhoI HA (C-terminus) Amp Site directed mutagenesis 
Vpu 64M pCR3.1 EcoRI/XhoI HA (C-terminus) Amp Site directed mutagenesis 
Vpu 64L pCR3.1 EcoRI/XhoI HA (C-terminus) Amp Site directed mutagenesis 





















Standard PCR (long primer) 
Subcloning 








Site directed mutagenesis 
Site directed mutagenesis 








Site directed mutagenesis 
Site directed mutagenesis 
Vpu A14L W22A pCR3.1 
NL4.3 






BirA pAIP XhoI/NotI Myc (N-terminus) Amp/ Purom BirA provided by: Kyle J. 
Roux 
pAIP provided by: Andrea 
Cimarelli 
B Vpu pAIP XbaI/XhoI Myc/ BirA 
(C-terminus) 




B Vpu ELV pAIP XbaI/XhoI Myc/ BirA 
(C-terminus) 
 
Amp/ Purom Synthesised and subcloned  
B Vpu 3/7A pAIP XbaI/XhoI Myc/ BirA 
(C-terminus) 
Amp/ Purom Synthesised and subcloned 
B Vpu I+I pAIP XbaI/XhoI Myc/ BirA 
(C-terminus) 
Amp/ Purom Synthesised and subcloned  
Vpu HRS CB pCR3.1 EcoRI/XhoI No tag Amp Standard PCR (long primer) 
Vpu HRS CB mut pCR3.1 EcoRI/XhoI No tag Amp Standard PCR (long primer) 
Vpu ELV CB pCR3.1 EcoRI/XhoI No tag Amp Standard PCR (long primer) 
Vpu ELV CB mut pCR3.1 EcoRI/XhoI No tag Amp Standard PCR (long primer) 
Vpu LILI CB pCR3.1 EcoRI/XhoI No tag Amp Standard PCR (long primer) 
Vpu LILI CB mut pCR3.1 EcoRI/XhoI No tag Amp Standard PCR (long primer) 
Vpu 2/6A CB pCR3.1 EcoRI/XhoI No tag Amp Standard PCR (long primer) 
Vpu 2/6A CB mut pCR3.1 EcoRI/XhoI No tag Amp Standard PCR (long primer) 
CI-M6PR pCR3.1 EcoRI/NotI CD8 (N-terminus) Amp Matthew Seaman 











HRS delCB pCR3.1 XhoI/NotI Myc (N-terminus) Amp Standard PCR 
HRS 1-500 pCR3.1 XhoI/NotI Myc (N-terminus) Amp Standard PCR 
HRS 1-280 pCR3.1 XhoI/NotI Myc (N-terminus) Amp Standard PCR 
HRS 1-250 pCR3.1 XhoI/NotI Myc (N-terminus) Amp Standard PCR 
HRS W25A L29D pCR3.1 XhoI/NotI Myc (N-terminus) Amp Site directed mutagenesis 
HRS A266/268Q pCR3.1 XhoI/NotI Myc (N-terminus) Amp Site directed mutagenesis 
GGA1 pCR3.1 EcoRI/XhoI Myc (N-terminus) Amp cDNA from 
GGA2 pCR3.1 EcoRI/NotI Myc (N-terminus) Amp cDNA from 
GGA3 pCR3.1 EcoRI/XhoI Myc (N-terminus) Amp cDNA from 
Ubiquitin  pCR3.1  HA (N-terminus) Amp Juan Martin-Serrano 
DN dynamin 2 pCR3.1 NotI/ NotI HA (C-terminus) Amp Stuart Neil 
WT dynamin 2 pCR3.1 NotI/ NotI HA (C-terminus) Amp Stuart Neil 
AP180c pCR3.1  Flag (N-terminus) Amp Heinrich Gottlinger 
VSV-G pCMV  No tag Amp Paul Bieniasz 
MLV gag-pol pCAGG
S 
 No tag Amp Paul Bieniasz 





3.2 WORKING WITH CELLS 
3.2.1 Cell Culture 
All adherent cells were maintained at 37°C and 5% CO2 under sterile conditions in 
Dulbecco’s Modified Eagle Medium (DMEM) (Invitrogen) supplemented with 10% fetal 
calf serum (FBS, Invitrogen – heat-inactivation for 30 minutes at 56°C) and 0.02 mg/ml 
gentamycin (Invitrogen). T-cell lines were grown at 37°C and 5% CO2 under sterile 
conditions in Roswell Park Memorial Institute medium (RPMI) supplemented with 10% 
fetal calf serum and 0.02 mg/ml gentamycin. Cell density was monitored daily and cells 
were passaged every two days or when required. Adherent cells lines were first 
washed in 5 ml of 1x phosphate buffered saline (PBS) and detached from the tissue 
culture plate using 1 ml of Trypsin (TrpLE Express + phenol red, Invitrogen). Cells were 
resuspended in warm DMEM and appropriate aliquots of the cell suspensions were 
transferred into a fresh tissue culture plate. T cell lines were passaged by aspiration of 
tissue culture medium (containing cells) and addition of fresh RPMI.  
For long time storage, detached cells were pelleted by centrifugation at 1500 rpm and 
resuspended in a 10% DMSO (Sigma) and 90% FBS (Invitrogen) solution. Cells were 
immediately placed in the -80°C freezer for 5 days before being transferred into a liquid 
nitrogen tank. All cell lines used can be seen in Table 8. 
    
Table 8 Cell lines used in this study 
Cell line Origin Source Culture 
medium 
Characteristics 
HeLa Adenocarcinoma cell 
line, isolated from 






HeLa-TZMbl Adenocarcinoma cell 
line, isolated from 









- Express HIV-1 
receptor CD4 and 
CCR5 






- Do not express 
tetherin 
HEK-293T Isolated from human 
embryonic kidney 





- Do not 
endogenously 
express tetherin but 
can be induced by 
IFN 







- Express HIV-1 
receptor CD4 and 
CXCR4 
 

















HEK-293T tetherin Isolated from human 
embryonic kidney 













Isolated from human 
embryonic kidney 














Isolated from human 
embryonic kidney 










truncated at GPI 
anchor under 
hygromycin selection 
















3.2.2 Transient transfection 
Cells were plated at a density of 5x105 in a 6-well plate or at 1.2x105 in a 24-well plate 
and grown for 24 hours to achieve a confluency of 50-60% at the time of transfection. 
For each transfection plasmid DNA concentrations were measured and appropriate 
amounts of pCR3.1 and/or NL4.3 expression vector were diluted in DMEM and mixed 
gently. The transfection reagent was diluted in DMEM and incubated at room 
temperature for 5 minutes before being combined with the diluted DNA, mixed gently, 
and incubated at room temperature for a further 20 minutes. The transfection mix was 
then added drop-wise to the cells, and medium was replaced 6 hours post transfection. 
Cells were incubated for 48 hours before analysis by Western blot or FACS.     
HeLa and HeLa-TZMbl cells were transfected according to manufacture’s instructions 
using Lipofectamine 2000 (Invitrogen), 293T and 293T tetherin cells were transfected 
using a 1 mg/ml polyethylenimine (PEI) solution (pH 7), while mouse fibroblasts were 
transfected according to manufactures instructions using FuGENE (Promega). The 
above transfection reagents facilitate cell entry of negative charged DNA through 
endocytosis. The DNA usually does not integrate into the genome and will be degraded 







3.2.3 Generation of stable cell lines using retroviral vectors 
Subconfulent 293T cells were plated in a 6-well plate and transfected with 1 µg of 
proviral plasmid (pLHCX or pCMS28) containing the protein of interest in combination 
with 200 ng of VSV-G and 1 µg of MLV gag-pol. 24 hours post-transfection, the 
medium was replaced and cells were incubated for another 24 hours. The supernatant 
containing virus like particles (VLPs) were filtered (0.45 µm) (Millipore) and used to 
transduce target 293T, HT1080 or murine fibroblasts cells. Spinoculation was used to 
enhance delivery of VLPs into target cells. Tissue culture plates were centrifuged for 3 
hours at 1500 rpm at room temperature and placed back into tissue culture incubator. 
48 hours post-transduction cells were split into 10 cm dishes, placed under antibiotic 
selection (usually at 100 µg/ml for Hygromycin B and 1 µg/ml for Puromycin) and 
incubated at 37°C and 5% CO2 to allow selection of stably expressing cells.  
 
3.2.4 Gene silencing by siRNA 
293T tetherin cells were seeded at a density of 2x105 cells per well in a 12-well plate. 
After 6 hours the first transfection was performed. For each well 2 µl of Dharmafect 
(Thermo Scientific) was added to 98 µl of Opti-MEM (Life Technologies), this solution 
was added to 5 µl of 20 µM siRNA in 95 µl of Opti-MEM according to manufacturers 
instructions. For HRS knockdown a siRNA oligonucleotide against HGS targeting the 
CCGGAACGAGCCCAAGTACAA sequence (QIAGEN) was used alongside a non-
targeting siRNA as control (Dharmafect). For a complete list of oligonucleotides see 
Table 9. The cells were subsequently re-seeded into a 24-well plate on day 2 and a 
second transfection was performed according to manufacturers instructions. The cells 
were then infected 3 hours post transfection with VSV-G-pseudotyped NL4.3 HIV-1 wt, 
HIV-1 delVpu at an MOI of 0.8 and harvested 48 hours later. Infectivity of viral 
supernatants was determined by infecting HeLa-TZMbl reporter cells as described in 
3.4.5. Cell lysates and viral particles were subjected to SDS-PAGE as described in 
3.4.4, and Western blot assays were performed using rabbit anti-HSP90 antibody 
(Santa Cruz Biotechnologies), monoclonal mouse anti-HIV-1 p24CA antibody (kindly 
provided by B Chesebro through the NIH AIDS Reagent Program), rabbit polyclonal 
anti-HRS (HGS) antibody (Millipore), a polyclonal rabbit anti-UBAP1 antibody 






Alternatively for clathrin adaptor and VPS27 knockdown, 293T tetherin or HeLa cells 
were seeded at a density of 2x105 cells per well in a 12-well plate. After 3 hours the first 
transfection was performed. For each well 3 µl of Oligofectamine (Invitrogen) was 
added to 10 µl of Opti-MEM (Life Technologies), this solution was then added to 5 µl of 
20 mM siRNA in 85 µl of Opti-MEM according to manufacturer’s instructions. For AP-1 
knockdown HeLa cells stably expressing doxycycline-inducible pTRIPZ shRNA 
directed against AP-1 γ1 (OpenBiosystems) were used in combination with siRNA 
oligonucleotides directed against AP-1 γ1. For AP-3 knockdown, SMARTpool siRNA 
targeting the AP-3 µ1 subunit was used in combination with SMARTpool siRNA 
targeting the AP-3 δ1 subunit (Dharmacon). Oligonucleotides used for AP-2 and 
VPS27 silencing are displayed in Table 9. After 24 hours the cells were re-seeded into 
a 24-well and a second transfection was performed according to manufacturers 
instructions. The cells were then infected 3 hours post the second transfection with 
VSV-G-pseudotyped HIV-1 wt or HIV-1 delVpu at a MOI of 0.8. In the case of AP-2 
knockdown the second transfection of oligonucleotides was performed in combination 
with indicated NL4.3 proviral plasmid using Lipofectamine 2000 (Invitrogen). The 
infectivity of viral supernatants was determined by infecting HeLa-TZMbl cells as 
described in 3.4.5. Cell lysates and viral particles were subjected to SDS-PAGE as 
described in 3.4.4, and Western blotted for appropriate proteins.   
 
Table 9 Sequences of siRNA oligonucleotides 
Protein Type Source Target sequence 
UBAP1 (Q3) siRNA QIAGEN CTCGACTATCTCTTTGCACAT  
UBAP1 (Q4) siRNA QIAGEN CAGCTAAAGTTGGTCTACCTA  
TSG101 siRNA Dharmacon CCUCCAGUCUUCUCUCGUC  
ALIX siRNA Dharmacon GAAGGAUGCUUUCGAUAAAUU  
HRS siRNA QIAGEN CCGGAACGAGCCCAAGTACAA 
AP-1 γ1 siRNA QIAGEN AAGAAGATAGAATTCACCTTT 
AP-1 γ1 doxycycline-inducible 
shRNA in pTRIPZ  
OpenBiosystems No sequence information available. 
Oligo ID: V2THS_201653 




AP-3 µ1 siRNA SMARTpool QIAGEN AAGGATAGCCCTTACACTCAT 




VPS27 siRNA QIAGEN AACCACCTATCCTGATGTTAA 
Non-targeting 
control 
siRNA SMARTpool Dharmacon No sequence information available. 





3.2.5 Isolation of CD4+ T lymphocytes from Peripheral Blood Mononuclear 
Cells (PBMCs) 
Fresh venous blood was drawn from healthy volunteers by a phlebotomist. Total 
peripheral blood mononuclear cells were isolated using a density gradient 
centrifugation method. First, blood was collected in heparin-coated tubes (BD 
Bioscience) and diluted by addition of an equal volume of 1x PBS. 30 ml of diluted 
blood was carefully layered over 15 ml of Lymphoprep (Axis-Shield) in a 50 ml Falcon 
tube and centrifuged for 30 minutes at 1000 x g (without brake) at room temperature. 
After centrifugation the PBMCs form a separate band (buffy coat) at the 
blood/Lymphoprep interface and cells were collected using a Pasteur pipette. This 
fraction was diluted in 40 ml of 1x PBS and cells were pelleted by centrifugation for 10 
minutes at 300 x g. This step was repeated three times or until supernatant became 
clear.    
CD4+ T lymphocytes were purified from PBMCs by negative isolation using the 
Dynabeads Untouched human CD4 T cells kit (Invitrogen). Isolation was performed 
according to manufacturers instructions. Briefly, PBMCs were depleted from CD8+ T 
cells, B cells, NK cells, monocytes, platelets, dendritic cells, granulocytes and 
erythrocytes by a mixture of mouse IgG antibodies directed against the non-CD4+ T 
cells and capture of antibody-labelled cells by magnetic Dynabeads. Only negatively 
selected and untouched CD4+ T cells are left in the samples that have not been in 
contact with the Dynabeads. Once selected a small portion of CD4+ T cells was kept to 
check purity by FACS using an anti-CD4 antibody coupled to an APC fluorochrome 
(BD Pharmingen).!
Purified CD4+ T cells were then activated for 48 hours using Dynabeads Human T-
Activator CD3/CD28 (Invitrogen) according to manufacturers instructions. Dynabeads 
mimic physiological T cell activation by antigen-presenting cells, providing both TCR 
and co-stimulating signals. After removal of the beads, cells were maintained in rhIL-2 






3.3 WORKING WITH PROTEINS 
3.3.1 SDS-PAGE and Western blotting 
The resolving gel was made up as described in Table 10 and the solution was pipetted 
quickly into a glass plate sandwich situated in a casting frame. The resolving gel was 
covered with isopropanol (Fischer) and allowed to set. Next, the gel was rinsed with 
ddH2O to remove excess isopropanol. The stacking gel was made up as described in 
Table 10 and the solution was pipetted on top of the resolving gel, a plastic comb (15 
wells/ 0.75 mm) was inserted and the solution was allowed to polymerize. The gel 
cassette was then placed into Mini- PROTEAN Tetra Cell electrophoresis system (Bio-
Rad) and filled up with running buffer containing 0.1% SDS, 25 mM Tris-Base and 200 
mM glycine pH 8.8. Samples were resuspended in 2x LB (20% glycerol, 4% SDS, 100 
mM Tris-HCl pH 6.8, 200 mM β-mercaptoethanol, 0.2% bromophenol blue) and boiled 
at 100°C for 10 minutes to denature proteins. 10 µl of each protein sample was loaded 
per well alongside 5 µl of molecular size marker (Prestained Protein Marker, broad 
range (7-175 kDa), New England Biolabs). The gel was subsequently run at 80V for 
about 10-15 minutes until samples started to migrate through the separating gel, and 
switched to 100V until the end of the run. 
Separated proteins were then transferred onto a 0.45 µm nitrocellulose membrane 
(Hybond ECL nitrocellulose membrane, GE-Amersham Biosciences) using a Criterion 
Blotter with Plate Electrodes (Bio-Rad). Transfer was conducted in transfer buffer 
containing 20% ethanol, 25 mM Tris-Base and 200 mM glycine pH 8.8 and run at 100V 
for 1 hour or at 18V for 16 hours. The membrane was then incubated in blocking 
solution (5% milk (Marvel) in 1x PBS/ 0.1% Tween 20) on a shaker for 30 minutes at 
room temperature or at 4°C overnight. Next, the membrane was probed with primary 
antibody (see Table 11) diluted in blocking solution for 1 hour at room temperature or at 
4°C overnight. The primary antibody solution was subsequently removed and the 
membrane was washed 3 times for 10 minutes with 1x PBS/ 0.1% Tween 20. The 
membrane was then incubated with the secondary antibody (see Table 12) diluted in 
blocking solution for 1 hour at room temperature and washed 3 times for 10 minutes 
with 1x PBS/ 0.1% Tween 20. Membranes incubated with secondary antibodies 
conjugated to IRDye 800-700 were rinsed in 1x PBS and scanned using the LI-COR 
Odyssey infrared imaging system (LI-COR Biosciences). In contrast membranes 
incubated with horseradish peroxidase (HRP) conjugated secondary antibodies for 
detection by enhanced chemiluminescence (ECL) were incubated with SuperSignal 
West Pico Chemiluminescent solutions (Thermo Scientific) in a 1:1 ratio for 2 minutes 




Table 10 SDS-Page set-up 
Separating gel 10% 12% Stacking gel  
dH2O 5 ml 4.5 ml dH2O 3.25 ml 
1.5 M Tris pH 8.8  2.5 ml 2.5 ml 0.5 M Tris pH 6.8  1.25 ml 
Acrylamide (40%) 2.5 ml 3 ml Acrylamide (40%) 465 µl 
APS (10%) 50 µl 50 µl APS (10%) 25 µl 
TEMED 10 µl 10 µl TEMED 5 µl 
SDS (10%) 100 µl 100 µl SDS (10%) 50 µl 
 
Table 11 Primary antibodies used for Western blotting 
Antibody Species Antigen Source Dilution 
α-HSP90 Rabbit Human HSP90 Santa Cruz 
Biotechnology 
1:5000 
α-Vpu Rabbit NL4.3 Vpu  
(amino acids 33-81) 







NIH AIDS Reagent 
Program 
1:75 
α-HA  Mouse CYPYDVPDYASL 
HA.11 clone 16B12 
Covance 1:5000 
α-HA Rabbit HA epitope tag Rockland 1:5000 
α-myc Mouse Clone 9E10 Covance 1:1000 
α-BST-2 
(tetherin)  





Rabbit Epitope against SNX1 region  Millipore 1:1000 
α-UBAP1 Rabbit Human UBAP1 Proteintech 1:1000 
α-TSG101 Mouse TSG101 residues 167-374 
Clone 4A10 
Abcam 1:1000 
α-ALIX Rabbit Human ALIX W. Sundquist  1:1000 
α-AP-1 γ1 Mouse Derived from 100/3 hybridoma, AP-1 adaptor 




Mouse Mouse AP50 residues 110-230 BD Bioscience 1:250 
α-AP-3 δ1 Mouse Human adaptin δ residues 627-731 BD Bioscience 1:750 
α-AP-3 µ1 Rabbit Di vs47p affi M.S. Robinson 1:750 
α-VPS27 Rabbit Synthetic peptide derived from within 




Table 12 Secondary antibodies used for Western blotting 
Antibody Conjugation Source Dilution 
Goat α-mouse HRP Cell Signalling 1:5000 
Goat α-rabbit HRP Cell Signalling 1:5000 
Goat α-mouse IRDye 680 LI-COR Bioscience 1:5000 






3.3.2 Immunoprecipitation (for HRS/Vpu)  
Immunoprecipitation was performed as previously described (Kueck and Neil, 2012). In 
short 293T or 293T tetherin cells were plated into a 6-well plate and transfected with 
600 ng of pCR3.1 myc-HRS or indicated mutants/ truncations in combination with 
pCR3.1 Vpu-HA or indicated mutant or GFP expression plasmids. 48 hours post 
transfection cells were lysed on ice for 30 minutes in buffer containing 50 mM Tris pH 
7.4, 150 mM NaCl, 200 µM sodium orthovanadate, 5 mM NEM, complete protease 
inhibitors (Roche) and 1% digitonin. After removal of the nuclei by centrifugation 
supernatants were immunoprecipitated with 5 µg/ml monoclonal mouse anti-myc 
antibody (Covance) and protein G agarose beads (Invitrogen) for 3 hours and washed 
four times in lysis buffer containing 0.01% digitonin.  Cell lysates and 
immunoprecipitates were subjected to SDS-PAGE and Western blotted using a 
polyclonal rabbit anti-HA antibody (Rockland) and rabbit polyclonal anti-HRS (HGS) 
antibody (Millipore). Proteins were subsequently visualised by ImageQuant (GE) using 
corresponding HRP-linked secondary antibodies (Cell Signalling). 
  
3.3.3 Immunoprecipitation (for tetherin/Vpu) 
Immunoprecipitation was performed as indicated above. In these experiments 293T 
tetherin cells were transfected twice over 48 hours with siRNA oligonucleotides 
directed against UBAP1 targeting CTCGACTATCTCTTTGCACAT or non-targeting 
siRNA as control (Dharmacon). The cells were then infected with VSV-G-pseudotyped 
NL4.3 HIV-1 wt, HIV-1 delVpu, HIV-1 Vpu LILI or HIV-1 Vpu A14L W22A at an MOI of 
2 or transfected with 600 ng of pCR3.1 Vpu or indicated mutant or pCR3.1 GFP 
expression plasmids. 48 hours post infection cells were lysed on ice for 30 minutes in 
buffer containing 50 mM Tris pH 7.4, 150 mM NaCl, complete protease inhibitors 
(Roche) and 1% digitonin (Calbiochem). After removal of the nuclei by centrifugation 
supernatants were immunoprecipitated with 5 µg/ml mouse monoclonal anti-BST2 
antibody (eBiosciences) and protein G agarose beads (Invitrogen) for 3 hours before 
washing four times in lysis buffer containing 0.01% digitonin. Western blot assays of 
cell lysates and immunoprecipitates were performed using a rabbit anti-Vpu antibody 
(kindly provided by K. Strebel through the NIH AIDS Reagent Program), polyclonal 
rabbit anti-tetherin antibody (kindly provided by K. Strebel through the NIH AIDS 
Reagent Program), polyclonal rabbit anti-UBAP1 antibody (Proteintech) and visualised 






3.3.4 Cross-linking immunoprecipitations 
293T cells were co-transfected with 600 ng of pCR3.1 myc-β-TrCP2 and with either 
pCR3.1Vpu-HA, pCR3.1 Vpu LILI-HA, pCR3.1 Vpu 2/6A-HA or GFP expression 
plasmids. 48 hours post transfection cross-linking immunoprecipitation was performed 
as previously described (Niranjanakumari et al., 2002). In short cells were trypsinised, 
washed in 1x PBS and cross-linking was performed with 0.05% HCHO. Subsequently 
cells were lysed in buffer containing 150 mM NaCl, 10 mM Hepes pH 7, 6 mM MgCl2, 
2 mM DTT, 10% glycerol, 0.5% NP40, 200 µM sodium orthvanadate and complete 
protease inhibitors (Roche). Cleared lysates were immunoprecipitated with with 5 µg/ml 
of mouse anti-myc monoclonal antibody (Covance) and protein G agarose beads 
(Invitrogen). Cross-linking was reversed with 10 mM EDTA, 5 mM DTT and 1% SDS 
and cell lysates and immunoprecipitates were subjected to SDS-PAGE, and Western 
blotted using a polyclonal rabbit anti-HA antibody (Rockland) and mouse monoclonal 
anti-myc antibody (Covance). Visualisation of proteins was conducted by ImageQuant 
(GE) using corresponding HRP-linked secondary antibodies (Cell Signalling). 
 
3.3.5 BioID assay using BirA R118G (Roux et al., 2012) 
293T or 293T tetherin cells were plated into a 10cm dish and transfected with 5 ug of 
empty BirA vector, Vpu-myc-BirA or indicated mutant using polyethylenimine (PEI). 8 
hours post transfection medium was changed and cells were treated overnight with 100 
nM of Concanamycin A (Invitrogen) to prevent tetherin degradation, and 150 µM free 
biotin (life technologies) to induce biotinylation of surrounding proteins. Cells were then 
trypsinised, washed in 1x PBS and lysed in 1 ml of 50 mM Tris pH 7.4, 500 mM NaCl, 
0.4% SDS, 5 mM EDTA, 1 mM DTT and complete protease inhibitor (Roche). Next 
samples were sonicated for 20 seconds prior to the addition of Triton X-100 to 2% final 
concentration and an equal volume of 50 mM Tris pH 7.4. Lysates were cleared by 
centrifugation (5 minutes at maximum speed) and supernatants were incubated with 
200 µl avidin agarose (Pierce) for 3 hours. Avidin agarose beads were collected and 
washed twice with lysis buffer over chromatography columns (Bio-Rad) and were 
resuspended in 100 µl of 2x LB supplemented with biotin. Cell lysates and precipitates 
were subjected to SDS-PAGE, and Western blotted using HRP-conjugated streptavidin 
(Invitrogen), mouse monoclonal anti-myc antibody (Covance), mouse monoclonal anti-
AP-1 γ1 antibody (Sigma). Proteins were subsequently visualised by ImageQuant (GE) 





3.3.6 Immunofluorescence microscopy  
Cells were grown on coverslips and either infected with VSV-G-pseudotyped NL4.3 
HIV-1 wt, indicated mutants or transfected with indicated protein expression vectors. 48 
hours or 16 hours later cells were fixed in 4% paraformaldehyde, washed with 10 mM 
glycine and permeabilised in 1% bovine serum albumin/ 0.1% Tritin-X100 for 15 
minutes. Cells were then stained with primary antibodies diluted in 1% bovine serum 
albumin/ 0.01% Tritin-X 100 for 1 hour. Next, cells were stained for example using anti-
rabbit polyclonal Vpu (kindly provided by K. Strebel through the NIH AIDS Reagent 
Program) in combination with sheep anti-human TGN46 (AbD Serotec), mouse anti-
EEA1 (BD Biosciences), mouse anti-CD63 (Developmental Studies Hybridoma Bank, 
University of Iowa) or mouse polyclonal anti-BST-2 (Abnova) followed by appropriate 
secondary antibodies conjugated to Alexa 488 or 594 fluorophores (Molecular Probes, 
Invitrogen); for a list of primary and secondary antibodies see Table 13 and Table 14. 
The cells were then washed and mounted on glass slides using ProLong AntiFade- 
49,6-diamidino-2-phenylindole (DAPI) mounting solution (Molecular Probes, 
Invitrogen). Cells were visualised with a Leica DM-IRE2 confocal microscope (63x oil 
immersion lens) and images were analysed using the Leica Confocal Software and 
ImageJ. Alternatively, Z stacks were taken with a Nikon ESCLIPSE Ti inverted 
microscope (100x oil immersion lens), images were deconvoluted using AutoQuant X3 
and analysed using the ImageJ software. 
 
Table 13 Primary antibodies used in immunofluorescence microscopy 
Antibody Species Antigen Source Dilution 
α-Vpu Rabbit NL4.3 Vpu  
(amino acids 33-81) 
NIH AIDS Reagent Program 1:5000 
α-HA  Mouse CYPYDVPDYASL 
HA.11 clone 16B12 
Covance 1:1000 
α-HA Rabbit HA epitope tag Rockland 1:1000 
α-BST-2 
(tetherin)  
Mouse Human BST-2 residues 
40-181 
Abnova 1:200 
α-CD8 Mouse Human 
thymocytes/Sezary T cells 
Ancell 1:200 
α-TGN46 Sheep Human TGN46 AbD Serotec 1:100 
α-EEA1 Mouse Human EEA1 residues 3-
281 
BD Biosciences 1:200 
α-CD63  Mouse Human CD63 
(Hybridoma supernatant) 
Developmental Studies Hybridoma 








Table 14 Secondary antibodies used for immunofluorescence microscopy 
Antibody Conjugation Source Dilution 
Donkey α-mouse Alexa Fluor 488 
Alexa Fluor 594 
Alexa Fluor 630 
Molecular Probes (Invitrogen) 
Molecular Probes (Invitrogen) 




Goat α-mouse Alexa Fluor 488 
Alexa Fluor 594 
Alexa Fluor 630 
Molecular Probes (Invitrogen) 
Molecular Probes (Invitrogen) 




Donkey α-Rabbit Alexa Fluor 488 
Alexa Fluor 594 
Alexa Fluor 630 
Molecular Probes (Invitrogen) 
Molecular Probes (Invitrogen) 




Donkey α-Sheep Alexa Fluor 594 Molecular Probes (Invitrogen) 1:500 
 
 
3.3.7 Detection of tetherin surface levels: Flow cytometry (FACS)  
HeLa or HeLa-TZMbl cells were transfected with 400 ng of pCR3.1 GFP and 400 ng of 
pCR3.1 Vpu-HA or indicated mutants. 48 hours post transfection the cells were 
harvested and stained for surface tetherin using a monoclonal anti-BST2 IgG2a 
antibody (Abnova) and a goat-anti-mouse IgG2a-Alexa633 conjugated secondary 
antibody (Molecular Probes, Invitrogen, UK). The cells were detached for the tissue 
culture plate using 5 mM EDTA and washed in FACS buffer containing 1% BSA and 
0.1% sodium azide in 1x PBS. Cells were subsequently stained with primary antibody 
in FACS buffer for 1 hour on ice. Cells were then washed three times and incubated 
with the secondary antibody in FACS buffer on ice for 1 hour. Cells were washed twice 
in FACS buffer and once in 1x PBS. Tetherin expression on GFP positive cells was 
then analysed using a BD FACSCanto II flow-cytometer (Becton Dickinson) or 
FACSCalibur flow-cytometer (Becton Dickinson) and FlowJo software. 
 
3.3.8 Tetherin downregulation in AP-1 and AP-3 knockout fibroblasts 
Murine fibroblasts (knockout for: AP-1 µ1A -/- or AP-3 δ-/-) stably expressing human 
tetherin-HA were transduced with the pMigR1 based retroviral vector pCMS28-IRES-
eGFP or a derivative expressing the NL4.3 Vpu protein. 48 hours post transduction the 
cells were stained as described in 3.3.7 and analysed for surface HA versus GFP 
expression levels using FACSCalibur flow-cytometer (Becton Dickinson) and FlowJo 




3.4 WORKING WITH VIRUSES 
3.4.1 Preparation of VSV-G-pseudotyped HIV-1 virus stocks 
For the production of full-length HIV-1 NL4.3 wt, NL4.3 delVpu, NL4.3 Vpu LILI, NL4.3 
Vpu ELV, NL4.3 LILI ELV, NL4.3 Vpu 2/6A and NL4.3 Vpu A14L W22A virus stocks 
pseudotyped with the Vesicular Stomatitis Virus Glycoprotein (VSV-G) the following 
protocol was followed: 5x105 293T cells were plated in a 6-well plate and transfected 
with 2 µg of proviral plasmid in combination with 200 ng of VSV-G using 5 µg/ml 
polyethyleneimine (Polysciences). 24 hours post-transfection the medium was replaced 
and cells were incubated for another 24 hours before being harvested. The supernatant 
containing virions was filtered (0.45 µm) (Millipore), aliquoted and stored at -80°C.  
Viral endpoint titres were determined on HeLa-TZMbl cells as described previously (Le 
Tortorec and Neil, 2009) and in 3.4.2. 
 
3.4.2 Determination of virus stock titres on HeLa-TZMbl cells 
NL4.3 HIV-1 VSV-G-pseudotyped virus stocks prepared as in 3.4.1 were titrated on 
HeLa-TZMbl cells to determine virus titres. HeLa-TZMbl reporter cells were plated at a 
density of 104 per well in a 96-well plate and infected with 40 µ l of serial dilutions (from 
100 to 10-8) of virus stocks. 48 hours post transfection, cells were fixed in 0.5% 
glutaraldehyde for 15 minutes, washed in 1x PBS and incubated overnight at 37°C with 
X-Gal substrate solution containing 1 mg/ml X-gal-dimethylformamide in 5 mM K 
ferrocyanide, 5 mM ferricyanide, 2 mM MgCl2, 0.02% NP40, 0.01% Triton-X 100 in 1x 
PBS. Infected cells will tern blue as a result of the β-galactosidase activity induced by 
the HIV-1 Tat protein expression. End point titres (pfu/ml) were determined by counting 
blue colonies using a light microscope.  
      
Multiplicity of infection (MOI): The infectious virus particle yield per cell can be 
calculated from the titres obtained above and is displayed in the multiplicity of infection 
(MOI). MOI of 1 means that the number of infectious virus particles resembles the 
number of target cells. This value varies among different viruses and virus-host cell 
combinations. The Poisson distribution is used to calculate the distribution of virus 
particles per cell.  
Poisson distribution:   P(k)=e-mmk/k! 
Where P(k) is the fraction of cells infected with k virus particles and m resembles the 




3.4.3 Virus release assay 
For virus release assays using transient transfection subconfluent 293T cells were 
plated in a 24-well plate and transfected with 500 ng of NL4.3 proviral plasmid in 
combination with increasing concentrations of tetherin (0 ng, 25 ng, 50 ng and 100 ng), 
and 25 ng of Vpu-HA or mutants using 1 µg/ml polyethyleneimine (Polysciences) per 
well. Alternatively, 293T tetherin cells were plated in a 24-well plate and transfected 
with 500 ng of NL4.3 proviral plasmid, in combination with increasing concentrations or 
25 ng of Vpu-HA or indicated mutant using 1 µg/ml polyethyleneimine (Polysciences) 
per well. The medium was replaced 8 hours post transfection, cells and supernatants 
containing virions were harvested after 48 hours and analysed for physical virus 
particle release (as in 3.4.4) and infectious virus particle release using HeLa-TZMbl 
reporter cells (as in 3.4.5).  
 
3.4.4 Biochemical analysis of physical virus particle release  
The viral supernatant containing virus particles was harvested from each well using a 
syringe-driven filter unit (0.22 µm) (Millipore) and was transferred into a fresh 24-well 
plate. The syringe-driven filter unit removes cells and cell debris that the supernatant 
might contain. To harvest the virions 500 µl of the filtered supernatant was added 
slowly onto 500 µl of cold 1x PBS/20% sucrose in a microcentrifuge tube and 
centrifuged for 1.5 hours at 14,000 rpm and 4°C. The supernatant was carefully 
aspirated and the invisible pellet was resuspended in 30 µl of 2x LB followed by 
denaturation for 10 minutes at 100°C. Virions and corresponding cell lysates were then 
subjected to SDS-PAGE and Western blotted for rabbit anti-HSP90 (Santa Cruz 
Biotechnologies), monoclonal mouse anti-HIV-1 p24CA (kindly provided by B Chesebro 
through the NIH AIDS Reagent Program), monoclonal mouse anti-HA (Covance), 
polyclonal rabbit anti-HA (Rockland) and/ or polyclonal rabbit anti-Vpu antibody (kindly 
provided by K. Strebel through the NIH AIDS Reagent Program). Proteins were 
subsequently visualised by LiCor apparatus using fluorophores conjugated secondary 







3.4.5 Determination of infectious virus particle release 
The release of infectious virus particles from viral supernatants was determined by 
infecting HeLa-TZMbl, a HIV-1 β-galactosidase reporter cell line. HeLa-TZMbl reporter 
cells were plated at a density of 104 per well in a 96-well plate and infected with 20 µl of 
viral supernatant obtained from 3.4.3. 48 hours post transfection cells were lysed in 50 
µl of Tropix Galacto-Star Lysis solution (Applied Biosystems) for 30 minutes at room 
temperature. 10 µl of cell lysates were transferred into a white luminescence 96-well 
plate and incubated with 45 µl of a 1:50 dilution of Tropix Galacto-Star Substrate in 
Reaction Buffer Diluent (Applied Biosystems) for 15 minutes before measuring the β-
galactosidase induced light signal using a luminescence counter (Victor Light 1420-
Perkin Elmer) and Wallac 1420 software.  
 
3.4.6 Tetherin degradation assay 
1.5x105 293T tetherin cells (per well in a 24-well plate) were plated, infected with VSV-
G-pseudotyped NL4.3 HIV-1 wt, HIV-1 delVpu, HIV-1 Vpu LILI, HIV-1 Vpu ELV or HIV-
1 Vpu 2/6A at a MOI of 2 to ensure that approximately 90% of the cells were infected. 
The medium was replaced 4 hours after infection and 48 hours post infection cell were 
harvested in 250 µL 2x LB. Lysates were subsequently subjected to SDS-PAGE and 
Western blotted using rabbit anti-HSP90 (Santa Cruz Biotechnologies) and polyclonal 
rabbit anti-tetherin antibody (kindly provided by K. Strebel through the NIH AIDS 
Reagent Program), and visualised by LiCor apparatus using fluorophores conjugated 
secondary antibodies (IRDye 800 Goat anti-rabbit, IRDye 680 Goat anti-mouse).  
Alternatively, HT1080 cells stably expressing tetherin-HA were infected with VSV-G- 
pseudotyped NL4.3 HIV-1 wt, HIV-1 delVpu or HIV-1 Vpu ELV virus stocks at a MOI of 
2. The medium was replaced 4 hours after infection, and 48 hours post infection, cell 
lysates were harvested and processed as above, using a mouse anti-HA antibody 








3.4.7 One round virus release assay 
293T tetherin, Jurkat or CD4+ T cells were infected with VSV-G-pseudotyped NL4.3 
HIV-1 wt, HIV-1 delVpu or HIV-1 Vpu ELV at an MOI of 0.5-1. 16 hours post infection 
medium was replaced and cells (treated or not with 5000 U/ml of universal type-1 
interferon (PBL InterferonSource)) were cultured for a further 24 hours. The cells were 
harvested and infectivity of viral supernatants was determined by infecting HeLa-TZMbl 
(as described in 3.4.5) and biochemical analysis of physical virus particle release was 
performed as in 3.4.4.  
 
3.4.8 Intracellular p24 staining plus tetherin levels 
Jurkat or CD4+ T cells were infected with VSV-G-pseudotyped NL4.3 HIV-1 wt, HIV-1 
delVpu or HIV-1 Vpu ELV at an MOI of 1. 48 hours post infection, cells were stained for 
surface tetherin expression as in 3.3.7, then fixed and permeabilized for 20 minutes in 
Fixation/Permeabilization solution  (Cytofix/cytoperm Fixation/Permeabilization kit, BD 
Biosciences) and stained for intracellular HIV-1 p24CA using the KC57 antibody 
conjugated to PE (Beckman-Coulter) in BD Perm/Wash buffer (Cytofix/cytoperm 
Fixation/Permeabilization kit, BD Biosciences). The cells were then washed and 








Chapter 4 A cytoplasmic tail determinant in Vpu mediates 
targeting of tetherin for degradation and counteracts restriction 
 
Most of the results presented in this chapter were published as “A Cytoplasmic Tail 
Determinant in HIV-1 Vpu Mediates Targeting of Tetherin for Endosomal Degradation 
and Counteracts Interferon-Induced Restriction” (Kueck and Neil, 2012).  
  
4.1 INTRODUCTION 
Downregulation of cell surface immunomodulatory proteins is a common theme in the 
evasion of innate and adaptive immune responses by mammalian viruses. One host 
molecule targeted by diverse enveloped viruses is tetherin, an interferon-induced 
dimeric type II membrane protein, which inhibits the release of nascent virions from the 
cell surface (Neil et al., 2008) (Van Damme et al., 2008). The HIV-1 accessory protein 
Vpu antagonises tetherin anti-viral function. Vpu is a small integral membrane 
phospho-protein, which directly associates with tetherin through interactions between 
the transmembrane domains of both proteins (Iwabu et al., 2009) (Kobayashi et al., 
2011) (Dubé et al., 2010b) (Vigan and Neil, 2010).  
Recent evidence demonstrates that tetherin degradation is dependent on the ESCRT 
pathway (Janvier et al., 2011), however, tetherin degradation is not strictly required for 
Vpu activity (Goffinet et al., 2010) (Miyagi et al., 2009). Recruitment of the ESCRT-0 
subunit HRS by Vpu is essential to counteract tetherin activity (Janvier et al., 2011). 
Coupled with recent evidence that dysregulation of the entire late endosomal 
compartment by mutants of Rab7a (Caillet et al., 2011), this suggests an emerging 
picture in which Vpu alters tetherin trafficking to counteract its antiviral activity prior to 
lysosomal delivery. While HIV-2 and SIV tetherin antagonists Env and Nef promote 
tetherin internalisation through their interactions with AP-2, (Noble et al., 2006) (Le 
Tortorec and Neil, 2009) (Zhang et al., 2011b), Vpu does not enhance the rate of 
tetherin endocytosis (Dubé et al., 2010b) (Mitchell et al., 2009). Rather it is thought that 
Vpu/tetherin interactions preclude both the recycling of tetherin back to the cell surface 
and the transit of newly synthesized tetherin to the PM by trapping it in intracellular 
compartments, notably the TGN (Dubé et al., 2010b). Consistent with this, the ability of 
Vpu to localise to the TGN correlates with tetherin antagonism (Dube et al., 2009), and 
disruption of the recycling compartment by a dominant Rab11a mutant compromises 
Vpu activity (Varthakavi et al., 2006). Truncations of the Vpu cytoplasmic tail, 




anti-tetherin activity, suggesting it harbours a domain required for Vpu function (Dube 
et al., 2009). Amino acid sequence analysis of the cytoplasmic domain of HIV-1 Vpu 
revealed the presence of a putative trafficking signal in the second alpha helix that 
harbours a degree of amino acid variation among Vpu alleles from different subtypes 
(Dubé et al., 2010a). This signal resembles a variant of an acidic dileucine sorting 
signal (D/E)xxxL(L/I) found in the cytoplasmic tails of membrane proteins that traffic 
through endosomal compartments. Acidic dileucine trafficking motifs have been shown 
to bind to canonical clathrin adaptor proteins AP-1, AP-2 and AP-3. Clathrin adaptors 
are responsible for trafficking of transmembrane cargo proteins from the plasma 
membrane to early/recycling endosomes, transport between TGN/endosome and 
trafficking from early/recycling endosomes to late endosomal compartments (see 1.8). 
Interestingly, subtype C Vpu has been shown to bear a functional overlapping putative 
tyrosine and dileucine-based sorting EYxxL(L/I) motif in the membrane proximal region 
of its cytoplasmic tail. It has been shown model subtype C Vpu localises to the PM 
rather than the TGN and that this is in part due to this motif (Ruiz et al., 2008). 
Therefore, we investigated the role of clathrin adaptor proteins AP-1, AP-2 and AP-3 in 
Vpu subcellular trafficking that is required for tetherin counteraction, especially in 
context of the ExxxLV sorting motif in Vpu cytoplasmic tail.   
In this chapter we have examined the role of the second alpha helix of HIV-1 Vpu in 
tetherin antagonism. We identify a putative sorting signal, ExxxLV, which is required for 
post-binding trafficking of Vpu/tetherin complexes and inhibition of antiviral activity in 
primary CD4+ T cells. Moreover, because residual activity of the ExxxLV mutant 
requires an intact recycling signal in tetherin, we propose that the second alpha helix 
mutant is selectively defective for routing tetherin into an endosomal degradation 
pathway thereby inhibiting its transit to the PM and incorporation into nascent virions. 
Furthermore, we have examined the nature of the ExxxLV sorting singal in HIV-1 Vpu. 
While this motif can be functionally replaced by a clathrin adaptor binding peptide 
derived from HIV-1 Nef, however, Vpu activity does not require the canonical adaptors 





4.2.1 Determinants of tetherin inactivation in the second alpha helix of the Vpu 
cytoplasmic tail 
Truncations of the Vpu cytoplasmic tail lead to aberrant localisation and a reduction in 
its anti-tetherin activity (Dube et al., 2009). To further study the determinants within the 
second alpha helix of Vpu that account for TGN localisation, we performed overlapping 
triple-alanine mutagenesis through the second alpha helix of a codon optimized HIV-1 
NL4.3 Vpu construct bearing a C-terminal HA tag (Figure 4-1A). We then assayed 
these Vpu mutants for their ability to rescue Vpu-defective HIV-1 from tetherin 
restriction. 293T cells were transfected with wild-type HIV-1 (HIV-1 wt) or Vpu-defective 
HIV-1 (HIV-1 delVpu) proviruses in combination with a fixed dose of a human tetherin 
expression vector, and 25 ng of Vpu-HA or indicated mutant. 48 hours after 
transfection, cell lysates and supernatants were harvested and analysed for physical 
viral yield by Western blot (Figure 4-1B) or supernatant infectivity of HeLa-TZMbl 
indicator cells (Figure 4-1C). As expected, in the absence of Vpu, both supernatant 
particle yield and infectivity of HIV-1 delVpu was profoundly reduced in the presence of 
tetherin, expression of Vpu in trans rescued virus production to wild-type levels. By 
contrast, mutations encompassing residues E59 or L63 and V64, but not the 
intervening or subsequent amino acids, displayed defective rescue of HIV-1 delVpu 
(Figure 4-1 B and C). All Vpu mutants with the exception of Vpu 67-69A-HA were 
expressed equivalently. Vpu 63-65A-HA appeared to display a dominant interfering 
activity on HIV-1 wt titre, but this was not reflected as apparently in particle yield.  
These results suggested a functional requirement for residues E59 and L63/V64 in 
tetherin antagonism by Vpu. To confirm this we mutated these residues to alanine in 
the context of an HIV-1 NL4.3 provirus (NL4.3 Vpu ELV) and examined viral release 
from 293T cells in the presence of increasing expression levels of tetherin. Because 
this part of Vpu overlaps with start of the Env open reading frame in the provirus, these 
mutations were rendered silent in the +1 reading frame and displayed no defect in virus 
release in the absence of tetherin (Figure 4-1 D and E). In agreement with the virus 
rescue by Vpu expression in trans, NL4.3 Vpu ELV release was markedly defective in 
the presence of increasing tetherin doses, although it did display a residual antagonism 







Figure 4-1 Residues E59, L63 and V64 in Vpu are required for efficient counteraction of tetherin 
(A) Schematic representation of alanine scan mutagenesis in the second alpha helix of the codon-
optimized HIV-1 NL4.3 Vpu protein. (B) 293T cells were transfected with NL4.3 wt or NL4.3 delVpu 
proviruses in combination with tetherin and the indicated pCR3.1 Vpu-HA expression vectors. 48 hours 
post transfection, cell lysates and pelleted supernatant virions were harvested and subjected to SDS-
PAGE and analysed by Western blotting for HIV-1 p24CA, Vpu-HA and Hsp90 serving as loading control, 
and analysed by LiCor quantitative imager. (C) Viral supernatants from (B) were assayed for infectivity 
using HeLa-TZMbl reporter cells. Infectious virus release is plotted on a log scale as β-galactosidase 
activity in relative light units (RLU). Error bars represent standard deviations of the means of three 
independent experiments. (D) E59A, L63A and V64A mutations were inserted into the vpu gene of the 
NL4.3 provirus referred to as NL4.3 Vpu ELV. 293T cells were transfected with NL4.3 wt, NL4.3 delVpu or 
NL4.3 Vpu ELV proviral plasmids together with increasing doses of tetherin expression vector. The 
resulting infectivity was determined as in (C), error bars represent standard deviations of the means of 
three independent experiments. (E) Cell lysates and pelleted viral supernatants from 0 ng and 100 ng 
tetherin input from (D) were subjected to SDS-PAGE and analysed by Western blotting for HIV-1 p24CA 






We next examined the phenotypic basis for the defect in tetherin antagonism by Vpu 
ELV. Vpu stimulates the ubiquitin-dependent degradation of tetherin, most likely in 
lysosomal compartments (Douglas et al., 2009) (Mitchell et al., 2009). To this end, we 
infected HT1080 cells stably expressing human tetherin bearing an HA-tag in the 
extracellular domain (HT1080 tetherin-HA) with VSV-G-pseudotyped HIV-1 wt, HIV-1 
delVpu or HIV-1 Vpu ELV at an MOI of 2 to ensure >90% cell infection. 48 hours later, 
cells were lysed and Western blotting performed for relative tetherin-HA levels (Figure 
4-2A). As expected, cells infected with HIV-1 wt showed reduced steady state levels of 
tetherin that was not apparent in those infected with HIV-1 delVpu. Similarly, in cells 
infected with HIV-1 Vpu ELV there was no evidence of tetherin degradation, but 
interestingly there appeared to be enhanced levels of tetherin, perhaps suggesting 
stabilization of the protein in the presence of the mutant Vpu. Thus, E59, L63, V64 
mutations abolish the ability of Vpu to induce tetherin degradation. 
We then examined the ability of Vpu ELV mutants to downregulate surface tetherin 
levels. We first transfected HeLa cells (that express tetherin constitutively) with Vpu-HA 
or indicated mutant expression vectors in combination with a GFP reporter. 48 hours 
later, surface tetherin was assayed by flow cytometry in the GFP positive cells. As 
expected, wild-type Vpu expression reduced cell surface tetherin levels. Vpu mutants 
bearing E59A, L63A, V64A mutations, or the full ELV mutant all displayed a reduced 
capacity to downregulate surface tetherin levels (Figure 4-2 B and C). To confirm this in 
infected cells, we infected HeLa cells with HIV-1 wt, HIV-1 delVpu, HIV-1 Vpu ELV or 
HIV-1 Vpu 2/6A. 48 hours post infection, cells were stained for surface tetherin and co-
stained for intracellular p24CA as a marker of infection (Figure 4-3A). Cells infected 
with HIV-1 wt showed a dramatic downregulation of tetherin on the surface of p24CA 
positive cells. While, tetherin was not downregulated from the surface of either HIV-1 
delVpu, HIV- 1 Vpu 2/6A or HIV-1 Vpu ELV infected cells. We also performed the same 
experiment in a more relevant cell-type. To this end, we infected CD4-positive Jurkat T 
cells and analysed them for surface tetherin levels (Figure 4-3B). To discriminate 
between truly infected cells, and those that acquired p24+ debris by exposure of cells 
to high titre (MOI 1) of viral inoculum, we compared to cells exposed to virus in the 
presence of 50 mM AZT (Figure 4-3C). Cultures infected with HIV-1 wt showed clear 
downregulation of tetherin on the surface of p24CA positive cells. By contrast, tetherin 
was not downregulated from the surface of either HIV-1 delVpu, HIV- 1 Vpu 2/6A or 
HIV-1 Vpu ELV infected cells. Rather, tetherin levels were raised on some infected 
cells, perhaps reflecting accumulation of tethered virions on the cell surface. Although 
in HeLa cells, we could not detect enhanced tetherin surface levels on cells infected 





Figure 4-2 Vpu ELV mutants are defective for tetherin degradation and downregulation 
(A) HT1080 cells stably expressing tetherin-HA were infected with VSV-G-pseudotyped HIV-1 wt, HIV-1 
delVpu or HIV-1 Vpu ELV at an MOI of 2. 48 hours post infection, cells were harvested and subjected to 
SDS-PAGE and analysed by Western blotting for tetherin-HA, Vpu and Hsp90, and analysed by LiCor 
quantitative imager. Relative tetherin-HA levels are indicated below each lane. The blot shown is a 
representative example of 3 independent experiments. (B) HeLa cells were co-transfected with pCR3.1 
Vpu-HA or indicated Vpu mutant in combination with a GFP expression construct. Cell surface staining for 
endogenous tetherin was analysed by flow cytometry 48 hours post transfection. GFP positive cells were 
gated and tetherin levels (solid lines) were compared to those of un-transfected HeLa cells (dotted lines). 
Numbers indicate median fluorescence intensities of surface tetherin on transfected cells. The solid peak 
in the upper left histogram represents the binding of the isotype control. (C) HeLa cells were treated and 





Figure 4-3 Vpu ELV mutants are defective for tetherin downregulation in infected Jurkat T-cells 
(A) HeLa cells were infected with VSV-G-pseudotyped HIV-1 wt, HIV-1 delVpu, HIV-1 Vpu ELV or HIV-1 
Vpu 2/6A at an MOI of 1. 48 hours post infection, cells were stained for cell surface tetherin and 
intracellular p24CA, and analysed by flow cytometry  (B) Jurkat cells were infected as in (A). Productively 
infected cells were identified by comparing with cultures infected with the same MOI in the presence of 50 





4.2.2 Vpu ELV mutants localise to early endosomal compartments 
The E59xxxL63V64 motif in Vpu resembles an acidic dileucine sorting signal 
(D/E)xxxL(L/I) found in the cytoplasmic tails of membrane proteins that traffic through 
endosomal compartments (reviewed by (Bonifacino and Traub, 2003)). We therefore 
addressed whether mutation of this motif affected Vpu subcellular localisation. To this 
end, we infected 293T expressing tetherin or not, as well as Jurkat and HeLa cells with 
VSV-G-pseudotyped HIV-1 NL4.3 and NL4.3 Vpu ELV and stained them for Vpu in 
combination with several subcellular markers 48 hours later. As expected, in all cells, 
the predominant localisation of wild-type Vpu was in association with the TGN, with 
between 20-50% of the Vpu immunoreactivity visible in TGN46-positive compartments 
(Figure 4-4 A-D). The proportion of the Vpu ELV mutant in TGN46-positive 
compartments was significantly reduced in 293T tetherin, Jurkat and HeLa, and 
appeared as ‘‘endosome-like’’ punctae in the cytoplasm and associated on or near the 
plasma membrane (Figure 4-4 A-C and E). Interestingly, in the parental 293T cells, 
which lack tetherin expression, Vpu and Vpu ELV localisation was indistinguishable, 
and predominantly associated with TGN46-positive compartments (Figure 4-4 D and 
E). Thus, the difference in Vpu ELV localisation appeared to be tetherin dependent. 
The nature of these extra-TGN compartments was further analysed in HeLa cells and 
revealed that Vpu ELV accumulated in EEA1-positive early/sorting endosomal 
compartments, but not CD63-positive late endosomes (Figure 4-4F). Thus, mutation of 
the ExxxLV motif leads to endosomal and surface localisation of Vpu consistent with it 





Figure 4-4 ExxxLV mutants localise to early endosomal compartments 
(A) 293T tetherin, (B) HeLa, (C) Jurkat or  (D) parental 293T were infected with HIV-1 wt or HIV-1 Vpu 
ELV at an MOI of 1. 48 hours later, cells were fixed and stained for Vpu (green) and the TGN marker 
TGN46 (red) and examined by confocal microscopy. Panels are of representative examples. (E) The 
percentage of the total Vpu immunoreactivity localised to TGN46+ compartments was calculated for cells 
(n=20) from (A–D) using the Leica Confocal Software. Results were analysed by unpaired 2-tailed t-test - 
** P=10-8 or lower. (F) HeLa cells as in B were stained for Vpu (green) and the early endosomal marker 





4.2.3 Vpu ELV mutants interact with cellular host factors as well as tetherin and 
are incorporated into virions 
Since tetherin degradation is dependent on Vpu binding to β-TrCP2 via a 
phosphorylated pair of serine residues in the Vpu cytoplasmic tail (S52 and S56) 
(Margottin et al., 1998) (Mitchell et al., 2009) (Mangeat et al., 2009), we tested whether 
Vpu ELV mutants were defective for interaction with β-TrCP2 in co-
immunoprecipitations from transfected cells (Figure 4-5A). Myc-β-TrCP2 was co-
immunoprecipitated with Vpu-HA and Vpu ELV-HA, but as expected, not the phospho-
mutant Vpu 2/6-HA, ruling out this defect in Vpu ELV. Recent data suggests that 
ESCRT-mediated degradation of tetherin in the presence of Vpu is mediated by 
interaction of Vpu with HRS (ESCRT-0) (Janvier et al., 2011). We could further show 
that both Vpu and Vpu ELV also co-precipitated with HA-HRS from transfected 293T 
cells (Figure 4-5B) indicating that an inability to recruit ESCRT-0 does not explain the 
defect in Vpu ELV-mediated degradation of tetherin. 
  
 
Figure 4-5 Vpu ELV interaction with cellular co-factors essential for tetherin antagonism 
(A) 293T cells were transfected with pCR3.1 Vpu-HA, Vpu 2/6A-HA, or Vpu ELV-HA in combination with 
pCR3.1 myc-b-TrCP2. 48 hours post transfection, cells were lysed and immunoprecipitated with anti-HA 
antibody. Lysates and precipitates were subjected to SDS-PAGE and analysed by Western blotting for 
Vpu and myc-b-TrCP2, and analysed by ImageQuant. The star represents an unspecific band. (B) 
Similarly, 293T cells were transfected with pCR3.1 HA-HRS in combination with Vpu-GFP or Vpu ELV-
GFP expression constructs. Cell lysates were precipitated with an anti-HA antibody and analysed as in (A). 
 
As a putative trafficking signal, the ExxxLV motif may exert its effect on tetherin 
antagonism in two ways. Firstly, the sequence may be required to permit Vpu to traffic 
to a compartment where it can interact with tetherin; secondly, the sequence may be 
required for post-interaction trafficking of Vpu/tetherin complexes such that tetherin is 
not incorporated into budding virions and expression on the cell surface is reduced. A 
potential confounding factor in investigating, however, is that wild-type Vpu induces 




applicable, controversies surrounding the nature of its phenotype in terms of tetherin 
counteraction also make it problematic. To alleviate these issues, we took advantage of 
our recent observations with the novel ESCRT-I subunit, UBAP1 (Stefani et al., 2011) 
(Agromayor et al., 2012), (data presented in 5.2.1). Interestingly, UBAP1 is essential 
for Vpu-mediated degradation of tetherin, but is not required for Vpu-mediated tetherin 
antagonism, implying that commitment of tetherin into a degradative pathway by Vpu, 
but not ESCRT-I function itself, counteracts tetherin activity (Agromayor et al., 2012). 
We therefore first examined whether Vpu or Vpu ELV interacted with tetherin in 
immunoprecipitations from infected cells in the presence or absence of siRNA-
mediated silencing of UBAP1. To this end, 293T tetherin cells were treated twice over a 
period of 48 hours with non-coding siRNA or two different siRNA oligonucleotides 
directed against UBAP1, and infected with HIV-1 wild-type or HIV-1 delVpu. 48 hours 
post infection, cells were lysed and tetherin was immunoprecipitated and visualised by 
Western blotting (Figure 4-6A). As expected, UBAP1 siRNA treatment rescued tetherin 
levels from Vpu-mediated degradation, but also further enhanced total cellular levels of 
tetherin (Agromayor et al., 2012), consistent with the known role of ESCRT in tetherin’s 
natural turnover (Janvier et al., 2011). Interestingly, UBAP1 siRNA also enhanced the 
total cellular content of wild-type Vpu to that of the Vpu ELV mutant (approximately 4/5-
fold). Immunoprecipitation of tetherin from the lysates from these cells revealed a 
similar picture. Wild-type Vpu was detected associated with residual tetherin 
precipitated from cells, and this was markedly increased upon UBAP1 knockdown. This 
data strongly suggests that Vpu itself may be co-degraded with tetherin in endosomal 
compartments. The Vpu ELV mutant efficiently co-precipitated with tetherin irrespective 
of UBAP1 knockdown, and as expected the Vpu A14L/W22A tetherin binding mutant 
(Vigan and Neil, 2010)  failed to co-precipitate under either condition. Interestingly, 
however, the ratio of relative band intensities between of Vpu or Vpu ELV precipitated 
with tetherin in the presence UBAP1 siRNA was equivalent, indicating that Vpu ELV 
was not defective for physical tetherin interaction, suggesting that the Vpu ELV 
mutant’s defect in tetherin antagonism is due to an inability to mediate post-binding 
trafficking of Vpu/tetherin complexes into an ESCRT-dependent pathway in which both 
proteins are degraded. Consistent with this notion, Vpu ELV co-localised with tetherin 
in infected HeLa and 293T tetherin, both in peripheral endosomal structures and at the 
cell surface (Figure 4-6B). By contrast, the little tetherin visible in cells infected with 
wild-type virus co-localised with Vpu in peri-nuclear areas. 
Vpu is not a constituent of HIV-1 particles. We therefore reasoned that if the ExxxLV 
motif was required to prevent tetherin trafficking to viral budding sites and commit it for 




in nascent viral particles. To test this hypothesis we took advantage of a tetherin 
mutant lacking its GPI anchor (tetherin delGPI), which despite its high surface 
expression, does not restrict virus particle release, but accumulates in virus particles 
and is sensitive to Vpu (Perez-Caballero et al., 2009). 293T tetherin delGPI cells were 
mock-transfected or transfected with NL4.3 wt, NL4.3 Vpu ELV, and NL4.3 delVpu. 48 
hours later, cell supernatants were centrifuged through a sucrose cushion and 
analysed for tetherin incorporation by Western blot (Figure 4-6 C and D). As expected, 
high levels of tetherin delGPI could be detected in NL4.3 delVpu viral pellets, but not in 
pelleted supernatants from mock-transfected cells. Tetherin delGPI incorporation was 
reduced in the wild-type virus consistent with tetherin removal from the cell surface. 
The level of tetherin incorporation in NL4.3 Vpu ELV particles was similar to that of the 
Vpu-defective mutant. Interestingly, NL4.3 Vpu ELV particles contained detectable 
levels of Vpu (in this case Vpu appears as a doublet band, which we suggest may be 
due to exposure to active HIV-1 protease in the particle). By contrast, no Vpu was 
detectable in any viral particles derived from 293T cells, indicating that Vpu ELV 
incorporation into viral particles was tetherin dependent. Taken together, these data 
indicate that the ExxxLV motif is required for efficient tetherin antagonism, by 
modulating the trafficking of tetherin such that it cannot become efficiently incorporated 






Figure 4-6 Vpu ELV interacts with tetherin and is incorporated into nascent virions 
(A) 293T tetherin cells were transfected twice over 48 hour with siRNA oligonucleotide directed against 
UBAP1 or Non-targeting control. The cells were then infected with the indicated virus at an MOI of 2. 48 
hours later, cell lysates were immunoprecipitated with an anti-tetherin monoclonal antibody. Lysates and 
immunoprecipitates were separated by SDS-PAGE and blotted for tetherin, UBAP1 or Vpu using LiCor 
quantitative Western blotting. Numbers under the Vpu lanes of the cell lysate represent relative band 
intensities. The histogram below the IP represents the ratio of tetherin band intensity to that of Vpu in the 
co-immunoprecipitation. (B) HeLa and 293T tetherin cells were infected as in Figure 4-4, and stained for 
Vpu (green) and tetherin (red) and examined by confocal microscopy. Adjacent histograms quantify the 
degree of co-localisation of Vpu ELV and tetherin (Pearson’s Correlation Coefficient calculated using 
ImageJ) for 20 individual cells. (C and D) 293T or 293T cells stably expressing tetherin delGPI were 
infected with HIV-1 wt, HIV-1 Vpu ELV or HIV-1 delVpu at an MOI of 1. 48 hours post infection, cells were 
harvested and viral supernatants were pelleted through a 20% sucrose cushion. Cells and virions were 
subjected to SDS-PAGE and Western blotting for tetherin delGPI, Vpu, HIV-1 p24CA and Hsp90 and 





Recent data suggests that Vpu blocks both the transit of de novo synthesized tetherin 
to the cell surface as well as the recycling of endocytosed tetherin from the plasma 
membrane, with the relative importance of these processes currently a matter of 
debate (Tervo et al., 2011) (Schmidt et al., 2011). Tetherin recycling requires a dual 
tyrosine YxYxxφ  motif in its cytoplasmic tail that acts as a binding site for AP-2 (for 
internalisation) and AP-1 (for recycling via the Golgi) (Rollason et al., 2007) 
(Masuyama et al., 2009). Mutation of this motif enhances tetherin surface expression, 
but only has minor effects on its ability to restrict virus release or its sensitivity to Vpu 
(Iwabu et al., 2009) (Dubé et al., 2010b). Given that the ExxxLV motif was defective for 
post-binding inactivation of tetherin, but retained a low residual activity against tetherin 
in transient transfection assays, we asked whether Vpu ELV was differentially defective 
against tetherin mutants bearing lesions in its own sorting sequence. We infected 293T 
tetherin and 293T tetherin Y6,8A cells with HIV-1 wt, HIV-1 delVpu and HIV-1 Vpu ELV 
at a fixed dose (MOI 1) and measured viral release 48 hours later (Figure 4-7 A and B). 
Vpu-defective viral release was approximately 35-fold reduced from 293T tetherin cells 
compared to the wild-type virus, and as expected NL4.3 Vpu ELV had an intermediate 
phenotype in this assay (6-fold less release than wt). However, in 293T tetherin Y6,8A 
all residual antagonistic activity of Vpu ELV was abolished with viral release equivalent 
to that of the Vpu deleted virus. By contrast, the wild-type virus retained the majority of 
its anti-tetherin activity. This again was not due to a defect of Vpu interaction with 
tetherin, as immunoprecipitation of tetherin after UBAP1 siRNA treatment 
demonstrated equivalent levels of Vpu and Vpu ELV co-precipitation from both tetherin 
and tetherin Y6,8A expressing cells (Figure 4-7C). Thus, residual activity of Vpu ELV 








Figure 4-7 Residual activity of Vpu ELV mutants requires an intact recycling signal in tetherin 
(A) 293T tetherin or 293T tetherin Y6,8A mutant were infected with VSV-G-pseudotyped HIV-1 wt, HIV-1 
delVpu or HIV Vpu ELV at an MOI of 0.5. Supernatants and cell lysates were harvested 48 hours later and 
analysed for infectious virus release on HeLa-TZMbl as Figure 4-1. Error bars represent the standard 
deviation of three independent experiments. (B) Corresponding Western blots of cell lysates and virions 
from A. (C) 293T tetherin Y6,8A cells treated with control or UBAP1 specific siRNAs were infected with 
VSV-G-pseudotyped HIV-1 wt, HIV Vpu ELV, HIV-1 Vpu A14L/W22A or HIV-1 delVpu at an MOI of 2. 48 
hours post infection, cells were lysed and immunoprecipitated with an anti-tetherin antibody. Lysates and 
immunoprecipitates were subjected to SDS-PAGE and analysed by Western Blotting for tetherin, UBAP1 
and Vpu, and analysed by LiCor quantitative imager. Ratios of Vpu/ tetherin band intensities in the co-





4.2.4 Tetherin antagonism by Vpu is clathrin-dependent 
The implication of putative clathrin adaptor sites in Vpu-mediated tetherin antagonism 
led us to first test whether inhibition of overall clathrin function inhibits Vpu activity. 
Overexpression of the C-terminal fragment of the neuronal adaptor AP180 (AP180c) 
that inhibits clathrin/membrane interactions (Ford et al., 2001), was recently shown to 
inhibit tetherin downregulation from the surface (Lau et al., 2011). To this end, 293T 
tetherin expressing cells were transfected with increasing concentrations of AP180c in 
combination with NL4.3 wt or NL4.3 delVpu. 48 hours post transfection, cells and 
supernatant containing virions were harvested and analysed by Western Blot. 
Overexpression of AP180c specifically blocked Vpu-dependent particle release (Figure 
4-8A), indicating clathrin-dependent subcellular trafficking is essential for Vpu activity. 
Infectious yield could not be determined in this experiment because AP180c 
overexpression inhibits envelope processing and blocks clathrin incorporation into 
particles, which has been shown to play a role in retroviral particle infectivity (Popov et 
al., 2011) (Zhang et al., 2011b). Interestingly AP180c expression, like UBAP1 siRNA 
treatment (Figure 4-6A), enhanced total Vpu expression levels, indicating that clathrin-
dependent transport is involved in the turnover of Vpu. Visualization of Vpu-YFP 
localisation in 293T tetherin cells overexpressing AP180c showed vesicular rather than 
peri-nuclear localisation similar to that seen in the same cells infected with HIV-1 Vpu 
ELV (Figure 4-8B), and this was not apparent in the parental tetherin negative 293T 
cells, suggesting again this difference was driven by interaction with tetherin.  
 
Figure 4-8 AP180c inhibits Vpu-mediated tetherin antagonism 
(A) 293T tetherin were transfected with NL4.3 wt or NL4.3 delVpu proviral plasmids in combination with 
either YFP or increasing doses of an AP180c expression vector. 48 hours post transfection, cell lysates 
and pelleted supernatant virions were harvested and subjected to SDS-PAGE and analysed by Western 
blotting for HIV-1 p24CA, Vpu and Hsp90 serving as loading control, and analysed by LiCor quantitative 
imager. (B) 293T or 293T tetherin cells were transfected with pCR3.1 Vpu-YFP with or without AP180c co-




The dominant negative mutant of the GTPase dynamin 2 (K44A) has also been 
described to have an intermediate effect on tetherin counteraction by Vpu, compared to 
the complete disruption of HIV-2 Env function which, like SIV Nef, is dependent on AP-
2 and endocytosis (Lau et al., 2011). We transfected increasing doses of HA-tagged 
dominant negative dynamin 2 or the wild-type protein along with HIV-1 proviruses into 
293T tetherin and parental cells (Figure 4-9 A-C). In agreement with Lau et al (Lau et 
al., 2011) dominant negative dynamin 2, but not equivalent levels of the wild-type 
dynamin 2, partially blocked the release of wild-type HIV-1 (Figure 4-9 A-C). 
Furthermore, dominant negative dynamin 2 expression levels in these assays were 
sufficient to block transferrin uptake in parallel cultures tested by fluorescence imaging 
(Figure 4-9D). Interestingly, dominant negative dynamin 2 also blocked residual Vpu 
ELV-mediated and even the low level Vpu-defective viral release proportionally (7x, 4x 
and 8x for WT, Vpu-defective or Vpu ELV respectively), suggesting that this effect was 
independent of the ELV motif. Given that dominant negative dynamin 2 inhibits tetherin 
endocytosis (Lau et al., 2011), this data suggests that its effect on restriction may be 
due more to the build up of tetherin at the cell surface that cannot be turned over rather 







Figure 4-9 Effects of dominant negative dynamin 2 on Vpu-mediated HIV-1 release 
(A and B) 293T tetherin cells were transfected with the indicated HIV-1 provirus and increasing doses of 
HA-tagged dominant negative dynamin 2 (A) or the wild-type protein (B). 48 hours later, cell lysates and 
viral supernatants were harvested and subjected to SDS-PAGE and analysed by Western blotting for HIV-
1 p24CA, dynamin 2-HA and Hsp90, and analysed by LiCor quantitative imager. Histograms below the 
blots indicate particle release efficiency compared to wild-type virus release in the absence of dynamin 2 
or increasing doses of dynamin 2 expression vector. (C) Corresponding infectivity of viral supernatants 
from (A and B) on HeLa-TZMbl cells alongside those from a parallel experiment in parental 293T cells. (D) 
293T tetherin cells were transfected with pCR3.1 YFP with or without increasing doses of dominant 
negative dynamin 2. 48 hours later, cells were starved in serum-free medium for 30 minutes and then 
treated for a further 15 minutes with 10 µg/ml Alexa-594-conjugated transferrin, before fixation and 





4.2.5 Second alpha helix can be functionally replaced by D/ExxxLL-containing 
peptide from HIV-1 Nef 
Acidic dileucine-based sorting signals, D/ExxxL(L/I), act as binding sites for a hemi-
complex of sigma and adaptin subunits of the canonical clathrin adaptors AP-1, AP-2 
and AP-3, and are required for endocytic and endosomal/Golgi trafficking (see 1.8). 
While the requirement for the acidic and first leucine residues are absolute, the third 
position is less well conserved, and can be L, I or on occasion V or M. Analysis of the 
cytoplasmic tails of Vpu sequences from most clades of HIV-1 group M, show that a 
putative ExxxL(V/M/I) is well conserved in the second alpha helix (Figure 4-10A). In 
contrast to other HIV-1 subgroups, Clade C and F isolates have an ExxxLL motif 
juxtaposed to the plasma membrane in helix 1 (not shown), which has been previously 
suggested to be a determinant of Clade C Vpu localisation to the PM (Ruiz et al., 
2008). In subgroup B, the V64 position is usually V or M, although occasional I or L 
residues are found at this position. We mutated position 64 to M, L or I in NL4.3 Vpu 
and examined the mutant Vpu proteins for tetherin antagonism and their ability to 
downregulate tetherin form the cell surface. To study antagonism, 293T cells 
expressing tetherin were transfected with Vpu-HA or indicated mutant in combination 
with wild-type HIV-1 provirus NL4.3 (NL4.3 wild-type) or Vpu-defective NL4.3 (NL4.3 
delVpu). 48 hours after the transfection cell lysates and supernatants containing viral 
particles were harvested and analysed for physical virus yield by Western blot (Figure 
4-10B). To study downregulation, HeLa cells were transfected with a GFP reporter in 
combination with Vpu-HA or indicated mutant protein. 48 hours post transfection, cell 
surface levels of tetherin were analysed by flow cytometry (Figure 4-10C). We found no 
defect in the mutant proteins abilities to counteract or downregulate tetherin from the 
surface (Figure 4-10 B and C), in agreement with the above data demonstrating that 
this position is the least important of the three, and consistent with the role of this motif 





Figure 4-10 Vpu Exxx(V/M/I/L) is conserved in most HIV-1 clades 
(A) LogoPlots of Vpu cytoplasmic tail portions encompassing the conserved phosphorylation motif 
(DSGNES) and helix 2 from HIV-1 subgroup M clades A, B, D, G and H generated from sequences 
obtained from the Los Alamos database (www.hiv.lanl.gov). (B) 293T cells were transfected with NL4.3 or 
NL4.3 delVpu proviruses in combination with tetherin and Vpu-HA, Vpu 64I-HA, Vpu 64M-HA or Vpu 64L-
HA expression vectors. 48 hours post transfection, cell lysates and pelleted supernatant virions were 
harvested and subjected to SDS-PAGE and analysed by Western blotting for HIV-1 p24CA, Vpu-HA and 
Hsp90, and analysed by LiCor quantitative imager. (C) HeLa cells were co-transfected with Vpu or 
indicated Vpu mutant and a GFP expression construct. Cell surface staining for endogenous tetherin was 
analysed by flow cytometry 48 hours post transfection, as in Figure 4-2. 
 
The Nef proteins of primate immunodeficiency viruses are also multifunctional adaptor 
proteins, targeting a variety of immune regulatory cell surface molecules for 
downregulation and degradation (reviewed by (Kirchhoff, 2010)). Nef interacts 
promiscuously with AP-1, AP-2 and AP-3 through a conserved C-terminal D/ExxxLL 
motif (Janvier et al., 2003) (Chaudhuri et al., 2007). The interaction of AP-2 with this 
site is essential for Nef targeting of CD4 for ESCRT-dependent lysosomal degradation 




requires AP-1 (Lubben et al., 2007). Importantly, several SIV Nef proteins are also 
tetherin antagonists (Jia et al., 2009) (Zhang et al., 2009) and again this is dependent 
on the D/ExxxLL motif (Zhang et al., 2011a). We therefore asked whether the C-
terminus of HIV-1 Vpu could be functionally substituted with a known AP-binding site 
from these proteins. The EVSALV motif of NL4.3 Vpu was first replaced with the core 
AP-binding site from NL4.3 Nef, ENTSLL (Figure 4-11A), and this Vpu protein was as 
functional as the wild-type protein in virus rescue experiments (Figure 4-11 B and C). 
We then replaced the entire cytoplasmic tail of Vpu from residue 58 with a 19 amino 
acid stretch derived from Nef including the ENTSLL and a downstream dual-aspartic 
acid motif that has been previously shown to stabilize AP-2 interactions (Lindwasser et 
al., 2008). Remarkably, when we tested the ability of these proteins to antagonise 
tetherin function, the Vpu-Nef chimeric protein substantially recovered tetherin 
antagonistic activity (Figure 4-11 B and C). Moreover, this chimera also displayed 
improved tetherin downregulation from the surface of transfected HeLa cells (Figure 
4-11 D). This activity was entirely dependent on the key amino acids required for AP-
interaction as a chimera in which E, LL and DD positions were mutated to alanine was 
unable to counteract tetherin or downregulate it from the surface (Figure 4-11 B-D). 
Examination of the subcellular distribution of Vpu-Nef or the mutant fused to CherryFP 
suggested that the mutant was localised more prominently to the PM consistent with a 
defect in trafficking imparted by the mutation (Figure 4-11E). Thus, Vpu function can be 
substantially recovered by replacing its entire second alpha helix with a promiscuous 
AP-binding (D/E)xxxL(L/I) sorting signal, indicating that linking Vpu directly to the 







Figure 4-11 The second alpha helix of Vpu can be functionally replaced by D/ExxxLL endocytic 
signal from HIV-1 Nef 
(A) Schematic representation of Vpu ENTSLL and Vpu-Nef chimeric constructs. (B) 293T cells were 
transfected with NL4.3 wt or NL4.3 delVpu proviral plasmids in combination with tetherin and indicated 
pCR3.1 Vpu-HA or Vpu-Nef-HA chimera. 48 hours post transfection, cell lysates and pelleted supernatant 
virions were harvested and subjected to SDS-PAGE and analysed by Western blotting for HIV-1 p24CA, 
Vpu-HA and Hsp90, and analysed by LiCor quantitative imager. (C) Infectivity of viral supernatants from 
(B) was determined on HeLa-TZMbl cells as in Figure 4-1. Error bars represent standard deviation of three 
independent experiments. (D) HeLa cells were co-transfected with Vpu or indicated Vpu mutant and a 
GFP expression construct. Cell surface staining for endogenous tetherin was analysed by flow cytometry 
48 hours post transfection, as in Figure 4-2. (E) HeLa cells were transfected with Vpu-Nef or Vpu-Nef-mu 






4.2.6 Vpu-mediated tetherin antagonism is independent of canonical adaptor 
proteins 
The similarities between the ExxxLV motif and acidic dileucine sorting signals, and its 
functional replacement with the promiscuous ENTSLL motif in HIV-1 Nef led us to test 
whether the major known adaptors involved in trafficking of membrane proteins 
between the PM, endosomes and Golgi compartments were required for Vpu-mediated 
tetherin antagonism. Clathrin-mediated endocytosis requires AP-2, whereas AP-3 
controls early to late endosomal/lysosomal trafficking. AP-1 plays a role in trafficking of 
cargo between early endosomes and the TGN, with evidence that it can function in 
either direction, discussed 1.8. To this end we examined the effects of siRNA-mediated 
silencing of AP-1 (AP-1 γ1), AP-2 (AP-2 µ1), AP-3 (AP-3 µ1/AP-3 δ1). HeLa or 293T 
tetherin expressing cells were treated twice over a period of 48 hours with non-coding 
siRNA or indicated siRNA oligos directed against the clathrin adaptors, and infected or 
transfected with HIV-1 wild-type or HIV-1 delVpu. 48 hours post infection, cells were 
lysed and analysed by Western blot. For AP-1, siRNA-mediated silencing was 
inefficient in 293T tetherin cells (not shown) and we therefore constructed a HeLa cell 
line containing a doxycycline-inducible shRNA hairpin against AP-1 γ1. Induction of this 
hairpin coupled with simultaneous depletion of AP-1 γ1 by oligonucleotide transfection 
led to approximately 95% knockdown efficiency. This treatment had no specific effect 
on Vpu-dependent virus particle yield in HeLa cells indicating that tetherin antagonism 
again was not compromised (Figure 4-12A), and furthermore tetherin surface 
downregulation was not defective in mouse AP-1 µ1a -/- fibroblasts (Figure 4-12B) 
(Zizioli et al., 1999). Similarly AP-3 µ1 and AP-3 δ1 co-depletion had no detectable 
effect on tetherin activity or Vpu-mediated counteraction (Figure 4-12C). Furthermore, 
human tetherin could also be downregulated from the surface of mouse fibroblasts 
defective in AP-3 δ1 when transduced to express Vpu (Peden et al., 2002) (Figure 
4-12D). Depletion of AP-2 by RNAi in 293T tetherin cells had only minor effects on 
Vpu-dependent virus particle release, suggesting that unlike SIV Nef and HIV-2 Env, 
and consistent with the reports that Vpu does not enhance tetherin endocytosis, AP-2 






Figure 4-12 Clathrin adaptor AP-1, AP-2 and AP-3 are dispensable for Vpu-mediated tetherin 
antagonism 
(A) HeLa cells expressing a doxycycline-inducible shRNA hairpin against AP-1 γ1 were transfected twice 
with pooled control or siRNA pools against AP-1 γ1. 4 hours post the second transfection the cells were 
infected with VSV-G-pseudotyped HIV-1 wt or HIV-1 delVpu virus stock at an MOI of 1. 48 hours post 
infection, cell lysates and pelleted supernatant virions were harvested and subjected to SDS-PAGE and 
analysed by Western blotting for HIV-1 p24CA, AP-1 γ and Hsp90 serving as loading control, and analysed 
by LiCor quantitative imager. The percentage of AP-1 γ1 knockdown was determined by the relative band 
intensity and is indicated below the blot panel. (B) Fibroblasts from AP-1 µ1A −/− mice or their 
reconstituted counterparts were transduced to express human tetherin bearing an extracellular HA-tag. 
The cells were then transduced with retroviral vector constructs encoding IRES-linked Vpu GFP. 48 hours 
later, cells were surface stained for human tetherin expression using anti-HA antibodies and analysed by 
flow cytometry. (C) 293T cells stably expressing tetherin were transfected twice with pooled control or 
siRNA pools against AP-3 δ1 and AP-3 µ1. 4 hours post the second transfection, cells were infected with 
VSV-G-pseudotyped HIV-1 wt or HIV-1 delVpu virus stock at an MOI of 1. Cells were harvested and 
analysed as in (A). (D) Fibroblasts from pearl AP3 δ −/− mice or their reconstituted counterparts were 
treated and analysed as in (B). (E) 293T cells stably expressing tetherin were transfected twice with 
pooled control or AP-2 µ1 siRNA and co-transfected with NL4.3 wt, NL4.3 delVpu or GFP expression 




Finally, we examined whether there was any role for the retromer complex, in Vpu-
mediated tetherin antagonism. Retromer regulates retrieval and recycling of endosomal 
proteins to the TGN and is known to act co-operatively or antagonistically with AP-1 
(reviewed by (Attar and Cullen, 2010)). The retromer complex consists of several 
sorting nexins (SNX), and a core complex containing cargo binding component, 
VPS34, and two essential co-factors, VPS26 and VPS29. We performed siRNA-
mediated knockdown of VPS26 (Figure 4-13A). At levels of knockdown that were 
sufficient to re-localise the CD8-cation-independent mannose-6-phosphate receptor 
(CD8-CI-M6PR) (Figure 4-13B), disruption of retromer had no detectable effect of Vpu-
mediated HIV-1 release from 293T tetherin cells. 
Taken together these results demonstrate that neither depletion of individual cellular 
adaptor proteins known to bind to (D/E)xxxL(L/I) motifs, nor disruption of retromer-
mediated endosome-to-TGN retrieval, were sufficient to recapitulate the phenotype of 
the Vpu ELV mutant. 
  
 
Figure 4-13 The retromer complex is dispensable for Vpu-mediated tetherin antagonism 
(A) 293T cells stably expressing tetherin were transfected twice with pooled control or siRNA pools against 
the retromer subunit VPS26 and co-transfected with NL4.3 wt, NL4.3 delVpu or GFP expression vectors. 
48 hours post transfection, cell lysates and pelleted supernatant virions were harvested and subjected to 
SDS-PAGE and analysed by Western blotting for HIV-1 p24CA, VPS26 and Hsp90 serving as loading 
control, and analysed by LiCor quantitative imager. The percentage of VPS26 knockdown was determined 
by the relative band intensity and is indicated below the blot panel. (B) HeLa cells stably expressing the 
CD8-CI-M6PR were treated with control or VPS26 siRNA. 48 hours later, cells were fixed and stained for 






4.2.7 AP-1 binding to Vpu/tetherin complexes is dependent on the ExxxLV motif 
in biochemical studies  
The context dependency of (D/E)xxxL(L/I) motifs that governs which adaptor they bind 
to in vivo is poorly defined at present, meaning that RNAi depletion is the most reliable 
method for identifying the cellular factor involved. While individual depletion of AP-1, 2 
or 3 in our experiments had no effect on Vpu-mediated tetherin antagonism, 
replacement of the second alpha helix with the promiscuous AP-binding peptide from 
HIV-1 Nef and treatment with AP180c did recover function, underscoring that linking 
Vpu to the clathrin trafficking machinery promotes its ability to counteract tetherin. We 
have so far been unable to demonstrate direct interaction between the Vpu ExxxLV 
motif and adaptors AP-1, 2 or 3. The low affinity of these interactions, their transient 
nature, and the complex interactions of the adaptor protein with membrane lipids 
means that adaptor binding is rarely measurable in co-precipitations from cells.  
However, data presented at the 2013 Cold Spring Harbour Meeting on Retroviruses 
(this study is currently under revision) demonstrated that Vpu/tetherin complexes bind 
to the clathrin adaptor AP-1 (Figure 4-14). The Yong Xiong laboratory performed 
crystal structure studies in which they fused Vpu and tetherin cytoplasmic tails to bring 
them in close proximity. They were able to show that, σ and γ subunits of AP-1 bind to 
the ExxxLV motif in Vpu while the µ subunit binds to the YDYxxφ motif in tetherin, 
which in turn recruits the β subunit, resulting in a Vpu/tetherin/AP-1 complex.  
This data is in agreement with our Vpu ExxxLV results, in which this trafficking motif is 
required for post-binding trafficking of Vpu/tetherin complexes and inhibition of antiviral 
activity. Moreover, because residual activity of the ExxxLV mutant requires an intact 
recycling signal in tetherin, YDYxxφ, we proposed that the second alpha helix mutant is 
selectively defective for routing tetherin into an endosomal degradation pathway, and 





Figure 4-14 Clathrin adaptor AP-1 binds Vpu/ tetherin complexes (CSH 2013 Yong Xiong lab) 
The Yong Xiong lab fused Vpu cytoplasmic tail with the cytoplasmic tail of tetherin and performed 
crystallography studies. They obtained crystal structures, which revealed that the σ and γ subunits of AP-1 
bind to the Vpu ExxxLV motif while the YDYxxφ motif in tetherin binds to the µ subunit which in turn 
recruits the β subunit of the AP-1 complex (unpublished data). 
 
    
We therefore took advantage of a new technique to identify proteins in close proximity, 
called proximity dependent biotin identification (BioID) (Roux et al., 2012). This 
technique makes use of a highly promiscuous form of the E. coli biotin R113G ligase 
(BirA), which when fused to a protein of interested biotinylates proximate proteins. This 
allows harsh lysis conditions, biotinylated proteins can be affinity purified and analysed 
by Western blot or mass spectrometry. To this end, we fused BirA to myc-tagged 
consensus subgroup B Vpu wild-type and ELV mutant and expressed the fusion 
proteins in 293T tetherin cells. The cells were treated overnight with free biotin and 
concanamycin A to block tetherin degradation, followed by affinity purification and 
Western blot analysis for avidin, Vpu-myc-BirA and AP-1. Using the new BioID 
technique we were able to demonstrate that AP-1 interacts with Vpu wild-type in 
tetherin positive cells (Figure 4-15 A and B). Interestingly, this interaction was 
dependent on an intact ExxxLV trafficking motif in Vpu (Figure 4-15A), confirming the 
crystal structure data form Yong Xiong’s laboratory, suggesting a role of AP-1 in Vpu-






Figure 4-15 AP-1 interaction with Vpu is dependent on intact ExxxLV motif 
(A) 293T tetherin cells were transfected with subgroup B Vpu-myc-BirA, Vpu ELV-myc-BirA or empty 
vector control. 6 hours post transfection, cells were treated with 10 nM concanamycin A in the presence of 
150 µM free Biotin. 16 hours later, cells were washed, lysed, sonicated and biotinylated proteins were 
recovered on streptavidin-conjugated beads and analysed by Western blot for avidin, Vpu-myc-BirA and 
AP-1 γ. Asterisk: Vpu-myc-BirA band. (B) Same as in (A) but with 293T cells (performed together with Dr 





4.2.8 Vpu ELV is defective for tetherin antagonism in CD4+ T cells after 
treatment with type I interferon 
The results presented hitherto have demonstrated a requirement for the Vpu ELV motif 
in counteracting tetherin in cells stably expressing it or mutants thereof, and that it is 
required in constitutively-expressing target cells such as Jurkat to reduce surface 
tetherin levels. However, some studies have cast doubt as to whether tetherin 
degradation and/or surface reduction is essential for Vpu function (Tervo et al., 2011) 
(Schmidt et al., 2011). Furthermore, in contrast to 293T tetherin, release of HIV-1 Vpu 
ELV from HeLa was only 3-fold less efficient than wild-type in one round release 
(Figure 4-16A).  
 
Figure 4-16 Effect of ELV mutants on HIV-1 infectious virus particle release 
(A) HeLa cells were infected with VSV-G-pseudotyped stocks of the indicated virus at an MOI of 0.5. 48 
hours later, the cell supernatants were harvested and infectivity determined on HeLa-TZM cells. Error bars 
represent the standard deviation of three independent experiments.  
 
We therefore explored whether there was a requirement for the ELV motif in HIV-1 
release from physiologically relevant target cells, namely Jurkat or primary human 
CD4+ T cells, particularly after treatment with type I IFN which upregulates tetherin. 
Infection of Jurkat at an MOI of 1 resulted in a partial defect in release of the HIV-1 Vpu 
ELV mutant compared to the controls (Figure 4-17 A and B). However, induction of 
higher tetherin expression by overnight treatment with universal type I IFN effectively 
reduced HIV-1 Vpu ELV particle release to levels similar to that of the Vpu-defective 
control while only reducing the wild-type release moderately. Similarly, interferon 
treatment of purified activated human CD4+ T cells led to a selective defect in the 
production of cell-free HIV-1 Vpu ELV virions (Figure 4-17C) consistent with a 
concomitant up-regulation of surface tetherin levels (Figure 4-17D), and the lack 
surface tetherin downregulation (Figure 4-17E). Taken together with results presented 
above, these data demonstrate that the ability to downregulate and degrade tetherin 




primary HIV target cells, and becomes essential when tetherin expression is enhanced 
by an antiviral stimulus. 
 
Figure 4-17 Residues E59, L63 and V64 are essential to counteract tetherin-mediated restriction of 
cell-free HIV-1 particle release from CD4+ T cells treated with interferon 
(A and B) Jurkat cells were infected with the indicated HIV-1 mutant at an MOI of 1. 16 hours later, the 
cells were treated or not with 5000 U/ml universal type I IFN. Cell lysates and viral supernatants were 
harvested a further 24 hours later and analysed for infectivity on HeLa-TZMbl or physical particle yield and 
cellular viral and tetherin expression by quantitative Western blotting. Error bars represent the standard 
deviation of three independent experiments. (C) A representative example of primary human CD4+ T cells 
treated as in (A and B). (D) MFI of surface tetherin levels on these cells with or without 24 hours type I IFN 
treatment as analysed by flow cytometry. Error bars represent the standard deviation of three independent 
experiments. (E) Human CD4+ T cells were infected with the indicated virus. 48 hours later, cells were 






In this chapter we have identified a determinant within the second alpha helix of the 
cytoplasmic tail of HIV-1 NL4.3 Vpu, E59xxxL63V64, which is required for efficient 
antagonism of tetherin. Mutation of this site blocks the ability of Vpu to mediate tetherin 
downregulation from the cell surface and its ESCRT-dependent degradation, but does 
not abolish its interaction with tetherin, nor recruitment of β-TrCP2 or the ESCRT-0 
component HRS. Importantly, this motif is required to counteract tetherin in CD4+ T 
cells, particularly after their exposure to type I IFN. Vpu ELV mutants localise to the cell 
surface and early/recycling endosomal compartments rather than the TGN by virtue of 
their interaction with tetherin. This is consistent with a role for this determinant in Vpu-
mediated inhibition of the transit of newly synthesized and/or recycling tetherin to the 
cell surface, its internal sequestration and targeting for endo/lysosomal degradation. 
Residual Vpu ELV activity against tetherin was entirely dependent on an intact 
recycling motif in tetherin’s cytoplasmic tail, suggesting that this motif differentially 
affects antagonism of newly synthesized tetherin rather than pre-existing pools 
recycling to the PM. There has been much debate as to whether the reduction of 
tetherin levels at the plasma membrane is required to counteract its antiviral activity, 
particularly in CD4+ T cells (reviewed in (Le Tortorec et al., 2011)). In our hands, 
tetherin surface levels are reduced in HIV-1 infected primary T cells and Jurkat cells. 
However, under these conditions, the viral release phenotype of the Vpu ELV mutant is 
only a few fold different than the wild-type protein. Interestingly this changes upon 
treatment of the cells with type I IFN, which upregulates tetherin expression levels. In 
this case Vpu ELV mutant release is reduced almost to that of the Vpu-defective virus, 
but only minor further reductions are observed for the wild-type virus. This therefore 
indicates that the requirement for surface reduction/degradation of tetherin becomes 
much more important at higher expression levels of the restriction factor (something 
that has been suggested previously by Goffinet et al (Goffinet et al., 2009)). The fact 
that tetherin antagonism is a highly conserved attribute amongst primate 
immunodeficiency viruses implies its importance in vivo. Since interferon treatment of 
CD4+ T cells magnifies the defective phenotype of a Vpu ELV mutant, the ability to 
mediate tetherin’s surface reduction and target it for endosomal degradation is likely to 
be essential for the virus to avoid restriction under pro-inflammatory conditions it is 
likely to encounter in vivo, particularly during acute infection (Stacey et al., 2009) 
(Jacquelin et al., 2009). 
It is now clear that Vpu-mediated tetherin degradation is ubiquitin-dependent and 
occurs in lysosomes rather than early reports of proteasomal processing (Douglas et 




(Janvier et al., 2011). Depletion of both TSG101 and VPS4 inhibits Vpu-mediated 
tetherin degradation, and recruitment of HRS has been reported to be required for Vpu-
mediated tetherin antagonism (Janvier et al., 2011), as has ubiquitination on multiple 
residues in the tetherin cytoplasmic tail (Tokarev et al., 2011) (Gustin et al., 2012). 
However, tetherin’s ultimate degradation itself is not essential for Vpu or other lentiviral 
countermeasures to inactivate its function. Our recent observations with the novel 
ESCRT-I subunit, UBAP1, (Chapter 5 and the results presented herein), demonstrate 
that ESCRT-I function is unlikely to be required for tetherin antagonism, but its 
commitment to endosomal degradation is. Interestingly, the concomitant enhancement 
of wild-type Vpu levels, both co-precipitating with tetherin and at steady state, suggest 
that Vpu is likely co-degraded with its target. Alongside the current literature our data 
suggests that Vpu interaction with tetherin leads to a differential trafficking of tetherin in 
the TGN and/or recycling compartments rather than enhancing tetherin internalisation 
(Figure 7-1). This inhibits forward trafficking of either recycling or newly synthesized 
tetherin to the PM, and commits it to a pathway that ultimately targets it to 
endo/lysosomal compartments for degradation. We suggest that it is this commitment, 
regulated by the ExxxLV motif in second helix, rather than degradation per se, that is 
principally responsible for antagonizing tetherin. Where Vpu interacts with tetherin in 
the cell is likely to be related temporally to the viral replication cycle, tetherin 
expression level, and its natural turnover rate. Vpu is expressed ‘‘late’’ in replication 
from the same mRNA as Env (reviewed by (Dubé et al., 2010a)), at the time new 
virions are being built. Thus, Vpu must deal with two pools of tetherin: pre-existing 
protein in the periphery recycling via the TGN (Rollason et al., 2007) and de novo 
synthesized tetherin trafficking through the Golgi en route from the ER to the surface. 
Therefore we predict that Vpu must interact with tetherin in TGN associated 
compartments to engage these two pools of tetherin, although our recent data 
suggests that binding to newly synthesized tetherin may occur prior to this in the ER 
(Vigan and Neil, 2010). Thereafter, a sorting event determined by the second alpha 
helix, ExxxLV motif, precludes Vpu/tetherin complexes transiting to the PM. This 
intracellular sequestration of tetherin is further coupled to late endosomal targeting and 
ESCRT-dependent degradation through the recruitment of HRS and tetherin 
ubiquitination (Tokarev et al., 2011) (Janvier et al., 2011). In line with this, global 
disruption of early to late endosomal transition by dominant negative Rab7a also 
appears to inhibit Vpu activity (Caillet et al., 2011). Interestingly, ubiquitinated cargo 
destined for ESCRT-dependent degradation via HRS recruitment has been shown to 
partition differentially to areas of early/sorting endosomal membranes rich in flat 
clathrin lattices, thereby anchoring it away from the recycling machinery (Raiborg et al., 




sufficient to antagonize its function. In the absence of the ExxxLV motif, tetherin is not 
committed to this differential sorting in the TGN, and Vpu/tetherin complexes are 
targeted to the cell surface and thereafter back into the recycling system, accounting 
for the localisation of Vpu ELV in infected cells and its incorporation into virions. 
Therefore, in addition to acting as an adaptor for the recruitment of ESCRT-0 and E3 
ubiquitin ligase activity to tetherin, we propose that through the ExxxLV motif, Vpu 
directly chaperones associated tetherin molecules into an endosomal compartment 
from which they cannot recycle to the PM. ExxxLV mutants retain some residual 
antagonistic activity that is entirely dependent on the AP-1/AP-2-binding motif in 
tetherin. This would suggest that the action of the ExxxLV motif does not solely 
account for the inhibition of tetherin by Vpu. Vpu ELV still interacts with β-TrCP2, 
suggesting that tetherin ubiquitination, which is important for counteracting its activity 
(Tokarev et al., 2011), may still take place during the recycling process and effect 
antiviral function. Also physical interaction between Vpu and tetherin may be sufficient 
to interfere with some level tetherin function provided tetherin can still associate with 
the clathrin-dependent endocytic machinery.  
Furthermore, we were able to functionally complement Vpu function by grafting the 
D/ExxxL(L/I/M) motif from HIV-1 Nef in place of helix-2, we could detect no effect of 
depletion of the canonical clathrin adaptor proteins AP-1, AP-2 or AP-3 on Vpu-
mediated tetherin antagonism. The inhibition by AP180c overexpression, however, 
implicates clathrin function in Vpu-mediated tetherin antagonism. These results are in 
contrast to the recent study by Lau et al who were unable to demonstrate a phenotype 
for an LV63,64AA mutant despite interfering with Vpu activity with AP180c (Lau et al., 
2011). Given that we have demonstrated phenotypes in several cellular systems 
including CD4+ T cells for the Vpu ELV mutant, the reason for this discrepancy is 
unclear. 
The D/ExxxL(L/I/M) motif is conserved in Vpu proteins from HIV-1 M group subtypes A, 
B, D, G and H (Figure 4-10A). While Group O Vpus cannot antagonize tetherin (Sauter 
et al., 2009), this maps to defective TM domain-mediated interaction and the 
membrane proximal hinge region. When replaced by those from a Group M Vpu these 
are sufficient to confer tetherin inactivation implying that C-terminal determinants retain 
function (Vigan and Neil, 2011). In Group M clades C and F, the equivalent position is 
(D/E)xxxL(S/A) respectively, suggesting that the site may not be functional in those 
Vpus, with the caveat that the second position in the dileucine motif is less important. 
Intriguingly, both these subtypes bear EYxxL(L/I) motifs in the membrane proximal 
region of their cytoplasmic tails that encompass both a putative tyrosine and dileucine-




model subtype C Vpu localises to the PM rather than the TGN and that this is in part 
due to this motif. While LL mutations in this subtype C Vpu confer T cell line replication 
phenotypes suggestive of a failure to downmodulate tetherin, no direct experiments on 
the role of this motif in tetherin-mediated HIV-1 release have been thus far performed, 
nor whether this site can bind known clathrin adaptors. 
The context dependency of D/ExxxL(L/I) motifs that governs which adaptor they bind to 
in vivo is poorly defined at present, meaning that RNAi depletion is the most reliable 
method for identifying the cellular factor involved. While individual depletion of AP-1, 2 
or 3 in our experiments had no effect on Vpu-mediated tetherin antagonism, 
replacement of the second alpha helix with the promiscuous AP-binding peptide from 
HIV-1 Nef did recover function. This site in Nef is essential for several functions 
including CD4 and MHC class I downregulation, the former being AP-2-dependent 
(Chaudhuri et al., 2007), the latter requiring AP-1 (Lubben et al., 2007). Importantly, 
binding of AP-2 to this site in SIV Nef proteins is required for their counteraction of non-
human primate tetherins (Zhang et al., 2011a). Thus, there are several possibilities. 
The ExxxLV motif in Vpu might be a promiscuous AP-binding site and adaptor usage 
may be redundant. The subcellular localisation of tetherin/Vpu ELV complexes in 
EEA1-positive endosomes and the partial effect of dominant negative dynamin 2 would 
argue against a significant role for AP-2, the major regulator of clathrin-mediated 
transport from the plasma membrane. However, toxicity associated with simultaneous 
knockdown of multiple adaptors has precluded us from addressing this possibility so 
far. A novel approach to study clathrin adaptor-mediated trafficking using a rapamycin 
induced protein dimerisation together with trapping these proteins on mitochondria 
named “knocksideways” has been described by Margret Robinson (Robinson et al., 
2010). This method overcomes artefacts induced by prolonged clathrin adaptor 
knockdown, in which other adaptor proteins are able to compensate and mask the real 
phenotype. However, this method requires rapamycin treatment that is toxic to cells if 
used for a longer period of time, which would be necessary to study Vpu-mediated 
virus particle release.     
Vpu activity was insensitive to retromer (VPS26) depletion, which is essential for 
endosome to TGN retrieval and recycling (reviewed by (Attar and Cullen, 2010)), we 
suggest that Vpu targets tetherin into the ESCRT-dependent degradative pathway from 
the TGN to endosomal compartments, and an ensuing swift degradation accounts for 
the observed sequestration in TGN46-positive compartments. In the absence of the 
ExxxLV motif, tetherin is not committed to this differential sorting in the TGN, and 




recycling system, accounting for the localisation of Vpu ELV in infected cells and its 
incorporation into virions. 
Alternatively, replacement of the second alpha helix with the Nef peptide recovers 
function because it confers AP-2 binding to Vpu, thus allowing Vpu to counteract 
tetherin in a manner similar to SIV Nef and HIV-2/SIV Envs that both require AP-2 
interactions (Noble et al., 2006) (Le Tortorec and Neil, 2009) (Zhang et al., 2011a) 
(Serra-Moreno et al., 2011). However, these data do underscore that linking Vpu to the 
clathrin trafficking machinery promotes its ability to counteract tetherin. If Vpu-mediated 
tetherin antagonism is clathrin-dependent, but independent of AP-1, AP-2 or AP-3, 
what other adaptors might be important? Two further heterotetrameric adaptors, AP-4 
and AP-5, have been identified, but understanding of their role in subcellular trafficking 
is limited, siRNA depletion of AP-4 or AP-5 had no effect virus particle release (data not 
shown), and at present they are not known to bind to acidic dileucine motifs or to 
control clathrin-mediated transport (reviewed by (Bonifacino and Traub, 2003)) (Hirst et 
al., 2011). The monomeric GGA1, -2, and -3 proteins also function as clathrin adaptors 
that regulate Golgi to endosome transport are potentially attractive candidates, whose 
dysregulation has been reported to inhibit HIV-1 assembly (Joshi et al., 2008). 
However, known GGA binding motifs in cellular cargoes correspond to a DxxLL 
consensus where the spacing of the leucines from the acidic residue is thought critical 
and overexpression of GGA1, GGA2 or GGA3 had only minor effects on Vpu-mediated 
virus particle release (Chapter 6). 
We have so far been unable to demonstrate direct interaction between the Vpu ExxxLV 
motif and adaptors AP-1, 2 or 3 that are known to bind acidic dileucine signals via a 
hemicomplex of their σ and adaptin subunits (reviewed by (Bonifacino and Traub, 
2003)). These interactions have been demonstrated in yeast 3-hybrid assays 
previously for HIV-1 Nef (Janvier et al., 2003) (Chaudhuri et al., 2007), but not all 
interactions are amenable to this method and in our hands the Vpu cytoplasmic tail is a 
constitutive activator of transgene expression precluding its use. Furthermore, the low 
affinity of these interactions, their transient nature, and the complex interactions of the 
adaptor protein with membrane lipids means that adaptor binding is rarely measurable 
in co-precipitations from cells.  
Crystal structure data presented at the 2013 CSH Retrovirology meeting revealed that 
the σ and γ subunits of AP-1 bind to the Vpu ExxxLV motif while the YDY motif in 
tetherin binds to the µ subunit which in turn recruits the β subunit of the AP-1 complex. 
We therefore applied the new technique BioID to study Vpu/tetherin and AP-1 




dependent on an intact ExxxLV motif in the second alpha helix of Vpu. Advantages 
using this technique are: detection of protein interactions in their cellular context, 
biotinylation occurs before solubilisation therefore it should detect both weak and 
transient interactions Disadvantages are: interactions might be indirect or even vicinal 
and biotinylation might not be able to cross-link proteins that interact via their 
transmembrane domains. Clearly, a more detailed analysis of the functional 
requirements of these clathrin adaptors in particular AP-1 in Vpu/tetherin complex 
trafficking is required and siRNA depletion studies particularly of clathrin adaptors 




Chapter 5 HIV-1 Vpu-mediates ESCRT-dependent degradation 
of tetherin 
 
Some of the results presented in this chapter were published in collaboration with 
Monica Agromayor from Juan Martin-Serrano’s research group as “The UBAP1 




Recently, HIV-1 Vpu-mediated tetherin lysosomal degradation has been shown to be 
dependent on the ESCRT machinery (Janvier et al., 2011). The ESCRT-0 component 
HRS (also known as hepatocyte growth factor-regulated tyrosine kinase substrate 
(HGS)) recognizes ubiquitinated cargo proteins in the endosome membrane and 
prevents their cellular recycling and retrograde trafficking. HRS then recruits the 
ESCRT-I component TSG101 via a PSAP motif and therefore induces deformation of 
the endosomal membrane, invagination of cargo proteins and final abscission forming 
intraluminal vesicles (ILVs) (discussed in detail in 1.9). However, HRS is not required 
for HIV-1-related budding events (Pornillos et al., 2003). Another group was able to 
demonstrate that tetherin itself is routed for ESCRT-dependent lysosomal degradation, 
and upon Vpu expression this degradation is enhanced. They were also able to show 
that HRS interacts with both Vpu and tetherin in co-immunoprecipitation studies. 
Knockdown of HRS revealed a role in tetherin surface downregulation, degradation as 
well as tetherin-mediated restriction of virus particle release (Janvier et al., 2011). Data 
from the same group showed that the late endosomal small GTPase Rab7A, which is 
key regulatory protein which is important for biogenesis and maintenance of the 
structure of late endosomal and lysosomal compartments, plays a role in Vpu-mediated 
antagonism of tetherin (Caillet et al., 2011).   
In this chapter we have examined the role of the ESCRT pathway in endosomal sorting 
of tetherin-mediated by HIV-1 Vpu, concentrating on the newly identified mammalian 
ESCRT-I component UBAP1. UBAP1 contains a region that is highly conserved in 
MVB12 and this region has been termed a UBAP1-MVB12-associated (UMA) domain 
(de Souza and Aravind, 2010). UBAP1 has been shown to be part of a complex with 
ESCRT-I subunits TSG101 and VPS37, and be involved in endosomal sorting of 
ubiquitinated cargo but not in cytokinesis (Stefani et al., 2011). A postdoctoral fellow in 




genes from individuals infected with HIV-1 and tested all unique Vpus for their ability to 
downregulate CD4 and antagonise tetherin (Pickering et al., 2014). In this chapter we 
also investigate the virological phenotype of one naturally occurring HIV-1 clade B Vpu 
that bears mutants in the first alpha helix that are important for Vpu anti tetherin 
function.  
Our results show that newly identified ESCRT-I component UBAP1 is essential for 
Vpu-mediated tetherin lysosomal degradation and that Vpu is able to counteract 
tetherin virus restriction in UBAP1 depleted cells. Furthermore, in this chapter we were 
able to show that the hydrophobic residues in Vpu cytoplasmic helix 1 are essential for 
Vpu/HRS interaction and that this interaction is dependent on residues that bind 
ubiquitin in the double ubiquitin-binding motif (DUIM) of HRS. Interestingly, Vpu/HRS 
interaction in the presence or absence of tetherin is independent of β-TrCP2, the only 
know E3 ubiquitin ligase known to interact with HIV-1 Vpu. Additionally, we were able 
to demonstrate, by siRNA interference that ALIX, and by overexpression that GGA1, -2 





5.2.1 ESCRT-I component UBAP1 is essential for tetherin degradation 
The ESCRT machinery plays a role in sorting of ubiquitinated membrane proteins for 
lysosomal degradation and virus budding (see 1.9). Here we test the role of a novel 
ESCRT-I component UBAP1 in Vpu-mediated tetherin degradation. UBAP1 has 
recently been shown to interact with ESCRT-I components TSG101, VPS28, and 
VPS37, and to be required for ESCRT-mediated endosomal sorting of the EGFR but 
not cytokinesis (Stefani et al., 2011) (Agromayor et al., 2012). Furthermore, recent data 
has shown that Vpu-mediated tetherin degradation is dependent on ESCRT-I 
component TSG101 and ATPase VPS4 (Janvier et al., 2011). VPS4 is thought to 
mediate stepwise removal of ESCRT-III and generates constrictive forces that are 
crucial for abscission. TSG101 is also recruited to sites of budding virions by interacting 
with the major structural virus protein gag, which in turn recruits ESCRT-III. Failure to 
recruit TSG101 leads to accumulation of budding-deficient virus particles at the plasma 
membrane.  
To this end, 293T tetherin cells were treated twice over a period of 48 hours with non-
coding siRNA or two different siRNA oligonucleotides directed against UBAP1, and 
infected with HIV-1 wild-type or HIV-1 delVpu. 48 hours post infection, cells were lysed 
and tetherin was immunoprecipitated, de-glycosylated, and visualised by Western blot. 
As expected, cells transfected with non-targeting control and infected with HIV-1 wild-
type had greatly reduced tetherin levels (Figure 5-1A). However, in cells depleted for 
UBAP1 and infected with HIV-1 wild-type tetherin degradation was prevented and 
tetherin amounts similar to uninfected cells could be detected. Tetherin levels in cells 
infected with HIV-1 delVpu and treated with siRNA directed against UBAP1 were, as 
expected, also high and similar to uninfected cells. Next, we looked at post-
translational modifications of tetherin in cells depleted for UBAP1, using a similar 
approach as above with cells transfected also with a fixed dose of HA-ubiquitin. 
Tetherin was highly ubiquitinated in cells infected with HIV-1 wild-type and depleted for 
UBAP1 when compared to cells treated with non-targeting control (Figure 5-1B). This 
data suggests that ubiquitin-dependent sorting of tetherin by the ESCRT-dependent 
MVB pathway is inhibited when UBAP1 is depleted. 





Figure 5-1 UBAP1 is essential for Vpu-mediated degradation of tetherin 
(A) 293T tetherin expressing cells were transfected twice over a 48 hour period with siRNA 
oligonucleotides directed against UBAP1 or non-targeting control. The cells were then infected with HIV-1 
wild-type or HIV-1 delVpu at an MOI of 2. 48 hours later, cells were lysed, immunoprecipitated with anti-
tetherin antibody and de-glycosylated. Total cell lysates and precipitates were subjected to SDS-PAGE 
and analysed by Western blotting for tetherin, UBAP1 and HSP90, and analysed by ImageQuant. (B) 293T 
tetherin cells were treated as in (A) and cells were then transfected with a HA-ubiquitin expression vector 
and infected with HIV-1 wild-type or HIV-1 delVpu at an MOI of 2. 48 hours later, cells were lysed, 
immunoprecipitated with anti-tetherin antibody and de-glycosylated. Total cell lysates and precipitates 
were subjected to SDS-PAGE and analysed by Western blotting for tetherin, UBAP1 and Tubulin, and 
analysed by ImageQuant. (C) 293T tetherin cells were treated as in (A) and infected with HIV-1 wild-type 
or HIV-1 delVpu at an MOI of 0.8. 48 hours post infection, infectivity of viral supernatants was assayed on 
HeLa-TZMbl reporter cells. Infectious virus release was plotted as β-galactosidase activity in relative light 
units (RLU). Error bars represent the standard deviation of three independent experiments. 
 
The infectivity of supernatant containing virions from cells treated with UBAP1 siRNA 
and infected with HIV-1 wild-type or HIV-1 delVpu at an MOI of 0.8 was measured on 
HeLa-TZMbl indicator cells. Surprisingly, despite the block of tetherin degradation in 
UBAP1 depleted cells infected with wild-type HIV-1, release of infectious virus particles 
was not affected (Figure 5-1C). However, virus particle release from HIV-1 delVpu 
infected cells was approximately 100-fold less compared to HIV-1 wild-type infected 






Another approach to determine to role of UBAP1 in Vpu induced tetherin degradation, 
was to visualise cellular localisation of tetherin in UBAP1 depleted cells. To this end, 
293T tetherin cells were treated twice over a period of 48 hours with non-coding siRNA 
or siRNA directed against UBAP1, and infected with HIV-1 Nef IRES GFP. 48 hours 
post infection, cells were fixed and stained for tetherin in combination with CD63 (late 
endosomes) or FK2 (ubiquitin) subcellular markers. As expected, tetherin levels in HIV-
1 infected cells treated with non-targeting siRNA were largely reduced. Consistent with 
inhibition of tetherin degradation and accumulation of ubiquitinated forms of tetherin in 
UBAP1 depleted cell, as shown in Figure 5-1 A and B, tetherin accumulated in 
intracellular structures that show co-localisation with the late endosomal marker CD63 
(Figure 5-2A) and with the ubiquitin marker FK2, which detects both mono- and poly-
ubiquitinated proteins but not free ubiquitin (Figure 5-2B). Collectively, Vpu-mediated 
ESCRT degradation of tetherin is dependent on UBAP1, while ultimate degradation of 
tetherin is separable from the ability of Vpu to counteract the anti-viral activity of 
tetherin. These results suggest, that Vpu interacts with tetherin prior to the recruitment 
of ESCRT-I, and inactivates tetherin by committing it to an early/late endosomal 







Figure 5-2 UBAP1 depletion induces tetherin accumulation in late endosomal compartments 
(A) 293T tetherin cells were transfected twice over a 48 hour period with siRNA oligonucleotides directed 
against UBAP1 or non-targeting control and infected with VSV-G-pseudotyped HIV-1 Nef IRES GFP at an 
MOI of 0.5. 24 hours post transfection, cells were fixed and stained for tetherin (red) and late endosomes 
(CD63 antibody) (blue) and examined by fluorescent microscopy. Panels are of representative examples. 
(B) HeLa cells were transfected as in (A) and stained for tetherin (red) and ubiquitin (FK2 antibody) (blue) 






5.2.2 A derivative of naturally occurring HIV-1 clade B Vpu mutant is unable to 
counteract tetherin function 
Single genome analysis of vpu genes from individuals infected with HIV-1 clade B 
revealed that two isoleucine residues (I43 and I46) in the first alpha helix are important 
for Vpu anti-tetherin function (Figure 5-3, I43/I46 mutant is encircled in red). To 
investigate the effects of these naturally occurring helix 1 Vpu mutants on tetherin 
function, in a replicating competent molecular clone, we replaced hydrophobic amino 
acids leucine/isoleucine 41/42 and leucine/isoleucine 45/46 in the HIV-1 NL4.3 Vpu 
protein with nonpolar alanine residues.  
  
Figure 5-3 Functional analysis of HIV-1 clade B patient Vpu proteins 
Functional profiles for 304 tested HIV-1 clade B patient Vpus shown as tetherin antagonism vs CD4 
downregulation. Functionality was measured as percentage of NL4.3 Vpu activity (see red arrow). Defects 
are pinpointed to responsible amino acid changes and each defective Vpu protein is colour-coded 
according to the location of inactivating amino acid change, as shown in the key (adapted from (Pickering 
et al., 2014)) 
 
We then assayed these Vpu mutants, termed Vpu LILI, for their ability to counteract 
tetherin restriction. 293T cells were transfected with a fixed dose of either wild-type 
HIV-1 provirus NL4.3 (NL4.3 wild-type), Vpu-defective NL4.3 (NL4.3 delVpu), Vpu LILI 
mutant (NL4.3 Vpu LILI), Vpu ELV trafficking mutant (NL4.3 Vpu ELV) or Vpu S52/56A 
phosphorylation mutant (NL4.3 Vpu 2/6A) (Figure 5-4A) and examined for viral release 
in the presence of increasing tetherin concentrations. 48 hours after transfection, cell 
lysates and supernatants containing viral particles were harvested and analysed for 
viral infectivity on HeLa-TZMbl reporter cells (Figure 5-4B) or physical virus yield by 
Western blot (Figure 5-4C). As expected, the infectivity and supernatant viral particle 
yield were both profoundly reduced with increasing tetherin expression in NL4.3 Vpu 
deficient provirus compared to the NL4.3 wild-type counterpart. NL4.3 Vpu LILI provirus 




comparable to the trafficking and phosphorylation defect of NL4.3 Vpu ELV and Vpu 
2/6A respectively. All tested Vpu mutants however displayed a residual activity against 
tetherin when compared to the Vpu deletion mutant (Figure 5-4 B and C). Next we 
wanted to know if the hydrophobic amino acids could be found in multiple HIV-1 clades. 
Sequences were obtained from the Los Alamos database (www.hiv.lanl.gov), and we 
generated LogoPlots covering the first alpha helix of HIV-1 subgroups A, B, C, D, G 
and H. This revealed that the leucine and isoleucine residues are highly conserved 
throughout different HIV-1 group M clades (Figure 5-4D). However, these amino acid 
sequences slightly deviate from the NL4.3 Vpu protein as this Vpu contains an 
additional isoleucine residue. 
 
Figure 5-4 Naturally occurring Vpu LILI mutant is required for tetherin antagonism 
(A) L41A I42A L45A I46A mutations were introduces into the NL4.3 vpu gene referred to as NL4.3 Vpu 
LILI. 293T cells were transfected with NL4.3 wild-type, NL4.3 delVpu, NL4.3 Vpu LILI, NL4.3 Vpu ELV or 
NL4.3 Vpu 2/6A together with increasing concentrations of pCR3.1 tetherin-HA expression plasmid. 
Infectivity of viral supernatants was assayed on HeLa-TZMbl reporter cells. Infectious virus release was 
plotted as β-galactosidase activity in relative light units (RLU). Error bars represent the standard deviation 
of three independent experiments. (B) Cell lysates and sucrose purified viral supernatants form 50 ng 
tetherin input were subjected to SDS-PAGE and analysed by Western blotting for Hsp90, HIV-1 p24CA 
and Vpu, and analysed by LiCor quantitative imager. (C) LogoPlots of first alpha helix of the Vpu 
cytoplasmic tail from HIV-1 subgroup M clades A, B, C, D, G and H generated from sequences obtained 




We then characterized the phenotype of Vpu LILI mutants further and examined the 
ability of Vpu LILI to down-modulate tetherin from the plasma membrane. HeLa-TZMbl 
cells were transfected with the indicated Vpu-HA expression vectors in combination 
with a GFP expression plasmid. 48 hours post transfection, tetherin surface levels were 
analysed by flow cytometry in GFP positive cells (Figure 5-5A). As expected, Vpu wild-
type reduced tetherin levels at the plasma membrane, but Vpu LILI mutants were 
defective in reducing tetherin surface levels. The Vpu LILI defect on tetherin cell 
surface down-regulation was more apparent than the deficiencies of mis-localised Vpu 
ELV or Vpu 2/6A mutants, which is unable to recruit the E3 ubiquitin ligase β-TrCP2 
(Figure 5-5A). It has been demonstrated that Vpu stimulates ubiquitination and 
ESCRT-dependent degradation of tetherin via lysosomal compartments. Therefore we 
examined the ability of Vpu LILI to induce tetherin degradation. 293T cells stably 
expressing tetherin were infected with VSV-G-pseudotyped HIV-1 wild-type, HIV-1 
delVpu, HIV-1 Vpu LILI, HIV-1 Vpu ELV or HIV-1 Vpu 2/6A at an MOI of 2 to ensure 
high infection rates. The cells were lysed 48 hours after infection and Western blotting 
was performed for cellular tetherin levels (Figure 5-5B). As expected, tetherin levels at 
steady state were reduced in cells infected with HIV-1 wild-type compared to 
uninfected cells and cells infected with HIV-1 delVpu. Interestingly, tetherin levels in 
cells treated with HIV-1 Vpu LILI were not reduced (Figure 5-5B), implicating that Vpu 
LILI is unable to induce tetherin degradation like the Vpu ELV and 2/6A mutants.  
The failure of Vpu LILI mutants to degrade tetherin molecules may be due to the 
inability of LILI mutants to bind to tetherin or other known cellular co-factors. To 
address the first question we took advantage of the fact that tetherin degradation, but 
not antagonism, is completely dependent on the ESCRT-I component UBAP1 
(Agromayor et al., 2012). Using siRNA directed against UBAP1 we were able to block 
Vpu-mediated tetherin degradation and perform immunoprecipitation studies using 
infected cells (Figure 5-5C). 293T tetherin expressing cells were treated twice over a 
period of 48 hours with non-coding siRNA or siRNA oligonucleotides directed against 
UBAP1 and infected with HIV-1 wild-type, HIV-1 Vpu LILI, HIV-1 del Vpu or HIV-1 Vpu 
A14L W22A, a Vpu mutant that renders mutations in the Vpu interface which is 
important for tetherin binding (Vigan and Neil, 2010) (Skasko et al., 2012). 48 hours 
post infection, cells were lysed, tetherin immunoprecipitated and analysed by Western 
blotting for Vpu (Figure 5-5C). As shown in the previous chapter, Vpu wild-type was 
detected in cells associated with tetherin, blocking of Vpu/tetherin complex degradation 
using UBAP1 depletion enhanced this effect, whereas Vpu A14L/W22A failed to 
interact with tetherin under these conditions. The amount of Vpu LILI precipitated in 




the wild-type protein. Interestingly, the relative band intensity ratio determined by 
Western blotting of Vpu LILI and wild-type Vpu in cells depleted for UBAP1 and 
immunoprecipitated for tetherin was the same. This demonstrates that Vpu LILI 
mutants are able to interact with tetherin to the same extent as the wild-type protein. 
Indicating that the defect in tetherin degradation and surface downregulation is 
independent of tetherin binding. Since tetherin degradation has also been shown to be 
dependent on the ubiquitination of the tetherin intracellular domain by the E3 ubiquitin 
ligase β-TrCP2, which binds to Vpu via a phosphorylated pair of serine residues in the 
cytoplasmic tail of Vpu (S52 and S56) (Figure 5-4A) (Margottin et al., 1998) (Mitchell et 
al., 2009) (Mangeat et al., 2009), we tested binding of Vpu LILI mutants to the E3 
ubiquitin ligase β-TrCP2 next (Figure 5-5D). 293T cells were transfected with myc-
β-TrCP2 in combination with Vpu-HA or indicated mutant. 48 hours post transfection, 
cells were lysed and immunoprecipitated using an anti myc antibody and analysed by 
Western blot. As expected, Vpu was co-immunoprecipitated with myc-β-TrCP2 while 
the phosphorylation mutant Vpu 2/6A was not. Interestingly, Vpu LILI was co-
precipitated with a similar efficiency to the wild-type Vpu protein (Figure 5-5D), 







Figure 5-5 Vpu LILI mutants are defective for tetherin cell surface downregulation and degradation 
(A) HeLa-TZMbl cells were co-transfected with pCR3.1 Vpu-HA or indicated mutant and a GFP expression 
vector. Cell-surface tetherin levels were analysed 48 hours post transfection by flow cytometry. GFP 
positive cells were gated and tetherin levels (solid lines) were compared to un-transfected cells or 
transfected with indicated Vpu (dotted lines). Numbers indicate median fluorescence intensities of 
endogenous tetherin surface levels. The solid peak in the upper histogram in the middle of the panel 
represents binding of the isotype control. (B) HeLa cells were infected with VSV-G-pseudotyped HIV-1 
wild-type, HIV-1 delVpu, HIV-1 Vpu LILI, HIV-1 Vpu ELV or HIV-1 Vpu 2/6A at an MOI of 2. 48 hours post 
infection, cell lysates were subjected to SDS-PAGE and analysed by Western blotting for Hsp90, tetherin 
and Vpu, and analysed by LiCor quantitative imager. (C) 293T tetherin expressing cells were transfected 
twice over a 48 hour period with siRNA oligonucleotide directed against UBAP1 or non-targeting control. 
The cells were then infected with HIV-1 wild-type, HIV-1 Vpu LILI, HIV-1 Vpu A14L W22A or HIV-1 delVpu 
at an MOI of 2. 48 hours later, cells were lysed and immunoprecipitated with anti-tetherin antibody. Total 
cell lysates and precipitates were subjected to SDS-PAGE and analysed by Western blotting for tetherin, 
UBAP1 and Vpu, and analysed by ImageQuant. (D) 293T cells were transfected with pCR3.1 Vpu-HA or 
indicated mutant in combination with a pCR3.1 myc-β-TrCP2 expression vector. 48 hours post 
transfection, cells were lysed and immunoprecipitated with anti-myc antibody. Total cell lysates and 
precipitates were subjected to SDS-PAGE and analysed by Western blotting for myc-β-TrCP2 and Vpu-





5.2.3 ESCRT-0 component HRS is involved in Vpu-mediated virus release 
HRS binds to ubiquitinated cargo proteins that are delivered for lysosomal degradation, 
and Vpu has been shown to promote tetherin ubiquitination and to co-precipitate with 
HRS (Janvier et al., 2011). We therefore tested whether Vpu LILI mutants were 
defective for interaction with HRS in co-immunoprecipitations in transfected 293T or 
293T cells stably expressing tetherin. As expected, Vpu wild-type and Vpu ELV were 
co-precipitated with HRS in the presence or absence of tetherin (Figure 5-6 A and B). 
As Vpu interacts with HRS in the absence of tetherin, it might induce ESCRT-
dependent degradation of an unknown cellular factor, or Vpu itself directly interacts 
with HRS. Vpu LILI mutants were unable to interact with HRS in both the presence or 
the absence of tetherin (Figure 5-6 A and B), indicating that Vpu LILI is unable to 
recruit ESCRT-0. This could explain the defect in tetherin degradation and virological 
phenotype demonstrated in Figure 5-4 A and B and in Figure 5-5 A and B. Since HRS 
has been shown to orchestrate degradation of ubiquitinated membrane proteins, we 
decided to include the phospho-mutant Vpu 2/6A in our analysis. Vpu 2/6A is unable to 
recruit the SCF E3 ubiquitin ligase complex containing β-TrCP2, which has been 
shown to induce tetherin ubiquitination. Surprisingly, Vpu 2/6A mutants retained the 
ability to interact with HRS (Figure 5-6 A and B), indicating that Vpu and Vpu/tetherin 
complex interaction with HRS is independent of β-TrCP2 ligase recruitment.   
 
 
Figure 5-6 Vpu LILI mutants are defective for HRS interaction 
(A and B) 293T or 293T tetherin cells were transfected with pCR3.1 Vpu-HA or indicated mutant in 
combination with a pCR3.1 myc-HRS expression vector. 48 hours post transfection, cells were lysed and 
immunoprecipitated with anti-myc antibody. Total cell lysates and precipitates were subjected to SDS-





Next, we tested the effect of HRS knockdown on virus release using oligonucleotides. 
293T tetherin cells were treated twice over a period of 48 hours with non-coding siRNA 
or siRNA directed against HRS, and against downstream ESCRT-I components 
UBAP1 or TSG101, and cells were then infected with HIV-1 wild-type or HIV-1 delVpu. 
48 hours post infection, cells were lysed and analysed by Western blot, and viral 
infectivity was measured on HeLa-TZMbl indicator cells. Knockdown efficiencies of 
ESCRT components were monitored in every individual experiment; see Figure 5-7A 
for a representative example. First, we tested the role of HRS in virus particle release. 
Depletion of HRS led to a small decrease in physical virus particle release (4.8-fold), 
whereas depletion of TSG101, as expected, inhibited budding of virus particles from 
the plasma membrane (Figure 5-7B). Notably knockdown of HRS enhanced total 
cellular levels of Vpu similarly to what has been observed with UBAP1 depletion, 
indicating that Vpu is most likely co-degraded with tetherin via the lysosome (Kueck 
and Neil, 2012). The effect of HRS knockdown on infectious virus particle release was 
equally mild (2-fold decrease) when compared to wild-type levels. As expected, 
TSG101 depletion resulted in a 20-fold decrease while UBAP1 levels remained 
unaffected (Figure 5-7C). Next, we tested the role of HRS in Vpu-mediated tetherin 
degradation in infected cells. 293T tetherin cells were treated as above and infected 
with a MOI of 2 to ensure a > 90% cell infection rate. As expected, tetherin levels were 
considerably reduced in cells infected with wild-type virus compared to both uninfected 
cells and cells infected with Vpu deletion virus (Figure 5-7D). As expected, natural 
turnover of tetherin was affected by depletion of HRS in uninfected cells (about 30% 
more compared to control siRNA). However, tetherin levels were rescued from 
degradation in cells depleted for HRS and infected with wild-type virus (about 50% 
more compared to control siRNA), while there was no difference in tetherin levels in 
HIV-1 delVpu infected cells (Figure 5-7 D and E). Our results show additionally that 
rescue of tetherin from ESCRT-mediated degradation was significantly higher in cells 
treated with UBAP1 or TSG101 siRNA oligonucleotides (Figure 5-7D), suggesting that 
HRS depletion in our system only partially blocks Vpu-mediated virus particle release 
and tetherin degradation, or that HRS depletion obtained was high enough. The above-







Figure 5-7 HRS knockdown partially blocks virus particle release and tetherin degradation 
(A) Representative example of siRNA knockdown efficiencies. 293T tetherin expressing cells were 
transfected twice over a 48 hour period with siRNA oligonucleotide directed against HRS, UBAP1, 
TSG101 or non-targeting control. (B) 293T tetherin cells were treated as in (C), cells were then infected 
with HIV-1 wild-type or HIV-1 delVpu at an MOI of 0.8. Cell lysates and sucrose purified viral supernatants 
form (D) were subjected to SDS-PAGE and analysed by Western blotting for Hsp90, HIV-1 p24CA and 
Vpu, and analysed by LiCor quantitative imager. (C) Infectivity of viral supernatants form C was assayed 
on HeLa-TZMbl reporter cells. Infectious virus release was plotted as β-galactosidase activity in relative 
light units (RLU). Error bars represent the standard deviation of three independent experiments. (D) Cells 
were treated like in (D) but infected with an MOI of 2. Cell lysates were subjected to SDS-PAGE and 
analysed by Western blotting for Hsp90 and tetherin, and analysed by LiCor quantitative imager. (E) 
Percentage of tetherin in cells transfected with HRS or non-targeting siRNA oligonucleotides and infected 






5.2.4 Vpu LILI mutants localise to early endosomal compartments 
In Vpu LILI mutants the hydrophobic leucine and isoleucine residues were replaced 
with non-polar residues. This might have an effect on the conformation of the first alpha 
helix, which in wild-type Vpu is thought to be embedded into the plasma membrane 
(Maldarelli et al., 1993) (Wray et al., 1995) and result in a mis-folded and/or mis-
trafficked Vpu LILI protein. Most mis-folded secretory proteins might remain in the ER 
until routed for ERAD degradation, and therefore never reaching the trans-Golgi 
network where wild-type Vpu can be found (Varthakavi et al., 2006) (Dubé et al., 2009). 
To this end, we decided to look at the cellular localisation of Vpu LILI mutants using 
fluorescent microscopy. 293T tetherin cells were transfected with Vpu-HA, Vpu LILI-HA 
or Vpu ELV-HA, 16 hours post transfection and then fixed and stained for Vpu-HA in 
combination with TGN46 or EEA1 subcellular markers. As expected, wild-type Vpu 
localises mainly to TGN46-positive compartments (Figure 5-8 A and B). The proportion 
of Vpu LILI mutants in TGN46-positive compartments was significantly reduced and 
surprisingly resembled the amount of Vpu ELV trafficking mutants typically found in the 
TGN (Figure 5-8 A and B). Both Vpu LILI and ELV mutants appeared more as 
“endosome-like” punctate structures within the cytoplasm and associated on or close to 
the plasma membrane (Figure 5-8A). It has been shown previously that some of these 
punctate structures in the case of Vpu ELV mutants were EEA1-positive early/sorting 
endosomal compartments (Kueck and Neil, 2012). When we further analysed the 
puncta in the case of Vpu LILI mutants we observed that they appeared to be EEA1 
positive compartments, indicating that Vpu LILI mutants were pheno-copying Vpu ELV 
localisation (Figure 5-8C), and in turn showing that Vpu LILI mutants accumulate in 
EEA1-positive early/sorting endosomal compartments to which HRS is known to 
localise (Raiborg et al., 2001). Therefore Vpu LILI mutants accumulate in the cellular 
compartment where HRS is present but they do not interact. Vpu LILI mutants pheno-
copy the early endosomal localisation of ELV trafficking mutants and display a similar 
defect in tetherin antagonism. However, Vpu ELV mutants retain the ability to bind to 





Figure 5-8 Vpu LILI mutants pheno-copy Vpu ELV early endosomal localisation 
(A) 293T tetherin expressing cells were transfected with 75 ng of pCR3.1 Vpu-HA and indicated mutants. 
16 hours post transfection, cells were fixed and stained for HA (green) and the TGN marker TGN46 (red) 
and examined by fluorescent microscopy. Panels are of representative examples. (B) Z stacks were taken 
of all cells (n=15), images were deconvoluted using the AutoQuant X3 software and Pearson’s correlations 
were calculated for all Z stacks using ImageJ. Results were analysed by unpaired 2-tailed t-test - *** P = 
10-5 or lower. (C) 293T tetherin cells were transfected as in (A) and stained for HA (green) and the early 
endosome using the marker EEA1 (red) and examined by fluorescent microscopy. Panels are 





5.2.5 Vpu/HRS interaction is dependent on the ubiquitin binding motif (DUIM) in 
HRS 
We next decided to study the nature of Vpu and HRS interaction in greater detail and 
concentrated on the mechanistic features in HRS that are required for Vpu interaction. 
To this end, we created a series of C-terminal HRS truncations, starting with truncating 
the clathrin-binding box (HRS delCB), the unstructured domain (HRS 1-500), the PSAP 
motif (which links HRS to ESCRT-I component TSG101) (HRS 1-280), and the double 
ubiquitin-binding motif (DUIM) (HRS 1-250) (Figure 5-9A). 293T cells were transfected 
with myc-HRS or indicated truncation in combination with Vpu-HA. 48 hours post 
transfection, cells were lysed and immunoprecipitated using an anti-myc antibody and 
analysed by Western blot. As expected, Vpu was co-immunoprecipitated with myc-
HRS (Figure 5-9B). Interestingly, when we truncated beyond the DUIM of HRS, Vpu 
was not co-precipitated efficiently, suggesting that the ability of HRS to bind to ubiquitin 
is important for Vpu interaction. Therefore we point mutated residues in the DUIM and 
VHS domains that previously have been shown to bind ubiquitin (Hirano et al., 2006) 
(Ren and Hurley, 2010) and performed another co-immunoprecipitation. Vpu was not 
precipitated with point mutations in the DUIM of HRS which Vpu was precipitated with 
point mutations in the VHS domain (Figure 5-9C), indicating that Vpu/HRS interactions 







Figure 5-9 Vpu/HRS interaction is dependent on residues in the DUIM of HRS that bind ubiquitin 
(A) Schematic representation of HRS C-terminal truncations. (B) 293T cells were transfected with pCR3.1 
Vpu-HA in combination with a pCR3.1 myc-HRS or myc-HRS truncation expression vector. 48 hours post 
transfection cells were lysed and immunoprecipitated with anti-myc antibody. Total cell lysates and 
precipitates were subjected to SDS-PAGE and analysed by Western blotting for myc-HRS and Vpu, and 
analysed by ImageQuant. Start/asterisk: Heavy chain from myc antibody. (C) Immunoprecipitation was 






5.2.6 Role of other potential ESCRT-0 components 
Depletion of HRS partially blocks virus particle release and tetherin degradation. 
Proteins that share molecular characteristics with the ESCRT-0 subunit HRS might 
also function as ubiquitin receptors for cargo protein sorting into multivesicular 
endosomes. One recently suggested candidate is ALIX, which has been shown to bind 
to ubiquitinated cargo and to be responsible for sorting of these cargo molecules into 
multivesicular endosomes (Dowlatshahi et al., 2012) (Pashkova et al., 2013).  
Next, we therefore tested the effect of ALIX knockdown on virus release and tetherin 
degradation. 293T tetherin cells were treated twice over a period of 48 hours with either 
non-coding siRNA or siRNA directed against ALIX and HRS, alone or in combination, 
and infected with HIV-1 wild-type or HIV-1 delVpu. 48 hours post infection, viral 
infectivity was measured on HeLa-TZMbl indicator cells. Depletion of ALIX caused no 
decrease in physical virus particle release (see Figure 5-10A), which is consistent with 
functional studies demonstrating that ALIX is not required for P(S/T)AP-dependent viral 
budding (reviewed by (Martin-Serrano and Neil, 2011)). Depletion of HRS led to a small 
decrease in physical virus particle release (3-fold) when compared to wild-type levels 
which was also observed in Figure 5-7C. Both, ALIX and HRS have been shown to sort 
ubiquitinated cargo into MVBs for lysosomal degradation. As such they might have 
additive effects on each other, and depletion of one alone might not be enough to 
unravel a strong phenotype regarding virus particle release phenotype. To this end, 
ALIX and HRS were depleted in combination, but no effect on virus particle release 
was observed (see Figure 5-10A). Next, we tested the role of ALIX in Vpu-mediated 
tetherin degradation in infected cells. 293T tetherin cells were treated as above and 
infected with a MOI of 2 to ensure a > 90% cell infection rate. 48 hours post infection, 
cells were lysed and analysed by Western blot. As expected, tetherin levels were 
considerably reduced in cells infected with wild-type virus when compared to 
uninfected and cells infected with Vpu deletion virus. Tetherin levels were rescued from 
degradation in cells depleted for HRS and infected with wild-type virus, while there was 
no difference in tetherin levels in HIV-1 delVpu infected cells (see Figure 5-10B). 
However, tetherin levels were not rescued from ESCRT-mediated degradation in ALIX 
depleted. Rescue of tetherin levels in cells co-depleted of ALIX and HRS was similar to 
the degradation rescue in HRS knockdown cells (see Figure 5-10B), suggesting that 





Figure 5-10 Vpu-mediated tetherin degradation is independent of ALIX 
(A) 293T tetherin expressing cells were transfected twice over a 48 hour period with siRNA oligonucleotide 
directed against HRS, ALIX or non-targeting control. The cells were then infected with HIV-1 wild-type or 
HIV-1 delVpu at an MOI of 0.8. Infectivity of viral supernatants form C was assayed on HeLa-TZMbl 
reporter cells. Infectious virus release was plotted as β-galactosidase activity in relative light units (RLU). 
(B) Cell lysates and sucrose purified viral supernatants form (A) were subjected to SDS-PAGE and 
analysed by Western blotting for Hsp90, HIV-1 p24CA, Vpu, HRS and ALIX and analysed by LiCor 
quantitative imager. 
 
Another group of potential ESCRT-0 complex candidates are the monomeric clathrin 
adaptor GGA proteins, These proteins function in cargo trafficking between the TGN 
and endosomes, which could be consistent with Vpu’s ability to subvert tetherin 
trafficking. Furthermore, overexpression of these proteins has been shown to induce 
accumulation of cellular compartments containing TSG101 and HRS and lead to 
disruption in endosomal sorting (Joshi et al., 2009). 
Next, we tested the effect of GGA overexpression on tetherin-mediated virus particle 
release. To this end, 293T tetherin cells were transfected with increasing 
concentrations of GGA1, GGA2 or GGA3 in combination with a fixed dose of NL4.3 
wild-type or NL4.3 delVpu provirus. 48 hours after the transfection, cell lysates and 
supernatants containing viral particles were harvested and analysed for viral infectivity 




(Figure 5-11B). As expected, virus particle release in NL4.3 delVpu expressing cells is 
about 23-fold lower than virus release from NL4.3 wild-type cells. GGA1 
overexpression results in a dramatic decrease in infectious virus release in both wild-
type and delVpu treated cells, with levels close to the detection limit of the dynamic 
range of the β-galactosidase-based assay. However, GGA2 overexpression in NL4.3 
wild-type transfected cells resulted in 19-fold decrease, and in NL4.3 delVpu 
transfected cells in a 13-fold decrease in infectious virus particle release could be 
observed when compared to control cells. GGA3 overexpression resulted in a 46-fold 
decrease in wild-type and 15-fold decrease in delVpu transfected cells (Figure 5-11A). 
Notably, overexpression of GGA1 has been shown to inhibit virus assembly and 
release by disrupting ADP ribosylation factor (Arf) protein activity, therefore disrupting 
Gag binding to membranes (Joshi et al., 2008). GGA overexpression induced 
accumulation of cellular compartments containing TSG101, HRS and poly-ubiquitin, 
which in turn led to disruption in endosomal sorting (Joshi et al., 2009). Next, we looked 
at physical virus particle release and Gag processing by Western blot. GGA1 
overexpression induced a slight degradation of the viral structural protein Gag, 
resulting in a drastic decrease in virus release, while overexpression of GGA2 and 
GGA3 had no effect on Gag processing (Figure 5-11B). Overexpression of GGA2 and 
GGA3 in NL4.3 wild-type cells resulted in a decrease in virus particle release of 5 and 
25-fold respectably, while the effect in NL4.3 delVpu was residual (Figure 5-11B). Next, 
we tested the effect of GGA overexpression in tetherin negative 293T cells, which were 
treated as above and transfected with 250 ng of GGA1, GGA2 or GGA3. As expected, 
virus particle release from wild-type and delVpu was unchanged (Figure 5-11C). While 
particle release in GGA overexpressed cells was dramatically reduced, there was no 






Figure 5-11 Role of GGA proteins in tetherin antagonism by Vpu 
(A) 293T tetherin cells were transfected with increasing concentrations of pCR3.1 myc-GGA1, GGA2 or 
GGA3 expression vector (100 ng, 250 ng and 500 ng) or YFP expression plasmid together with NL4.3 
wild-type or NL4.3 Vpu delVpu. Infectivity of viral supernatants was assayed on HeLa-TZMbl reporter cells. 
Infectious virus release was plotted as β-galactosidase activity in relative light units (RLU). Error bars 
represent the standard deviation of three independent experiments. (B) Cell lysates and sucrose purified 
viral supernatants were subjected to SDS-PAGE and analysed by Western blotting for Hsp90, HIV-1 
p24CA, Vpu, myc and analysed by LiCor quantitative imager. (C) 293T cells or 293T tetherin cells were 
transfected as in (A) and transfected with a fixed dose of myc-GGA1, GGA2 or GGA3. Error bars represent 








In this chapter we have identified the role of the newly identified ESCRT-I subunit 
UBAP1 in Vpu-mediated tetherin degradation, which was part of a project that resulted 
in a publication in Structure (Agromayor et al., 2012). In this manuscript, we were able 
to show that UBAP1 forms a complex with TSG101, VPS28 and VPS37 with a 1:1:1:1 
stoichiometry. Co-depletion studies demonstrated that binding to TSG101 stabilizes 
endogenous UBAP1 and that UBAP1 is able to recruit ESCRT subunits in a TSG101-
dependent manner. This evidence suggested that UBAP1 is part of the human ESCRT-
I complex, which is consistent with results published earlier by Woodman and 
colleagues (Stefani et al., 2011). We were able to demonstrate that UBAP1 is able to 
bind to ubiquitin using its novel C-terminal solenoid of overlapping ubiquitin-associated 
(SOUBA) domain to increase ESCRT-I interaction with ubiquitin. The SOUBA domain 
consist of three ubiquitin-associated (UBA) domains that bind to three mono-ubiquitin 
molecules adjacent to one another. All three UBAs bind to the hydrophobic region of 
ubiquitin that includes residues isoleucine 44 and valine 70. ESCRT-I subunit UBAP1 is 
essential for ESCRT-mediated degradation of ubiquitinated cargo via the lysosome but 
dispensable for HIV-1 budding and cytokinesis. The KSHV ubiquitin ligase K5 induces 
endo/lysosomal degradation of tetherin via the lysine 18 amino acid residue in the 
tetherin cytoplasmic tail (Mansouri et al., 2009) (Pardieu et al., 2010), and this 
degradation is dependent on the ESCRT-I subunit UBAP1. The HIV-1 accessory 
protein Vpu targets tetherin for lysosomal degradation (Douglas et al., 2009) (Iwabu et 
al., 2009) (Mitchell et al., 2009), a process that is dependent on the ESCRT-0 subunit 
HRS (Janvier et al., 2011). We were able to demonstrate that UBAP1 is essential for 
Vpu-mediated tetherin degradation, which is nevertheless dispensable for Vpu anti-
tetherin activity. Furthermore, in UBAP1 depleted cells, ubiquitinated tetherin proteins 
accumulate in late endosomal structures, which are not affecting the efficiency of Vpu 
to antagonise tetherin. This knowledge provides us with a powerful tool to study the 
mechanism of Vpu-mediated counteraction of tetherin without using lysosomal 
inhibitors that can be toxic when used for a prolonged period of time. While UBAP1 
activity is dispensable for cell division and virus budding, depleted cells remain healthy 
after a 72 hour treatment with siRNA oligonucleotides. However, UBAP1 could stabilise 
binding of multiple mono-ubiquitinated cargo molecules or clustered mono-
ubiquitinated cargo. Further studies are needed to understand the in detail nature of 
ubiquitin binding of cargo proteins designated for lysosomal degradation via the 
SOUBA domain.    
In this chapter we also identified hydrophobic residues in the first alpha helix of the 




for the antagonism of tetherin restriction. Naturally occurring mutations of these 
residues were also found in a single genome sequencing study of HIV-1 infected 
individuals (Pickering et al., 2014). Mutation of these residues blocks the ability of Vpu 
to mediate tetherin surface downregulation and induce ESCRT-dependent degradation 
of tetherin. Vpu LILI mutants retain the ability to interact with tetherin via their 
respective transmembrane domains, and to recruit the ubiquitin ligase SCF-β-TrCP2 
complex via a pair of phosphorylated serine residues in the highly conserved region 
between cytoplasmic helix 1 and 2. Vpu LILI mutants pheno-copy the cellular 
localisation of trafficking Vpu ELV mutants in which they localise to early/recycling 
endosomal structures and the plasma membrane rather than the TGN.  
A previous study has demonstrated that both Vpu and tetherin interact with the 
ESCRT-0 component HRS and that HRS is important for tetherin cell surface 
downregulation and degradation (Janvier et al., 2011). Interestingly, Vpu LILI mutants 
failed to co-precipitate with HRS. This loss of interaction might explain why Vpu LILI 
mutants are unable to antagonise tetherin function. Another possibility is that Vpu LILI 
mutants are defective in tetherin antagonism for unrelated reasons. For example, LILI 
mutants fail to interact with the clathrin adaptor AP-1, and on top of that are unable to 
recruit HRS (see Chapter 6 for further characterisation of Vpu mutants). Vpu/HRS 
interaction is likely to occur via ubiquitin, as mutation of the residues known to bind to 
ubiquitin in the DUIM motif in HRS completely abolished co-precipitation of Vpu. We 
were unable to find any evidence of ubiquitinated forms of Vpu in our 
immunoprecipitations, despite performing our experiments in the presence of de-
ubiquitinase inhibitors, and potentially enriching for ubiquitinated proteins by 
precipitating myc-HRS. This means that Vpu/HRS interaction is likely to be indirect. 
Interestingly, Vpu wild-type interacts with HRS in the presence or absence of tetherin, 
indicating a role for another cellular factor that is being ubiquitinated and is “bridging” 
between Vpu and HRS. This cellular factor is unlikely to be the lipid-antigen presenting 
protein CD1d or the natural killer cell ligand NTB-A, as degradation of these proteins is 
not induced by HIV-1 Vpu (Moll et al., 2010) (Shah et al., 2010). In addition, CD1d and 
NTB-A are not expressed in 293T cells, which were used in the co-immunoprecipitation 
studies. We found that the phospho-mutant Vpu 2/6A which is unable to recruit the only 
E3 ubiquitin ligase known to induce tetherin as well as CD4 ubiquitination, is able to 
interact with HRS in both presence and absence of tetherin. Vpu/HRS interaction is 
independent of β-TrCP2 but dependent on ubiquitin, highlighting the potential role of a 
to date unknown ligase which ubiquitinates Vpu’s target membrane proteins for 
degradation. The importance of the DSGNES phosphorylation motif and subsequent 




has been subject to debate, as β-TrCP is not strictly required for Vpu-mediated tetherin 
antagonism (Tervo et al., 2011) (Schmidt et al., 2011). Tetherin is ubiquitinated on 
multiple residues within its cytoplasmic tail. This ubiquitination has been shown to be 
crucial for degradation (Tokarev et al., 2011) (Gustin et al., 2012) and might be induced 
by ligases other than β-TrCP2. However, the type of ubiquitination (mono-ubiquitination 
and/or poly-ubiquitination), as well as the nature of chain linkages still needs to be 
evaluated. Different ubiquitin patterns can have detrimental effects on the fate of 
recycling membrane proteins. Multiple mono-ubiquitination and lysine 63-linked poly-
ubiquitination function as sorting motifs in early/recycling endosomes for lysosomal 
degradation, whereas lysine 48-linked poly-ubiquitination leads to proteosomal 
degradation (reviewed by (Raiborg and Stenmark, 2009)).  
Depletion studies of HRS using siRNA showed a partial phenotype for virus particle 
release and tetherin degradation. HRS knockdown could have an effect on HIV-1 
envelope trafficking to the plasma membrane. Therefore affecting the infectious virus 
particle release, analysed by β-galactosidase-based reporter assay, might be lower 
than the physical particle yield analysed by Western blot. Furthermore, there are 
discrepancies between our results and published data (Janvier et al., 2011): we show a 
partial phenotype for virus particle release and tetherin degradation while Janvier et al 
propose that Vpu-mediated tetherin degradation is dependent on HRS and that HRS 
depletion induces a tetherin phenotype on efficient virus release. These differences 
might be due to the nature of assays or cell lines used in the knockdown experiments. 
We present our virus particle release results in “fold differences” while Janvier et al 
used “percentages”, which tends to make small differences appear more significant. 
Therefore one could argue if there are differences in actual results obtained, or only 
differences in presentation and subsequent interpretation of these results.  
There has been a debate as to whether HRS is the only ESCRT-0 component which is 
able to sort ubiquitinated cargo or if there are structurally similar proteins that might be 
able to act as an alternative way into the ESCRT machinery. Potential candidates are 
members of the GGA protein family and TOM1 or TOM1L1-like proteins as all share 
common features with HRS: VHS domains, ubiquitin-binding motifs, clathrin-binding 
boxes and PSAP/PTAP ESCRT-binding motifs (reviewed by (Raiborg and Stenmark, 
2009)). Furthermore, GGA3 has also been shown to interact with ESCRT-I subunit 
TSG101 (Puertollano and Bonifacino, 2004). Another report highlighted the potential 
role of ALIX as an ESCRT-0 component, binding to ubiquitinated cargo and sorting 
these into multivesicular endosomes (Dowlatshahi et al., 2012) (Pashkova et al., 2013). 
We tested this hypothesis and depleted ALIX alone or in combination with HRS and 




see any effect of ALIX depletion on Vpu-mediated virus particle release or infectivity 
and tetherin degradation in preliminary experiments. Overexpression of monomeric 
alternative clathrin adaptors GGA1, GGA2 and GGA3 indicated that there might be a 
Vpu and tetherin specific role in infectious virus particle release for GGA2 and GGA3 in 
initial experiments. GGA proteins are monomeric alternative clathrin adaptor proteins 
that function in cargo trafficking between the TGN and endosomes (reviewed by (Lafer, 
2002)), which is consistent with Vpu’s ability to subvert tetherin trafficking to the plasma 
membrane and re-routing it for ESCRT-dependent endo/lysosomal degradation. 
Overexpression has been shown to induce accumulation of cellular compartments 
containing TSG101, HRS and poly-ubiquitin, which in turn lead to disruption in 
endosomal sorting (Joshi et al., 2009). Furthermore, overexpression studies of GGA 
proteins have been shown to induce artificial intracellular compartments that in case of 
GGA1 sequester HIV-1 gag and virus particles. Additionally, GGA proteins have been 
shown to be important modulators of retrovirus release, and overexpression of these 
proteins impairs the trafficking of gag to the plasma membrane (Joshi et al., 2008). 
Therefore it is important to perform further studies using knockdown techniques of 
especially GGA2 and GGA3 to evaluate their role in Vpu-mediated tetherin 
antagonism, cell surface downregulation and degradation. As GGA proteins play a role 
in gag trafficking, siRNA studies should be performed without full-length virus in order 
to unmask any GGA-dependent effect on Vpu-mediated tetherin antagonism. Due to 
the high degree of homology between GGA1, GGA2, and GGA3 initial depletion 
studies revealed that knockdown of one of the GGA proteins can have an effect on 
expression levels of other GGA family members. Therefore it is important to monitor 
expression levels of all three GGA proteins closely. It is also important to perform 
cellular localisation studies for both GGA overexpression and depletion studies to 
detect any effect on subcellular trafficking of Vpu and tetherin proteins.   
While there is no full-length crystal structure of Vpu, structural studies using 
transmembrane or cytoplasmic domains have revealed that the first alpha helix of Vpu 
is embedded into the host plasma membrane due to its charged and hydrophilic nature 
(Maldarelli et al., 1993) (Wray et al., 1995). Mutating isoleucine and leucine residues 
into nonpolar alanine residues in the first alpha helix might weaken the helix structure, 






Chapter 6 Further studies on the relationship between Vpu 
mutants and the clathrin machinery 
6.1 Introduction 
We have noticed that Vpu ELV (Chapter 4) and LILI (Chapter 5) cytoplasmic tail 
mutants, as well as the previously characterised Vpu 2/6A phospho-mutant, 
predominately localise to punctate structures within the cytoplasm (Figure 6-1), which 
we predict to be early/recycling endosomal compartments. Therefore, Vpu LILI and 
Vpu 2/6A mutants pheno-copy the localisation defect of Vpu ELV mutants, which is 
unable to interact with the clathrin adaptor AP-1, and as a result accumulate in 
endosomal compartments. We consequently asked the question if Vpu LILI and Vpu 
2/6A mutants are also defective for AP-1 interaction.   
Data presented in Chapter 4 implicates a function of clathrin in Vpu-mediated tetherin 
antagonism. However, we could not detect any effects of depletion of the canonical 
clathrin adaptor proteins AP-1, AP-2 or AP-3 on Vpu-mediated tetherin antagonism. 
This is potentially suggestive of redundancy in the clathrin adaptor pathway, thus 
making depletion experiments difficult to interpret. By replacing the second alpha helix 
of Vpu cytoplasmic tail, containing a trafficking motif with the D/ExxxL(L/I/M) motif from 
HIV-1 Nef that has been demonstrated to bind canonical clathrin adaptors AP-1, AP-2 
and AP-3 (Janvier et al., 2003) (Chaudhuri et al., 2007), we were able to indirectly link 
Vpu to the clathrin machinery and to functionally complement Vpu function.  
Acidic amino acid residues or phosphorylated serine residues downstream of acidic 
dileucine-based sorting motifs can add potency to the signals and enhance clathrin 
adaptor binding (Mauxion et al., 1996). Interestingly, immediate upstream of the 
ExxxLV sorting signal in HIV-1 Vpu, is a highly conserved DSGNES motif containing a 
pair of serine residues that are phosphorylated by casein kinase II. In the Vpu 2/6A 
mutant these serine residues are mutated, potentially leading to the destabilisation of 
Vpu/AP-1 complexes mediated by the ExxxLV motif in the second alpha helix of Vpu.      
Vpu LILI mutants display a defect in tetherin antagonism that renders it unable to 
interact with the ESCRT-0 component HRS, responsible for binding to ubiquitinated 
transmembrane cargo molecules and delivers them for endo/lysosomal degradation. 
HRS also sequesters cargo molecules into micro-domains in early endosomal 
compartments by directly binding to flat clathrin lattices. Therefore, inhibiting the 
recycling of cargo molecules designated for degradation back to the plasma 
membrane. Flat clathrin lattices are organised differently from clathrin-coated pits at the 




layered and well-organised coat, while HRS containing endosomal clathrin lattices are 
flat and bi-layered (Raiborg et al., 2002).  
Therefore, Vpu ELV, Vpu LILI and Vpu 2/6A mutants indirectly interact or potentially 
stabilise binding to the cellular clathrin machinery, but these clathrin interactions occur 
in different cellular compartments. One could argue that Vpu/tetherin complexes have 
to interact with the clathrin machinery independent of cellular localisation in order to be 
sorted for lysosomal degradation. 
In this chapter we have examined the effect of fusing the clathrin-binding box of HRS to 
the C-terminus of different Vpu mutants, including ESCRT-0 interaction mutant (Vpu 
LILI), phospho-mutant (Vpu 2/6A) and trafficking mutants (Vpu ELV). Interestingly, all 
mutants, when fused to a direct clathrin-binding motif, rescue tetherin antagonism. This 
indicates that interaction with the clathrin machinery within the cell is critical for Vpu to 
exclude tetherin away virus budding sites at the plasma membrane, and into the 
degradative ESCRT-dependent pathway. 
 
 
Figure 6-1 Comparison of Vpu mutant subcellular localisation 
(A) 293T tetherin expressing cells were transfected with 75 ng of pCR3.1 Vpu-HA and indicated mutants. 
16 hours post transfection, cells were fixed and stained for HA (green) and the TGN marker TGN46 (red) 
and examined by fluorescent microscopy. Panels are of representative examples. (B) Z stacks were taken 
of all cells (n=15), images were deconvoluted using the AutoQuant X3 software and Pearson’s correlations 
were calculated for all Z stacks using ImageJ. Results were analysed by unpaired 2-tailed t-test - *** P = 
10-5 or lower. Data for: Vpu wt, Vpu LILI and Vpu ELV is the same as presented in 5.2.4. Same data set as 





6.2.1 Vpu cytoplasmic tail mutants can be functionally rescued by a clathrin-
binding motif 
Vpu ELV, Vpu LILI and Vpu 2/6A mutants have the same localisation defect, so we 
reasoned that they all have defective interactions with clathrin. If so, then we 
hypothesised that bypassing the defect and linking Vpu directly to clathrin might restore 
anti-tetherin function. We therefore decided to fuse the C-terminal clathrin-binding box 
of HRS to the cytoplasmic tail mutants Vpu LILI, Vpu 2/6A and Vpu ELV, and study 
their ability to counteract tetherin restriction. To this end, we fused the AQLISFD 
clathrin heavy chain-binding motif of HRS or corresponding mutant to the carboxyl-
terminus of Vpu cytoplasmic tail mutants (Figure 6-2A). 293T tetherin cells were co-
transfected with increasing concentrations of a tetherin expression vector and indicated 
Vpu clathrin box chimeras in combination with a fixed dose of NL4.3 delVpu provirus. 
48 hours after the transfection, cell lysates and supernatants containing viral particles 
were harvested and analysed for physical virus yield by Western blot (Figure 6-2 B and 
C) and viral infectivity on HeLa-TZMbl reporter cells (Figure 6-2 D until F). Remarkably, 
when we tested the ability of these proteins to antagonise tetherin function, all Vpu 
cytoplasmic tail mutant clathrin box chimeric proteins substantially recovered tetherin 
anti-viral activity (Figure 6-2 B and C). This effect could also be observed with two 
different clathrin-binding motifs from GGA2 (preliminary results). Moreover, these 
chimeras also displayed improved tetherin downregulation from the surface of 
transfected HeLa-TZMbl cells that were analysed for tetherin cell surface levels by flow 
cytometry (Figure 6-3 A until E). This activity was entirely dependent on the key amino 
acids required for clathrin interaction as chimeras in which L and I positions were 
mutated to alanine were unable to counteract tetherin or to induce tetherin cell surface 
downregulation (Figure 6-2 and Figure 6-3). Thus, Vpu function can be substantially 
recovered by fusing Vpu cytoplasmic tail ESCRT-0, phospho- and trafficking mutants to 
a clathrin-binding signal AQLISFD, indicating that linking Vpu directly to the clathrin 







Figure 6-2 Virus particle release of Vpu cytoplasmic tail mutants can be rescued by clathrin-
binding motif of HRS  
(A) Schematic representation of Vpu HRS CB chimera constructs (Jonathon Sumner contributed to the 
cloning process of the indicated constructs). (B) 293T tetherin cells were transfected with NL4.3 delVpu 
proviral plasmid in combination with YFP expression vector, pCR3.1 Vpu, pCR3.1 Vpu HRS CB, pCR3.1 
Vpu HRS CB mut or indicated Vpu LILI CB chimera construct. 48 hours post transfection, cell lysates and 
pelleted supernatant virions were harvested and subjected to SDS-PAGE and analysed by Western 
blotting for HIV-1 p24CA, Vpu and Hsp90, and analysed by LiCor quantitative imager. (C) Same 
experiment as in (A) but with pCR3.1 Vpu 2/6A or pCR3.1 Vpu ELV CB chimera as indicated. (D) 
Infectivity of viral supernatants from (B) was determined on HeLa-TZMbl cells as in Figure 4-1. Error bars 
represent standard deviation of three independent experiments. (E) Infectivity of viral supernatants from 
(C) using pCR3.1 Vpu 2/6A constructs. Error bars represent standard deviation of three independent 
experiments. (F) Infectivity of viral supernatants from (C) using pCR3.1 Vpu ELV constructs. Error bars 






Figure 6-3 Vpu cytoplasmic tail mutants fused to a clathrin-binding box are able to downregulate 
tetherin from the plasma membrane 
(A) HeLa-TZMbl cells were co-transfected with pCR3.1 Vpu or indicated mutant and a GFP expression 
vector. Cell-surface tetherin levels were analysed 48 hours post transfection by flow cytometry. GFP 
positive cells were gated and tetherin levels (solid lines) were compared to mock-transfected cells or 
transfected with indicated Vpu (dotted lines). Numbers indicate median fluorescence intensities of 
endogenous tetherin surface levels. The solid peak in the upper left histogram represents binding of the 
isotype control. (B) Same as in (A) but transfected with pCR3.1 Vpu LILI or indicated mutant. (C) Same as 
in (A) but transfected with pCR3.1 Vpu 2/6A or indicated mutant. (D) Same as in (A) but transfected with 
pCR3.1 Vpu ELV or indicated mutant. (E) Percentages of tetherin surface expression levels calculated 




Recent data suggests that Vpu blocks both the transit of de novo synthesised tetherin 
to the cell surface as well as the recycling of endocytosed tetherin molecules from the 
plasma membrane. Tetherin recycling requires a dual tyrosine YxYxxφ  motif in its 
cytoplasmic tail that acts as a binding site for AP-2 (for internalisation) and AP-1 (for 
recycling via the Golgi) (Rollason et al., 2007) (Masuyama et al., 2009). Mutation of this 
motif enhances tetherin surface expression, but only has minor effects on its ability to 
restrict virus release or its sensitivity to Vpu (Iwabu et al., 2009) (Dubé et al., 2010b). 
Since tetherin is degraded by an ubiquitin-dependent process, and Vpu-mediated 
recruitment of the SCF-β-TrCP E3 ubiquitin ligase complex has been shown to induce 
tetherin ubiquitination at multiple residues in its cytoplasmic tail, one being a 
serine/threonine motif (STS) (Tokarev et al., 2011), we asked whether Vpu LILI, 2/6A 
and ELV clathrin box chimeras were differentially defective against tetherin mutants 
bearing changes in its sorting sequence and ubiquitination motif. We transfected 293T 
tetherin STS mutant and 293T tetherin Y6,8A cells with NL4.3 delVpu in combination 
with increasing concentrations of indicated Vpu clathrin box chimera expression 
vectors, and measured viral release 48 hours later (Figure 6-4 A until F). Vpu ESCRT, 
phospho- and trafficking mutants when fused to the HRS clathrin box displayed the 
ability to antagonise tetherin function to levels similar to the wild-type Vpu protein in 
tetherin cells defective for the serine/threonine motif (Figure 6-4 A until C). These levels 
were also comparable with rescue of virus release obtained in wild-type tetherin cells 
(Figure 6-2 D until F). Interestingly, mutant Vpu clathrin box chimeras failed to rescue 
virus particle release from tetherin mutant cells bearing lesions in its sorting motif 
YxYxxφ  (Figure 6-4D until F), suggesting that the rescue of three different Vpu mutants 
by addition of a C-terminal clathrin-binding motif requires tetherin to retain its capacity 







Figure 6-4 Virus particle release rescue is dependent on an intact YxYxxφ  motif in tetherin 
(A) 293T tetherin STS cells were transfected with NL4.3 delVpu proviral plasmid in combination with YFP 
expression vector, pCR3.1 Vpu, pCR3.1 Vpu HRS CB, pCR3.1 Vpu HRS CB mut or Vpu LILI CB chimera. 
48 hours post transfection, infectivity of viral supernatants from was determined on HeLa-TZMbl. (B) Same 
as in (A) but with pCR3.1 Vpu 2/6A CB chimera constructs. (C) Same as in (A) but with pCR3.1 Vpu ELV 
CB chimera constructs. (D) 293T tetherin Y6,8A cells were transfected with NL4.3 delVpu proviral plasmid 
in combination with YFP expression vector, pCR3.1 Vpu, pCR3.1 Vpu HRS CB, pCR3.1 Vpu HRS CB mut 
or Vpu LILI CB chimera. 48 hours post transfection, infectivity of viral supernatants from was determined 
on HeLa-TZMbl. (E) Same as in (D) but with pCR3.1 Vpu 2/6A CB chimera constructs. (F) Same as in (D) 












Next, we tested if the rescue of tetherin antagonism demonstrated in Figure 6-2 and 
Figure 6-3 was sensitive to inhibition of overall clathrin function. We therefore 
performed an overexpression experiment using the C-terminal fragment of the neuronal 
adaptor AP180 (AP180c) that inhibits clathrin/membrane interactions (Ford et al., 
2001), co-transfected with NL4.3 delVpu and indicated Vpu clathrin box chimera, and 
tested physical virus particle release from tetherin positive cells (Figure 6-5A). As 
expected, physical virus particle release from wild-type Vpu transfected cells was 
blocked upon AP180c expression by approximately 7-fold, while release from mock-
infected cells was unchanged. AP180c expression had only minor effects on Vpu LILI, 
2/6A or ELV mutants (2-, 3- and 5-fold respectively). Interestingly, the rescue of Vpu 
mutants by fusion to a clathrin-binding motif was sensitive to relative available cellular 
clathrin. Virus release from Vpu LILI, 2/6A and ELV was dramatically decreased by 
AP180c expression (6-, 5- and 6.5-fold respectively). Interestingly, AP180c expression 
enhanced total Vpu levels (like observed in Figure 4-6), indicating a clathrin-dependent 
transport in natural turnover of Vpu proteins. Thus, Vpu function can be substantially 
recovered by fusing Vpu cytoplasmic tail LILI, 2/6A and ELV mutants to a clathrin-
binding signal, indicating that linking Vpu directly to the clathrin trafficking machinery 
can restore its activity. Furthermore, the recovery observed is dependent on cellular 
clathrin levels.  
 
 
Figure 6-5 Functional rescue of Vpu cytoplasmic tail mutants is dependent on clathrin 
(A) 293T tetherin expressing cells were co-transfected with NL4.3 delVpu proviral plasmid and YFP, Vpu, 
Vpu HRS CB, Vpu HRS CB mut expression vector or indicated mutant in combination with AP180c. 48 
hours post transfection, cell lysates and pelleted supernatant virions were harvested and subjected to 
SDS-PAGE and analysed by Western blotting for HIV-1 p24CA, Vpu and Hsp90, and analysed by LiCor 





6.2.2 Are Vpu ESCRT-0-binding mutant, phospho-mutant, and trafficking 
mutant defective for the same reason? 
Next, we wanted to explore why tetherin antagonism by Vpu ESCRT-0 and phosho-
mutants was rescued by C-terminal fusion to the HRS clathrin-binding motif. Since 
these Vpu mutants are defective in their interaction with both the ESCRT-0 component 
HRS and the SCF E3 ubiquitin ligase complex, which binds to two phosphorylated 
serine residues in Vpu cytoplasmic tail, and have not been associated with the clathrin 
machinery. While it is not surprising that Vpu ELV trafficking mutants are able to 
interact with clathrin adaptor AP-1 (Figure 4-15), these are being rescued by 
introduction of a direct clathrin-binding sequence, therefore bypassing the need for an 
adaptor protein. To get a better understanding of the cellular implications of the 
ESCRT-binding and phospho-mutant we made use the BioID assay. To this end, we 
fused BirA to myc-tagged subgroup B Vpu 3/7A (resembles phospho-mutant) and Vpu 
I+I (ESCRT-0 binding mutant) and transfected 293T tetherin cells with either mutant, 
wild-type or ELV Vpu proteins. As expected, using this new BioID assay we were able 
to demonstrate that AP-1 interacts with wild-type Vpu. However, Vpu I+I mutants failed 
to interact with AP-1 similarly to the defect observed in Vpu ELV mutants, while Vpu 
3/7A interaction with AP-1 was impaired. These results allow us to conclude that AP-1 
interaction with Vpu is highly sensitive and dependent on an overall intact Vpu 








Figure 6-6 Vpu phospho-mutant and ESCRT-0 interaction mutant are defective for AP-1 interaction 
in tetherin positive cells 
(A) 293T tetherin cells were transfected with subgroup B Vpu-myc-BirA, B Vpu ELV-myc-BirA, B Vpu 3/7A-
myc-BirA (phospho-mutant), B Vpu I+I-myc-BirA (naturally occurring ESCRT interaction mutant) or empty 
vector control. 6 hours post transfection, cells were treated with 10 nM concanamycin A in the presence of 
150 µM free Biotin. 16 hours later, cells were washed, lysed, sonicated and biotinylated proteins were 
recovered on streptavidin-conjugated beads and analysed by Western blot for avidin, Vpu-myc-BirA and 
AP-1 γ. Asterisk: Vpu-myc-BirA band. (B) Same as in (A) but with 293T cells (performed together with Dr 






In this chapter we have been able to functionally substitute Vpu LILI, 2/6A and ELV 
mutants with a direct clathrin heavy chain-binding motif of the ESCRT-0 component 
HRS, which is highly conserved among HRS homologues in yeast, nematodes and 
flies. By fusing the clathrin-binding sequence to the C-terminus of Vpu cytoplasmic tail 
mutants we were able to rescue infectious virus particle release in a clathrin-dependent 
manner, as well as tetherin cell surface downregulation to almost wild-type Vpu levels. 
We were also able to confirm these results with a different clathrin heavy chain-binding 
motif from GGA2 (RNLLDLL) that is not located at either C- or N-terminus of the 
protein. This indicates that the observed rescue is dependent on clathrin heavy chain-
binding per se and not specific clathrin-binding motif peptides. To date there is no full-
length crystal structure of Vpu or Vpu and tetherin complexes, making it difficult to 
predict the impact of an additional C-terminal clathrin-binding motif on the structural 
integrity of the cytoplasmic tail of Vpu, which is thought to be dynamic. Since we were 
able to rescue all tested Vpu mutants to similar levels, one could speculate that the 
additional 7 residues of the clathrin-binding box lead to an alteration of the structure of 
the cytoplasmic tail, blocking host cell protein interactions and therefore making all Vpu 
mutants dependent on the clathrin interaction despite their different underlying defects.  
We were able to functionally rescue the Vpu 2/6A phospho-mutant with the addition of 
a clathrin-binding motif but without restoring binding to the SCF-β-TrCP E3 ubiquitin 
ligase complex. This and previous studies suggest that serine phosphorylation and 
recruitment of SCF-β-TrCP may be dispensable for tetherin antagonism (Tervo et al., 
2011). Indeed, a dual function of the DSGNES motif has been suggested in 
accordance with previous demonstrations that β-TrCP is not strictly required for tetherin 
trafficking by Vpu (Schmidt et al., 2011), and that Vpus with N55H or E56G mutations 
within the DSGNES motif affected tetherin counteraction but were still able to bind to β-
TrCP (Pickering et al., 2014). It is possible that these residues are required to facilitate 
access to either of the two cytoplasmic helices. In this regard, acidic dileucine 
trafficking motifs, such as the ExxxLV signal of Vpu, have been associated with 
upstream serine phosphorylation in the trafficking of the CI-M6PR (Mauxion et al., 
1996).          
The clathrin box-mediated rescue of tetherin antagonism by Vpu is dependent on an 
intact trafficking signal (YxYxxφ) in the tetherin cytoplasmic tail but independent of the 
ubiquitination motif STS. As demonstrated in Chapter 4 residual activity of Vpu ELV 
mutants is dependent on an intact YxYxxφ  motif in tetherin and Vpu ELV mutants fail to 




mutants being dragged to the plasma membrane by tetherin where they are being 
incorporated into budding virions. Therefore it would be interesting to see if all Vpu 
cytoplasmic tail mutants and/or Vpu clathrin box chimeras are being incorporated into 
virions like ELV mutants.   
We propose that ESCRT-0, phospho- and trafficking Vpu mutants are defective for the 
same reasons, namely that they are unable to interact with the cellular clathrin 
machinery. To this end, our preliminary data suggests that as expected Vpu ELV 
mutants are defective in interacting with AP-1, and interestingly Vpu ESCRT-0 and 
phospho-mutants also displayed a defect in AP-1 binding. However, more work needs 
to be done to answer questions like: whether other clathrin adaptors like AP-2 are able 
to interact with Vpu additionally to AP-1. Due to technical problems we were unable to 
demonstrate direct binding of Vpu clathrin box chimeras to the clathrin heavy chain 
using recombinant proteins, but more experiments are being performed to answer this 
question. 
Vpu-mediated ESCRT-dependent degradation of tetherin is defective for Vpu LILI, 2/6A 
and ELV mutants. Therefore it would be interesting to see if addition of the clathrin-
binding sequence restores tetherin degradation. Another important unanswered 
question is the subcellular localisation of the Vpu clathrin box chimeras. Especially, if 
the chimeras accumulate at endosomal compartments, as the HRS clathrin-binding 
sequence has been shown to be important for scaffolding of HRS into clathrin rich 
dynamic micro-domains, important for the degradation of the endocytosed epidermal 
growth factor (EGF) (Raiborg et al., 2006). To date, these clathrin-binding motif 
induced micro-domains have only been observed on endosomal membranes (Raiborg 
et al., 2002).  
By fusing the clathrin-binding box directly to the C-terminus of Vpu we might have 
introduced an additional (D/E)xxxL(L/I) motif starting at residue D80 which is highly 
conserved and important for tetherin antagonism (Pickering et al., 2014). We therefore 
introduced a short linker sequence between Vpu and the clathrin box and repeated the 
experiments to ensure that the observed effect is due to direct binding to the clathrin 
heavy chain and not due to interaction with clathrin adaptors. Preliminary data suggest 
that the rescue in virus particle release is only mildly affected by introducing a linker 






Chapter 7 GENERAL CONCLUSION AND FUTURE DIRECTIONS 
Since Vpu was first discovered in 1988 its list of functions has increased steadily. To 
date the major roles attributed to Vpu include rapid degradation of the cell surface 
receptor CD4, enhancement of virus particle release by counteraction of tetherin and 
downmodulation of CD1d and NTB-A. Vpu targets these membrane-associated 
proteins to allow HIV-1 to escape immune activation and to create optimal condition for 
virus replication. However, the importance of Vpu during HIV-1 infection might still be 
incomplete. In vivo there is selective pressure for maintaining a functional vpu gene, as 
for example monkeys infected with a Vpu-defective SHIV variant carrying an ATG to 
ACG mutation revert back to a functional open reading frame during the course of 
infection (McCormick-Davis et al., 1998). Furthermore, a single genome analysis of vpu 
alleles from HIV-1 clade B infected individuals showed that despite extensive amino 
acid diversity of the Vpu protein, the Vpu functions of targeting CD4 and counteracting 
both physical virus restriction and NF-κB activation by tetherin are rarely impaired 
(Pickering et al., 2014). These observations highlight the importance of maintaining 
Vpu function throughout HIV-1 infection. It is intriguing that Vpu, an 81 amino acid 
protein, can interact with a broad range of cellular target proteins sharing little or no 
homology. One of the best-characterised examples to illustrate the role of Vpu in 
antagonising cellular innate immune defences is the restriction factor tetherin. The 
studies of the mechanism by which Vpu antagonises the anti-viral function of tetherin 
provide a powerful tool to understand the complex interactions between virus and host.   
Towards a unified mechanistic model of tetherin antagonism by HIV-1 Vpu   
In Chapter 4, through mutational analysis of the second alpha helix of HV-1 Vpu 
(NL4.3), we have identified a determinant, E59xxxL63V64, which is required for 
efficient antagonism of tetherin. Importantly, this motif is required to counteract tetherin 
in CD4+ T cells, particularly after their exposure to type I IFN. Mutation of this site 
blocks the ability of Vpu to mediate downregulation of tetherin cell surface expression 
and its ESCRT-dependent degradation, but does not abolish its interaction with 
tetherin, nor recruitment of β-TrCP2 or the ESCRT-0 component HRS. Vpu ELV 
mutants localise to the cell surface and early/recycling endosomal compartments rather 
than the TGN by virtue of their interaction with tetherin. Residual Vpu ELV activity 
against tetherin was entirely dependent on an intact recycling motif in tetherin’s 
cytoplasmic tail, suggesting that this motif differentially affects antagonism of newly 
synthesized tetherin rather than pre-existing pools recycling to the PM. Using the new 
BioID technique we were able to demonstrate that Vpu interacts with AP-1 in the 
presence of tetherin, and that this interaction is dependent on an intact ExxxLV motif in 




structure, presented at the 2013 CSH Retrovirology meeting, that shows that the σ and 
γ subunits of AP-1 bind to the Vpu ExxxLV motif while the YDY motif in tetherin binds 
to the µ subunit which in turn recruits the β subunit of the AP-1 complex.    
Therefore, in the presence of an intact ExxxLV motif, Vpu mediates the inhibition of 
transit of newly synthesised and/or recycling tetherin to the cell surface, its internal 
sequestration and targeting for endo/lysosomal degradation occuring via an AP-1-
dependent mechanism. In the absence of an intact ExxxLV motif, Vpu/tetherin 
complexes recycle via the plasma membrane dependent on the YxYxxV sorting motif in 
the tetherin cytoplasmic tail, which interacts with AP-2 and AP-1. During the recycling 
process, physical interaction of Vpu and/or modification by ubiquitin ligases, such as 
SCF-β-TrCP2, may further interfere with tetherin function to a variable degree in the 
absence of cell-surface downregulation (Figure 7-1).  
 
 
Figure 7-1 Unified mechanistic model of tetherin antagonism by HIV-1 Vpu 
Newly synthesised tetherin molecules reach the plasma membrane by using the secretory pathway. At the 
plasma membrane tetherin incorporates into viral particles or recycles constitutively via early/sorting 
endosomal compartments and the TGN. Vpu interacts with recycling tetherin in the TGN (and with newly 
synthesised tetherin molceules perhaps earlier) through transmembrane domain-mediated interactions. 
Vpu/tetherin complexes are targeted to early endosomal compartments by a clathrin-dependent transport 
mechanism. During this process, physical interaction of Vpu and/or modification by ubiquitin ligases, such 
as SCF-β-TrCP2, lead to ubiquitination of tetherin on multiple cytoplasmic tail residues. In early/recycling 
endosomes ubiquitin-dependent recruitment of HRS promotes sorting of Vpu/tetherin complexes for 
ESCRT-dependent degradation in lysosomes. In the absence of an ExxxLV motif, Vpu/tetherin complexes 
recycle via the PM, which is dependent on the YxYxxφ  sorting sequence in the tetherin cytoplasmic tail 
that interacts with AP-2 and AP-1. Blue arrows indicate normal tetherin recycling; black arrows indicate 
Vpu-mediated tetherin transport for ultimate degradation; and red bars indicate Vpu mutations or siRNA 
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In Chapter 5, we have identified a role for the ESCRT-I component UBAP1 in Vpu-
mediated tetherin degradation (Figure 7-1). However, degradation per se is 
dispensable for Vpu-induced anti-tetherin activity. Furthermore, we have identified 
naturally occurring hydrophobic residues in the first alpha helix of the cytoplasmic tail of 
the HIV-1 NL4.3 Vpu, LI 41/42 AA LI 45/46 AA, which are required for the antagonism 
of tetherin restriction. Mutation of these residues blocks the ability of Vpu to mediate 
tetherin surface downregulation and induce ESCRT-dependent degradation of tetherin. 
Vpu LILI mutants retain the ability to interact with tetherin and to recruit the ubiquitin 
ligase SCF-β-TrCP2 complex. Interestingly, Vpu LILI mutants pheno-copy the cellular 
localisation of trafficking mutants, in which they localise to early/recycling endosomal 
structures and the plasma membrane rather than the TGN. 
Taking all data together, we propose the following model for Vpu-mediated ESCRT-
dependent tetherin and/or target protein degradation (Figure 7-2A): HIV-1 Vpu binds to 
its target designated for lysosomal degradation, where the target protein can be 
tetherin or an yet unidentified cellular interaction partner. Vpu induces ubiquitination of 
its target by β-TrCP2, and potentially by another to date unknown ubiquitin ligase. The 
Vpu/target protein complexes are shuttled to endosomal compartments where the 
ubiquitinated target membrane protein interacts with ESCRT-0 component HRS via the 
double ubiquitin-binding motif (DUIM) in the HRS cytoplasmic tail. Clathrin and HRS 
form a matrix, which allows the trapping and concentrating of ubiquitinated 
transmembrane proteins on the surface of recycling/sorting endosomes. ESCRT-I, 
including the newly identified subunit UBAP1, and ESCRT-II and -III complexes are 
then sequentially recruited, delivering Vpu/target complexes to the intracellular lumen 
of late endosomal structures also called multivesicular bodies, which in turn fuse to 







Figure 7-2 Model for Vpu-mediated ESCRT-dependent tetherin degradation  
HIV-1 Vpu binds to its target (tetherin or potentially other proteins) designated for lysosomal degradation, 
the target protein could be tetherin or a unidentified cellular interaction partner. Vpu induces ubiquitination 
of its target by β-TrCP2 and potentially another to date unknown ubiquitin ligase. The Vpu/target protein 
complexes are shuttled to endosomal compartments where the ubiquitinated target membrane protein 
interacts with ESCRT-0 component HRS via the double ubiquitin-binding motif (DUIM) in the HRS 
cytoplasmic tail. ESCRT-I, -II and -III complexes are being sequentially recruited, delivering Vpu/target 
complexes to the intracellular lumen of late endosomal structures also called multivesicular bodies (MVBs) 



















Vpu ELV, LILI and 2/6A cytoplasmic tail mutants predominately localise to punctate 
structures within the cytoplasm, which are most likely early/recycling endosomal 
compartments. Therefore, Vpu LILI and Vpu 2/6A mutants pheno-copy the localisation 
defect of Vpu ELV mutants that are unable to bind the clathrin adaptor AP-1. We 
consequently asked the question if Vpu LILI and Vpu 2/6A mutants are also defective 
for clathrin adaptor binding. In Chapter 6, we were able to functionally substitute Vpu 
LILI, 2/6A and ELV mutants. By fusing a clathrin-binding motif to the C-terminus of 
these mutants we were able to rescue infectious virus particle release in a clathrin-
dependent manner, as well as tetherin cell surface downregulation. Interestingly in 
case of the Vpu 2/6A clathrin-binding motif chimera we were able to rescue anti-
tetherin function in the absence of recruitment of the SCF-β-TrCP E3 ubiquitin ligase 
complex. We concluded from this data that Vpu ELV, LILI and 2/6A mutants are 
defective for the same reason, which is that they fail to induce binding to the cellular 
clathrin adaptor machinery.  
Viral proteins, including HIV-1 Vpu, often target numerous cellular factors. A diversified 
set of protein conformational subpopulations is required for productive interaction with 
multiple targets. Since there is no full-length crystal structure of Vpu, Vpu/tetherin 
complexes, or Vpu in combination with cellular binding partners it is difficult to predict 
the conformation of the cytoplasmic tail. However, Vpu conformation might adapt for 
interactions with various cellular proteins. The Vpu cytoplasmic tail exhibits a certain 
degree of structural flexibility in NMR studies (Wittlich et al., 2009), which lead us to 
propose the following hypothesis: In a closed confirmation, the second alpha helix 
ExxxLV motif is embedded within the tertiary structure. The conserved W at amino acid 
position 76 (Pickering et al., 2014) (Jafari et al., 2014) folds back and interacts with 
acidic residues within the DSGNES motif, to keep the cytoplasmic tail locked in an 
auto-inhibited position. However, upon phosphorylation; change in cellular 
environment, for example pH; or binding to tetherin or a cellular binding partner, Vpu 
undergoes a conformational change and adapts an open configuration in which the 
ExxxLV motif is accessible to bind AP-1 (Figure 7-3). Mutations within the LILI and 
DSGNES motifs or the conserved W interfere with tertiary structural rearrangements 
and render Vpu defective in tetherin counteraction. 
 
 




Currently, we are planning a series of experiments that will help us to understand the 
impact of phosphorylation on cytoplasmic tail rearrangements. To this end, we are 
planning to make use of the Vpu cytoplasmic tail mutant clathrin-binding box chimeras. 
If our hypothesis is true, CKII phosphorylation inhibitors will affect Vpu wild-type ability 
to counteract tetherin, but not Vpu wild-type clathrin-binding box equivalent, as this 
construct is able to link Vpu to the clathrin machinery directly without having to undergo 
a conformational change. Furthermore, CKII inhibitors will abrogate binding of wild-type 
Vpu to AP-1 in BioID pull-down assays.  
 
 
Figure 7-3 Does serine phosphorylation expose the ExxxLV motif? 
(A) NL4.3 Vpu amino acid sequence. Highlighted are conserved motifs within the cytoplasmic tail that are 
required for tetherin antagonism. (B) Structure of the Vpu CT in the presence of membrane simulating 
dodecylphosphatidylcholine (DPC) micelles obtained by high-resolution liquid state NMR adapted from 
(Wittlich et al., 2009). (C) Structure of the Vpu CT in aqueous buffer obtained by high-resolution liquid state 
NMR adapted from (Wittlich et al., 2009). Highlighted and colour-coordinated are motifs from (A) (images 
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A Cytoplasmic Tail Determinant in HIV-1 Vpu Mediates
Targeting of Tetherin for Endosomal Degradation and
Counteracts Interferon-Induced Restriction
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Abstract
The HIV-1 accessory protein Vpu counteracts tetherin (BST-2/CD317) by preventing its incorporation into virions, reducing
its surface expression, and ultimately promoting its degradation. Here we characterize a putative trafficking motif, EXXXLV,
in the second alpha helix of the subtype-B Vpu cytoplasmic tail as being required for efficient tetherin antagonism. Mutation
of this motif prevents ESCRT-dependent degradation of tetherin/Vpu complexes, tetherin cell surface downregulation, but
not its physical interaction with Vpu. Importantly, this motif is required for efficient cell-free virion release from CD4+ T cells,
particularly after their exposure to type-1 interferon, indicating that the ability to reduce surface tetherin levels and promote
its degradation is important to counteract restriction under conditions that the virus likely encounters in vivo. Vpu EXXXLV
mutants accumulate with tetherin at the cell surface and in endosomal compartments, but retain the ability to bind both b-
TrCP2 and HRS, indicating that this motif is required for a post-binding trafficking event that commits tetherin for ESCRT-
dependent degradation and prevents its transit to the plasma membrane and viral budding zones. We further found that
while Vpu function is dependent on clathrin, and the entire second alpha helix of the Vpu tail can be functionally
complemented by a clathrin adaptor binding peptide derived from HIV-1 Nef, none of the canonical clathrin adaptors nor
retromer are required for this process. Finally we show that residual activity of Vpu EXXXLV mutants requires an intact
endocytic motif in tetherin, suggesting that physical association of Vpu with tetherin during its recycling may be sufficient
to compromise tetherin activity to some degree.
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Introduction
The downregulation of cell-surface immunomodulatory pro-
teins is a common theme in the evasion of innate and adaptive
immune responses by mammalian viruses. One host molecule
targeted by diverse enveloped viruses is tetherin (CD317/BST-2),
an interferon-induced dimeric type-II membrane protein, which
inhibits the release of nascent virions from the cell surface [1,2]. By
virtue of an unusual topology that consists of an N-terminal
transmembrane domain and a C-terminal glycophosphatidylino-
sitol (GPI)-linkage separated by an extended parallel coiled-coil
domain [3–6], tetherin partitions into budding virus particles and
is thought to directly cross-link the nascent virion to the plasma
membrane (PM) [7]. Tethered virions may then be endocytosed
and degraded in endosomes. Tetherin itself constitutively recycles
between the PM, endosomal and trans-Golgi network (TGN)
compartments through a non-canonical trafficking motif (YX-
YXXV) in its N-terminal cytoplasmic tail, which engages clathrin
adaptors AP-1 and AP-2 [8,9]. Since tetherin targets a structural
component of the virion not encoded by the viral genome, namely
the host-cell derived membrane, its potential importance in the
innate antiviral response is highlighted by multiple examples of
virally-encoded countermeasures (reviewed in [10]).
The ability to counteract tetherin is conserved among human
and simian immunodeficiency viruses (HIVs/SIVs), although the
viral proteins tasked with this activity vary [10]. In HIV-1 the
accessory protein Vpu fulfills this role. Vpu, a small integral
membrane phosphoprotein, directly associates with tetherin
through interactions between the transmembrane domains of
both proteins [11–14]. Vpu blocks tetherin incorporation into
assembling virions [7] and leads to a reduction of tetherin levels on
the plasma membrane (PM) [2]. Subsequently, tetherin is
degraded, most likely in lysosomal compartments, by an
ubiquitin-dependent mechanism [15,16]. Phosphorylation of
Vpu on two conserved serine residues recruits a SCF b-TrCP1/
2 E3 ligase complex [17] that ubiquitinates the tetherin
cytoplasmic tail on multiple residues [18], and recent evidence
demonstrates that this tetherin degradation is dependent on the
ESCRT pathway [19]. However, tetherin degradation is not
strictly required for Vpu activity [20,21]. While recruitment of the
ESCRT-0 subunit HRS by Vpu counteracts tetherin activity [19],
a novel core component of ESCRT-1, Ubiquitin Associated
Protein 1 (UBAP1), essential for tetherin degradation induced by
both Vpu and the KSHV ubiquitin ligase K5, is dispensable [22].
Coupled with recent evidence that dysregulation of the entire late
endosomal compartment by mutants of Rab7a [23], this suggests
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an emerging picture that Vpu alters tetherin trafficking to
counteract its antiviral activity prior to lysosomal delivery. While
HIV-2 and SIV tetherin antagonists Env and Nef promote
tetherin internalization through their interactions with AP-2, [24–
26], Vpu does not enhance the rate of tetherin endocytosis
[13,16]. Rather it is thought that Vpu/tetherin interactions
preclude both the recycling of tetherin back to the cell surface
and the transit of newly synthesized tetherin to the PM by trapping
it in intracellular compartments, notably the TGN [13].
Consistent with this, the ability of Vpu to localize to the TGN
correlates with tetherin antagonism [27], and disruption of the
recycling compartment by a dominant Rab11a mutant compro-
mises Vpu activity [28]. Truncations of the Vpu cytoplasmic tail,
particularly the second alpha helix, lead to aberrant localization
and a reduction in its anti-tetherin activity, suggesting it harbors a
domain required for Vpu function [29].
In this study we have examined the role of the second alpha
helix of HIV-1 Vpu in tetherin antagonism. We identify a putative
sorting signal that is required for post-binding trafficking of Vpu/
tetherin complexes and inhibition of antiviral activity in primary
CD4+ T cells. While this signal can be functionally replaced by a
clathrin adaptor binding peptide derived form HIV-1 Nef, Vpu
activity does not require the canonical adaptors AP-1, AP-2 or AP-
3. Moreover, because residual activity of second helix mutants
requires an intact recycling signal in tetherin, we propose that
second alpha helix mutants are selectively defective for routing
tetherin into an endosomal degradation pathway thereby inhib-
iting its transit to the PM and incorporation into nascent virions.
Results
Determinants of tetherin inactivation in the second alpha
helix of the Vpu cytoplasmic tail
Truncations of the Vpu cytoplasmic tail lead to aberrant
localization and a reduction in its anti-tetherin activity [29]. To
further study the determinants within the second alpha helix of
Vpu that account for TGN localization, we performed overlap-
ping triple-alanine scan mutagenesis through the second alpha
helix of a codon optimized HIV-1 NL4.3 Vpu construct bearing a
C-terminal HA tag (Figure 1A). We then assayed these Vpu
mutants for their ability to rescue Vpu-defective HIV-1 from
tetherin restriction. 293T cells were transfected with wildtype
HIV-1 (HIV-1 wt) or Vpu defective HIV-1 (HIV-1 delVpu)
proviruses in combination with fixed doses of a human tetherin
expression vector, and 25 ng of Vpu-HA or mutant thereof. 48 h
after transfection cell lysates and supernatants were harvested and
analyzed for physical viral yield by Western blot (Figure 1B) or
supernatant infectivity of HeLa-TZMbl indicator cells (Figure 1C).
As expected, in the absence of Vpu, both supernatant particle yield
and infectivity of HIV-1 delVpu was profoundly reduced in the
presence of tetherin, expression of Vpu in trans rescued virus
production to wildtype levels. By contrast mutations encompassing
either E59 or L63 and V64 but not the intervening or subsequent
amino acids displayed defective rescue of HIV-1 delVpu (Figure 1B
and C). All Vpu mutants with the exception of Vpu 67-69A-HA
were expressed equivalently. Vpu 63-65A-HA appeared to display
a dominant interfering activity on HIV-1wt titer, but this was not
reflected as apparently in particle yield. Thus these data suggested
a functional requirement for E59 and L63/V64 in tetherin
antagonism by Vpu. To confirm this we mutated these residues to
alanine in the context of an HIV-1 NL4.3 provirus (NL4.3 Vpu
ELV) and examined viral release from 293T cells in the presence
of increasing expression of tetherin. Because this part of Vpu
overlaps with start of the Env open reading frame in the provirus,
these mutations were rendered silent in the +1 reading frame and
displayed no defect in virus release in the absence of tetherin
(Figure 1D and E). In agreement with the virus rescue in trans,
NL4.3 Vpu ELV release was markedly defective in the presence of
increasing tetherin doses, although it did display a residual
antagonism of tetherin when compared to the full Vpu-defective
deletion (Figure 1D and E).
We next examined the phenotypic basis for the defect in tetherin
antagonism by Vpu ELV. Vpu stimulates the ubiquitin-dependent
degradation of tetherin, most likely in lysozomal compartments. We
infected HT1080 cells stably expressing human tetherin bearing an
HA-tag in the extracellular domain (HT1080/tetherin-HA) with
VSV-G-pseudotyped HIV-1 wt, HIV-1 delVpu or HIV-1 Vpu
ELV at an MOI of 2 to ensure .90% cell infection. 48 h later the
cells were lysed and Western blotting performed for relative
tetherin-HA levels (Figure 2A). As expected, cells infected with
HIV-1 wt showed reduced steady state levels of tetherin that was not
apparent in those infected with HIV-1 delVpu. Similarly, in cells
infected with HIV-1 Vpu ELV there was no evidence of tetherin
degradation, but interestingly there appeared to be enhanced levels
of tetherin, perhaps suggesting stabilization of the protein in the
presence of the mutant Vpu. Thus E59, L63, V64 mutations abolish
the ability of Vpu to induce tetherin degradation. Since this
degradation is dependent on Vpu binding to b-TrCP2 via a
phosphorylated pair of serines (S52 and S56) [16,17,30], we tested
whether Vpu ELV mutants were defective for interaction with b-
TrCP2 in co-immunoprecipitations from transfected cells
(Figure 2B). b-TrCP2 was co-immunoprecipitated with Vpu-HA
and Vpu ELV-HA, but as expected, not the phospho-mutant Vpu
2/6-HA, ruling out this defect in Vpu ELV.
Recent data suggests that ESCRT-mediated degradation of
tetherin in the presence of Vpu is mediated by interaction of Vpu
with HRS (ESCRT-0) [19]. We could further show that both Vpu
and Vpu ELV also co-precipitated with HA-HRS from transfected
293T cells (Figure 2C) indicating that an inability to recruit
ESCRT-0 does not explain the defect in Vpu ELV-mediated
degradation of tetherin.
Author Summary
Tetherin inhibits the release of several diverse enveloped
viruses from infected cells and is counteracted by the HIV-
1 accessory gene Vpu. Vpu prevents tetherin’s incorpora-
tion into nascent viral particles, promotes its downregu-
lation from the cell surface and targets tetherin for
degradation. Here we identify a determinant that resem-
bles an acidic-dileucine-based sorting sequence in the Vpu
cytoplasmic tail that is required for efficient counteraction
of tetherin activity, particularly in CD4+ T cells treated with
type-1 interferon. Mutation of this motif prevents cell-
surface downregulation and degradation of Vpu/tetherin
complexes but does not affect their interaction. Rather, in
its absence, Vpu accumulates in early endosomes and at
the cell surface where it becomes incorporated into
assembling virions with tetherin, indicating that this motif
modulates sub-cellular trafficking of tetherin. Furthermore
Vpu activity is clathrin-dependent and can be reconstitut-
ed by replacing a portion of the cytoplasmic tail
encompassing this motif with one derived from HIV-1
Nef that is known to bind several clathrin adaptors. Finally,
we demonstrate that residual function of the mutant Vpu
requires a trafficking motif in tetherin, suggesting that
physical interaction of tetherin with Vpu during its
recycling to the cell-surface can interfere with its function
to a variable extent.
A Trafficking Motif for Vpu/Tetherin Complexes
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Figure 1. E59, L63 and V64 in the second alpha helix of the Vpu cytoplasmic tail are required to efficiently counteract tetherin. (A)
Schematic representation of alanine scan mutagenesis in the second alpha helix of the codon-optimized HIV-1 NL4.3 Vpu protein. (B) 293T cells were
transfected with NL4.3 wt or NL4.3 delVpu proviruses in combination with tetherin and the indicated pCR3.1 Vpu-HA expression vectors. 48 h post
transfection, cell lysates and pelleted supernatant virions were harvested and subjected to SDS-PAGE and analyzed by Western blotting for HIV-1
p24CA, Vpu-HA and Hsp90 serving as loading control, and analyzed by LiCor quantitative imager. (C) Viral supernatants from B were assayed for
infectivity using HeLa-TZMbl reporter cells. Infectious virus release is plotted on a log scale as b-galactosidase activity in relative light units (RLU). Error
bars represent standard deviations of the means of three independent experiments. (D) E59A, L63A and V64A mutations were inserted into the vpu
gene of the NL4.3 provirus referred to as NL4.3 Vpu ELV. 293T cells were transfected with NL4.3 wt, NL4.3 delVpu or NL4.3 Vpu ELV proviral plasmids
together with increasing doses of tetherin expression vector. The resulting infectivity was determined as in C, error bars represent standard
deviations of the means of three independent experiments. (E) Cell lysates and pelleted viral supernatants from 0 ng and 100 ng tetherin input from
D were subjected to SDS-PAGE and analyzed by Western blotting for HIV-1 p24CA and Hsp90, and analyzed by LiCor quantitative imager.
doi:10.1371/journal.ppat.1002609.g001
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We then examined the ability of Vpu ELV mutants to
downregulate surface tetherin levels. We first transfected HeLa
cells (that express tetherin constitutively) with Vpu-HA expression
vectors in combination with a GFP reporter. 48 h later surface
tetherin was assayed by flow cytometry in the GFP positive cells
(Figure 2D). As expected, wildtype Vpu expression reduced cell
surface tetherin levels. Vpu mutants bearing E59A, LV63,64A
mutations, or the full ELV mutant all displayed a reduced capacity
to downregulate surface tetherin levels (Figure 2D and S1A). To
confirm this in a relevant cell-type, we then infected CD4 positive
Jurkat T cells with HIV-1 wt, HIV-1 delVpu, HIV-1 Vpu ELV or
HIV-1 Vpu 2/6A. 48 h later, the cells were stained for surface
tetherin and co-stained for intracellular p24CA as a marker of
infection (Figure 2E). To discriminate between truly infected cells,
and those that acquired p24+ debris by exposure of cells to high
titre (MOI 1) of viral inoculum, we compared to cells exposed to
virus in the presence of 50 mM AZT (Figure S1C). Cultures
infected with HIV-1 wt showed clear downregulation of tetherin
on the surface of p24CA positive cells. By contrast, tetherin was
not downregulated from the surface of either HIV-1 delVpu, HIV-
1 Vpu 2/6A or HIV-1 Vpu ELV infected cells. Rather, tetherin
levels were raised on some infected cells, perhaps reflecting
accumulation of tethered virions on the cell surface. A similar
result was observed for HeLa cells infected with the same viral
stocks (Figure S1B), although in this case we could detect no
enhanced tetherin surface expression on cells infected with Vpu
Figure 2. Vpu ELV mutants are defective for tetherin degradation and cell-surface downregulation. (A) HT1080 cells stably expressing
tetherin-HA were infected with VSV-G-pseudotyped HIV-1 wt, HIV-1 delVpu or HIV-1 Vpu ELV at an MOI of 2. 48 h post infection, cells were harvested
and subjected to SDS-PAGE and analyzed by Western blotting for tetherin-HA, Vpu and Hsp90, and analyzed by LiCor quantitative imager. Relative
tetherin-HA levels are indicated below each lane. The blot shown is a representative example of 3 independent experiments. (B) 293T cells were
transfected with pCR3.1 Vpu-HA, Vpu 2/6A-HA, or Vpu ELV-HA in combination with pCR3.1 myc-b-TrCP2. 48 h post transfection, cells were lysed and
immunoprecipitated with anti-HA antibody. Lysates and precipitates were subjected to SDS-PAGE and analyzed by Western blotting for Vpu and
myc-b-TrCP2, and analyzed by ImageQuant. The star represents an unspecific band. (C) Similarly, 293T cells were transfected with pCR3.1 HA-HRS in
combination with Vpu-GFP or Vpu ELV-GFP expression constructs. Cell lysates were precipitated with an anti-HA antibody and analyzed as in C. (D)
HeLa cells were co-transfected with pCR3.1 Vpu-HA or indicated Vpu mutant in combination with a GFP expression construct. Cell surface staining for
endogenous tetherin was analyzed by flow cytometry 48 h post transfection. GFP positive cells were gated and tetherin levels (solid lines) were
compared to those of untransfected HeLa cells (dotted lines). Numbers indicate median fluorescence intensities of surface tetherin on transfected
cells. The solid peak in the upper middle histogram represents the binding of the isotype control. (E) Jurkat cells were infected with VSV-G-
pseudotyped HIV-1 wt, HIV-1 delVpu, HIV-1 Vpu ELV or HIV-1 Vpu 2/6A at an MOI of 1. 48 h post infection, cells were stained for cell surface tetherin
and intracellular p24CA, and analyzed by flow cytometry. Productively infected cells were identified by comparing with culture infected with the
same MOI in the presence of 50 mM AZT to control for p24CA uptake of the inoculum (Figure S1C).
doi:10.1371/journal.ppat.1002609.g002
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mutants, likely due to their endocytic removal from the cell surface
[31].
Vpu ELV mutants localize to early endosomal
compartments and the cell surface
The E59XXXL63V64 motif in Vpu resembles an acidic
dileucine sorting signal (D/E)XXXL(L/I/M/V) found in the
cytoplasmic tails of membrane proteins that traffic through
endosomal compartments (reviewed in [32]). We therefore
addressed whether mutation of this motif affected Vpu subcellular
localization. To this end we infected 293T expressing tetherin or
not, as well as Jurkat and HeLa cells with VSV-G-pseudotyped
HIV-1 NL4.3 and NL4.3 Vpu ELV and stained them for Vpu in
combination with several subcellular markers 48 h later. As
expected, in all cells, the predominant localization of wildtype
Vpu was in association with the TGN, with between 20–50% of
the Vpu immunoreactivity visible in TGN46+ compartments
(Figure 3A–D). The proportion of the Vpu ELV mutant in
TGN46+ compartments was significantly reduced in 293T/
tetherin, Jurkat and HeLa, and appeared as ‘‘endosome-like’’
puncta in the cytoplasm and associated on or near the plasma
membrane (Figure 3A–C and E). Interestingly in the parental
293T cells, which lack tetherin expression, Vpu and Vpu ELV
localization was indistinguishable, and predominantly associated
with TGN46+ compartments (Figure 3D and E). Thus the
difference in Vpu ELV localization appeared to be tetherin-
dependent. The nature of these extra-TGN compartments was
further analyzed in HeLa cells and revealed that Vpu ELV
accumulated in EEA1+ early/sorting endosomal compartments,
but not CD63+ late endosomes (Figure 3F). Thus mutation of the
EXXXLV motif leads to endosomal and surface localization of
Vpu consistent with it being required for modulating the
trafficking of tetherin.
Vpu ELV mutants interact with tetherin in infected cells
and are incorporated into nascent virions in a tetherin-
dependent manner
As a putative trafficking signal, the EXXXLV motif may exert
its effect on tetherin antagonism in two ways. Firstly, the
sequence may be required to permit Vpu to traffic to a
compartment where it can interact with tetherin; secondly, the
sequence may be required for post-interaction trafficking of
Vpu/tetherin complexes such that tetherin is not incorporated
into budding virions and expression on the cell surface is
reduced. A potential confounding factor in investigating however
is that wildtype Vpu induces tetherin degradation, while Vpu
ELV does not. Whilst a Vpu 2/6 control maybe applicable,
controversies surrounding the nature of its phenotype in terms of
tetherin counteraction also make it problematic. To alleviate
these issues, we took advantage of our recent observations with
novel ESCRT-I component, UBAP1 [22]. UBAP1 contains 3-
tandem ubiquitin-binding domains and is found in complex with
the core ESCRT-I components TSG101, VPS28 and VPS36.
However unlike them, UBAP1 is only required for ESCRT-
dependent endosomal degradation and not viral assembly or
cytokinesis [22,33]. Interestingly, UBAP1 is essential for both
Vpu and K5-mediated degradation of tetherin, but is not
required for Vpu-mediated tetherin antagonism, implying that
commitment of tetherin into a degradative pathway by Vpu, but
not ESCRT-I function itself, counteracts tetherin activity [22].
We therefore first examined whether Vpu or Vpu ELV
interacted with tetherin in immunoprecipitations in the presence
or absence of siRNA-mediated silencing of UBAP1 by quanti-
tative Western blotting (Figure 4A). 293T/tetherin cells were
transfected twice over 48 h with either UBAP1 or control
siRNA, before being infected with HIV-1 wt, HIV-1 Vpu ELV,
HIV-1 delVpu, or HIV-1 Vpu A14L/W22A that contains a Vpu
transmembrane mutation that abolishes tetherin interaction
[14]. As expected, while tetherin levels were reduced in HIV-1
wt infected cells, they were unaffected by Vpu-defective or
A14L/W22A mutants and, as in Figure 2, stabilized in cells
infected with the Vpu ELV mutant. Furthermore, as expected,
UBAP1 siRNA treatment rescued tetherin levels from Vpu-
mediated degradation, but also further enhanced total cellular
levels of tetherin [22] consistent with the known role of ESCRT
in tetherin’s natural turnover [19]. Interestingly, UBAP1 siRNA
also enhanced the total cellular content of wildtype Vpu to that
of the Vpu ELV mutant (approximately 4–5 fold). Immunopre-
cipitation of tetherin from the lysates from these cells revealed a
similar picture. Wildtype Vpu was detected associated with
residual tetherin precipitated from cells, and this was markedly
increased upon UBAP1 knockdown. This data strongly suggests
that Vpu itself may be co-degraded with tetherin in endosomal
compartments. The Vpu ELV mutant efficiently co-precipitated
with tetherin irrespective of UBAP1 knockdown, and as expected
the A14L/W22A failed to co-precipitate under either condition.
Interestingly, however, the ratio of relative band intensities
between of Vpu or Vpu ELV precipitated with tetherin in the
presence UBAP1 siRNA was equivalent, indicating that Vpu
ELV was not defective for physical tetherin interaction,
suggesting that the Vpu ELV mutant’s defect in tetherin
antagonism is due to an inability to mediate post-binding
trafficking of Vpu/tetherin complexes into an ESCRT-depen-
dent pathway in which both proteins are degraded. Consistent
with this notion, Vpu ELV co-localized with tetherin in infected
HeLa and 293T/tetherin, both in peripheral endosomal
structures and at the cell surface (Figure 4B). By contrast, the
little tetherin visible in cells infected with wildtype virus co-
localized with Vpu in perinuclear areas.
Vpu is not a constituent of HIV-1 particles. We therefore
reasoned that if the EXXXLV motif was required to prevent
tetherin trafficking to viral budding sites and commit it for
degradation, interaction with tetherin itself might lead to Vpu
ELV mutant accumulation in nascent viral particles. To test this
hypothesis we took advantage of a tetherin mutant lacking its GPI
anchor (tetherin-delGPI), which despite its high surface expression,
does not restrict virus particle release, but accumulates in virus
particles and is sensitive to Vpu [7]. 293T/tetherin-delGPI cells
were mock-transfected or transfected with NL4.3 wt, NL4.3 Vpu
ELV, and NL4.3 delVpu. 48 h later cell supernatants were
centrifuged through a sucrose cushion and analyzed for tetherin
incorporation (Figure 4C and D). As expected, high levels of
tetherin-delGPI could be detected in NL4.3 delVpu viral pellets,
but not in pelleted supernatants from mock-transfected cells.
Tetherin-delGPI incorporation was reduced in the wildtype virus
consistent with tetherin removal from the cell surface. The level of
tetherin incorporation in NL4.3 Vpu ELV particles was similar to
that of the Vpu-defective mutant. Interestingly, NL4.3 Vpu ELV
particles contained detectable levels of Vpu (in this case Vpu
appears as a doublet band which we suggest may be due to
exposure to active HIV-1 protease in the particle). By contrast, no
Vpu was detectable in any viral particles derived from 293T cells,
indicating that Vpu ELV incorporation into viral particles was
tetherin-dependent. Taken together these data indicate that the
EXXXLV motif is required for efficient tetherin antagonism, by
modulating the trafficking of tetherin such that it cannot become
efficiently incorporated into nascent viral particles.
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The second alpha helix of Vpu can be complemented by
a D/EXXXLL-containing peptide derived from HIV-1 Nef
Acidic-dileucine based sorting signals, D/EXXXL(L/I), act as
binding sites for a hemicomplex of sigma and adaptin subunits of
the canonical clathrin adaptors AP-1, AP-2 and AP-3, and are
required for endocytic and endosomal/Golgi trafficking of these
proteins [32]. While the requirement for the acidic and first
leucine residues are absolute, the third position is less well
conserved, and can be L, I or on occasion V or M. Analysis of the
cytoplasmic tails of Vpu sequences from most clades of HIV-1
group M, show that a putative EXXXL(V/M/I) is well conserved
in the second alpha helix (Figure S2A). In contrast to other HIV-1
subgroups, Clade C and F isolates have an EXXXLL motif
juxtaposed to the plasma membrane in helix 1 (not shown), which
has been previously suggested to be a determinant of Clade C Vpu
localization to the PM [34]. In subgroup B, the V64 position is
usually V or M, although occasional I or L residues are found at
this position. We mutated position 64 to M, L or I in NL4.3 Vpu
and found no defect in these proteins’ ability to counteract or
downregulate tetherin from the surface (Figure S2B and S2C), in
agreement with the above data demonstrating that this position is
the least important of the three, and consistent with the role of this
motif as a sorting signal.
The Nef proteins of primate immunodeficiency viruses are also
multifunctional adaptor proteins, targeting a variety of immuno-
regulatory cell surface molecules for downregulation and degra-
dation [35]. Nef interacts promiscuously with AP-1, AP-2 and AP-
3 through a conserved C-terminal EXXXLL motif [36,37]. The
interaction of AP-2 with this site is essential for Nef targeting of
CD4 for ESCRT-dependent lysozomal degradation [37], but Nef-
mediated downmodulation of Class I MHC molecules requires
AP-1 [38]. Importantly several SIV Nef proteins are also tetherin
antagonists [39,40] and again this is dependent on the EXXXLL
motif [26]. We therefore asked whether the C-terminus of HIV-1
Vpu could be functionally substituted with a known AP-binding
site from these proteins. The EVSALV motif of NL4.3 Vpu was
first replaced with the core AP-binding site from NL4.3 Nef,
ENTSLL (Figure 5A). Since this is similar to sites already tested in
the previous experiment shown in Figure S2, this Vpu was as
functional as the wildtype protein in virus rescue experiments
(Figure 5B and C). We then replaced the entire cytoplasmic tail of
Vpu from residue 58 with a 19 amino acid stretch derived from
Nef including the ENTSLL and a downstream dual-aspartic acid
motif that has been previously shown to stabilize AP-2 interactions
[41]. Remarkably, the Vpu/Nef chimeric protein substantially
recovered tetherin antagonistic activity (Figure 5B and C).
Moreover, this chimera also displayed improved tetherin down-
regulation from the surface of transfected HeLa cells (Figure 5D).
This activity was entirely dependent on the key amino acids
required for AP-interaction as a chimera in which E, LL and DD
positions were mutated to alanine was unable to counteract
tetherin or downregulate it from the surface (Figure 5B–D).
Examination of the subcellular distribution of Vpu-Nef or the
mutant fused to CherryFP suggested that the mutant was localized
more prominently to the PM consistent with a defect in trafficking
imparted by the mutation (Figure 5E). Thus Vpu function can be
substantially recovered by replacing its entire second alpha helix
with a promiscuous AP-binding (D/E)XXXL(L/I) sorting signal,
indicating that linking Vpu directly to the clathrin trafficking
machinery can restore its activity in absence of the second alpha
helix.
Tetherin antagonism by Vpu is clathrin-dependent, but
independent of canonical adaptor proteins that bind
acidic di-leucine motifs
The implication of putative clathrin adaptor sites in Vpu-
mediated tetherin antagonism led us to test whether inhibition of
clathrin function inhibits Vpu activity. Overexpression of the C-
terminal fragment of the neuronal adaptor AP180 (AP180c) that
inhibits clathrin/membrane interactions [42], which was recently
shown to inhibit tetherin downregulation from the surface [43],
specifically blocked Vpu-dependent particle release of HIV-1 wt
from 293T cells expressing tetherin (Figure 6A), indicating
clathrin-dependent subcellular trafficking is essential for Vpu
activity. Infectious yield could not be determined in this
experiment because AP180c overexpression inhibits envelope
processing and blocks clathrin incorporation into particles, which
has been shown to play a role in retroviral particle infectivity
[44,45]. Interestingly AP180c expression, like UBAP1 siRNA
treatment, enhanced total Vpu expression levels, indicating
clathrin-dependent transport is involved in the turnover of Vpu.
Visualization of Vpu-YFP localization in 293T/tetherin cells
overexpressing AP180c showed vesicular rather than peri-nuclear
localization similar to that seen in the same cells infected with
HIV-1 Vpu ELV (Figure 6B), and this was not apparent in the
parental (tetherin negative) 293T cells, suggesting again this
difference was driven by interaction with tetherin.
The similarities between the EXXXLV motif and acidic
dileucine sorting signals, and its functional replacement with the
promiscuous ENTSLL motif in HIV-1 Nef led us to test whether
the major known adaptors involved in trafficking of membrane
proteins between the PM, endosomes and Golgi compartments
were required for Vpu-mediated tetherin antagonism. Clathrin-
mediated endocytosis requires AP-2, whereas AP-3 controls early-
to-late endosomal/lysosomal trafficking. AP-1 plays a role in
trafficking of cargo between early endosomes and the TGN, with
evidence that it can function in either direction [32]. To this end
we examined the effects of siRNA-mediated silencing of AP-1 (AP-
1c1), AP-2 (AP-2m1), AP-3 (AP-3m1/AP-3d1). Depletion of AP-2
by RNAi in 293T/tetherin cells had only minor effects on Vpu-
dependent virus particle release, suggesting that unlike SIV Nef
and HIV-2 Env, and consistent with the reports that Vpu does not
enhance tetherin endocytosis, AP-2 activity is dispensable for Vpu-
mediated tetherin antagonism (Figure 6C). Similarly AP-3m1/AP-
3d1 depletion had no detectable effect on tetherin activity or Vpu-
mediated counteraction (Figure 6D). Furthermore, human tetherin
could also be downregulated from the surface of mouse fibroblasts
defective in AP-3d1 when transduced to express Vpu [46] (Figure
S3A). For AP-1, siRNA-mediated silencing was inefficient in 293T
(not shown). We therefore constructed a HeLa cell line containing
a doxycycline-inducible shRNA hairpin against AP-1c1. Induction
of this hairpin coupled with simultaneous depletion of AP-1c1 by
Figure 3. Vpu ELV mutants localize to early endosomal compartments in tetherin-expressing cells. 293T/tetherin (A), HeLa (B), Jurkat
(C) or parental 293T (D) were infected with HIV-1 wt or HIV-1 Vpu ELV at an MOI of 1. 48 h later the cells were fixed and stained for Vpu (green) and
the TGN marker TGN46 (red) and examined by confocal microscopy. Panels are of representative examples. (E) The percentage of the total Vpu
immunoreactivity localized to TGN46+ compartments was calculated for cells (n = 20) from A–D using the Leica Confocal Software. Results were
analyzed by unpaired 2-tailed t-test - ** P = 1028 or lower. (F) HeLa cells as in B were stained for Vpu (green) and the early endosomal marker EEA1 or
late endosomal marker CD63 (red).
doi:10.1371/journal.ppat.1002609.g003
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Figure 4. Vpu ELV interacts and colocalizes with tetherin, and is incorporated into nascent virions. (A) 293T/tetherin cells were
transfected twice over 48 h with siRNA oligonucleotide directed against UBAP1 or Non-targeting control. The cells were then infected with the
indicated virus at an MOI of 2. 48 h later cell lysates were immunoprecipitated with an anti-tetherin monoclonal antibody. Lysates and
immunoprecipitates were separated by SDS-PAGE and blotted for tetherin, UBAP1 or Vpu using LiCor quantitative Western blotting. Numbers under
the Vpu lanes of the cell lysate represent relative band intensities. The histogram below the IP represents the ratio of tetherin band intensity to that
of Vpu in the co-IP. (B) HeLa and 293T/tetherin cells were infected as in Figure 3 and stained for Vpu (green) and tetherin (red) and examined by
confocal microscopy. Adjacent histograms quantify the degree of co-localization of Vpu ELV and tetherin (Pearson’s Correlation Coefficient calculated
using ImageJ) for 20 individual cells. (C) and (D) 293T or 293T cells stably expressing tetherin delGPI were infected with HIV-1 wt, HIV-1 Vpu ELV or
HIV-1 delVpu at an MOI of 1. 48 h post infection, cells were harvested and viral supernatants were pelleted through a 20% sucrose cushion. Cells and
virions were subjected to SDS-PAGE and Western blotting for tetherin delGPI, Vpu, HIV-1 p24CA and Hsp90 and analyzed by LiCor quantitative
imager.
doi:10.1371/journal.ppat.1002609.g004
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Figure 5. The second alpha helix of Vpu can be functionally replaced by the D/EXXXLL endocytic signal from HIV-1 Nef. (A)
Schematic representation of Vpu ENTSLL and Vpu-Nef chimeric constructs. (B) 293T cells were transfected with NL4.3 wt of NL4.3 delVpu proviral
plasmids in combination with tetherin and indicated pCR3.1 Vpu-HA or Vpu-Nef-HA chimera. 48 h post transfection, cell lysates and pelleted
supernatant virions were harvested and subjected to SDS-PAGE and analyzed by Western blotting for HIV-1 p24CA, Vpu-HA and Hsp90, and analyzed
by LiCor quantitative imager. (C) Infectivity of viral supernatants from B was determined on HeLa-TZMbl cells as in Figure 1B. Error bars represent
standard deviation of three independent experiments. (D) HeLa cells were co-transfected with Vpu or indicated Vpu mutant and a GFP expression
construct. Cell surface staining for endogenous tetherin was analyzed by flow cytometry 48 h post transfection, as in Figure 2D. (E) HeLa cells were
transfected with Vpu-Nef or Vpu-Nef-mu CherryFP fusions (red) and counterstained for TGN46 (green) and DAPI (blue) and examined by confocal
microscopy.
doi:10.1371/journal.ppat.1002609.g005
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Figure 6. AP180c inhibits Vpu-mediated tetherin antagonism but AP-1, AP-2, AP-3 and retromer are dispensable. (A) 293T/tetherin
were transfected with NL4.3 wt or NL4.3 delVpu proviral plasmids in combination with either YFP or increasing doses of an AP180c expression vector.
48 h post transfection, cell lysates and pelleted supernatant virions were harvested and subjected to SDS-PAGE and analyzed by Western blotting for
HIV-1 p24CA, Vpu and Hsp90 serving as loading control, and analyzed by LiCor quantitative imager. (B) 293T or 293T/tetherin transfected with pCR3.1
Vpu-YFP with or without AP180c co-expression were fixed and imaged after 48 h (C) 293T cells stably expressing tetherin were transfected twice with
pooled control or AP-2m1 siRNAs and co-transfected with NL4.3 wt, NL4.3 delVpu or GFP expression vectors. Cell lysates and supernatants were
analyzed by Western blotting 48 h later as described in Figure 1B. (D) 293T cells stably expressing tetherin were transfected twice with pooled control
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oligonucleotide transfection led to approximately 95% knockdown
efficiency. This treatment had no specific effect on Vpu-dependent
virus particle yield in HeLa cells indicating that tetherin-
antagonism again was not compromised (Figure 6E), and
furthermore tetherin surface downregulation was not defective in
mouse AP-1c1a 2/2 fibroblasts (Figure S3B) [47].
Finally, we examined whether there was any role for the
retromer complex, in Vpu-mediated tetherin antagonism. Retro-
mer regulates retrieval and recycling of endosomal proteins to the
TGN and is known to act co-operatively or antagonistically with
AP-1 (reviewed in [48]). The retromer complex consists of several
sorting nexins (SNX), and a core complex containing cargo
binding component, Vps34, and two essential co-factors, Vps26
and Vps29. We performed siRNA-mediated knockdown of Vps26
(Figure 6F). At levels of knockdown that were sufficient to
relocalize the CD8-cation-independent mannose-6-phosphate
receptor (CD8-CI-M6PR) (Figure S3C), disruption of retromer
had no detectable effect of Vpu-mediated HIV-1 release from
293T/tetherin cells.
Taken together these data demonstrate that neither depletion of
individual cellular adaptor proteins known to bind to (D/
E)XXXL(L/I) motifs, nor disruption of retromer-mediated
endosome-to-TGN retrieval, were sufficient to recapitulate the
phenotype of the Vpu ELV mutant.
Residual function of Vpu ELV requires an intact recycling
signal in tetherin
Recent data suggests that Vpu blocks both the transit of de novo
synthesized tetherin to the cell surface as well as the recycling of
tetherin endocytosed from the plasma membrane, with the relative
importance of these processes currently a matter of debate.
Tetherin recycling requires a dual tyrosine YXYXXV motif in its
cytoplasmic tail that acts as a binding site for AP-2 (for
internalization) and AP-1 (for recycling via the Golgi) [8,9].
Mutation of this site enhances tetherin’s surface expression, but
has minor effects on its ability to restrict virus release or its
sensitivity to Vpu [11,13]. Given that the EXXXLV motif was
defective for post-binding inactivation of tetherin, but retained a
low residual activity against tetherin in transient transfection
assays, we asked whether Vpu ELV was differentially defective
against tetherin mutants bearing lesions in its own sorting
sequence. We infected 293T/tetherin and 293T/tetherin Y6,8A
cells with HIV-1 wt, HIV-1 delVpu and HIV-1 Vpu ELV at fixed
dose (MOI 1) and measured viral release 48 h later (Figure 7A and
B). Vpu-defective viral release was approximately 35-fold reduced
from 293T/tetherin cells compared to the wildtype virus, and as
expected NL4.3 Vpu ELV had an intermediate phenotype in this
assay (6 fold less release than wt). However, in 293T/tetherin
Y6,8A all residual antagonistic activity of Vpu ELV was abolished
with viral release equivalent to that of the Vpu-deleted virus. By
contrast the wildtype virus retained the majority of its anti-tetherin
activity. This again was not due to a defect of Vpu interaction with
tetherin, as immunoprecipitation of tetherin after UBAP1 siRNA
treatment demonstrated equivalent levels of Vpu and Vpu ELV
co-precipitation from both tetherin and tetherin Y6,8A expressing
cells (Figure 7C). Thus residual activity of Vpu ELV requires that
tetherin retains its capacity to recycle from the PM. These data
suggest that Vpu ELV is specifically defective in blocking tetherin
transit to the PM, implying that Vpu/tetherin complexes are re-
routed in a Golgi-associated compartment into a pathway that
ultimately results in tetherin’s endosomal destruction. In the
absence of the EXXXLV sequence, tetherin/Vpu ELV complexes
traffic to the PM. The residual activity of Vpu ELV therefore may
be reflective of steric inhibition of tetherin function.
The dominant-negative mutant of dynamin 2 (K44A) has also
been described to have an intermediate effect on tetherin
counteraction by Vpu, compared to the complete disruption of
HIV-2 Env function which, like SIV Nef, is dependent on AP-2
and endocytosis [43]. We transfected increasing doses of HA-
tagged dominant negative dynamin 2 or the wildtype protein
along with HIV-1 proviruses into 293T/tetherin and parental cells
(Figure S4A). In agreement with Lau et al [43] dominant negative
dynamin 2, but not equivalent levels of the wild type dynamin 2
partially blocked the release of wildtype HIV-1 (Figure S4A–D).
Furthermore dominant negative dynamin 2 expression levels in
these assays were sufficient to block transferrin uptake in parallel
cultures (Figure S4B). Interestingly dominant negative dynamin 2
also blocked residual Vpu ELV-mediated, and even the low level
Vpu-defective viral release proportionally (7X, 4X and 8X for
WT, Vpu-defective or Vpu ELV respectively), suggesting that this
effect was independent of the ELV motif. Given that dominant
negative dynamin 2 inhibits tetherin endocytosis [43], this data
suggests that its effect on restriction may be due more to the build
up of tetherin at the cell surface that cannot be turned over rather
than a direct effect on Vpu function itself.
Vpu ELV is defective for tetherin antagonism in CD4+ T
cells after treatment with type-1 interferon
The results presented hitherto have demonstrated a require-
ment for the Vpu ELV motif in counteracting tetherin in cells
stably expressing it or mutants thereof, and that its is required in
constitutively-expressing target cells such as Jurkat to reduce
surface tetherin levels. However some studies have cast doubt as to
whether tetherin degradation and/or surface reduction is essential
for Vpu function. Furthermore, in contrast to 293T/tetherin,
release of HIV-1 Vpu ELV from HeLa was only 3-fold less
efficient than wildtype in one round release (Figure S5). We
therefore explored whether there was a requirement for the ELV
motif in HIV-1 release from physiologically relevant target cells,
namely Jurkat or primary human CD4+ T cells, particularly after
treatment with type-1 interferon. Infection of Jurkat at an MOI of
1 resulted in a partial defect in release of the HIV-1 Vpu ELV
mutant compared to the controls (Figure 8A and B). However
induction of higher tetherin expression by overnight treatment
with universal type-1 interferon effectively reduced HIV-1 Vpu
ELV particle release to levels similar to that of the Vpu-defective
control while only reducing the wildtype release moderately.
Similarly interferon treatment of purified activated human CD4+
T cells led to a selective defect in the production of cell-free HIV-1
Vpu ELV virions (Figure 8C) consistent with a concomitant
upregulation of surface tetherin levels (Figure 8D), and surface
tetherin downregulation (Figure 8E). Taken together with results
or siRNA pools against AP-3d1 and AP-3m1. 4 h post the second transfection the cells were infected with VSV-G-pseudotyped HIV-1 wt or HIV-1
delVpu virus stock at an MOI of 1. Cell lysates and supernatants were analyzed by Western blotting 48 h later as described in Figure 1B. (E) HeLa cells
expressing a doxycycline-inducible shRNA hairpin against AP-1c1were transfected twice with pooled control or siRNA pools against AP-1c1. The cells
were infected and analyzed as in C. (F) 293T cells stably expressing tetherin were transfected twice with pooled control or siRNA pools against the
retromer subunit Vps26. Cells were infected and analyzed as in C. In all siRNA knockdown experiments, the % knockdown of the indicated protein as
determined by the relative band intensity in the western is indicated below the blot panel.
doi:10.1371/journal.ppat.1002609.g006
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presented above, these data demonstrate that the ability to
downregulate and degrade tetherin imparted by the EXXXLV
motif is required for cell-free virion release from relevant primary
HIV target cells, and becomes essential when tetherin expression is
enhanced by an antiviral stimulus.
Discussion
In this study we have identified a determinant within the second
alpha helix of the cytoplasmic tail of HIV-1 NL4.3 Vpu,
E59XXXL63V64, which is required for efficient antagonism of
tetherin. Mutation of this site blocks the ability of Vpu to mediate
tetherin downregulation from the cell surface and its ESCRT-
dependent degradation, but does not abolish its interaction with
tetherin, nor recruitment of b-TrCP2 or the ESCRT-0 component
HRS. Importantly, this motif is required to counteract tetherin in
CD4+ T cells, particularly after their exposure to type-I interferon.
Vpu ELV mutants localize to the cell surface and early/recycling
endosomal compartments rather than the TGN by virtue of their
interaction with tetherin. This is consistent with a role for this
determinant in Vpu-mediated inhibition of the transit of newly
synthesized and/or recycling tetherin to the cell surface, its
Figure 7. Residual activity of Vpu ELV requires an intact recycling signal in tetherin. (A) 293T/tetherin or 293T/tetherin Y6,8A mutant were
infected with VSV-G-pseudotyped HIV-1 wt, HIV-1 delVpu or HIV Vpu ELV at an MOI of 0.5. Supernatants and cell lysates were harvested 48 h later
and analyzed for infectious virus release on HeLa-TZMbl as in Figure 1C. (B) Corresponding Western blots of cell lysates and virions from A. (C) 293T/
tetherin Y6,8A cells treated with control or UBAP1 specific siRNAs were infected with VSV-G-pseudotyped HIV-1 wt, HIV Vpu ELV, HIV-1 Vpu A14L/
W22A or HIV-1 delVpu at an MOI of 2. 48 h post infection, cells were lysed and immunoprecipitated with an anti-tetherin antibody. Lysates and
immunoprecipitates were subjected to SDS-PAGE and analyzed by Western Blotting for tetherin, UBAP1 and Vpu, and analyzed by LiCor quantitative
imager. Ratios of Vpu/tetherin band intensities in the coIP are plotted on the histogram below.
doi:10.1371/journal.ppat.1002609.g007
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internal sequestration and targeting for endo-lysosomal degrada-
tion. However, while we could functionally complement Vpu
function by grafting the D/EXXX(L/I/M) motif from HIV-1 Nef
in place of helix-2, we could detect no effect of depletion of the
canonical clathrin adaptor proteins AP-1, AP-2 or AP-3 on Vpu-
mediated tetherin antagonism. The inhibition by AP180c
overexpression, however, implicates clathrin function in Vpu-
mediated tetherin antagonism. Finally, residual Vpu ELV activity
against tetherin was entirely dependent on an intact recycling
motif in tetherin’s cytoplasmic tail, suggesting that this motif
differentially affects antagonism of newly synthesized tetherin
rather than pre-existing pools recycling to the PM. These results
are in contrast to the recent study by Lau et al who were unable to
demonstrate a phenotype for an LV63,64AA mutant despite
interfering with Vpu activity with AP180c [43]. Given that we
have demonstrated phenotypes in several cellular systems
including CD4+ T cells for the Vpu ELV mutant, the reason for
this discrepancy is unclear.
There has been much debate as to whether the reduction of
tetherin levels at the plasma membrane is required to counteract
its antiviral activity, particularly in CD4+ T cells (reviewed in
[10]). In our hands, tetherin surface levels are reduced in HIV-1
infected primary T cells and Jurkat cells. However, under these
conditions, the viral release phenotype of the Vpu ELV mutant is
only a few-fold different than the wildtype protein. Interestingly
this changes upon treatment of the cells with type-I interferon,
which upregulates tetherin expression levels. In this case Vpu ELV
mutant release is reduced almost to that of the Vpu-defective virus,
but only minor further reductions are observed for the wildtype
virus. This therefore indicates that the requirement for surface
Figure 8. The EXXXLV motif is essential to counteract tetherin-mediated restriction of cell-free HIV-1 particle release from CD4+ T
cells treated with type-1 interferon. Jurkat cells were infected with the indicated HIV-1 mutant at an MOI of 1. 16 h later the cells were treated or
not with 5000 U/ml universal type-I interferon. Cell lysates and viral supernatants were harvested a further 24 h later and analyzed for infectivity on
HeLa-TZM (A) or physical particle yield and cellular viral and tetherin expression by quantitative Western blotting (B). (C) A representative example of
primary human CD4+ T cells treated as in (B) and the MFI of surface tetherin levels on these cells with or without 24 h type-I interferon treatment as
analyzed by flow cytometry (D). (E) Human CD4+ T cells were infected with the indicated virus. 48 h later cells were stained for surface tetherin and
intracellular p24CA and analyzed by flow cytometry.
doi:10.1371/journal.ppat.1002609.g008
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reduction/degradation of tetherin becomes much more important
at higher expression levels of the restriction factor (something that
has been suggested previously by Goffinet et al [49]). Recent
conflicting data have addressed the effect of tetherin and
interferon on cell-cell transmission between T cells [50,51], which
when taken together show that if tetherin does restrict this mode of
virion transfer, it is far less efficient than its effect on cell-free viral
release. Thus, the fact that tetherin antagonism is such a highly
conserved attribute amongst primate immunodeficiency viruses
implies its importance in vivo. Since interferon treatment of CD4+
T cells magnifies the defective phenotype of a Vpu ELV mutant,
the ability to mediate tetherin’s surface reduction and target it for
endosomal degradation is likely to be essential for the virus to
avoid restriction under proinflammatory conditions it is likely to
encounter in vivo, particularly during acute infection [52,53].
Our results are consistent with the notion that Vpu blocks
delivery of tetherin to the plasma membrane [13,54] and suggest
that Vpu exerts its effect on tetherin trafficking in the TGN/
recycling compartment in a manner determined in part by this
putative sorting sequence. It is now clear that Vpu-mediated
tetherin degradation is ubiquitin-dependent and occurs in
lysosomes rather than early reports of proteasomal processing
[15,16], and that this process requires the ESCRT pathway [19].
Depletion of both TSG101 and Vps4 inhibits Vpu-mediated
tetherin degradation, and recruitment of HRS (ESCRT-0) has
been reported to be required for Vpu-mediated tetherin
antagonism [19], as has ubiquitination on multiple residues in
the tetherin cytoplasmic tail [18]. However tetherin’s ultimate
degradation itself is not essential for Vpu or other lentiviral
countermeasures to inactivate it. Our recent observations with the
novel ESCRT-I subunit, UBAP1, ([22] and the results presented
herein), demonstrate that ESCRT-I function is unlikely to be
required for tetherin antagonism, but its commitment to
endosomal degradation is. Interestingly, the concomitant enhance-
ment of wildtype Vpu levels, both co-precipitating with tetherin
and at steady state, suggest that Vpu is likely co-degraded with its
target.
Alongside the current literature our data suggests that Vpu
interaction with tetherin leads to a differential trafficking of
tetherin in the TGN and/or recycling compartments rather than
enhancing tetherin internalization (Figure 9). This inhibits forward
trafficking of either recycling or newly synthesized tetherin to the
PM, and commits it to a pathway that ultimately targets it to
endolysosomal compartments for degradation. We suggest that it is
this commitment, regulated by the EXXXLV motif in second
helix, rather than degradation per se, that is principally responsible
for antagonizing tetherin. Where Vpu interacts with tetherin in the
cell is likely to be related temporally to the viral replication cycle,
tetherin expression level, and its natural turnover rate. Vpu is
expressed ‘‘late’’ in replication from the same mRNA as Env [55],
at the time new virions are being built. Thus Vpu must deal with
two pools of tetherin; pre-existing protein in the periphery
recycling via the TGN [9], and de novo synthesized tetherin
trafficking through the Golgi en route from the endoplasmic
reticulum (ER) to the surface. Therefore we predict that Vpu
must interact with tetherin in TGN-associated compartments to
engage these two pools of tetherin, although our recent data
suggests that binding to newly synthesized tetherin may occur
prior to this in the ER [14]. Thereafter, a clathrin-dependent
sorting event determined by the helix-2 EXXXLV motif precludes
Vpu/tetherin complexes transiting to the PM. This intracellular
sequestration of tetherin is further coupled to late endosomal
targeting and ESCRT-dependent degradation through the
recruitment of HRS and tetherin ubiquitination [18,19]. In line
with this, global disruption of early to late endosomal transition by
dominant negative Rab7a also appears to inhibit Vpu activity
[23]. Interestingly, ubiquitinated cargo destined for ESCRT-
dependent degradation via HRS recruitment has been shown to
partition differentially to areas of early/sorting endosomal
membranes rich in flat clathrin lattices, thereby anchoring it
away from the recycling machinery [56]. Recruitment of tetherin
into such structures in the sorting compartment may be sufficient
to antagonize its function, offering an explanation as to why
clathrin is essential for Vpu activity but dynamin 2 mutants only
effect the residual activity of Vpu ELV. Because Vpu activity was
insensitive to retromer (Vps26) depletion, which is essential for
endosome-to-TGN retrieval and recycling [48], we suggest that
Vpu targets tetherin into this pathway from the TGN to
endosomal compartments, and an ensuing swift degradation
accounts for the observed sequestration in TGN46 positive
compartments. In the absence of the EXXXLV motif, tetherin
is not committed to this differential sorting in the TGN, and Vpu/
tetherin complexes are targeted to the cell surface and thereafter
back into the recycling system, accounting for the localization of
Vpu ELV in infected cells and its incorporation into virions.
Therefore in addition to acting as an adaptor for the recruitment
of ESCRT-0 and E3 ubiquitin ligase activity to tetherin, we
propose that through the EXXXLV motif, Vpu directly
chaperones associated tetherin molecules into an endosomal
compartment from which they cannot recycle to the PM.
EXXXLV mutants retain some residual antagonistic activity
that is entirely dependent on the AP-1/AP-2-binding motif in
tetherin. This would suggest that the action of the EXXXLV motif
does not solely account for the inhibition of tetherin by Vpu. Vpu
ELV still interacts with b-TrCP2, suggesting that tetherin
ubiquitination, which is important for counteracting its activity
[18], may still take place during the recycling process and effect
antiviral function. Also physical interaction between Vpu and
tetherin may be sufficient to interfere with some level tetherin
function provided tetherin can still associate with the clathrin-
dependent endocytic machinery. Since biochemical evidence
strongly favors a direct cross-linking model for tetherin’s antiviral
activity [7], either of these processes could in principle affect the
qualitative nature of tetherin distribution at viral assembly
domains at the PM such that tethers do not form efficiently,
something that is plausible in the light of Habermann et al’s
quantitative Cryo-EM analysis of tetherin localization at the PM in
infected HeLa cells [57]. The relative efficiency of this ‘‘second-
ary’’ inhibition of tetherin activity will thus be dependent on
cellular tetherin levels and the temporal stage of viral replication
(ie: the expression level of Vpu). Since Vpu-defective mutants of
HIV-1 in some studies show enhanced cell-to-cell transmission and
that tetherin may play a role in virological synapse formation
[51,58,59], such a differential effect on de novo synthesized versus
the recycling pool tetherin may favor viral transmission during
early stages of viral production, but effectively antagonize
induction of tetherin expression and potent restriction by a pro-
inflammatory response.
We have so far been unable to demonstrate direct interaction
between the Vpu EXXXLV motif and adaptors AP-1, 2 or 3 that
are known to bind acidic dileucine signals via a hemicomplex of
their sigma and adaptin subunits [32]. These interactions have
been demonstrated in yeast 3-hybrid assays previously for HIV-1
Nef [36,37], but not all interactions are amenable to this method
and in our hands the Vpu cytoplasmic tail is a constitutive
activator of transgene expression precluding its use. Furthermore,
the low affinity of these interactions, their transient nature, and the
complex interactions of the adaptor protein with membrane lipids
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means that adaptor binding is rarely measurable in co-precipita-
tions from cells. The context dependency of (D/E)XXXL(L/I)
motifs that governs which adaptor they bind to in vivo is poorly
defined at present, meaning that RNAi-depletion is the most
reliable method for identifying the cellular factor involved. While
individual depletion of AP-1, 2 or 3 in our experiments had no
effect on Vpu-mediated tetherin antagonism, replacement of the
second alpha helix with the promiscuous AP-binding peptide from
HIV-1 Nef did recover function. This site in Nef is essential for
several functions including CD4 and MHC Class I downregula-
tion, the former being AP-2-dependent [37], the latter requiring
AP-1 [38]. Importantly, binding of AP-2 to this site in SIV Nef
proteins is required for their counteraction of non-human primate
tetherins [26]. Thus there are several possibilities. The EXXXLV
motif in Vpu might be a promiscuous AP-binding site and adaptor
usage may be redundant. The subcellular localization of tetherin/
Vpu ELV complexes in EEA1 positive endosomes and the partial
effect of dominant negative dynamin 2 would argue against a
significant role for AP-2, the major regulator of clathrin-mediated
transport from the PM. However toxicity associated with
simultaneous knockdown of multiple adaptors has precluded us
from addressing this possibility so far. Alternatively, replacement
of the second alpha with the Nef peptide recovers function because
it confers AP-2 binding to Vpu, thus allowing Vpu to counteract
tetherin in a manner similar to SIV Nef and HIV-2/SIV Envs that
both require AP-2 interactions [24–26,60]. However, these data
do underscore that linking Vpu to the clathrin trafficking
machinery promotes its ability to counteract tetherin.
If Vpu-mediated tetherin antagonism is clathrin-dependent, but
independent of AP-1, AP-2 or AP-3 (for which the importance of
clathrin is debated), what other adaptors might be important? Two
further heterotetrameric adaptors, AP-4 and AP-5, have been
identified, but understanding of their role in subcellular trafficking
is limited and at present they are not known to bind to acidic
dileucine motifs or to control clathrin-mediated transport [32,61].
The monomeric GGA (Golgi-associated, c-ear containing, ARF-
cofactors) 1–3 proteins that also function as clathrin adaptors that
regulate Golgi-to-endosome transport are potentially attractive
candidates, whose dysregulation has been reported to inhibit HIV-
1 assembly [62]. However, known GGA-binding motifs in cellular
cargoes correspond to a DXXLL consensus where the spacing of
the leucines from the acidic residue is thought critical.
The (E/D)XXXL(V/M/I) motif is conserved in Vpu proteins
from HIV-1 M group subtypes A, B, D, G and H (Figure S2), as
Figure 9. Model for the role of the EXXXLV motif in tetherin antagonism. Tetherin is expressed at the plasma membrane where it can
become incorporated into viral particles or recycles constitutively via early/sorting endosomal compartments and the TGN. Vpu interacts with
tetherin in the TGN (and perhaps earlier) through TM-domain-mediated interactions. In the presence of a functional EXXXLV motif, tetherin/Vpu
complexes are prevented from trafficking to the PM and routed for ESCRT-dependent endosomal degradation via a clathrin-dependent mechanism.
In the absence of an EXXXLV motif, tetherin/Vpu complexes recycle via the PM dependent on the YXYXXV sorting sequence in the tetherin
cytoplasmic tail, which interacts with AP-2 and AP-1. During the recycling process, physical interaction of Vpu and/or modification by ubiquitin
ligases, such as SCF-b-TrCP2, may further interfere with tetherin function to a variable degree in the absence of cell-surface downregulation.
doi:10.1371/journal.ppat.1002609.g009
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well as in Group O (www.hiv.lanl.gov). While Group O Vpus
cannot antagonize tetherin [63], this maps to defective TM
domain-mediated interaction and the membrane proximal hinge
region. When replaced by those from a Group M Vpu these are
sufficient to confer tetherin inactivation implying that C-terminal
determinants retain function [64]. In Group M clades C and F, the
equivalent position is (D/E)XXXL(S/A) respectively, suggesting
that the site may not be functional in those Vpus, with the caveat
that the second position in the dileucine motif is less important.
Intriguingly both these subtypes bear EYXXL(L/I) motifs in the
membrane proximal region of their cytoplasmic tails that
encompass both a putative tyrosine and dileucine-based sorting
sequence. Evidence from Ruiz et al [34] has shown that a model
subtype C Vpu localizes to the PM rather than the TGN and that
this is in part due to this motif. While LL mutations in this subtype
C Vpu confer T-cell line replication phenotypes suggestive of a
failure to downmodulate tetherin, no direct experiments on the
role of this motif in tetherin-mediated HIV-1 release have been
thus far performed, nor whether this site can bind known clathrin
adaptors.
In summary our data implicate a trafficking determinant in the
Vpu cytoplasmic tail that is required for tetherin downregulation,
degradation and efficient antagonism, and suggest that it governs
differential sorting of Vpu/tetherin complexes in the TGN to




HEK293T, HeLa and Jurkat cells were obtained from ATCC
(American Tissue Culture Collection). 293T/tetherin and 293T/
tetherin-delGPI and HT1080/tetherin-HA are cell lines stably
expressing human tetherin or mutant thereof, with or without a
hemagglutinin (HA) epitope tag inserted at nucleotide 463,
which has been previously described [1,65]. The reporter cell
line HeLa-TZMbl, was kindly provided by John Kappes through
the NIH AIDS Reagents Repository Program (ARRP). All
adherent cells were maintained in Dulbecco’s modified Eagle
medium (DMEM) (Invitrogen, UK) supplemented with 10%
fetal calf serum and Gentamycin; T-cell lines were grown in
Roswell Park Memorial Institute medium (RPMI) supplemented
with 10% fetal calf serum and Gentamycin. Murine fibroblasts
from pearl and AP1c1a deficient mice and derivative in which
AP3m or AP1c1a were re-expressed were kindly provided by
Andrew Peden [46] and Peter Schu [47] respectively. These cells
were transduced to express HA-tagged human tetherin using
pLHCX-THN-HA463 [65] and maintained in hygromycin
selection.
Wildtype HIV-1 NL4.3 (obtained from NIH-ARRP), a Vpu-
defective counterpart and pCR3.1 Vpu-HA containing a modified
codon optimized NL4.3 Vpu has been described previously [31].
All second alpha helix mutants of Vpu and mutations in the NL4.3
proviral genome were generated by Quick-change site-directed
mutagenesis PCR according to standard protocols using Phusion-
II polymerase (New England Biolabs). Vpu-Nef chimeras and
corresponding mutants were made with long reverse PCR primers
encoding Nef clathrin adaptor binding sites, cloned into pCR3.1
expression vectors encoding tagged or untagged tetherins which
have been described elsewhere [1]. b-TrCP2 was cloned from
HeLa cDNA and inserted into pCR3.1 with a C-terminal myc-tag.
pCR3.1 HA-HRS was kindly provided by Juan Martin-Serrano
[66]. pCR3.1 dynamin 2-HA and dominant negative dynamin 2-
HA have been previously described by [31].
Primary human CD4+ T cells were isolated from fresh venous
blood drawn from healthy volunteers. CD4+ T cells were purified
from total peripheral blood mononuclear cells (PBMC) isolated by
lymphoprep (AXIS-SHIELD) gradient centrifugation using a
CD4+ T cell Dynabeads isolation kit (Invitrogen). T cells were
then activated for 48 h using anti-CD3/anti-CD28 magnetic
beads (Invitrogen). The beads were then removed cells were then
maintained in rhIL-2 (20 U/ml) (Roche).
Production of viral and vector stocks
For full-length HIV-1 stocks pseudotyped with the Vesicular
Stomatitis Virus Glycoprotein (VSV-G), 293T cells were trans-
fected with 2 mg of proviral plasmid and 200 ng of pCMV VSV-
G. 48 h post-transfection, viral stocks were harvested and endpoint
titers were determined on HeLa-TZMbl cells as described below
[25].
Virus release assay
For transient-transfection-based virus release assays, subcon-
fluent 293T cells were plated on 24 well plates and transfected
with 500 ng proviral clone, in combination with 50 ng of tetherin
and 25 ng of Vpu-HA or mutants using 1 mg/ml polyethylenei-
mine (Polysciences). The medium was replaced 5 h and 16 h post-
transfection, cells were harvested after 48 h. The infectivity of viral
supernatants was determined by infecting HeLa-TZMbl, 48 h
later cells were assayed for b-galactosidase activity using the
chemiluminescence Tropix GalactoStar kit (Applied Biosystems).
For biochemical analysis of virus particle release, supernatants
were filtered (0.22 mm) and pelleted through a 20% sucrose/PBS
cushion at 20,000 g for 90 min at 4uC, and pellets were lysed in
SDS-PAGE loading buffer. Virion and cell lysates were then
subjected to SDS-PAGE and Western blotted for HIV-1 p24CA
(monoclonal antibody 183-H12-5C; kindly provided by B
Chesebro through the NIH ARRP), rabbit anti-Hsp90 (Santa
Cruz Biotechnologies), monoclonal mouse anti-HA.11 (Covance),
polyclonal rabbit anti-HA (Rockland) and/or Vpu (rabbit
polyclonal; kindly provided by K. Strebel through the NIH
ARRP [67], and visualized by LiCor apparatus using fluorophores
conjugated secondary antibodies (IRDye 800 Goat anti-rabbit,
IRDye 680 Goat anti-mouse).
One round viral release assay
56105 cells (293T/tetherin, Jurkat or CD4+ T cells) were
infected with VSV-G-pseudotyped HIV-1 wt, HIV-1 delVpu or
HIV-1 Vpu ELV at an MOI of 0.5–1. 16 h post infection medium
was replaced and cells (treated or not with 5000 U/ml of universal
type-1 interferon (PBL InterferonSource)) were cultured for a
further 24 h. The cells harvested, the infectivity of viral
supernatants was determined by infecting HeLa-TZMbl and
biochemical analysis of virus particle release was performed as in
Virus release assay. For examining tetherin degradation HT1080
cells stably expressing tetherin-HA were infected with VSV-G-
pseudotyped HIV-1 wt, HIV-1 delVpu or HIV-1 Vpu ELV virus
stocks at a multiplicity of infection (MOI) of 2 to ensure that
approximately 90% of the cells were infected. The medium was
replaced 4 h after infection. 48 h post infection cell lysates were
harvested and processed as described above.
Flow cytometry
HeLa cells were transfected with 400 ng of pCR3.1 GFP and
400 ng of pCR3.1 Vpu-HA or indicated mutants. 48 h post
transfection the cells were harvested and stained for surface
tetherin using a specific anti-BST2 monoclonal IgG2a antibody
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(Abnova) and goat-anti-mouse IgG2a-Alexa633 conjugated sec-
ondary antibody (Molecular Probes, Invitrogen, UK). Tetherin
expression on GFP positive cells was then analyzed using a
FacsCalibur flow-cytometer (Becton Dickinson) and the FlowJo
software. Murine fibroblasts were transduced with the pMigR1-
based retroviral vector pCMS28-IRES-eGFP or a derivative
expressing NL4.3 Vpu. 48 h after transduction the cells were
stained for surface HA versus GFP expression. Jurkat or CD4+ T
cells were infected with VSV-G-pseudotyped HIV-1 wt, HIV-1
delVpu or HIV-1 Vpu ELV at an MOI of 1. 48 h post infection
cells were stained for surface tetherin expression as above, then
fixed and permeabilized for 20 minutes (Cytofix/cytoperm
Fixation/Permeabilization kit, BD Biosciences) and stained for
intracellular HIV-1 p24CA using the KC57 antibody conjugated
to PE (Beckman- Coulter).
Immunofluorescence microscopy
Cells were grown on coverslips and infected with VSV-G-
pseudotyped HIV-1 wt or HIV-1 Vpu ELV, 48 h later cells were
fixed in 4% paraformaldehyde/PBS, washed with 10 mM
glycine/PBS, and permeabilized in 1% bovine serum albumin/
0.1% Tritin-X100/PBS for 15 min. The infected cells were
stained using anti-rabbit polyclonal Vpu in combination with
sheep anti-human TGN46 (AbD Serotec), mouse anti-EEA1 (BD
Biosciences), mouse anti-CD63 (Developmental Studies Hybrid-
oma Bank, University of Iowa) or mouse polyclonal anti-BST-2
(Abnova) followed by the appropriate secondary antibodies
conjugated to Alexa 488 or 594 fluorophores (Molecular Probes,
Invitrogen). The cells were then mounted on glass slides using
ProLong AntiFade- 49,6-diamidino-2-phenylindole (DAPI) mount-
ing solution (Molecular Probes, Invitrogen). Cells were visualized
with a Leica DM-IRE2 confocal microscope. Images were
analyzed using Leica Confocal Software and ImageJ.
Immunoprecipitations
293T cells stably expressing tetherin were transfected twice over
48 h with siRNA oligonucleotide against UBAP1 targeting
CTCGACTATCTCTTTGCACAT or Non-targeting siRNA
was used as control (Dharmacon). The cells were then infected
with VSV-G-pseudotyped HIV-1 wt, HIV-1 delVpu, HIV-1 Vpu
ELV or HIV-1 Vpu A14L,W22A at an MOI of 2. 48 h post
infection the cells were lysed on ice for 30 min in buffer containing
50 mM Tris-HCL pH 7.4, 150 mM NaCl, complete protease
inhibitors (Roche) and 1% digitonin (Calbiochem). After removal
of the nuclei, the supernatants were immunoprecipitated with
5 mg/ml mouse monoclonal anti-BST2 antibody (eBiosciences) for
1.5 h at 4uC. Sepharose-protein G beads were washed in lysis
buffer before they were added to the samples and incubated for
further 3 h. The beads were washed extensively in lysis buffer
containing 0.1% digitonin and resuspended in SDS-PAGE loading
buffer. Cell lysates and immunoprecipitates were subjected to
SDS-PAGE, and Western blot assays were performed using a
rabbit anti-Vpu antibody (kindly provided by K Strebel through
the NIH ARRP), polyclonal rabbit anti-tetherin antibody (kindly
provided by K Strebel through the NIH ARRP) and polyclonal
rabbit anti-UBAP1 antibody (Proteintech), and visualized by
ImageQuant using corresponding HRP-linked secondary antibod-
ies (New England Biolabs, UK). For HRS/Vpu coIP, 293T cells
were co-transfected with 700 ng of pCR3.1 HA-HRS and pCR3.1
Vpu-YFP, pCR3.1 Vpu ELV-YFP or pCR3.1 YFP expression
plasmids. 48 h post transfection the cells were lysed in buffer
containing 0.1 M MES-NaOH pH 6.5, 1 mM magnesium
acetate, 0.5 mM EGTA, 200 mM sodium ortho-vanadate,
10 mM NEM, complete protease inhibitors (Roche) and 1%
digitonin. After removal of the nuclei, the supernatants were
immunoprecipitated with 5 mg/ml monoclonal mouse anti-HA.11
antibody (Covance). Immunoprecipitation was performed as
described above and Western blot assays were performed using
a polyclonal rabbit anti-HA antibody (Rockland) and an anti-Vpu
antibody.
Crosslinking IP
293T cells were co-transfected with 700 ng of pCR3.1 myc b-
TrCP 2 and pCR3.1Vpu-HA, pCR3.1 Vpu ELV-HA, pCR3.1
Vpu 2/6A-HA or pCR3.1 YFP expression plasmids. 48 h post
transfection, Crosslinking Immunoprecipitation was performed as
previously described [68]. Cell lysates and immunoprecipitates
were subjected to SDS-PAGE, and Western blot assays were
performed using a rabbit anti-Vpu antibody and mouse anti-myc
antibody (kindly provided by M. Malim), and visualized by
ImageQuant (GE) using corresponding HRP-linked secondary
antibodies (New England Biolabs).
siRNA-mediated clathrin adaptor knockdown
293T cells stable expressing tetherin or HeLa cells were seeded
at a density of 26105 cells per well in a 12 well plate. After 3 h, the
first transfection was performed. For each well, 3 ml Oligofecta-
mine (Invitrogen) was added to 10 ml of Opti-MEM (Life
Technologies), this solution was added to 5 ml of 20 mM siRNA
in 85 ml of Opti-MEM according to manufactures protocol. For
AP-1 knockdown, HeLa cells stably expressing doxycycline-
inducible pTRIPZ shRNA against AP-1c1 (OpenBiosystems) were
used in combination with siRNA oligonucleotide against AP-1c1
targeting AAGAAGATAGAATTCACCTTT. For AP-2 knock-
down, SMARTpool siRNA targeting the AP-2 m1 subunit was
used (Dharmacon). For AP-3 knockdown, SMARTpool siRNA
targeting the AP-3 m1 subunit was used in combination with
SMARTpool siRNA targeting the AP-3d1 subunit (Dharmacon).
For Vps26 knockdown, siRNA targeting the AACCACC-
TATCCTGATGTTAA sequence was used (Qiagen). On Non-
targeting siRNA was used as control (Dharmafect). The cells were
reseeded into a 24 well plate on day 2 and a second transfection
was performed according to manufactures protocol. The cells were
infected 3 h post transfection with VSV-G-pseudotyped HIV-1 wt,
HIV-1 delVpu at an MOI of 0.8. The infectivity of viral
supernatants was determined by infecting HeLa-TZMbl as
described above. Cell lysates and viral particles were subjected
to SDS-PAGE, and Western blot assays were performed using a
mouse monoclonal AP-1c1 antibody (Sigma), mouse anti-AP50
(AP-2m1) and mouse anti-AP-3d1antibodies (BD Bioscience),
polyclonal rabbit AP-3m1 antibody (kindly provided by M.S.
Robinson) and rabbit polyclonal Vps26 antibody (Abcam).
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Supporting Information
Figure S1 Effect of Vpu helix 2 mutants on surface
tetherin expression in HeLa cells. (A) The full panel of helix
2 alanine scan mutants performed as described for Figure 2D. (B)
HeLa cells were infected with the indicated VSV-G pseudotyped
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HIV-1 mutant at an MOI of 0.5. 48 h later cells were stained for
surface tetherin and intracellular p24CA. (C) Productively infected
Jurkat cells in Figure 2E were discriminated from those acquiring
p24+ matter from the inoculum by exposing them to the same
dose of wildtype HIV-1 in presence of AZT.
(TIF)
Figure S2 Vpu EXXXL(V/M/I/L) is conserved in most
HIV-1 clades. (A) LogoPlots of Vpu cytoplasmic tail portions
encompassing the conserved phosphorylation motif (DSGNES)
and helix 2 from HIV-1 subgroup M clades A,B,D,G and H
generated from sequences obtained from the Los Alamos database
(www.hiv.lanl.gov). (B) 293T cells were transfected with NL4.3 or
NL4.3 delVpu proviruses in combination with tetherin and Vpu-
HA, Vpu 64I-HA, Vpu 64M-HA or Vpu 64L-HA expression
vectors. 48 h post transfection, cell lysates and pelleted superna-
tant virions were harvested and subjected to SDS-PAGE and
analyzed by Western blotting for HIV-1 p24CA, Vpu-HA and
Hsp90, and analyzed by LiCor quantitative imager. (C) HeLa cells
were co-transfected with Vpu or indicated Vpu mutant and a GFP
expression construct. Cell surface staining for endogenous tetherin
was analyzed by flow cytometry 48 h post transfection, as in
Figure 2D.
(TIF)
Figure S3 Effects of Vpu on surface expression of
human tetherin in murine fibroblasts deficient for AP3
or AP1. Fibroblasts from pearl (AP3d2/2) (A) or AP-1m1A2/2
mice (B) or their reconstituted counterparts were transduced to
express human tetherin bearing an extracellular HA-tag. The cells
were then transduced with retroviral vector constructs encoding
Vpu linked to GFP via an IRES. 48 h later the cells were surface
stained for human tetherin expression using anti-HA antibodies.
(C) HeLa-CD8-CI-M6PR cells were treated with control or Vps26
siRNAs. 48 h later the cells were fixed and stained for CD8 (green)
and TGN46 (red).
(TIF)
Figure S4 Effects of dominant negative dynamin 2 on
Vpu-mediated HIV-1 release. 293T/tetherin cells were
transfected with the indicated HIV-1 provirus and increasing
doses of HA-tagged dominant negative dynamin 2 (A) or the
wildtype protein (B). 48 h later, cell lysates and viral supernatants
were harvested and subjected to SDS-PAGE and analyzed by
Western blotting for HIV-1 p24CA, dynamin 2-HA and Hsp90,
and analyzed by LiCor quantitative imager. Histograms below the
blots indicate particle release efficiency compared to wildtype virus
release in the absence of dynamin 2 or increasing doses of
dynamin 2 expression vector. (C) Corresponding infectivity of viral
supernatants from A and B on HeLa-TZM cells alongside those
from a parallel experiment in parental 293T cells. (D) 293T/
tetherin cells were transfected with pCR3.1 YFP with or without
increasing doses of dominant negative dynamin 2. 48 h later the
cells were starved in serum-free medium for 30 minutes and then
treated for a further 15 minutes with 10 mg/ml Alexa-594-
conjugated transferrin, before fixation and imaging.
(TIF)
Figure S5 Effect ELV mutant on HIV-1 infectious
release from HeLa cells. HeLa cells were infected with
VSV-G pseudotyped stocks of the indicated virus at an MOI of
0.5. 48 h later the cell supernatants were harvested and infectivity
determined on HeLa-TZM cells.
(TIF)
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SUMMARY
The endosomal sorting complexes required for
transport (ESCRTs) facilitate endosomal sorting of
ubiquitinated cargo, MVB biogenesis, late stages of
cytokinesis, and retroviral budding. Here we show
that ubiquitin associated protein 1 (UBAP1), a subunit
of human ESCRT-I, coassembles in a stable 1:1:1:1
complex with Vps23/TSG101, VPS28, and VPS37.
The X-ray crystal structure of the C-terminal region
of UBAP1 reveals a domain that we describe as a
solenoid of overlapping UBAs (SOUBA). NMR anal-
ysis shows that each of the three rigidly arranged
overlapping UBAs making up the SOUBA interact
with ubiquitin. We demonstrate that UBAP1-contain-
ing ESCRT-I is essential for degradation of anti-
viral cell-surface proteins, such as tetherin (BST-
2/CD317), by viral countermeasures, namely, the
HIV-1 accessory protein Vpu and the Kaposi
sarcoma-associated herpesvirus (KSHV) ubiquitin
ligase K5.
INTRODUCTION
The endosomal sorting complex required for transport (ESCRT)
machinery facilitates the lysosomal degradation of ubiquitinated
cell surface receptors (Hurley and Stenmark, 2011; Katzmann
et al., 2001). ESCRT proteins are conserved from yeast to hu-
mans and form four multiprotein complexes termed ESCRT-0,
ESCRT-I, ESCRT-II, and ESCRT-III (Henne et al., 2011; Williams
and Urbe´, 2007). ESCRT-0, -I, and -II capture ubiquitinated
membrane proteins for sorting into intraluminal vesicles (ILV)
within endosomes to form structures known as multivesicular
endosomes or multivesicular bodies (MVB) (Shields and Piper,
2011).
The ESCRT machinery is also essential for resolution of the
midbody during cytokinetic abscission (Carlton and Martin-
Serrano, 2007; Morita et al., 2007b), a process that is topologi-
cally equivalent to MVB formation. The ability of the ESCRTs to
mediate scission of a thin membranous stalk is also exploited
by several enveloped viruses such as HIV-1 to facilitate their
release from infected cells (Baumga¨rtel et al., 2011; Jouvenet
et al., 2011; Martin-Serrano and Neil, 2011; Morita and Sund-
quist, 2004; Morita et al., 2011; Weissenhorn and Go¨ttlinger,
2011). In particular, HIV-1 encodes a PTAP motif that recruits
ESCRT-I to the sites of viral budding through a direct interaction
with theUEV domain in TSG101 (Pornillos et al., 2002). Additional
roles of ESCRT-I in viral pathogenesis include its cooption by
gamma-herpesviruses (Nathan and Lehner, 2009) and HIV for
the degradation of various antiviral cell-surface proteins such
as tetherin (BST-2/CD317) (reviewed in Martin-Serrano and
Neil, 2011). Tetherin is an antiviral type II membrane glycoprotein
that is induced by interferons and physically inhibits enveloped
virus particle release from infected cells by cross-linking nascent
virions to the plasma membrane. Specifically, the HIV-1 acces-
sory protein Vpu counteracts tetherin activity and promotes its
ESCRT-dependent degradation via the lysosomal pathway
(Janvier et al., 2011). Kaposi sarcoma-associated herpesvirus
(KSHV) encodes K5, a membrane-bound E3 ubiquitin ligase
that results in a similar effect (Bartee et al., 2006; Mansouri
et al., 2009; Pardieu et al., 2010).
ESCRT-I is formed by four subunits, Vps23/TSG101, Vps28,
Vps37, and Mvb12. The yeast ESCRT-I heterotetramer contains
a fan-shaped headpiece formed by a heterotrimeric core con-
sisting of the C-terminal ‘‘steadiness box’’ of Vps23p, the
N-terminal half of Vps28p, and the C-terminal half of Vps37p
(Kostelansky et al., 2006; Teo et al., 2006). This headpiece
connects to an extended stalk formed by Mvb12p, Vps23p,
and Vps37p. The stalk is essential for yeast ESCRT-I function
in cargo sorting. The C-terminal domain of Vps28p is flexibly
tethered to the headpiece and binds ESCRT-II, whereas the flex-
ibly attached UEV domain of Vps23p binds to ESCRT-0 (Koste-
lansky et al., 2007). This structural organization is thought to be
conserved in mammalian ESCRT-I and was used as the basis to
identify, to our knowledge, novel subunits of the complex.
However, in mammalian cells, ESCRT-I has evolved a much
greater diversity of subunits than in yeast, including multiple
isoforms of VPS37 and MVB12 (Bache et al., 2004; Eastman
et al., 2005; Morita et al., 2007a; Stuchell et al., 2004).
Using our sensitive generalized profile method for sequence
comparison (Bucher et al., 1996), we identified a highly signif-
icant relationship between a profile constructed from different
vertebrate and invertebrate MVB12 sequences and the protein
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UBAP1. An independent report also predicted a shared domain
between UBAP1 and MVB12 that was named UBAP1-MVB12-
associated (UMA) domain (de Souza and Aravind, 2010) (Fig-
ure 1A). The UMA domain corresponds to a region that was
previously described as the ESCRT-I binding box (EBB)
(Morita et al., 2007a) and is located in the C terminus of
MVB12 and in the N terminus of UBAP1. UBAP1 is expressed
in a wide range of tissues and is embryonic lethal when
deleted in mice (http://www.sanger.ac.uk/mouseportal/
search?query=ubap1). It is part of a locus that experiences
a loss of heterozygosity in human nasopharyngeal cancers
(Qian et al., 2001). Recently, UBAP1 was identified as a risk
factor in familial frontotemporal lobar dementia (FTLD) (Rollin-
son et al., 2009).
In contrast to the MVB12A and MVB12B subunits, which have
an N-terminal extension consisting of a MABP b-prism domain
(de Souza and Aravind, 2010), UBAP1 has a greatly expanded
C-terminal region, which contains three putative ubiquitin asso-
ciated (UBA) domains. A number of ubiquitin-binding domains
(UBDs) have been described, including CUE, UIM, NZF, UEV,
GLUE, GGA, GAT, and UBA (Dikic et al., 2009). The UBA domain
is the most frequently occurring UBD, with 84 sequences in the
human genome according to Pfam (http://pfam.sanger.ac.uk).
UBAs have about 45 residues folded into a compact three-helix
bundle with a right-handed twist. UBA domains have a
conserved signature motif M/L-G-Y/F in the a1/a2 loop that
forms part of the interaction with ubiquitin, and there is a
conserved di-leucine motif at the end of helix a3 (Hofmann and
Bucher, 1996; Mueller and Feigon, 2002; Ohno et al., 2005).
UBAs have been grouped in four classes according to their
preference for polyubiquitin linkages: K48-linked polyubiquitin,
K63-linked polyubiquitin, promiscuous recognition of multiple
polyubiquitin linkages, and no ubiquitin recognition (Raasi
et al., 2005). UBA domains typically also bind monoubiquitin,
but generally with much lower affinity.
UBAs have important roles in many different contexts,
including diverse degradative pathways. Several UBA-contain-
ing proteins, such as Rad23 and Dsk2, function as adaptors
for proteasome degradation (Clague and Urbe´, 2010). Degrada-
tion of polyubiquitinated protein aggregates depends on their
recruitment to autophagosomes by the UBA domain of p62
(Pohl, 2009). The ESCRT complexes involved in MVB sorting in
yeast contain a number of UBDs, including UIMs, VHS, NZF,
andUEV domains (Shields and Piper, 2011). However, disruption
of the individual UBDs in the ESCRT complexes does not
block the MVB pathway and only a quadruple mutant that is
completely defective for ubiquitin binding shows severe sorting
defects (Shields et al., 2009). Intriguingly, UBA domains are
absent from the MVB pathway in yeast.
We report here the structure of the C-terminal region of UBAP1
that folds as a solenoid of overlapping UBAs (SOUBA) domain.
NMR data show that each of the three UBA domains composing
SOUBA binds monoubiquitin. This is consistent with the specific
role of UBAP1 in endosomal sorting of ubiquitinated membrane
cargo as shown recently for EGFR by Woodman and colleagues
(Stefani et al., 2011). We show that UBAP1 is required for
ubiquitin-dependent degradation of the antiviral protein tetherin
triggered by the viral countermeasures HIV-I protein Vpu and
KSHV viral protein K5.
RESULTS
Composition and Stoichiometry of ESCRT-I Complexes
Containing UBAP1
Recombinant full-length human UBAP1, when coexpressed in
Escherichia coli together with ESCRT-I subunits VPS28,
TSG101, and VPS37A, forms a stable complex with 1:1:1:1
stoichiometry of the four subunits (Figure 1B; Figure S1 available
online). The cores of VPS37A, VPS37B, VPS37C, or VPS37D all
give rise to stable recombinant ESCRT-I complexes with UBAP1
in E. coli (Figure S1A). Endogenous UBAP1 from HEK293 cell
lysate eluted close to the 440 kDa marker in a complex contain-
ing TSG101 (Figure S1B). In addition, endogenous UBAP1 was
efficiently copurified with TSG101 and VPS37A from a cell line
stably expressing TSG101 with a One-Strep tag (OSHA-
TSG101) (Figure 1C). The OSHA-TSG101 fusion is expressed
at endogenous levels in these cells (McDonald and Martin-
Serrano, 2008), allowing affinity purification of TSG101-binding
proteins under physiological conditions. Similarly, endogenous
TSG101 also bound UBAP1 and VPS28 when these proteins
were overexpressed in 293T cells as GST fusions and purified
with glutathione beads (Figure S1C). As observed for other
ESCRT-I subunits, UBAP1 functionally recruits the ESCRT
machinery in a trans-complementation assay based on the
rescue of a L-domain defective HIV-1 by direct fusion of
a component of the ESCRTmachinery to a defective Gag protein
(Martin-Serrano et al., 2001). Expression of UBAP1 fused to the
C terminus of the complementing Gag protein restored infec-
tious virus production (Figures S1E–S1H).
Deletion analysis using recombinant proteins showed that the
N-terminal fragment of UBAP1 comprising residues 1 to 68 is
sufficient to form a stable complex with TSG101, VPS28, and
VPS37A (Figure 1D). This N-terminal construct corresponds to
the UMA domain (Figure 1A). Overexpression of UMA domain
constructs YFP-UBAP11-68 and YFP-UBAP11-92 in 293T cells
transfected with HIV-1 proviral DNA has a dominant negative
effect, resulting in approximately 5-fold inhibition of HIV-1 infec-
tious virus release (Figure S1D). This suggests that overexpres-
sion of the UBAP1’s ESCRT-I binding region disrupts the
stoichiometric composition or proper localization of endogenous
ESCRT-I, thus inhibiting HIV-1 budding, as previously shown for
TSG101 (Martin-Serrano et al., 2003).
To identify UMA residues necessary for interaction with other
ESCRT-I subunits, we tested point mutants in several conserved
residues of this domain for their ability to form ESCRT-I
complexes (UMA mutants M1 to M4 in Figure 1A). Given that
yeast Mvb12 is involved in direct contact with Vps37 (Kostelan-
sky et al., 2007), we tested the ability of UMA mutants to
assemble into ESCRT-I complexes containing either VPS37A
or VPS37B. Cells were transfected with plasmids expressing
GST-TSG101, Myc-VPS28, HA-VPS37A/B, and HA-UBAP1,
followed by purification using glutathione-coated beads and
immunodetection of tagged ESCRT-I subunits. Alanine substitu-
tions L17D18D19/AAA and V20P21F22/AAA (mutants M1 and M2)
led to a complete block in ESCRT-I binding (Figure 1E, lanes
4 to 7), whereas F28A (mutant M3) did not (Figure 1E, lanes 8
and 9). Interestingly, mutation of the conserved Glu-59 (E59A,
mutant M4) resulted in loss of binding to ESCRT-I when
HA-VPS37B was cotransfected but not when HA-VPS37A was
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Figure 1. UBAP1 Forms a Stable Heterotetrameric Complex with ESCRT-I Subunits TSG101, VPS28, and VPS37 In Vitro and In Vivo
(A) Schematic representation of the ESCRT-I heterotetramer illustrating the putative UBAP1 arrangement relative to other ESCRT-I subunits. The top sequence
alignment shows the UMA domain, also present in the C-terminal part of MVB12A and MVB12B. The bottom part shows a detailed view of the conserved
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present in the protein complex (Figure 1E, lanes 10 and 11), sug-
gesting that the VPS37 subunits interact directly with UBAP1.
These results were confirmed with the HIV-1 trans-complemen-
tation assay, showing that fusing UBAP1 constructs bearing the
mutations M1, M2, or M4 to Gag did not restore release of
a budding deficient HIV-1 as compared to wild-type UBAP1 or
M3, indicating that these residues are needed for UBAP1’s inter-
action with ESCRT-I components (Figure S1H).
UBAP1 Functions in MVB Sorting of the Antiviral
Protein Tetherin
Given the role of the ESCRT machinery in sorting ubiquitinated
membrane proteins, we tested the function of UBAP1 in this
process. We took advantage of the ability of several viruses to
reduce cell surface expression of the antiviral protein tetherin
in infected cells via the ESCRTmachinery. The first experimental
approach is based on HIV-1’s Vpu capacity to mediate tetherin
degradation. Thus, 293T cells stably expressing human tetherin
(293T/tetherin) were treated with UBAP1-specific siRNA or a
nontargeting control and subsequently were infected with either
HIV-1 (HIV-1 wt) or Vpu-defective HIV-1 (HIV-1 delVpu) as
a control. Tetherin was then immunoprecipitated, deglycosy-
lated, and visualized by western blot. As expected, cells infected
with HIV-1 wild-type have greatly reduced levels of tetherin
(Figure 2A). However, this tetherin degradation was prevented
in UBAP1-depleted cells infected with HIV-1 wild-type virus,
and a large amount of tetherin was detected in these cells.
This tetherin in UBAP1-depleted, HIV-1-infected cells is highly
ubiquitinated (compare the first and second lanes in Figure 2B),
suggesting that the ubiquitin-dependent sorting by the MVB
pathway is inhibited in the absence of UBAP1. Tetherin levels
in cells infected with a Vpu-defective HIV were high, similar to
uninfected cells. Despite the restoration of tetherin levels in the
UBAP1-depleted cells infected with wild-type HIV-1, viral
release was not affected (Figure 2C). As expected, Vpu-defec-
tive virus release was approximately 100-fold less efficient
than the wild-type virus in tetherin-expressing cells (Neil et al.,
2008), and UBAP1 depletion did not affect this. These results
show that, although Vpu induces targeting of tetherin for
UBAP1-dependent ESCRT-mediated degradation, tetherin’s
ultimate destruction is not mandatory for Vpu to counteract its
antiviral activity. Rather it suggests that Vpu interactions with
tetherin (prior to UBAP1/ESCRT-I recruitment) inactivate the
protein by committing it to an endosomal pathway from which
it cannot escape back to the cell surface to inhibit virus release.
Furthermore, the ability of tetherin to restrict HIV-1 delVpu
release equivalently in UBAP1-depleted cells suggests that this
knockdown has no significant effect on tetherin trafficking to
the plasma membrane.
The second approach to determine UBAP1’s function in endo-
somal sorting involved K5, a KSHV-encoded ubiquitin ligase that
reduces cell surface expression of tetherin (Mansouri et al., 2009;
Pardieu et al., 2010). We followed a knockdown approach in
HT1080 cells stably expressing an HA-tetherin construct in addi-
tion to K5 (HT1080/HA-THN/K5). A quantitative western blot
analysis was used to measure the total levels of HA-tetherin
present in these cells. As expected, cells expressing K5 ubiquitin
ligase had much lower levels of HA-tetherin (Figure 3A, lower
panel). Transfection of siRNAs targeting UBAP1 prevented
K5-mediated tetherin degradation, and tetherin protein levels
were significantly rescued (lower panel in Figure 3A). Impor-
tantly, no changes in HA-tetherin were found when the same
siRNAs were transfected into cells lacking K5. As a control,
depletion of TSG101 also resulted in impairment of HA-tetherin
degradation by K5 (Figure 3A). In agreement with the Vpu data,
high-molecular-weight forms of tetherin, suggesting ubiquiti-
nated species of the protein, were accumulated both in UBAP1
and TSG101 depleted cells (Figure 3A). Consistent with inhibition
of endosomal sorting in UBAP1-depleted cells, HA-tetherin
accumulated in intracellular punctae that display partial colocal-
ization with the late endosomal marker CD63 and with ubiquitin
(Figure 3B), a phenotype that is also observed in TSG101-
depleted cells. Overall, these results show that UBAP1 is re-
quired for MVB sorting of an ubiquitinated cargo protein, namely
tetherin.
UBAP1 Is Not Required for HIV-1 Budding or Cytokinesis
We also tested the role of UBAP1 in two other ESCRT-facilitated
processes, namely HIV-1 budding and the resolution of the mid-
body during cytokinesis. Surprisingly, depletion of UBAP1 (more
than 92%decrease in protein level) with two different siRNAs did
not alter significantly HIV-1 budding, whereas TSG101 depletion
inhibited infectious HIV-1 production as expected (Figure 4A). A
similarly negative result was obtained in cytokinesis: although
depletion of hIST1, an ESCRT-related protein essential for cyto-
kinesis (Agromayor et al., 2009; Bajorek et al., 2009), resulted in
cytokinesis failure and accumulation of multinucleated cells,
UBAP1 depletion did not (Figure 4B). The lack of an effect of
sequence corresponding to the SOUBA domain in the C-terminal region of UBAP1 from various species. Hallmark UBA residues homologous to the conserved
(M/L)-G-(Y/F) motif for the three successive UBA domains are identified by blue, pink, and orange triangles, respectively. Positions of the seven a helicesmapped
from the structure are shown above the alignment.
(B) Gel filtration of recombinant ESCRT-I containing UBAP1-His6 on a HiLoad 16/60 Superdex 200 column. The inset shows a Coomassie blue-stained
SDS-PAGE gel of the peak fraction containing the tetrameric ESCRT-I complex including UBAP1. See also Table S1 and Figure S1.
(C) ESCRT-I protein complexes from cells stably expressing One-Strep tagged TSG101 (OSHA-TSG101) were affinity purified on a Strep-Tactin matrix and
visualized by western blot. One percent of the starting cell lysate and 10% of the volume eluted from the matrix (pull-down) were analyzed by western blot with
anti-TSG101, anti-VPS37A, and anti-UBAP1 antibodies. As a control for the specificity of the binding, purification from cells stably expressing an empty vector
(OSHA) is also shown.
(D) Deletion analysis to determine the minimal ESCRT-I binding region on UBAP1. Recombinant UBAP1, either full length (lane 4) or N-terminal fragments
(1–92, lane 3; 1–77, lane 2; or 1–68, lane 1), with a His6 tag at the C terminus were coexpressed with TSG101/VPS28/VPS37A ESCRT-I components in E. coli
and purified by affinity chromatography and gel filtration. A Coomassie-stained SDS-PAGE of the purified complexes is shown.
(E) Coprecipitation studies to map the interaction of UBAP1 with ESCRT-I. 293T Cells were transfected with plasmids expressing GST-TSG101, Myc-VPS28,
HA-VPS37A/B, and HA-UBAP1 wild-type (WT) or mutant (M1 to M4), followed by purification using glutathione-coated beads. One percent of the starting cell
lysate and 10% of the volume eluted from the beads (pull-down) were analyzed by western blot with anti-HA antibody. See also Figure S1 and Table S1.
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UBAP1 depletion on cytokinesis is consistent with results
recently reported (Stefani et al., 2011). One possible explanation
for this lack of phenotype is that the residual amount of UBAP1
protein in siRNA treated cells might be sufficient to support
ESCRT-I function but the fact that similar levels of depletion in
control experiments result in endosomal defects (shown above)
argues against this possibility.
UBAP1 Is a Ubiquitin-Binding ESCRT-I Subunit
The specific requirement of UBAP1 in endosomal sorting and
the accumulation of ubiquitinated cargo after UBAP1 depletion
from the cell suggested that UBAP1 might promote recognition
of ubiquitinated cargo by ESCRT-I. We checked ubiquitin
binding in solution in a label-free setup, using isothermal titra-
tion calorimetry (ITC). Using a recombinant fragment of
UBAP1 consisting of the proposed UBA-containing region alone
(residues 389 to 502), the Kd for the interaction with ubiquitin
was about 70 mM (Figure 5A). This is on the higher-affinity end
of the 20–1300 mM range commonly observed for UBA domains
binding to monoubiquitin. Furthermore, this is a relatively high
affinity among UBDs in the ESCRT pathway. We also measured
binding of monoubiquitin to full-length UBAP1 in an ESCRT-I
complex containing a TSG101 subunit with the N-terminal ubiq-
uitin-binding UEV domain deleted in order to avoid ubiquitin
binding by TSG101. The apparent Kd for the interaction
between ESCRT-I/UBAP1 and monoubiquitin is about 140 mM
(Figure 5B). Because many UBAs bind K48-linked diubiquitin
with significantly higher affinity than monoubiquitin (typical
Kds for K48-linked diubiquitin are 1–10 mM) and some UBAs
bind K63-linked diubiquitin, we performed ITC experiments for
label-free K48-linked or K63-linked diubiquitin binding to the
SOUBA. We find that these diubiquitins bind the isolated
SOUBA with an affinity comparable to that observed with mono-
ubiquitin (Figure 5).
Structural Analysis of the C-Terminal UBA-Containing
Region of UBAP1
UBAP1 has two copies of an M/L-G-F/Y motif, which have
recently been shown by mutagenesis to be important for
endosomal sorting (Stefani et al., 2011). To gain insight into
Figure 2. UBAP1 Is Essential for Degradation of Tetherin Triggered by Viral Countermeasures
(A) Tetherin was immunoprecipitated from 293T cells stably expressing tetherin. The cells were uninfected (uninf), infected with HIV-1 (HIV-1 wt), or Vpu-defective
HIV-1 (HIV-1 delVpu) and were treated with irrelevant control siRNA (Cont) or with siRNAs against UBAP1 (UBAP1Q3 and UBAP1Q4). Western blots show the
immunoprecipitated tetherin (upper panel), siRNA-mediated silencing of the endogenous UBAP1 (middle panel), and the HSP90 as a protein loading control
(lower panel).
(B) Tetherin was immunoprecipitated from cells infected with HIV-1 (HIV-1 wt) and transfected with a plasmid expressing HA-tagged Ubiquitin and either control
(cont) or UBAP1 specific siRNA (UBAP1 Q3). Tetherin ubiquitination was visualized with anti-HA antibody (top panel, THN-Ubn). As a control, the same analysis
was performed in cells infected with a Vpu-defective HIV-1 (HIV-1 delVpu) and treated with an irrelevant siRNA (Cont). Bottom panels show immunoprecipitated
tetherin, UBAP1 depletion and tubulin as a loading control.
(C) Infectious HIV-1 virion production was measured by inoculation of TZM-bl indicator cells and is expressed as relative luminescence units (R.L.U.). Error bars
indicate the standard deviation from the mean of three independent experiments. See also Table S2.
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the organization and function of this region, we have deter-
mined its crystal structure and characterized its binding to
ubiquitin in solution by NMR. Two constructs covering the
UBAP1 C terminus, residues 381–502 and 389–502, produced
ample protein but did not crystallize. Therefore, we used the
surface entropy reduction approach (Derewenda, 2011) guided
by the SERp Server (Goldschmidt et al., 2007) (http://services.
mbi.ucla.edu/SER) to generate several mutants in which clus-
ters of charged surface residues were mutated to alanine.
One of these mutants, with 415-KKGE-418 mutated to AAGA,
readily crystallized. The 1.65 A˚ resolution crystal structure of
the UBA-containing C-terminal region from UBAP1 has two
molecules in the asymmetric unit that are linked to each other
through a disulfide bond. However, multiangle laser light scat-
tering indicates that the molecule is a monomer in solution
(data not shown). It appears that the disulfide-linked dimer is
formed as the protein oxidizes during the crystallization
process. The structure shows a single domain consisting of
seven a helices arranged as a right-handed solenoid that
contains three overlapping UBAs (UBA1, UBA2, and UBA3)
(Figure 6A). We will refer to this, to our knowledge, novel
domain as a solenoid of overlapping UBAs (SOUBA). The rela-
tionship of the SOUBA fold to conventional UBAs can best be
described by regarding the third helix of one UBAs being also
the first helix of the next UBA (Figures 6A and 6B). There are
several examples of proteins that have multiple UBAs con-
nected by linkers of low complexity that are probably structur-
ally disordered. However, this is the first example of a rigid
array of overlapping UBAs. The solenoid arrangement of the
three UBAs forms a convex surface containing helices one
and three from each UBA. The opposite face forms a concave
surface built from the second helix from each UBA. The angles
between helices in each of the UBAs are within the range
observed for other UBAs. Consequently, each of the compo-
nent UBAs align well with UBA structures from other proteins
(Figure 6C).
Interaction of the SOUBA with Monoubiquitin
Chemical shift perturbations (CSPs) of 15N-labeled ubiquitin on
the addition of unlabeled SOUBA show shifts of residues in
a hydrophobic patch on the surface of the ubiquitin that
includes Ile44 and Val70 (Figures 7A–7C). Extensive structural
analysis of diverse UBAs interacting with monoubiquitin has
shown that the interaction surface on UBAs commonly includes
two hydrophobic UBA patches, at the end of helix a1/loop 1
and on helix a3 (Zhang et al., 2008). Binding to K48-linked poly-
ubiquitin typically includes an additional patch on a2 and the
other side of a3. CSPs of the 15N-labeled SOUBA domain on
addition of three molar equivalents of unlabeled monoubiquitin
indicate that each of the three overlapping UBAs is influenced
by ubiquitin binding (Figures 7D–7F). The residues showing
the greatest perturbation lie along the convex face of the
SOUBA domain and cover an extended hydrophobic surface
(Figure 7F). The signature M/L-G-F/Y motifs are located along
one side of the SOUBA domain, and CSPs suggest that these
residues are involved in binding ubiquitin. This is consistent
with the ubiquitin binding that has been reported for UBAs
from other proteins (Long et al., 2008; Ohno et al., 2005; Vara-
dan et al., 2005; Zhang et al., 2008). The second UBA in the
UBAP1 SOUBA lacks the signature motif, and instead, it has
a KGF sequence in the analogous position. Nevertheless,
CSP mapping suggests that this KGF motif is also involved in
ubiquitin binding, because it has the highest CSP of all residues
upon ubiquitin binding. In addition to residues in these signature
motifs, other residues along the same face of the SOUBA also
show CSPs that are greater than 0.2 ppm. For UBA1 and
UBA2, almost all of these residues are at the end of the first
helix and on one face of the third helix within the UBAs.
Although the ‘‘di-leucine’’ motif in the third helix of UBA
domains is a second general signature motif, the equivalent
residues in SOUBA (residues 427-LF in UBA1, 461-LQ in
UBA2, and 495-LM in UBA3) do not show large CSPs on ubiq-
uitin binding. The leucine in each of these motifs is involved in
helical packing in the hydrophobic core. The largest CSPs
that we observe in UBA1 and UBA2 are consistent with interac-
tions that are typical of previously characterized UBA/monoubi-
quitin-interacting surfaces. However, the SOUBA UBA3 has a
broader distribution of residues with large CSPs on all three
of its helices, including a region that has been referred to as
the ‘‘backside’’ of the third UBA helix. This could be due to
conformational changes in the third UBA on ubiquitin binding,
or due to an additional ubiquitin-binding site.
Paramagnetic relaxation enhancement (PRE) measurements
were performed to probe directly the binding of each of the
three UBA domains in SOUBA to ubiquitin and to investigate
the relative orientation of SOUBA and monoubiquitin in the
complex. A paramagnetic spin label (SL) was attached to
a cysteine residue replacing a lysine in ubiquitin, in order to
induce a strong signal attenuation in nuclei that are near the
SL. Figure 7 depicts signal attenuations in the SOUBA in
a complex with ubiquitin spin-labeled at either residue 6
(K6C mutant, Figures 7G and 7H) or residue 48 (K48C mutant,
Figures 7I and 7J), compared to the same complexes in which
the SL probe is inactivated by ascorbic acid. The results clearly
show three regions of significant attenuation for K6C-SL
ubiquitin (corresponding to the end of helix 1 and the
loop between helix 1 and helix 2; the end of helix 3 and the
loop between helix 3 and helix 4; the end of helix 5 and
the loop between helix 5 and helix 6). Four regions of attenua-
tion were observed on SOUBA with the K48C-SL ubiquitin (the
loop between helix 1 and helix 2; the end of helix 3 and the
loop between helix 3 and helix 4; the end of helix 5 and
the loop between helix 5 and helix 6; and the end of helix 7).
The additional signal attenuation observed for K48C-SL would
suggest that the spin-label in K48C ubiquitin is close in space
to two regions of each UBA motif. No paramagnetic effects
were observed with D39C and S57C spin-labeled monoubiqui-
tins. A model of the SOUBA bound to three monoubiquitin
molecules reveals how the SL could achieve the effects
observed (Figures 7H and 7J). The PRE measurements appear
to match those observed by Zhang et al. (2008) when SL were
used to investigate binding of the UBA domain of ubiquilin-1
with monoubiquitin. It is worth noting that the attachment of
the SL to the mutant ubiquitins did not affect their ability to
interact with SOUBA. Comparison of the NMR spectra of
15N-SOUBA in the presence of WT-Ub and SL-Ub (K6C,
K39C, K48C, and K57C) revealed that the same CSP and
relaxation regimes were observed.
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Figure 3. UBAP1 Depletion Prevents K5-Mediated Tetherin Degradation
(A) Western blots of cell lysates from HT1080 cells stably expressing HA-tetherin alone (HT1080:HA-THN) or in combination with K5 (HT1080:HA-THN/K5) and
treated with siRNAs against an irrelevant control (cont), TSG101 or UBAP1. THN-HA was detected with anti-HA antibody, with tubulin as a loading control and
visualized using Li-Cor fluorescently coupled 650 and 800 nm secondary antibodies. The graphs show the percentage of mature tetherin levels, normalized to
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DISCUSSION
The results presented in this study demonstrate that recombi-
nant UBAP1 assembles with TSG101, VPS28, and VPS37 into
a complex with a 1:1:1:1 stoichiometry and, importantly, this
interaction is also observed in vivo with endogenous UBAP1
and physiological levels of the remaining ESCRT-I subunits.
Codepletion of TSG101 and UBAP1 in cells treated with
siRNA against TSG101 suggests that endogenous UBAP1 is
stabilized by its interaction with TSG101. Moreover, UBAP1’s
ability to functionally recruit the ESCRT machinery in
a TSG101-dependent manner provides further evidence for
a functional link between UBAP1 and ESCRT-I. On the basis
of these observations, we propose that UBAP1 is a stable
subunit of human ESCRT-I. While this manuscript was in
preparation, Woodman and colleagues have reported findings
tubulin loading. Error bars indicate the standard deviation from themean of three independent experiments. Lower panels show depletion of TSG101 andUBAP1,
and tubulin as a loading control.
(B) Confocal immunofluorescence showing localization of tetherin, CD63, and ubiquitin in cells treated with either control siRNA-, TSG101-, or UBAP1-specific
siRNA. A higher magnification of the boxed areas is shown in TSG101- and UBAP1-treated panels. In the overlay panels, DNA is shown in blue, tetherin in green,
and CD63 or ubiquitin in red. See also Table S3.
Figure 4. Role of UBAP1 in ESCRT-I Medi-
ated HIV-1 Release and Cytokinesis
(A) Infectious virus release upon coexpression of
an HIV-1 provirus with an irrelevant siRNA (Cont),
siRNA against TSG101 or two different siRNAs
against UBAP1. Western blots show intracellular
TSG101, UBAP1, and HSP90 (protein loading
control) as well as intracellular (cell lysates) and
virion-associated (virions) HIV Gag protein.
(B) Quantification of cells with multiple nuclei after
treatment with the irrelevant control siRNA (Cont),
siRNA against hIST1 (positive control), or with
either of the two different siRNAs against UBAP1.
As for (A), western blots show siRNA-mediated
silencing of the endogenous hIST1 and UBAP1
and HSP90 as a protein loading control. Error bars
indicate the standard deviation from the mean of
three independent experiments.
that are entirely consistent with our
results (Stefani et al., 2011).
In a recombinant system, UBAP1 can
form heterotetrameric complexes with
TSG101, VPS28, and each of the four
VPS37 subunits. Our results also show
that transiently transfected VPS37A and
VPS37B form UBAP1-containing
complexes in 293T cells. Similarly,
a recent study of UBAP1 expressed in
HeLa cells showed complex formation
with VPS37A. However, the same study
did not detect formation of UBAP1
complexes with VPS37C (Stefani et al.,
2011). This could mean that additional
factors such as posttranslational modifi-
cations could modulate the association
between UBAP1 and VPS37 subunits in
cells. Little is known about the tissue distribution and cellular
abundance of different VPS37 subunits or competing MVB12A
and MVB12B, all of which could affect association with UBAP1.
UBAP1’s function is exclusively required for degradation of
ubiquitinated endosomal cargo but not for other ESCRT-I-medi-
ated processes such as midbody abscission or viral budding.
More specifically, we show that UBAP1-containing ESCRT-I
complexes are parasitized by viral immunomodulatory proteins
that target host membrane proteins for endosomal degradation,
in particular the targeted destruction of the antiviral protein
tetherin by both HIV-1 Vpu and KSHV K5 ubiquitin ligase. The
essential role of UBAP1 in K5 function is entirely consistent
with previous findings showing the ESCRT-dependent destruc-
tion of tetherin via a single lysine in its cytoplasmic tail (Mansouri
et al., 2009; Pardieu et al., 2010). In contrast, the pathway
involved in tetherin degradation and antagonism by Vpu has
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Figure 5. Ubiquitin Binding to UBAP1
Binding of human UBAP1 SOUBA domain (389–502) or UBAP1-containing ESCRT-I complex consisting of full-length UBAP1, VPS28 (full-length), TSG101 (198–
390, i.e., lacking the UEV domain) and VPS37A (229–397, i.e., lacking the UEV domain). The experimental data (squares) were fit using a bindingmodel for a single
set of independent sites. The mean Kd and standard deviation were calculated from three independent measurements.
(A) ITC titration of monoubiquitin into a cell containing the UBAP1 SOUBA domain (389–502), with the thermogram shown on top and integrated peaks shown on
bottom.
(B) ITC titration of monoubiquitin into a cell containing ESCRT-I with full-length UBAP1: thermogram (top) and integrated peaks (bottom).
(C) ITC titration of the SOUBA domain into a cell containing K63 diubiquitin: thermogram (top) and integrated peaks (bottom).
(D) ITC titration of the SOUBA domain into a cell containing K48 diubiquitin: thermogram (top) and integrated peaks (bottom).
Structure
UBAP1 Is Required for Tetherin Degradation
422 Structure 20, 414–428, March 7, 2012 ª2012 Elsevier Ltd All rights reserved
been less clear (Martin-Serrano and Neil, 2011). Although early
studies suggested that Vpu induced proteasomal degradation
of tetherin (Goffinet et al., 2009), more recent reports show
that, in HIV-1-infected cells, tetherin is targeted to lysosomes
(Douglas et al., 2009; Iwabu et al., 2009; Mitchell et al., 2009)
and its inactivation is dependent on an association with Hrs
(ESCRT-0) (Janvier et al., 2011). Our demonstration that
UBAP1 is essential for Vpu-induced tetherin destruction shows
that tetherin is degraded in the MVB pathway rather than by
the proteasome. However, it is also clear that tetherin degrada-
tion is not a prerequisite for Vpu activity. Even though tetherin is
not degraded in UBAP1-depleted cells and accumulates in
endosomes, Vpu is still able to efficiently counteract tetherin’s
antiviral activity.
A Model of Ubiquitin Binding to the SOUBA
At a mechanistic level, we demonstrate the ability of UBAP1 to
promote the interaction of ESCRT-I with ubiquitin. A UBAP1-
containing ESCRT-I complex is able to bind ubiquitin via the
SOUBA domain located in the C-terminal region of UBAP1.
The importance of this interaction is suggested by a reported
frameshift mutation that precisely removes the SOUBA domain
(S391Afs21X) in one case of familial frontotemporal lobar degen-
eration (Rollinson et al., 2009). Accordingly, mutations in the
SOUBA domain disrupt sorting of endosomal cargo (Stefani
et al., 2011). To our knowledge, the structure of this region shows
a novel ubiquitin-binding fold, the SOUBA domain. The ability
of UBAP1 to bind monoubiquitin may be important for the
function of the ESCRT-I pathway, because half of conjugated
ubiquitin is in the form of monoubiquitin or endcaps of polyubi-
quitin chains (Ziv et al., 2011), and monoubiquitination is a suffi-
cient signal for vacuolar/lysosomal traffic (Stringer and Piper,
2011).
By superimposing the SOUBA domain on different UBAs
whose structures have been solved in complexes with monou-
biquitin, it is possible to generate a model of the SOUBA
bound to ubiquitin. In this model, SOUBA can easily accommo-
date three monoubiquitins adjacent to each other, on the
convex face of the domain (Figure 8). Each of the three UBAs
engages with the hydrophobic patch of ubiquitin that includes
Ile44 and Val70. Both the CSPs observed for 15N-labeled ubiqui-
tin upon addition of an excess of unlabelled SOUBA (Figure 7C)
and the relaxation induced by a paramagnetic probe attached
to ubiquitin in complex with the SOUBA (Figures 7G–7J), are
Figure 6. Overlapping UBAs Build a Compact SOUBA Domain
(A) Overview of UBAP1 SOUBA domain (389–502), showing the tandem arrangement of the three overlapping UBA domains rainbow colored from N terminus
(blue) to C terminus (red).
(B) Sequence alignment of each of the threeUBAdomains of UBAP1with three other well-characterizedUBAdomains. UBA signaturemotif residues are shown in
red and represented as sticks in (A). Residues mutated in the SOUBA crystal structure are shown with a blue background.
(C) Structural alignment of each of the three UBAP1 UBA domains with the three previously reported UBA domains present in the sequence alignment (B), namely
Ubiquilin1 (2JY5) in light gray, DSK2 UBA (2BWB) in medium gray, and HHR23A UBA2 (1DV0) in dark gray. See also Table 1.
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Figure 7. UBAP1 Interactions with Monoubiquitin Detected by NMR Chemical Shift Perturbations
(A) Overlay of HSQC spectra of 15N-labeledmonoubiquitin in the absence (black) and presence (red) of 2.5molar equivalents of unlabeled UBAP1 SOUBA. Amide
resonances with significant chemical shift changes have been annotated.
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consistent with this model of ubiquitin binding. In this model, the
orientations of the ubiquitins would not appear to allow the ubiq-
uitins occupying adjacent sites on the SOUBA to be linked to
each other either through K48 or K63 isopeptide bonds. This is
consistent with our ITC results suggesting that these linkages
bind no better than monoubiquitin to the SOUBA (Figure 5).
Previous NMR studies of UBAs from several different proteins
in the presence of K48-linked diubiquitin suggest a second
binding site for the secondubiquitin involving a separate interface
on the UBA (Sims et al., 2009; Song et al., 2009; Trempe et al.,
2005; Varadan et al., 2005). The solenoid arrangement of the
SOUBA would appear to block this type of binding, at least for
the first two UBAs.
The NMR data demonstrate that each of the three UBAs
is involved in ubiquitin binding, but it remains to be shown
whether all three UBAs can bind ubiquitin simultaneously. We
tried investigating the affinity of each UBA for ubiquitin by
generating double point mutants in the (M/K)G(F/Y) motifs: we
constructed three mutant SOUBAs, each having only one func-
tional UBA. However, NMR HSQC spectra revealed that each of
these mutants was unstructured, preventing further study.
ITC results for the full-length UBAP1 in the ESCRT-I complex
show a lower affinity for monoubiquitin than the isolated
SOUBA domain. This might suggest a more restricted access
to the SOUBA in the ESCRT-I complex. Because of the difficul-
ties associated with producing sufficient quantities of diubiqui-
tin, it was not possible to determine the affinity of UBAP1-
containing ESCRT-I for K63-linked and K48-linked diubiquitin
by ITC.
Because the shape of the SOUBA domain and the interaction
sites mapped by NMR lead to a model in which three bound
ubiquitins are aligned and close enough to be attached via
some other type of linkage than K48 or K63, it will be exciting
to examine UBAP1 affinities for other polyubiquitin linkages.
Alternatively, in addition to providing a grip on monoubiquiti-
nated cargo, the SOUBA domain could enable avid interaction
with multiply monoubiquitinated cargoes, or monoubiquitinated
clustered cargoes. All of these are frequent passengers in the
ESCRT-dependent sorting to MVBs.
EXPERIMENTAL PROCEDURES
Plasmid Construction
Human UBAP1 was amplified by PCR from IMAGE clone 40011243. All dele-
tions and point mutant derivatives were generated by PCR in a similar way. All
of the constructs used in the study are listed in Table S1.
Expression and Purification of Recombinant ESCRT-I Proteins
Genes coding for human VPS28 (full length or 1-122), TSG101 (198-390),
VPS37A (229-397), andUBAP1 (full length or deletion variantswith aC-terminal
His6-tag) were cloned in a polycistronic coexpression vector as described
Figure 8. Model of Monoubiquitin Binding
to the UBAP1 SOUBA
The UBA1, UBA2, and UBA3 are colored blue,
yellow, and red, respectively. UBAP1 residues
showing a CSP >0.2 ppm upon binding to mono-
ubiquitin are shown as green sticks. Three mon-
oubiquitins have been docked on the basis of
superposition of each UBA domain with the ubiq-
uilin UBA domain in complex with ubiquitin (PDB
ID 2JY6). Ubiquitin residues with CSPs >0.2 ppm
upon binding to the UBAP1 SOUBA are shown as
magenta sticks. The PRE and CSPmeasurements
show that all three UBAs bind ubiquitin. The
gradual addition of substoichiometric amounts of
ubiquitin causes chemical shifts for residues in all
three UBA motifs, suggesting that there is no
preference for the binding of ubiquitin to one site
versus another. The NMR data indicated that
binding occurs at each of the sites, but cannot
distinguish whether one, two, or three molecules
are bound at the same time. Nevertheless, there
appear to be no steric clashes in the model that
would prevent all three ubiquitins binding simul-
taneously.
(B) Plot of chemical shift perturbations (CSPs) for 15N-labeled monoubiquitin as a function of residue number. Proline residues (for which no data are available)
have been assigned a value of 0 ppm and are marked by an asterisk.
(C) CSPs for monoubiquitin mapped onto its structure.
(D) Overlay of HSQC spectra of 15N-labeled SOUBA in the absence (black) and presence (red) of three molar equivalents of unlabeled monoubiquitin.
(E) Plot of CSPs for 15N-labeled SOUBA as a function of residue number.
(F) CSPs for SOUBA mapped onto its structure.
(G–J) Paramagnetic relaxation enhancement effects in the SOUBA/Ub complex induced by the spin label attached to the K6C (G) and K48C (I) mutant ubiquitins.
The graphs plot experimental PREs observed in SOUBA upon addition of the SL-ubiquitin against residue number. Significant paramagnetic effects are illustrated
in green on a model of SOUBA bound to three molecules of ubiquitin for K6C-SL (H) and K48C-SL (J). The side chains of K6 and K48 (mutated to a Cys for spin
labeling) are shown as salmon sticks.
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elsewhere (Teo et al., 2006). The constructs expressed are listed in Table S1.
The expression and purification was performed as described in Supplemental
Experimental Procedures.
Expression and Purification of SOUBA
Human SOUBA domain (UBAP1 389-502) either wild-type or containing the
K415A, K416A, and E418A triple mutation was cloned in the pOPTH(tev)
expression vector downstream of an N-terminal His6-tag followed by a TEV
protease cleavage site. The expression and purification were performed as
described in Supplemental Experimental Procedures.
Crystallization, Data Collection, and Refinement of SOUBA
Seleno-methionine crystals of the human SOUBA domain (UBAP1 389-502)
with the K415A, K416A, and E418A triple mutation designed to reduce surface
enthropy charge (using SERp server: http://services.mbi.ucla.edu/SER/)
were used for crystallization (see Supplemental Experimental Procedures
and Table 1).
Isothermal Titration Calorimetry
Assays were performed using a Microcal ITC200, in 20 mM Tris-HCl (pH 7.5),
100 mM NaCl, and 1 mM TCEP. The ITC cell contained either the SOUBA
domain (UBAP1(389-502)) at 150 mM or full-length UBAP1 associated with
VPS28 (full-length), TSG101 (198-390, i.e., lacking the UEV domain), and
VPS37A (229-397, i.e., lacking the UEV domain), at 75 mM and was titrated
with 38 injections of monoubiquitin (SIGMA U6253) at 3 mM. Assays on
K63-linked and K48-linked diubiquitins were performed having diubiquitin in
the cell at 100 mM, titrated by 38 injections of the SOUBA domain at
2.3 mM. Data were fit with a binding model employing a single set of indepen-
dent sites.
Expression and purification of paramagnetically labeled monoubiquitin was
performed as described in Supplemental Experimental Procedures.
NMR Spectroscopy
Wild-type SOUBA (UBAP1_389-502) samples prepared for NMR spectros-
copy experiments were typically 1.0 mM in 90% H2O and 10% D2O in PBS
with 10 mM DTT. All spectra were acquired with either a Bruker Advance
700 or a DRX600 spectrometer at 20!C, and referenced relative to external
sodium 2,2-dimethyl-2-silapentane-5-sulfonate (DSS) for proton and carbon
signals, or liquid ammonium for nitrogen. Assignments were obtained using
standard NMRmethods with 13C/15N-labeled and 15N-labeled samples. Back-
bone assignments were obtained using the following standard set of 2D and
3D heteronuclear spectra: 1H-15N HSQC, HNCACB, CBCA(CO)NH, HACACO,
HNCO, CCCONH, and 1H-13C HSQC. HSQC titrations were performed using
0.5 mM 15N-labeled UBAP1 and varying concentrations of unlabeled ubiquitin.
Similar titrations were performed with 0.3 mM 15N-labeled ubiquitin and unla-









where DdH and DdN are the observed chemical shift changes for
1H and 15N,
respectively. Paramagnetic experiments were performed using sample con-
taining 0.3 mM SOUBA and 0.3 mM chemically modified monoubiquitin.
Generation of Stable Cell Lines
HT1080/THN-HA K5 cells have been described elsewhere (Pardieu et al.,
2010). To generate HeLa OSHA-TSG101, 293T cells were transfected with
100 ng of pHIT-VSVG, 700 ng of MLV-GagPol, and 200 ng of the pCMS28
retroviral packaging vector for 48 hr. Viral-containing supernatants were
collected and used to transduce HeLa. Selection with puromycin (200 ng/ml)
was applied 48 hr later, and cells were passaged under continual selection.
Coprecipitation Assays
These were performed as described in Supplemental Experimental
Procedures.
HIV Infectivity Assays
Cells (293T) were transfected with 250 ng of the YFP fusions and 300 ng of
pNL/HXB using polyethylenimine. Culture supernatants, collected 48 hr after
transfection, were clarified by low-speed centrifugation, and particles present
in 250 ml were obtained by centrifugation through a 20% sucrose cushion at
14,000 rpm for 2 hr. Viral protein content in cell and particle lysates was
analyzed bywestern blotting with an anti-Gag antibody. Alternatively, indicator
HeLa-TZM-bl cells (CD4+, CXCR4+, CCR5+, HIV-1 LTR- LacZ) (Derdeyn et al.,
2000) were infected with 1 ml of supernatant and 48 hr later, b-galactosidase
activities in cell lysates were measured using the chemiluminescent detection
reagent Galacto-Star (Applied Biosystems).
To assay inhibition of viral production by siRNA-mediated depletion of
cellular UBAP1, 293T cells were initially transfected with 50 pmol of siRNA
using Dharmafect1 (Dharmacon) and were split the next day. Forty-eight hours
after initial transfection, cells were cotransfected with 50 pmol of siRNA and
the HIV proviral plasmid using lipofectamine 2000 (Invitrogen). The detailed
sequence of the siRNA oligos used is provided in Table S2. The plasmids
and method for the trans-complementation assay have been described previ-
ously (Martin-Serrano et al., 2001).
Multinucleation Assays
The multinucleation assays for HeLa cells were performed as described in
Supplemental Experimental Procedures.
Vpu-Mediated Tetherin Degradation Assay
Subconfluent 293T cells stably expressing tetherin were seeded in a six-well
plate and 2 hr after plating were transfected with 50 pmol of siRNA using
Table 1. Crystallographic Statistics




a, b, c (A˚) 34.40, 43.48, 59.41
a, b, g (!) 102.57, 96.47, 113.24
Wavelength 0.98
Resolution (A˚) 38.3 (1.65)a
Rsym or Rmerge 0.055 (0.54)
I / sI 9.9 (1.9)















Bond lengths (A˚) 0.0165
Bond angles (!) 1.536
aThe values in parentheses are for the highest resolution shell, 1.74 A˚ to
1.65 A˚.
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Dharmafect-1 (Dharmacon). Forty-eight hours later, cells were reseeded and
transfected again with 50 pmol of siRNA. Six hours after the second RNAi
transfection, cells were infected with HIV-1 wild-type or Vpu-deficient at an
MOI of 2. At 48 hr after infection, the cells were lysed on ice for 30 min in buffer
containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, complete protease inhib-
itors (Roche), and 1% digitonin (Calbiochem). After removal of the nuclei, the
resulting supernatants were incubated with 1 mg/ml mouse anti-tetherin
(eBiosciences) for 2 hr at 4!C before addition of 40 ml of protein G-agarose
(Invitrogen) for a further 3 hr. The beads were then washed four times in lysis
buffer containing 0.1% digitonin. After the final wash, beads were resus-
pended in water and treated with the protein deglycosylation kit from New
England Biolabs under denaturing conditions as specified by the supplier.
Samples were resuspended in SDS-PAGE loading buffer and cell lysates
and immunoprecipitates were then western blotted for tetherin using rabbit
anti-BST2 (kindly provided by K. Strebel through the NIH ARRP).
K5-Mediated Tetherin Degradation Assay
Total tetherin-HA levels were analyzed by western blot of cell lysates after
siRNA treatment of HT1080 cells stably expressing HA-tetherin alone
(HT1080:HA-THN) or in combination with K5 (HT1080:HA-THN/K5). Tetherin-
HA was detected with anti-HA antibody, with tubulin as a loading control,
and visualized using Li-Cor fluorescently coupled 650 and 800 nm secondary
antibodies.
Western Blot Analysis
Cell extracts, as well as virion lysates, were separated on 10% or 12% poly-
acrylamide gels and transferred to nitrocellulose membranes. A list of anti-
bodies used is provided in Table S3.
Immunofluorescence Microscopy
HT1080:HA-THN and HT1080:HA-THN/K5 cells were treated with siRNA as
described above for the multinucleation assays. At 24 hr after transfection,
the cells were fixed in 4% paraformaldehyde, permeabilized in 0.1% Triton
X-100, and immunostained using a rabbit anti-HA antibody (Rockland) and
mouse anti-CD63 (Developmental studies Hybridoma Bank. University of
Iowa) or mouse anti-Mono and polyubiquitylated conjugates (clone FK2)
(Enzo Life Sciences) followed by the appropriate donkey secondary antibodies
coupled to Alexa 488 and 594 fluorophores (Invitrogen). Nuclei were visualized
using Hoechst 33258 and coverslips were mounted in Mowiol. Images were
taken using a Leica AOBS SP2 confocal microscope.
SUPPLEMENTAL INFORMATION
Supplemental Information includes one figure, three tables, and Supplemental
Experimental Procedures and can be found with this article online at doi:10.
1016/j.str.2011.12.013.
ACKNOWLEDGMENTS
J.M.S. is funded by the Lister Institute, the EMBO Young Investigator Pro-
gramme, and the Medical Research Council (grant G0802777). J.M.S. and
M.A. are funded by theWellcome Trust (grant WT093056MA). R.L.W. is funded
by the Wellcome Trust (grant 083639/Z/07/Z) and the Medical Research
Council (file referenceU105184308). We thankMichael Hadders for comments
on the manuscript, Chris Johnson for help with ITC, and Stephen McLaughlin
for help with Octet measurements. We thank David Cobessi and Elspeth Gor-
don for help with data collection at ESRF beamlines BM30A and ID23-1,
respectively.
Received: August 22, 2011
Revised: December 13, 2011
Accepted: December 30, 2011
Published: March 6, 2012
REFERENCES
Agromayor, M., Carlton, J.G., Phelan, J.P., Matthews, D.R., Carlin, L.M.,
Ameer-Beg, S., Bowers, K., and Martin-Serrano, J. (2009). Essential role of
hIST1 in cytokinesis. Mol. Biol. Cell 20, 1374–1387.
Bache, K.G., Slagsvold, T., Cabezas, A., Rosendal, K.R., Raiborg, C., and
Stenmark, H. (2004). The growth-regulatory protein HCRP1/hVps37A is
a subunit of mammalian ESCRT-I and mediates receptor down-regulation.
Mol. Biol. Cell 15, 4337–4346.
Bajorek, M., Morita, E., Skalicky, J.J., Morham, S.G., Babst, M., and
Sundquist, W.I. (2009). Biochemical analyses of human IST1 and its function
in cytokinesis. Mol. Biol. Cell 20, 1360–1373.
Bartee, E., McCormack, A., and Fru¨h, K. (2006). Quantitative membrane pro-
teomics reveals new cellular targets of viral immune modulators. PLoS
Pathog. 2, e107.
Baumga¨rtel, V., Ivanchenko, S., Dupont, A., Sergeev, M., Wiseman, P.W.,
Kra¨usslich, H.G., Bra¨uchle, C., Mu¨ller, B., and Lamb, D.C. (2011). Live-cell
visualization of dynamics of HIV budding site interactions with an ESCRT
component. Nat. Cell Biol. 13, 469–474.
Bucher, P., Karplus, K., Moeri, N., and Hofmann, K. (1996). A flexible motif
search technique based on generalized profiles. Comput. Chem. 20, 3–23.
Carlton, J.G., andMartin-Serrano, J. (2007). Parallels between cytokinesis and
retroviral budding: a role for the ESCRT machinery. Science 316, 1908–1912.
Clague, M.J., and Urbe´, S. (2010). Ubiquitin: same molecule, different degra-
dation pathways. Cell 143, 682–685.
de Souza, R.F., and Aravind, L. (2010). UMA andMABP domains throw light on
receptor endocytosis and selection of endosomal cargoes. Bioinformatics 26,
1477–1480.
Derdeyn, C.A., Decker, J.M., Sfakianos, J.N., Wu, X., O’Brien, W.A., Ratner, L.,
Kappes, J.C., Shaw, G.M., and Hunter, E. (2000). Sensitivity of human immu-
nodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by corecep-
tor specificity defined by the V3 loop of gp120. J. Virol. 74, 8358–8367.
Derewenda, Z.S. (2011). It’s all in the crystals.. Acta Crystallogr. D Biol.
Crystallogr. 67, 243–248.
Dikic, I., Wakatsuki, S., and Walters, K.J. (2009). Ubiquitin-binding domains—
from structures to functions. Nat. Rev. Mol. Cell Biol. 10, 659–671.
Douglas, J.L., Viswanathan, K., McCarroll, M.N., Gustin, J.K., Fru¨h, K., and
Moses, A.V. (2009). Vpu directs the degradation of the human immunodefi-
ciency virus restriction factor BST-2/Tetherin via a betaTrCP-dependent
mechanism. J. Virol. 83, 7931–7947.
Eastman, S.W., Martin-Serrano, J., Chung, W., Zang, T., and Bieniasz, P.D.
(2005). Identification of human VPS37C, a component of endosomal sorting
complex required for transport-I important for viral budding. J. Biol. Chem.
280, 628–636.
Goffinet, C., Allespach, I., Homann, S., Tervo, H.M., Habermann, A., Rupp, D.,
Oberbremer, L., Kern, C., Tibroni, N., Welsch, S., et al. (2009). HIV-1 antago-
nism of CD317 is species specific and involves Vpu-mediated proteasomal
degradation of the restriction factor. Cell Host Microbe 5, 285–297.
Goldschmidt, L., Cooper, D.R., Derewenda, Z.S., and Eisenberg, D. (2007).
Toward rational protein crystallization: aWeb server for the design of crystalliz-
able protein variants. Protein Sci. 16, 1569–1576.
Henne, W.M., Buchkovich, N.J., and Emr, S.D. (2011). The ESCRT pathway.
Dev. Cell 21, 77–91.
Hofmann, K., and Bucher, P. (1996). The UBA domain: a sequence motif
present in multiple enzyme classes of the ubiquitination pathway. Trends
Biochem. Sci. 21, 172–173.
Hurley, J.H., and Stenmark, H. (2011). Molecular mechanisms of ubiquitin-
dependent membrane traffic. Annu. Rev. Biophys. 40, 119–142.
Iwabu, Y., Fujita, H., Kinomoto, M., Kaneko, K., Ishizaka, Y., Tanaka, Y., Sata,
T., and Tokunaga, K. (2009). HIV-1 accessory protein Vpu internalizes cell-
surface BST-2/tetherin through transmembrane interactions leading to lyso-
somes. J. Biol. Chem. 284, 35060–35072.
Janvier, K., Pelchen-Matthews, A., Renaud, J.B., Caillet, M., Marsh, M., and
Berlioz-Torrent, C. (2011). The ESCRT-0 component HRS is required for
Structure
UBAP1 Is Required for Tetherin Degradation
Structure 20, 414–428, March 7, 2012 ª2012 Elsevier Ltd All rights reserved 427
HIV-1 Vpu-mediated BST-2/tetherin down-regulation. PLoS Pathog. 7,
e1001265.
Jouvenet, N., Zhadina, M., Bieniasz, P.D., and Simon, S.M. (2011). Dynamics
of ESCRT protein recruitment during retroviral assembly. Nat. Cell Biol. 13,
394–401.
Katzmann, D.J., Babst, M., and Emr, S.D. (2001). Ubiquitin-dependent sorting
into the multivesicular body pathway requires the function of a conserved en-
dosomal protein sorting complex, ESCRT-I. Cell 106, 145–155.
Kostelansky, M.S., Sun, J., Lee, S., Kim, J., Ghirlando, R., Hierro, A., Emr, S.D.,
and Hurley, J.H. (2006). Structural and functional organization of the ESCRT-I
trafficking complex. Cell 125, 113–126.
Kostelansky, M.S., Schluter, C., Tam, Y.Y., Lee, S., Ghirlando, R., Beach, B.,
Conibear, E., and Hurley, J.H. (2007). Molecular architecture and functional
model of the complete yeast ESCRT-I heterotetramer. Cell 129, 485–498.
Long, J., Gallagher, T.R., Cavey, J.R., Sheppard, P.W., Ralston, S.H., Layfield,
R., and Searle, M.S. (2008). Ubiquitin recognition by the ubiquitin-associated
domain of p62 involves a novel conformational switch. J. Biol. Chem. 283,
5427–5440.
Mansouri, M., Viswanathan, K., Douglas, J.L., Hines, J., Gustin, J., Moses,
A.V., and Fru¨h, K. (2009). Molecular mechanism of BST2/tetherin downregula-
tion by K5/MIR2 of Kaposi’s sarcoma-associated herpesvirus. J. Virol. 83,
9672–9681.
Martin-Serrano, J., and Neil, S.J. (2011). Host factors involved in retroviral
budding and release. Nat. Rev. Microbiol. 9, 519–531.
Martin-Serrano, J., Zang, T., and Bieniasz, P.D. (2001). HIV-1 and Ebola virus
encode small peptidemotifs that recruit Tsg101 to sites of particle assembly to
facilitate egress. Nat. Med. 7, 1313–1319.
Martin-Serrano, J., Zang, T., and Bieniasz, P.D. (2003). Role of ESCRT-I in
retroviral budding. J. Virol. 77, 4794–4804.
McDonald, B., andMartin-Serrano, J. (2008). Regulation of Tsg101 expression
by the steadiness box: a role of Tsg101-associated ligase. Mol. Biol. Cell 19,
754–763.
Mitchell, R.S., Katsura, C., Skasko, M.A., Fitzpatrick, K., Lau, D., Ruiz, A.,
Stephens, E.B., Margottin-Goguet, F., Benarous, R., and Guatelli, J.C.
(2009). Vpu antagonizes BST-2-mediated restriction of HIV-1 release via
beta-TrCP and endo-lysosomal trafficking. PLoS Pathog. 5, e1000450.
Morita, E., and Sundquist, W.I. (2004). Retrovirus budding. Annu. Rev. Cell
Dev. Biol. 20, 395–425.
Morita, E., Sandrin, V., Alam, S.L., Eckert, D.M., Gygi, S.P., and Sundquist,W.I.
(2007a). Identification of human MVB12 proteins as ESCRT-I subunits that
function in HIV budding. Cell Host Microbe 2, 41–53.
Morita, E., Sandrin, V., Chung, H.Y., Morham, S.G., Gygi, S.P., Rodesch, C.K.,
and Sundquist, W.I. (2007b). Human ESCRT and ALIX proteins interact with
proteins of the midbody and function in cytokinesis. EMBO J. 26, 4215–4227.
Morita, E., Sandrin, V., McCullough, J., Katsuyama, A., Baci Hamilton, I., and
Sundquist, W.I. (2011). ESCRT-III protein requirements for HIV-1 budding. Cell
Host Microbe 9, 235–242.
Mueller, T.D., and Feigon, J. (2002). Solution structures of UBA domains reveal
a conserved hydrophobic surface for protein-protein interactions. J. Mol. Biol.
319, 1243–1255.
Nathan, J.A., and Lehner, P.J. (2009). The trafficking and regulation of
membrane receptors by the RING-CH ubiquitin E3 ligases. Exp. Cell Res.
315, 1593–1600.
Neil, S.J., Zang, T., and Bieniasz, P.D. (2008). Tetherin inhibits retrovirus
release and is antagonized by HIV-1 Vpu. Nature 451, 425–430.
Ohno, A., Jee, J., Fujiwara, K., Tenno, T., Goda, N., Tochio, H., Kobayashi, H.,
Hiroaki, H., and Shirakawa, M. (2005). Structure of the UBA domain of Dsk2p in
complex with ubiquitin molecular determinants for ubiquitin recognition.
Structure 13, 521–532.
Pardieu, C., Vigan, R., Wilson, S.J., Calvi, A., Zang, T., Bieniasz, P., Kellam, P.,
Towers, G.J., and Neil, S.J. (2010). The RING-CH ligase K5 antagonizes
restriction of KSHV and HIV-1 particle release by mediating ubiquitin-depen-
dent endosomal degradation of tetherin. PLoS Pathog. 6, e1000843.
Pohl, C. (2009). Dual control of cytokinesis by the ubiquitin and autophagy
pathways. Autophagy 5, 561–562.
Pornillos, O., Alam, S.L., Davis, D.R., and Sundquist, W.I. (2002). Structure of
the Tsg101 UEV domain in complex with the PTAP motif of the HIV-1 p6
protein. Nat. Struct. Biol. 9, 812–817.
Qian, J., Yang, J., Zhang, X., Zhang, B., Wang, J., Zhou, M., Tang, K., Li, W.,
Zeng, Z., Zhao, X., Shen, S., et al. (2001). Isolation and characterization of
a novel cDNA, UBAP1, derived from the tumor suppressor locus in human
chromosome 9p21-22. J. Cancer Res. Clin. Oncol. 127, 613–618.
Raasi, S., Varadan, R., Fushman, D., and Pickart, C.M. (2005). Diverse poly-
ubiquitin interaction properties of ubiquitin-associated domains. Nat. Struct.
Mol. Biol. 12, 708–714.
Rollinson, S., Rizzu, P., Sikkink, S., Baker, M., Halliwell, N., Snowden, J.,
Traynor, B.J., Ruano, D., Cairns, N., Rohrer, J.D., et al. (2009). Ubiquitin asso-
ciated protein 1 is a risk factor for frontotemporal lobar degeneration.
Neurobiol. Aging 30, 656–665.
Shields, S.B., and Piper, R.C. (2011). How ubiquitin functions with ESCRTs.
Traffic 12, 1306–1317.
Shields, S.B., Oestreich, A.J., Winistorfer, S., Nguyen, D., Payne, J.A.,
Katzmann, D.J., and Piper, R. (2009). ESCRT ubiquitin-binding domains func-
tion cooperatively during MVB cargo sorting. J. Cell Biol. 185, 213–224.
Sims, J.J., Haririnia, A., Dickinson, B.C., Fushman, D., and Cohen, R.E. (2009).
Avid interactions underlie the Lys63-linked polyubiquitin binding specificities
observed for UBA domains. Nat. Struct. Mol. Biol. 16, 883–889.
Song, J., Park, J.K., Lee, J.J., Choi, Y.S., Ryu, K.S., Kim, J.H., Kim, E., Lee,
K.J., Jeon, Y.H., and Kim, E.E. (2009). Structure and interaction of ubiquitin-
associated domain of human Fas-associated factor 1. Protein Sci. 18, 2265–
2276.
Stefani, F., Zhang, L., Taylor, S., Donovan, J., Rollinson, S., Doyotte, A.,
Brownhill, K., Bennion, J., Pickering-Brown, S., and Woodman, P. (2011).
UBAP1 is a component of an endosome-specific ESCRT-I complex that is
essential for MVB sorting. Curr. Biol. 21, 1245–1250.
Stringer, D.K., and Piper, R.C. (2011). A single ubiquitin is sufficient for cargo
protein entry into MVBs in the absence of ESCRT ubiquitination. J. Cell Biol.
192, 229–242.
Stuchell, M.D., Garrus, J.E., Mu¨ller, B., Stray, K.M., Ghaffarian, S., McKinnon,
R., Kra¨usslich, H.G., Morham, S.G., and Sundquist,W.I. (2004). The human en-
dosomal sorting complex required for transport (ESCRT-I) and its role in HIV-1
budding. J. Biol. Chem. 279, 36059–36071.
Teo, H., Gill, D.J., Sun, J., Perisic, O., Veprintsev, D.B., Vallis, Y., Emr, S.D.,
and Williams, R.L. (2006). ESCRT-I core and ESCRT-II GLUE domain struc-
tures reveal role for GLUE in linking to ESCRT-I and membranes. Cell 125,
99–111.
Trempe, J.F., Brown, N.R., Lowe, E.D., Gordon, C., Campbell, I.D., Noble,
M.E., and Endicott, J.A. (2005). Mechanismof Lys48-linked polyubiquitin chain
recognition by the Mud1 UBA domain. EMBO J. 24, 3178–3189.
Varadan, R., Assfalg, M., Raasi, S., Pickart, C., and Fushman, D. (2005).
Structural determinants for selective recognition of a Lys48-linked polyubiqui-
tin chain by a UBA domain. Mol. Cell 18, 687–698.
Weissenhorn, W., and Go¨ttlinger, H. (2011). Essential ingredients for HIV-1
budding. Cell Host Microbe 9, 172–174.
Williams, R.L., and Urbe´, S. (2007). The emerging shape of the ESCRT
machinery. Nat. Rev. Mol. Cell Biol. 8, 355–368.
Zhang, D., Raasi, S., and Fushman, D. (2008). Affinity makes the difference:
nonselective interaction of the UBA domain of Ubiquilin-1 with monomeric
ubiquitin and polyubiquitin chains. J. Mol. Biol. 377, 162–180.
Ziv, I., Matiuhin, Y., Kirkpatrick, D.S., Erpapazoglou, Z., Leon, S.,
Pantazopoulou, M., Kim, W., Gygi, S.P., Haguenauer-Tsapis, R., Rein, N.,
et al. (2011). A perturbed ubiquitin landscape distinguishes between ubiquitin
in trafficking and in proteolysis. Mol. Cell Proteomics 10, M111.009753.
Structure
UBAP1 Is Required for Tetherin Degradation
428 Structure 20, 414–428, March 7, 2012 ª2012 Elsevier Ltd All rights reserved
Cell Host & Microbe
Article
Innate Sensing of HIV-1 Assembly by Tetherin
InducesNFkB-DependentProinflammatoryResponses
Rui Pedro Gala˜o,1,2 Anna Le Tortorec,1,2,3 Suzanne Pickering,1,2 Tonya Kueck,1 and Stuart J.D. Neil1,*
1Department of Infectious Disease, King’s College London School of Medicine, Guy’s Hospital, London SE1 9RT, UK
2These authors contributed equally to this study




Antiviral proteins that recognize pathogen-specific
or aberrantly located molecular motifs are perfectly
positioned to act as pattern-recognition receptors
and signal to the immune system. Here we in-
vestigated whether the interferon-induced viral
restriction factor tetherin (CD317/BST2), which is
known to inhibit HIV-1 particle release by physically
tethering virions to the cell surface, has such a
signaling role. We find that upon restriction of
Vpu-defective HIV-1, tetherin acts as a virus sensor
to induce NFkB-dependent proinflammatory gene
expression. Signaling requires both tetherin’s extra-
cellular domain involved in virion retention and
determinants in the cytoplasmic tail, including an
endocytic motif, although signaling is independent
of virion endocytosis. Furthermore, recruitment of
the TNF-receptor-associated factor TRAF6 and
activation of the mitogen-activated protein kinase
TAK1 are critical for signaling. Human tetherin’s
ability to mediate efficient signaling may have arisen
as a result of a five amino acid deletion that
occurred in hominids after their divergence from
chimpanzees.
INTRODUCTION
Tetherin is a broadly acting antiviral membrane protein that
blocks the release of diverse mammalian viruses from the
surface of infected cells and reduces retroviral pathogenesis
in vivo (Liberatore and Bieniasz, 2011; Martin-Serrano and
Neil, 2011). Tetherin partitions into assembling virions, cross-
linking them to the plasma membrane (PM) by virtue of its
unique topology. The potential importance of tetherin in innate
antiviral immunity is underscored by examples of virally en-
coded proteins that counteract its activity, the prototype being
the accessory gene product Vpu of human immunodeficiency
virus type 1 (HIV-1) (Le Tortorec et al., 2011). Vpu interacts
with human tetherin in infected cells, blocking its transit to
viral assembly sites on the PM (Dube´ et al., 2011; Kueck and
Neil, 2012; Schmidt et al., 2011) and promoting its endoso-
mal degradation (Agromayor et al., 2012; Janvier et al., 2011).
Among the primate lentiviruses, the species-specific target-
ing of tetherin is widespread, even though the vpu gene is
restricted to a subset of simian immunodeficiency viruses
(SIVs). In SIVs in which Vpu is absent, the Nef accessory
protein performs the role, and the sensitivity of primate
tetherins to SIV Nefs is determined by a five amino acid
patch in the protein’s cytoplasmic tail that was deleted after
hominids and chimpanzees diverged (Jia et al., 2009; Zhang
et al., 2009).
Accumulating evidence indicates that tetherin imposes a
powerful selective pressure on primate lentiviruses and that
its counteraction is essential for HIV/SIV replication and spread
in vivo. Adaptation of the SIVcpz Vpu to target human tetherin
efficiently is a feature of the major group (Group M) of HIV-1
that is responsible for the HIV/AIDS pandemic, but not the
separate SIVcpz species jumps that led to the N, O, and P
groups that have remained geographically restricted (Sauter
et al., 2009). Zoonotic spread of the Vpu(!) SIV of sooty
mangabeys (SIVsm) to become HIV-2, whose Nef protein
cannot target human tetherin, resulted in tetherin counteraction
developing in the envelope protein (Env) (Le Tortorec and Neil,
2009). Furthermore, a similar adaptation in Env has been
observed in macaques experimentally infected with a Nef-
defective SIVmac that reverted to pathogencity (Serra-Moreno
et al., 2011).
While tetherin potently blocks cell-free virion release, its ability
to block cell-to-cell transfer is controversial, and where it has
been observed, weak (Casartelli et al., 2010; Jolly et al., 2010).
In cultured primary CD4+ T cells, Vpu-defective viruses have
evenbeen observed to spread faster through the culture in a teth-
erin-dependent manner (Jolly et al., 2010). These superficially
paradoxical observations between viral replication in culture
and the evolutionary conservation of tetherin counteraction in
primate lentiviruses suggest that tetherin’s contribution to
the antiviral immune response is not limited to physical inhibition
of virion release. Interestingly, prior to its identification as an
antiviral factor, tetherin (BST2) was identified as an inducer of
NFkB activation in a whole-genome transfection screen (Mat-
suda et al., 2003). Furthermore, tetherin has been implicated
as a regulator of Toll-like receptor (TLR) function in plasmacytoid
dendritic cells through the activation of the inhibitory leukocyte
receptor ILT7 (Cao et al., 2009). We therefore hypothesized
that tetherin, like the retroviral restriction factor TRIM5a, might
act as a sensor for the presence of viral infection coupled to its
antiviral activity (Pertel et al., 2011). In this study we tested this
hypothesis.
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RESULTS
Restriction of Enveloped Virus Particle Release by
Human Tetherin Induces NFkB-Dependent Gene
Expression
We first sought to confirm whether tetherin was capable
of inducing NFkB activation when overexpressed. Transient
transfection of human tetherin into 293 cells potently induced
the activation of an NFkB-dependent firefly luciferase reporter
construct to levels similar to those seen with the MAVS/IPS1/
Cardif component of the cytoplasmic viral RNA-sensing pathway
(Takeuchi and Akira, 2010), confirming the previous observa-
tion from the genomic screen (Matsuda et al., 2003) (Figure 1A).
We then examined whether crosslinking of cell-surface tetherin
was capable of transducing a similar signal in 293 cells stably ex-
pressing human tetherin (293THN), but not vector control 293
cells. While background level of reporter gene activation in the
two cell types was less than 1.5-fold, crosslinking the surface
protein with a polyclonal antibody resulted in a 10-fold increase
in NFkB-dependent luciferase expression in tetherin-expressing
cells (Figure 1B) and led to the concomitant phosphorylation of
IKKa/b and degradation of IkB (Figure 1C). This suggested that
clustering of tetherin might mediate a proinflammatory signal
upon restriction of enveloped virus release. Consistent with
this, budding and assembly of HIV-1 lacking the tetherin counter-
measure Vpu (Neil et al., 2008), or encoding a point mutant of
Vpu (A14L) that is defective for interaction with tetherin (Vigan
and Neil, 2010), specifically induced enhanced NFkB reporter
activation in cells stably expressing tetherin while the wild-type
virus did not, correlating with physical particle release (Figure 1D
and see Figures S1A and S1B online). Furthermore, consistent
with the activation of the reporter gene, we could observe induc-
tion of the mRNA of a representative NFkB-dependent target
gene, the proinflammatory chemokine CXCL10, in the same cells
(Figure 1E).
Since tetherin restricts the release of a variety of mammalian
viruses, we then sought to determine whether other tetherin-
sensitive viral particles could activate the NFkB reporter. We
observed similar reporter activation by producing tetherin-sensi-
tive filoviral-like particles (VLPs) derived from the Ebolavirus
matrix protein VP40 (Jouvenet et al., 2009; Neil et al., 2007) (Fig-
ure 1F and Figure S1C). Furthermore, since previous studies
have demonstrated that tetherin restricts the release of fully
assembled virions that have separated their membranes from
that of the host cell, we then examined whether assembly-
defective retroviral particles could trigger tetherin-dependent
NFkB activation. For this we used a murine leukemia virus
(MLV) provirus, or derivatives with mutations in the p12Gag late-
domain sequence (MLVDPY) that facilitates virion budding and
membrane scission by recruiting the ESCRT-pathway (Martin-
Serrano and Neil, 2011). As expected, wild-type MLV release
was restricted in 293THN cells, whereas MLVDPY release was
Figure 1. Tetherin Induces NFkB-Dependent Responses upon Overexpression, Crosslinking, and Restriction of Virion Release
(A) Fold activation of a firefly-luciferase NFkB reporter gene in 293 cells transiently cotransfected with tetherin, MAVS, or control YFP vectors.
(B) Fold activation of the same reporter in 293 or 293THN cells treated for 24 hr with a rabbit anti-tetherin polyclonal serum and a secondary anti-rabbit
antibody.
(C) Time course of endogenous IkB degradation and IKKa/b phosphorylation in 293THN cells after antibody crosslinking.
(D and E) (D) Fold increases in NFkB-reporter activity in 293 and 293THN cells transfected with wild-type and Vpu(!) HIV-1 proviruses and (E) fold changes in
Cxcl10 mRNA levels compared to YFP transfection calculated relative to Gapdh by qRT-PCR.
(F and G) NFkB-reporter fold activation in 293 and 293THN cells transfected with GFP-fused Ebolavirus VP40 expression vector (F) or MLV provirus or derivatives
(MLVDPY and MLVDPY/p6) (G). Fold changes relative to 293 cells transfected with YFP control (A, D–G) or 293 nontreated cells (B). *p > 0.05 and ***p > 0.001 as
determined by two-tailed t test. All error bars represent ±SEM of three independent experiments.
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defective in both cell types (Figure S1D). Production of wild-
type MLV virions triggered enhanced NFkB reporter activity in
293THN cells, but the assembly-defective MLVDPY did not (Fig-
ure 1G). Interestingly, MLVDPY/p6, where the p12 late domain
has been replaced with one derived from HIV-1 p6gag, recovered
both virion production and the enhanced NFkB reporter activa-
tion in 293THN cells (Figure 1G and Figure S1D). Therefore acti-
vation of NFkB in tetherin-expressing cells requires full virion
assembly and scission of the cellular and virion membranes.
Together these data show that in cells constitutively expressing
tetherin, the restriction of enveloped virion release triggers a
proinflammatory response.
Tetherin-Sensitive HIV-1 Mutants Induce Enhanced
Proinflammatory Cytokine Expression in Infected CD4+
T Cells
We then asked whether tetherin-mediated restriction of HIV-1
particle release in primary human CD4+ T cells would induce
proinflammatory gene expression. Purified CD4+ T cells from
three donors were infected with wild-type HIV-1, Vpu(!) HIV-1,
or HIV-1 encoding tetherin binding-defective mutant Vpu-A14L
that retains all other known Vpu functions. As expected, cell-
free virus release of the Vpu mutant HIV-1s was impaired
compared towild-type in all donors (Figures 2A and 2B). Interest-
ingly, cultures infected with both Vpu(!) and Vpu-A14L HIV-1
mutants led to increased levels of mRNAs for proinflammatory
cytokines CXCL10 and IL-6 (Figure 2C). In two of the donors,
increased levels of Ifnb mRNA were also detected (Figure 2C).
Furthermore, these increases in mRNA levels were reflected in
significant increases in the concentrations of CXCL10, IL-6,
and bioactive type-1 IFN in the supernatant (Figure 2D). The
induction of type 1 IFN expression implied the activation of
interferon regulatory factors (IRFs) 3 or 7 in addition to NFkB.
In parallel reporter gene experiments to those described above,
however, tetherin overexpression, crosslinking, or Vpu(!) HIV-1
assembly could not activate an IFNb-promoter-luciferase re-
porter construct in 293THN cells. Neither did we observe any
induction of ifnbmRNA or phosphorylation of IRF3 in this system
(Figures S2A–S2C). However, in CD4+ T cells we could detect
IRF3 phosphorylation after 48 hr of HIV-1 infection. In contrast
to the induction of the NFkB-dependent Cxcl10 mRNA in
T cells or tetherin-mediated reporter gene activation in 293THN
cells, this IRF3 phosphorylation and the concomitant IFNb ex-
pression could be suppressed by inhibition of the TLR3 adaptor
TRIF (Figures S2D–S2G), suggesting that tetherin-mediated viral
retention may additionally augment viral recognition by other
host PRRs. Therefore, to confirm the tetherin dependency of
all these data, we transduced primary CD4+ T cells with lentiviral
vectors encoding shRNA hairpins against tetherin (shTHN) or an
irrelevant target (GFP) 24 hr prior to infection with the above
viruses. As expected, shTHN transduction reduced surface teth-
erin levels and rescued the release of Vpu(!) and Vpu-A14L
mutant viruses to wild-type levels (Figures S2H and S2I). It also
concomitantly reduced both Cxc10 and Ifnb mRNA induction
in the same cells (Figure 2E), demonstrating that proinflamma-
tory gene expression induced by Vpu(!) HIV-1 in target cells is
tetherin dependent. We thus provide evidence that interaction
of tetherin with HIV-1 induces proinflammatory gene expression
consistent with a direct signaling role.
Structural Determinants of Tetherin-Mediated Signaling
We then mapped the determinants of NFkB activation in human
tetherin. The primary sequence of the tetherin cytoplasmic tail
does not affect the protein’s antiviral activity (data not shown).
However, we reasoned that the cytoplasmic tail likely played
a role in signaling and screened a series of tetherin cytoplasmic
tail mutants for NFkB-dependent reporter gene activation (Fig-
ure 3A). This revealed defects in signaling that mapped to the
conserved YXY site that mediates tetherin’s endocytic recycling
to the PM (Rollason et al., 2007), as well as an adjacent CRV
motif. Mutations encompassing the two membrane-proximal
lysine residues, which can serve as ubiquitylation targets (Le Tor-
torec et al., 2011), were also defective for signaling. However,
these alanine mutants appeared immature in SDS-PAGE, sug-
gesting a trafficking defect, and mutation of the individual lysine
residues to arginine preserved signaling capacity (Figure S3A).
Stable cell lines expressing tetherin Y6,8A and 10-12A failed to
mediate reporter-gene activation in response to Vpu(!) HIV-1,
yet they retained potent viral particle restriction, consistent
with the hypothesis that thesemotifs are required for transducing
a signal initiated by virion retention (Figures 3B). By contrast, the
antiviral activity of tetherin depends upon the structural integrity
of its extracellular domain, particularly in its C-terminal GPI-
linked membrane anchor, its dimeric state, and its extracellular
coiled-coil domain (Perez-Caballero et al., 2009). Mutations in
the coiled coil (L123P), the extracellular cysteine residues that
mediate dimerization, or deletion of the GPI anchor, all of which
render tetherin unable to inhibit viral release, reduced the ability
of tetherin to promote NFkB-reporter gene activation both in
transient transfections and in stably expressing cells transfected
with tetherin-sensitive and -insensitive HIV-1 (Figure 3C and Fig-
ure S3B). Thus tetherin’s ability to mediate NFkB activation
requires the extracellular determinants essential for multimeriza-
tion and virion retention, and cytoplasmic tail motifs required to
transduce a signal dependent on this retention.
Tetherin-Mediated Signaling Is Independent of Virion
Endocytosis
Tetherin-mediated retention of Vpu(!) HIV-1 virions leads to their
accumulation in late endosomal compartments (Martin-Serrano
and Neil, 2011). The implication of the YXYmotif, which has been
previously shown to interact with both AP1 and AP2 clathrin
adaptors, suggested that endocytosis of virions might be
required for signaling. Consistent with this, a lower proportion
of cells exhibited distinct endosomal accumulations of HIV-1
Gag-GFP in 293THN-Y6,8A compared to 293THN 24 hr post-
transfection (48% versus 74%), suggesting that the YXY motif
may play a role in virion uptake (Figures 4A and 4B). Recent
evidence suggests that YXY mutants of tetherin are impaired
but not fully defective for endocytosis (Lau et al., 2011), poten-
tially accounting for this partial phenotype. However, siRNA
depletion of AP2m1 reduced endosomal virion localization to
levels comparable to the parental 293 cells, similar to the ex-
pected result observed by cotransfecting a dominant inhibitory
mutant S34N of the early endocytic GTPase Rab5a (Neil et al.,
2008). As a control, the proportion of transfected cells with ob-
servable endosomal Gag-GFP was unchanged when using the
dominantly active mutant, Rab5a(Q79L), with Gag-GFP VLPs
accumulating in the lumen of swollen Rab5+ve endosomes.
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Figure 2. Restriction of Tetherin-Sensitive HIV-1 Mutant Release from Infected CD4+ T Cells Induces Proinflammatory Gene Expression
(A and B) Purified CD4+ T cells from three independent donors were infected with the indicated virus at anmoi of 5, and 48 hr later viral release was determined by
infection of HeLa-TZM reporter cell lines (A) and western blot of cell lysates (B).
(C) Total RNA from three biological replicates of parallel cultures infected as in (A) was analyzed for Cxcl10, IL6, and Ifnb mRNA levels relative to Gapdh by
qRT-PCR.
(D) Protein levels in the supernatants from (A) were determined by ELISA (CXCL10 and IL-6) or by HEK-Blue indicator cells (IFNb).
(E) Activated CD4+ T cells were transduced with lentiviral vectors encoding short hairpin against GFP (sh-control) or against tetherin (shTHN) 24 hr prior to
infection as in (A). Total RNA from three biological replicates of parallel cultureswas analyzed forCxcl10 and IfnbmRNA levels relative toGapdh by qRT-PCR. Fold
changes relative to noninfected cells (C and E). *p > 0.05, **p > 0.01, and ***p > 0.001 as determined by two-tailed t test. All error bars represent ±SEM.
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We then examined the effects of these treatments on virion-
induced NFkB-reporter activation in 293THN cells. As expected,
Vpu(!) HIV-1 induced an increase in reporter activation com-
pared to wild-type virus. However, in the presence of AP2m1
depletion or Rab5a(S34N) overexpression, Vpu(!) virus-induced
signaling was significantly increased in 293THN cells (Figures 4C
and 4D). These data suggest that while the YDYCRV motif is
essential for virion-induced signaling, virion uptake is not, and
blockade of their delivery to late endosomes potentiates reporter
gene expression. Together, they suggest that tetherin-depen-
dent accumulation of virions on the cell surface triggers NFkB
activation.
TAK1 Activation and Recruitment of TRAF6 Are
Required for Tetherin-Mediated Signaling
Proinflammatory activation of NFkB from TNF receptors and
membrane-associated and cytosolic PRRs is mediated through
the mitogen-activated protein kinase TAK1 (MAP3K7) (Skaug
et al., 2009). We therefore asked whether there were similarities
between tetherin-mediated NFkB activation and that of other
viral PRRs. Depletion of TAK1 by siRNA completely abolished
the NFkB-reporter gene activation induced by tetherin overex-
pression or Vpu(!) HIV-1 in 293THN cells (Figure 5A), implicating
Figure 3. Determinants of Tetherin-Medi-
ated Signaling
(A) A series of alanine scan mutants in the cyto-
plasmic tail of human tetherin were assessed for
the ability to induce NFkB-Luc reporter activation
in transiently transfected 293 cells. Mutations en-
compassing residues 17–21 of the cytoplasmic tail
were discounted due to aberrant localization (data
not shown), and further mutants are presented in
Figure S3. Error bars are ±SEM.
(B) 293 cells stably expressing the Y6,8A and
10-12A mutants were further assessed for their
ability to induce NFkB-Luc reporter activation
upon transfection with wild-type or Vpu(!) HIV-1
proviral plasmids. Infectious virus release was
determined on HeLa-TZM indicator cells and
physical particle yield analyzed by western blot of
cell lysates and pelleted supernatants using an
anti-p24 monoclonal antibody.
(C)Mutations in the extracellular domain of tetherin
defective for inhibiting viral release (cysteine-less
3CA, the coiled-coil point mutant L123P, or a
truncation lacking the GPI anchor) were assayed
for NFkB-Luc reporter activation in transfected
293 cells. Fold changes ±SEM relative to 293 cells
transfected with YFP control (B and C).
the activation of TAK1 as critical in teth-
erin-mediated signaling. TAK1 activation
by host PRRs depends on the upstream
recruitment of family members of the
TNF-receptor-associated factor (TRAF)
family of E3 ubiquitin ligases, particularly
TRAF2 and TRAF6, and the E2 ligase
Ubc13 (UBE2N), which act to polymerize
K63-linked ubiquitin chains (Skaug et al.,
2009). RNAi depletion of these factors
similarly inhibited tetherin-mediated NFkB reporter activity (Fig-
ure 5B). Interestingly, while the human tetherin cytoplasmic
tail has a putative TRAF6 consensus-binding motif (PXEXX-
aromatic/acidic), disruption of this sequence by mutagenesis
did not impair tetherin signaling (Figure 3). However, tetherin
could be specifically coimmunoprecipitated with an HA-tagged
TRAF6 dependent on the presence of the YCRV motif that is
conserved in ape tetherins and partially overlaps the protein’s
endocytic motif (Figure 5C and Figure S4), although whether
this interaction is direct is unknown. Furthermore, mutation of
residues 10–12 (RVP) retained TRAF6 interaction despite losing
signaling activity, indicating that in conjunction with the RNAi
data, TRAF6 is necessary but not sufficient for tetherin signaling.
These data suggest that virion aggregation by tetherin leads to
YDYCRV-dependent recruitment of a signaling complex that
includes TRAF6 to induce TAK1-dependent NFkB activation
when viral release is restricted.
Signaling Is a Feature of Human and Chimpanzee
Tetherins and Is Augmented by a Hominid-Specific
Deletion in the Tetherin Cytoplasmic Tail
Tetherin’s antiviral activity is conserved in mammals. Surpris-
ingly, however, murine and old world monkey tetherins showed
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negligible ability to induce NFkB reporter activity despite
potently restricting HIV-1 particle release (Figure 6A). Chim-
panzee tetherin (cpz-tetherin), while capable of inducing reporter
gene activation, was less potent than the human protein (Fig-
ure 6A). Informed by ourmutagenesis studies (Figure 3), we iden-
tified three regions of species-specific changes between the
cytoplasmic tails of human, chimpanzee, and rhesus tetherins
that might contribute to the differences in signaling. First, a major
difference between human and other primate proteins is the
presence of a G/DDIWK motif that is absent in Homo sapiens.
The tryptophan in this motif is under high evolutionary positive
selection and determines the sensitivity of primate tetherins to
the Nef proteins of SIVs (Lim et al., 2010). Second, while the
two tyrosine residues in the YXYXXV endocytic motif are highly
conserved throughout mammalian evolution, differences occur
between humans/chimpanzees and old world monkeys at posi-
tions 9–11, a region we have identified as critical to human teth-
erin’s signaling ability. Both the C9 (Gupta et al., 2009; Lim et al.,
2010) and R10 (Gupta et al., 2009; McNatt et al., 2009) positions
have been previously ascribed to be under positive selection
throughout primate evolution. Third, in human and chimpanzee
tetherins a repeated glycine-isoleucine pair extends the tetherin
transmembrane helix, and is an important determinant of sensi-
tivity to HIV-1 Vpu (McNatt et al., 2009). A further difference
between human, chimpanzee, and rhesus encompasses an
ubiquitination site (STS) (Tokarev et al., 2011), although our
alanine mutagenesis suggests that this motif is not important.
Transfection of increasing amounts of hu- and cpz-tetherin
plasmids revealed that at low expression levels human tetherin
was markedly more efficient at inducing NFkB-reporter activa-
tion, and high levels of the chimpanzee protein never achieved
parity (Figure 6B). Deletion of the DDIWK motif enhanced cpz-
tetherin-mediated NFkB reporter gene activation to the level of
human protein, and its reintroduction into the human protein
Figure 4. Inhibition of Virion Endocytosis Enhances Tetherin-Dependent NFkB Activation
(A and B) The indicated cell lines were transfected with an HIV-1 Gag-GFP expression vector, with or without either pretreatment with control siRNA or AP2m1 for
48 hr or cotransfection with Cherry-FP fused mutants of Rab5a (S34N or Q79L). Twenty-four hours later, the cells were fixed and ten random fields were
enumerated on the basis of whether transfected cells displayed plasma-membrane only Gag-GFP localization or PM and distinct endsomal accumulation (A) and
imaged by confocal microscopy (B).
(C and D) The effects of AP2m1 siRNAs and Che-Rab5a-S34N on HIV-1 proviral-induced NFkB reporter gene activation were determined as above. Fold changes
relative to 293 cells transfected with YFP control with error bars representing ±SEM.
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severely impaired signaling. Neither of these changes affected
either expression, restriction of Vpu(!) HIV-1 release, or TRAF6
association (Figure 6B and Figure S5). Therefore efficiency of
NFkB activation between hu-tetherin and cpz-tetherin appears
to be an evolutionarily recent acquisition that has coincided
with the deletion of a motif known to act as a target for SIV teth-
erin countermeasures.
We then turned our attention to rh-tetherin. In rhesus
macaques, position 9 is polymorphic (either a C or an R), and
neither variant could mediate NFkB-reporter activity. Similarly,
a C9R change in human tetherin had no effect on signaling ability
(data not shown). Introduction of KM-to-RV changes into rh-teth-
erin did not endow it with any signaling activity, but the corre-
sponding RV-to-KM swap in human tetherin severely reduced
its NFkB-reporter induction without compromising antiviral
activity, confirming that these residues are necessary in human,
but not sufficient to explain the lack of rhesus signaling
(Figure 6B). To determine the minimal changes in rh-tetherin
that could confer signaling activity, we constructed chimeras
between rh-tetherin and cpz-tetherin. Again all proteins were
capable of restricting virion release. Surprisingly, only a chimera
bearing the cpz-tetherin cytoplasmic tail including the additional
TM-domain GI residues (rh-cpz 31) recovered any NFkB activa-
tion (Figure 6B). These results suggest multiple context-depen-
dent adaptations have resulted in human tetherin’s signaling
capacity. First, changes in the previously identified YXYXXV
motif in conjunction with a lengthened TM domain, which itself
may be expected to alter the conformation of the cytoplasmic
tail, are required to confer levels of signaling activity seen in
cpz-tetherin. Second, deletion of the DDIWK motif in human
ancestors greatly enhanced the efficiency of this activity.
DISCUSSION
In this study we have demonstrated that human tetherin can
transduce a proinflammatory signal when it restricts virion pro-
duction. This appears to be coupled to cell-surface aggregation
of virions, resulting in the TAK1-dependent activation of NFkB
Figure 5. Mechanistic Aspects of Tetherin-Mediated Signaling
(A) Depletion of TAK1 by siRNA in either 293 cells transfected with tetherin, or in 293 and 293THN cells transfected with Vpu(!) HIV-1 proviral plasmid, abolishes
NFkB-Luc reporter activation but has no effect on Gag production.
(B) Impairment of NFkB-Luc reporter activation by siRNA depletion of TRAF6, TRAF2, or Ubc13 in 293 cells transfected with tetherin.
(C) Coimmunoprecipitation of tetherin and tetherin(10-12A) but not tetherin Y6,8A with HA-TRAF6 in transiently transfected 293 cells. All error bars are ±SEM of
three independent experiments.
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and subsequent cytokine production. Importantly, we could
show that tetherin-sensitive mutants of HIV-1 induce enhanced
proinflammatory cytokine production in infected CD4+ T cells.
This suggests that the action of tetherin senses enveloped virus
assembly, and that the infected cell responds by releasing medi-
ators that can attract innate and adaptive immune cells to the
site of infection to augment the antiviral response. Thus we sug-
gest that in the context of an infected cell, a budding enveloped
virion constitutes a pathogen-associated molecular pattern, and
in addition to physically restricting virion release, tetherin acts as
the cognate PRR.
Mechanistically, tetherin signaling has similarities to TLRs
and other viral PRRs, including another retroviral restriction
factor, TRIM5a (Pertel et al., 2011; Skaug et al., 2009; Takeuchi
and Akira, 2010). NFkB is activated through the upstream
kinase TAK1. PRR-mediated TAK1 activation depends on the
association of its accessory factors TABs 1–3 with free polyubi-
quitin chains bearing K63 linkages, which in turn are synthe-
sized by the concerted action of TRAF E3 ligases with E2
complex of Ubc13/UBE1. TRAFs, particularly TRAFs 2, 3, 5,
and 6, play key roles in signal transduction from a host of proin-
flammatory cell-surface receptors, and TRAF2 and TRAF6 are
also essential cofactors for cytoplasmic RIG-I-like helicases.
Figure 6. Tetherin’s Signaling Activity Is
a Recent Acquisition in Primate Evolution
(A) NFkB-Luc reporter activation in 293 cells
transiently transfected with murine, rhesus, AGM,
chimpanzee, and human tetherins and their
respective ability to restrict Vpu-defective virus
release.
(B) Alignment of the cytoplasmic tails of primate
tetherins with regions differing from human shown
in gray. Species-specific changes were made
according to major differences indicated at
positions 1, 2, and 3 and tested for NFkB-Luc
reporter activation at varying expression levels. All
error bars represent ±SEM of three independent
experiments.
We found that RNAi-mediated knock-
down of TRAF2, TRAF6, and Ubc13 in-
hibited tetherin activation of NFkB, for
which TAK1 was also essential. Further-
more we could observe an interaction
between tetherin and TRAF6. While the
human tetherin cytoplasmic tail contains
a predicted TRAF6 binding site, we
found that this interaction was actually
determined by the adjacent endocytic
motif YDYCRV. How the YDYCRV motif
recruits TRAF6, and how this relates to
its endocytic function, remains to be
determined. While signaling is dependent
on this signal, which appears also to
play a partial role in virion internaliza-
tion, blockade of virion uptake itself by
AP2m siRNAs or Rab5(S34N) potentiates
NFkB activation. Since these treatments
do not affect tetherin’s physical antiviral
activity per se, these data strongly suggest that large surface
virion accumulations are the primary trigger of tetherin-medi-
ated signaling.
TRAF6 recruitment is not sufficient to explain tetherin-medi-
ated signal transduction, as mutation of residues 10–12 (RVP)
or reinsertion of the primate DDIWK motif also impairs signaling
while retaining TRAF6 binding ability. Interestingly, both the
cysteine (Lim et al., 2010) and the arginine (Gupta et al., 2009;
McNatt et al., 2009) residues have been reported to be under
positive selection in primates, and the YCRV motif is only found
in great apes. While the cysteine appears not to be required,
mutation of the R and V to the K and M found in macaques
impaired human tetherin signaling. Furthermore, the context
dependency on the insertion of the glycine-isoluecine pair in
the TM domain that allows gain of function of the rh-tetherin
when fused to the cpz-tetherin tail suggests that a global struc-
tural change in the orientation of the tetherin cytoplasmic tail
was a prerequisite for the acquisition of signaling capacity.
One caveat to the interpretation of these observations is that at
present they have not been performed in the cells from their
cognate primate species. Thus it is unknown whether any of
the context dependency reflects species-specific differences
in downstream cellular partners. Also whether similar signaling
Cell Host & Microbe
Tetherin Senses HIV Assembly
640 Cell Host & Microbe 12, 633–644, November 15, 2012 ª2012 Elsevier Inc.
attributes have developed in mammalian tetherins other than
those tested here remains to be determined.
We propose the following model (Figure 7): tetherin-mediated
virion retention triggers clustering of surface tetherin, targeting
it for endocytic uptake. Coupled to this surface clustering, a
signaling complex containing TRAF6 and perhaps TRAF2 is re-
cruited to the tetherin cytoplasmic tail. What other factors are
present in this complex, or whether it directly interacts with teth-
erin itself or an associated factor, remains to be determined. The
recruited complex then activates TAK1 through the polymeriza-
tion of ubiquitin chains dependent on Ubc13, which in turn leads
to IKK phosphorylation, IkB degradation, and translocation of
NFkB to the nucleus to activate proinflammatory gene expres-
sion. The data presented herein showing that late-domain
mutants of retroviral particles cannot trigger tetherin signaling
indicate that partitioning of tetherin into virions initiates signaling
dependent on the physical separation of budding virions from
the cell membrane. The topology of tetherin dimers that form
the physical tether is not entirely clear (Perez-Caballero et al.,
2009), but the evidence that they can transduce a signal implies
that at least some tetherin dimers must remain with their cyto-
plasmic tails in the cytoplasm. Recently it was demonstrated
that HIV-1 gp41 can also activate TAK1-dependent NFkB sig-
naling to potentiate viral replication in CD4+ T cells (Postler
and Desrosiers, 2012). Whether this underlies the lower level of
responses that we see in wild-type infected cells is unknown,
but may suggest that HIV-1 strikes a balance between maintain-
ing sufficient NFkB activation for viral gene expression and sup-
pressing proinflammatory responses derived from factors such
as tetherin.
While tetherin activated only NFkB reporter genes in 293 cells,
in some donors’ T cells, tetherin-sensitive HIV-1 also induced
Figure 7. Model for Tetherin’s Proinflamma-
tory Activity
Clustering of tetherin dimers upon restriction
of viral release promotes the recruitment of a
signaling complex that includes TRAF6, and
potentially TRAF2 and Ubc13 dependent on the
YDYCRV motif in tetherin. This leads to the
activation of TAK1, NFkB, and enhanced proin-
flammatory gene expression by the infected cells.
Additionally, in primary HIV-1 target cells, virion
retention and uptake potentially targets restricted
virions to compartments where viral components
are amenable to recognition by TLRs or other
PRRs, thereby indirectly inducing type 1 IFN
responses through the activation of IRFs.
detectable type 1 interferon secretion.
Again this was tetherin dependent, as
shRNAs against tetherin abolished it.
Since Vpu is not a constituent of incoming
viral particles, this tetherin dependence
of type 1 IFN induction indicates that it
requires a productive round of viral repli-
cation, rather than direct sensing of virion
components from the inoculum. The up-
regulation of IFNb by Vpu(!) HIV-1 and
HIV-1 Vpu-A14L, but not CXCL10, was
reduced by inhibitory peptides against TRIF, strongly suggesting
TLR3 as the source, which is known to be expressed on some
T cell subsets (Holm et al., 2009). As TLR3 resides primarily in en-
dosomes(Takeuchi and Akira, 2010), these data suggest that
immobilization and endocytic uptake of virions by tetherin may
also lead to augmented recognition of viral components by
membrane-associated PRRs expressed in primary HIV-1 target
cells (for example, virion-associated RNA molecules that may
be liberated upon virion degradation). Low levels of activated
IRF3 could be detected in all virus-infected T cells 48 hr after
infection, contrary to a recent study that suggested IRF3 itself
is degraded by Vpu (Doehle et al., 2012). While purified HIV-1
particles do not directly induce strong inflammatory responses
in most target cells, a recent study has indicated that HIV-in-
fected cells can trigger interferon release from bystanders
through the activation of IRF3 (Lepelly et al., 2011). This appears
to be related to cell-to-cell transmission of fusion-competent
virions, something that could conceivably be further augmented
in this case by tetherin-mediated virion retention (Jolly et al.,
2010). Finally, tetherin’s identification as a regulator of TLR7
activity in plasmacytoid dendritic cells via the inhibitory leuko-
cyte receptor ILT7 suggests that its signaling properties may
have further roles in host-cell pattern recognition (Cao et al.,
2009). The further characterization of virus-induced tetherin
signaling in primary cells and the cellular factors involved will
therefore determine the importance of this attribute in innate
immunity.
Tetherin counteraction is conserved among human and
primate lentiviruses, but the viral protein that performs this
role varies (Le Tortorec et al., 2011). While tetherin restricts
cell-free viral release, it poorly inhibits cell-to-cell viral trans-
fer between CD4+ T cells (Casartelli et al., 2010; Jolly et al.,
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2010), which likely represents a major route of viral spread
in vivo (Jolly and Sattentau, 2004). This suggests that avoid-
ance of tetherin-mediated restriction is required for initial viral
transmission, and/or tetherin’s antiviral activity imposes an
additional inhibition of viral replication in vivo beyond simply
blocking cell-free viral production. For example, accumulation
of virions on cell surfaces by tetherin may promote recogni-
tion of infected cells through the deposition of antibodies
and subsequent clearance by phagocytes. The acquisition
of the coupling of tetherin activity to direct proinflammatory
gene expression via NFkB activation may therefore significantly
augment this by attracting other leukocytes to a site of infec-
tion. The threshold cellular levels of tetherin that can induce
signaling may well be lower than those required for potent
virion retention, providing further impetus for human viruses
to efficiently remove tetherin from the PM. We note with in-
terest that while the Nef and Env countermeasures of SIVs
and HIV-2 do not promote tetherin degradation, HIV-1 Vpu
does (Le Tortorec et al., 2011). Moreover, only Vpu proteins
from the pandemic M Group of HIV-1 have acquired efficient
tetherin counteraction (Sauter et al., 2009). Thus we speculate
that the signaling activity of human tetherin that we have
uncovered contributes to its role in the early innate response
to HIV-1 and other viral infections, and may provide further
selective pressure on enveloped viral pathogens to counteract
its activity. The findings presented herein provide an intriguing
example of a functional activity within a mediator of intrinsic
viral defense that may have arisen to augment its overall




The molecular clones of HIV-1 NL4.3 and derived Vpu mutants have been
described previously (Neil et al., 2006; Vigan and Neil, 2010). Tetherin mutants
and species orthologs were made in pCR3.1 by standard molecular biological
methods. Chimpanzee tetherin was provided by G. Towers (UCL). pCR3.1-
GFP-EBoV Vp40, pMLVNCS (MLV), pMLVp6py, and pMLVNCSDpy plasmids
were provided by J. Martin-Serrano (KCL) (Martin-Serrano et al., 2004). The
NFkB-dependent 3xkB-pCONA-FLuc reporter construct, the CMV-RLuc
control plasmid, and human TRAF6 cDNAs were provided by A. MacDonald
(Mankouri et al., 2010) (University of Leeds). TRAF6 was subcloned with an
N-terminal HA tag into pCR3.1. The MAVS expression vector was provided
by J. Luban (University of Geneva) and the IFNb-promoter luciferase vectors
by M. Malim.
293 and 293T cells were obtained from the ATCC, while the reporter cell line
HeLa-TZMbl was provided by John Kappes through the NIH AIDS Reagents
Repository Program (ARRP). All adherent cells were maintained in DMEM sup-
plemented with 10% fetal calf serum (FCS) and gentamicin. Derivatives stably
expressing human tetherin or mutants thereof were produced by transducing
the cells with MLV-based retroviral vectors packaging a pLHCX (Clontech)
vector genome encoding the tetherin construct and selecting the cells in
hygromycin (Invitrogen).
Peripheral blood mononuclear cells were isolated from freshly drawn whole
blood on Lymphoprep (Axis-Shield). CD4+ T cells were then purified using an
Untouched CD4+ T cell Dynabead kit (Invitrogen), and then activated for 48 hr
with anti-CD3/anti-CD28 Dynabeads (Invitrogen) prior to use and cultured in
RPMI/10% FCS/gentamicin and 30 U/ml recombinant IL-2. CD4 and tetherin
expression were determined by flow cytometry using anti-CD4 APC (Becton
Dickinson) or anti-human BST2-PE (eBiosciences). HIV-1 infection of T cells
was monitored by flow cytometry using an intracellular anti-p24-PE (Beckam
Coulter) staining.
Reporter Gene Assays
For transient reporter gene assays, 105 293 cells were transfectedwith 50 ng of
pCR3.1 tetherin plasmid or control pCR3.1 YFP in combination with 10 ng of
3xkB-pCONA-FLuc or IFNb-luciferase reporter and 5 ng pCMV-RLuc. Forty-
eight hours after transfection, firefly andRenilla luciferase activity in cell lysates
was measured using a dual luciferase kit (Promega) and normalized. For anti-
body crosslinking experiments, 293 or 293THN cells were transfected with
10 ng of 3xkB-pCONA-FLuc and 5 ng pCMV-RLuc. Six hours later, the cells
were treated with a 1:100 dilution of rabbit-anti-BST2 polyclonal Ab (Miyagi
et al., 2009) (provided by K. Strebel through the NIH ARPP) followed by
addition of a donkey anti-rabbit secondary. Cell lysates were taken at various
time points thereafter and subjected to SDS-PAGE and western blot with
rabbit anti-IkB-a (Cell Signaling), rabbit monoclonal anti-Phospho-IKKa/b
(Ser176/180-clone 16A6, Cell Signaling), rabbit monoclonal anti-IRF3 (clone
D83B9, Cell Signaling), rabbit monoclonal anti-Phospho-IRF3 (clone S396,
Cell Signaling), rabbit anti-RelA, and rabbit anti-hsp90 (Santa Cruz Biotechnol-
ogies) and visualized either by Li-Cor apparatus using fluorophore-conjugated
secondary antibody (IRDye 800Goat anti-rabbi IRDye 680Goat anti-mouse) or
by ImageQuant using anti-rabbit HRP-linked secondary antibodies (NEB, UK).
Luciferase activities were determined at 24 hr posttreatment.
For viral-mediated reporter gene assays, 293 or 293THN cells were trans-
fected with 10 ng of 3xkB-pCONA-FLuc (or IFNb luciferase reporter) and
5 ng pCMV-RLuc in combination with 500 ng pNL4.3, pNL4.3 Vpu mutant,
pCR3.1-GFP-EBoV VP40), MLV, MLVDPY, or MLVDPY/p6 (Martin-Serrano
et al., 2001. For experiments with MLV or derivatives, 200 ng of pCNCG and
100 ng of pVSV-G were cotransfected. Luciferase activities were measured
48 hr posttransfection. Infectivity of viral supernatants and biochemical anal-
ysis of cell lysates and viral particles were performed as described below in
‘‘Virus Stocks and Release Assays.’’
For transient knockdown of signaling components, 105 cells were seeded
per well of a 24-well plate, and 6 hr later the cells were transfected with
50 pmol of siRNA in complex with Dharmofect-1 (Dharmacon). Forty-eight
hours later, cells were reseeded and 6 hr later cotransfected with a second
dose of siRNA alongside reporter constructs as per the transient reporter
gene assays. The following siRNAs were used: from QIAGEN, MAP3K7_5
(TAK1) (SI00300741); TRAF2_7 (SI03096009) for TRAF2; TRAF6_7 and _8
(SI03046043 and SI03050145) for TRAF6; Dharmacon ON-TARGETplus
SMARTpools for human AP2M1 (L-008170-00-0005) for AP2 and human
UBE2N (L-003920-00-0005) for Ubc13 and siControl nontargeting pool (D-
001810-10-20) as the siRNA control. Protein knockdowns were verified by
western blot using the following antibodies: rabbit anti-TAK1, rabbit anti-
TRAF2 (c192), rabbit anti-Ubc13 (Cell Signaling Technology), rabbit anti-
TRAF6 (H274, Santa Cruz), and mouse anti-AP2m1 (BD Biosciences).
Virus Stocks and Release Assays
HIV-1 NL4.3 and Vpu mutant viral stocks were produced in 293T cells by tran-
sient transfection, and endpoint titers were determined onHeLa-TZM indicator
cells as described previously (Le Tortorec and Neil, 2009). For primary cell
infections, viral stocks were treated for 2 hr with 10 U/ml DNase-I (Roche)
and then concentrated by ultracentrifugation through a 20% sucrose/PBS
cushion (30,000 rpm on a Sorvall SW41 rotor for 90 min) and resuspended in
RPMI.
For viral release assays, CD4+ T cells were infected with HIV-1 NL4.3 or Vpu
mutant at the required multiplicity, and washed. Forty-eight hours later, cell
lysates and filtered viral supernatants were harvested. The infectivity of viral
supernatants was determined on HeLa-TZMbl cells as described (Le Tortorec
and Neil, 2009). MLV titers were determined by transducing 293T cells and
enumerating the GFP-positive cells by FACS 48 hr later. HIV-1 particle release
was determined by quantitative western blot, as described (Vigan and Neil,
2010).
Primary Cell Infections
53 105 activated CD4+ T cells were infected at a multiplicity of infection (moi)
of 5 to ensure >90% p24+ cells 48 hr postinfection. Cells and supernatants
were then harvested and assayed for viral gene expression, and virus particle
production as described above. Cells were also harvested for total RNA and
supernatants for cytokine production. When required, equal amounts of acti-
vated CD4+ T cells were transduced with lentiviral vectors (pCSGW) encoding
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U6-driven shRNA-GFP, 50-GUUCAUCUGCACCACCGGCAAGCUUCGGCUU
GCCGGUGGUGCAGAUACUU-30; or shRNA-THN, 50-GGAGTTCTGGTG
TTCCTGATTATTTCGATGATCAGGAGCACCGAATTCC-30, provided by G.
Towers (UCL) at an input equivalent to a moi of 5 when titered on 293T cells.
The transduced cells were infected 24 hr later and harvested as described
above. Surface tetherin levels were determined by flow cytometry at 48 hr
posttransduction. For TLR inhibition studies, infected cells were cultured in
the presence of 40 mM of control, TRIF, and MyD88-inhibitory peptides
(Invivogen).
Quantitative RT-PCR
Total RNA was isolated and purified from transfected or infected cells using a
QIAGEN RNeasy kit, and 50 ng of RNA was reverse transcribed by random
hexamer priming using a High Capacity cDNA Reverse Transcription kit
(ABI). Of the reaction, 5 ml was subjected to quantitative PCR using ABI
primer/probe sets for human Cxcl10, IL6, Ifnb, and Gapdh in an ABIPrism
7900HT Sequence Detections System. Ct data was processed relative to
the GAPDH control using the ABI RQ Manager 1.2 software.
Cytokine Production
Supernatants for infected T cells were analyzed for CXCL10 and IL-6 protein
levels using specific Quantikine ELISAs (R+D Systems). Levels of bioactive
type-I IFN were determined using HEK-Blue indicator cells (InVivoGen).
Immunoprecipitations
293 cells were transfected with 700 ng of HA-TRAF6 in combination with equal
quantities of pCR3.1-GFP or pCR3.1 tetherin constructs. Forty-eight hours
posttransfection, cells were lysed in 1% digitonin in 50 mM Tris-HCL (pH
7.4)/150 mM NaCl with protease inhibitors (Roche) and N-ethymaleimide.
Postnuclear supernatants were immunoprecipitated with 5 mg of anti-HA.11
mAb (Covance) and protein G agarose beads (Invitrogen). Cell lysates and
IPs were subjected to SDS-PAGE and western blots performed using rabbit
anti-HA (Rockland) and rabbit anti-BST2 antibodies and visualized by Image-
Quant using HRP-linked anti-rabbit secondary Abs (NEB, UK).
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